{
  "file_name": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
  "total_pages": 88,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "24.0": 3,
      "18.0": 11,
      "21.959999084472656": 1,
      "11.039999961853027": 688,
      "17.03999900817871": 5,
      "12.960000038146973": 1133,
      "14.039999961853027": 81,
      "20.03999900817871": 1,
      "12.0": 415,
      "15.960000038146973": 26,
      "9.960000038146973": 392,
      "15.0": 81,
      "9.0": 62,
      "7.679999828338623": 3,
      "6.359999656677246": 8,
      "8.279999732971191": 5,
      "4.028091907501221": 6,
      "5.4574151039123535": 26,
      "9.461679458618164": 7,
      "9.828072547912598": 5,
      "8.499602317810059": 2,
      "9.59999942779541": 1
    },
    "heading_sizes": [
      24.0,
      18.0,
      17.03999900817871,
      15.960000038146973,
      15.0,
      14.039999961853027
    ]
  },
  "table_analysis": {
    "total_tables": 24,
    "tables_info": [
      {
        "bbox": [
          68.04000091552734,
          165.9442901611328,
          533.3206787109375,
          589.7083129882812
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          56.63999938964844,
          174.3599853515625,
          538.4405517578125,
          300.9120178222656
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          151.1999969482422,
          580.3043212890625,
          315.23968505859375,
          658.7083129882812
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          97.43999481201172,
          152.95974731445312,
          526.7015991210938,
          645.9803466796875
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          131.0399932861328,
          180.04458618164062,
          496.8443298339844,
          581.0552978515625
        ],
        "num_rows": 6,
        "num_cols": 3
      },
      {
        "bbox": [
          64.08000183105469,
          532.904296875,
          535.6998291015625,
          758.3082885742188
        ],
        "num_rows": 5,
        "num_cols": 2
      },
      {
        "bbox": [
          64.08000183105469,
          72.34429931640625,
          535.6998291015625,
          572.6683349609375
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          64.08000183105469,
          72.34429931640625,
          532.2006225585938,
          703.6873168945312
        ],
        "num_rows": 4,
        "num_cols": 3
      },
      {
        "bbox": [
          64.08000183105469,
          72.34429931640625,
          532.2006225585938,
          696.6073608398438
        ],
        "num_rows": 5,
        "num_cols": 3
      },
      {
        "bbox": [
          188.406005859375,
          83.50731658935547,
          406.52325439453125,
          216.70077514648438
        ],
        "num_rows": 8,
        "num_cols": 3
      },
      {
        "bbox": [
          69.5999984741211,
          253.4399871826172,
          545.041015625,
          423.9119873046875
        ],
        "num_rows": 3,
        "num_cols": 4
      },
      {
        "bbox": [
          146.0399932861328,
          397.6045837402344,
          497.9243469238281,
          693.3753051757812
        ],
        "num_rows": 6,
        "num_cols": 3
      },
      {
        "bbox": [
          72.83999633789062,
          522.8242797851562,
          523.8497924804688,
          605.04736328125
        ],
        "num_rows": 5,
        "num_cols": 3
      },
      {
        "bbox": [
          160.3199920654297,
          182.98822021484375,
          487.9573974609375,
          569.1724243164062
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          69.0,
          228.53460693359375,
          484.9786071777344,
          507.972412109375
        ],
        "num_rows": 5,
        "num_cols": 2
      },
      {
        "bbox": [
          97.7168960571289,
          119.214599609375,
          453.9599914550781,
          394.8124084472656
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          97.7168960571289,
          259.49462890625,
          453.9599914550781,
          535.0924072265625
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          96.27690124511719,
          227.69459533691406,
          452.5199890136719,
          503.29241943359375
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          96.27690124511719,
          222.77459716796875,
          452.5199890136719,
          498.3724060058594
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          96.27690124511719,
          96.29460144042969,
          452.5199890136719,
          371.89239501953125
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          97.31999969482422,
          96.29460144042969,
          452.5199890136719,
          371.89239501953125
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          96.27690124511719,
          96.29460144042969,
          452.5199890136719,
          371.89239501953125
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          73.79999542236328,
          392.5394592285156,
          537.6187133789062,
          739.3483276367188
        ],
        "num_rows": 12,
        "num_cols": 3
      },
      {
        "bbox": [
          72.1199951171875,
          329.1951599121094,
          498.237060546875,
          622.9551391601562
        ],
        "num_rows": 5,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "의약품 중 변이원성‧발암성 불순물",
      "font_size": 24.0,
      "font_name": "H2hdrM",
      "bbox": [
        114.83999633789062,
        244.11843872070312,
        488.3521728515625,
        268.1184387207031
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전관리 가이드라인 [민원인안내서]",
      "font_size": 24.0,
      "font_name": "H2hdrM",
      "bbox": [
        103.43999481201172,
        288.5184326171875,
        491.7121887207031,
        312.5184326171875
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 불순물 중“니트로사민류”를 중심으로 -",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        121.55999755859375,
        332.9088134765625,
        473.5741271972656,
        350.9088134765625
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2024. 6.",
      "font_size": 21.959999084472656,
      "font_name": "H2hdrM",
      "bbox": [
        255.47999572753906,
        474.8295593261719,
        339.72784423828125,
        496.78955078125
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 등록번호",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        80.04000091552734,
        92.98429870605469,
        184.5596466064453,
        107.6683578491211
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[ 안내서-1209-02 ]",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        112.4242935180664,
        180.24374389648438,
        127.10835266113281
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        169.44000244140625,
        82.45288848876953,
        424.44000244140625,
        99.49288177490234
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        118.61460876464844,
        525.0784912109375,
        135.8524169921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        118.61460876464844,
        525.0784912109375,
        135.8524169921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        166.44000244140625,
        146.9842987060547,
        427.8093566894531,
        161.66836547851562
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.79999542236328,
        305.5042724609375,
        114.83966064453125,
        320.1883544921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        323.144287109375,
        103.91999816894531,
        337.828369140625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        165.9442901611328,
        422.44091796875,
        180.62835693359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        182.50428771972656,
        296.3210144042969,
        197.1883544921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        166.54429626464844,
        506.6396484375,
        196.58836364746094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        166.54429626464844,
        506.6396484375,
        196.58836364746094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        200.38429260253906,
        530.5195922851562,
        215.068359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        216.9442901611328,
        534.4014282226562,
        248.1883544921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        216.9442901611328,
        534.4014282226562,
        248.1883544921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        249.9442901611328,
        525.4837646484375,
        264.62835693359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        268.6642761230469,
        314.6809997558594,
        283.3483581542969
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        285.2242736816406,
        415.72100830078125,
        316.4683532714844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        285.2242736816406,
        415.72100830078125,
        316.4683532714844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        277.5442810058594,
        506.6396484375,
        307.5883483886719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        277.5442810058594,
        506.6396484375,
        307.5883483886719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.94427490234375,
        506.6396484375,
        348.9883728027344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.94427490234375,
        506.6396484375,
        348.9883728027344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.94427490234375,
        506.6396484375,
        348.9883728027344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 일회성 지시ㆍ명령에 해당하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        350.7442626953125,
        506.6396484375,
        380.7883605957031
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        350.7442626953125,
        506.6396484375,
        380.7883605957031
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        350.7442626953125,
        506.6396484375,
        380.7883605957031
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        382.5442810058594,
        506.6396484375,
        412.5883483886719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        382.5442810058594,
        506.6396484375,
        412.5883483886719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        382.5442810058594,
        506.6396484375,
        412.5883483886719
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        414.3442687988281,
        438.88092041015625,
        429.0283508300781
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        429.70428466796875,
        251.56101989746094,
        444.38836669921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        414.3442687988281,
        506.6396484375,
        444.38836669921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        414.3442687988281,
        506.6396484375,
        444.38836669921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        446.2642822265625,
        527.6813354492188,
        477.38836669921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        446.2642822265625,
        527.6813354492188,
        477.38836669921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.23999786376953,
        502.4242858886719,
        126.28350067138672,
        517.1083374023438
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.27999877929688,
        519.9442749023438,
        102.36042785644531,
        534.6282958984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        479.144287109375,
        446.8798522949219,
        493.828369140625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        494.624267578125,
        375.3637390136719,
        509.308349609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        479.144287109375,
        533.3206787109375,
        509.308349609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        479.144287109375,
        533.3206787109375,
        509.308349609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        511.6642761230469,
        450.76129150390625,
        526.3483276367188
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        527.0242919921875,
        450.7603454589844,
        557.1882934570312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술하는 것입니까? (민원인용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        527.0242919921875,
        450.7603454589844,
        557.1882934570312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■예(☞안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        519.3442993164062,
        529.0006713867188,
        549.50830078125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        519.3442993164062,
        529.0006713867188,
        549.50830078125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.04000091552734,
        575.0242919921875,
        117.5999984741211,
        589.7083129882812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        592.5443115234375,
        103.91999816894531,
        607.2283325195312
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        559.5443115234375,
        433.48028564453125,
        574.2283325195312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        575.0242919921875,
        335.7979736328125,
        589.7083129882812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        559.5443115234375,
        506.6396484375,
        589.7083129882812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        559.5443115234375,
        506.6396484375,
        589.7083129882812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        591.4642944335938,
        530.5215454101562,
        606.1483154296875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        607.904296875,
        370.81500244140625,
        622.5883178710938
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        214.67999267578125,
        623.7443237304688,
        380.52935791015625,
        638.4283447265625
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2024 년  6 월  26 일",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        232.3199920654297,
        656.6243286132812,
        351.4800109863281,
        671.308349609375
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "담당자",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.1600036621094,
        690.2243041992188,
        522.8399658203125,
        720.8683471679688
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.1600036621094,
        690.2243041992188,
        522.8399658203125,
        720.8683471679688
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문 은 희",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        329.1600036621094,
        690.2243041992188,
        522.8399658203125,
        720.8683471679688
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        65.76000213623047,
        494.6946105957031,
        543.1178588867188,
        511.9324035644531
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품관리과로 문의하시기 바랍니다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        83.5199966430664,
        518.0946044921875,
        287.594970703125,
        535.3324584960938
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화번호: 043-719-2654",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        85.79999542236328,
        564.8945922851562,
        229.2615966796875,
        582.1324462890625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스번호: 043-719-2650",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        85.79999542236328,
        588.2945556640625,
        229.2615966796875,
        605.5324096679688
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        110.35916137695312,
        543.73583984375,
        129.03346252441406
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        139.7591552734375,
        529.696533203125,
        158.43345642089844
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한 것입니다.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        169.15916442871094,
        172.63124084472656,
        187.83346557617188
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        208.63916015625,
        529.696533203125,
        227.31346130371094
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다. 또한,",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        238.03915405273438,
        529.8155517578125,
        256.71343994140625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        267.43914794921875,
        529.6961059570312,
        286.11346435546875
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        296.8391418457031,
        529.697265625,
        315.5134582519531
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        326.2391357421875,
        380.5362854003906,
        344.9134521484375
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        378.29461669921875,
        524.760009765625,
        395.53240966796875
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        82.79999542236328,
        399.17462158203125,
        529.3162841796875,
        416.41241455078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        82.79999542236328,
        419.9346008300781,
        419.02874755859375,
        437.1723937988281
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제·개정 이력",
      "font_size": 20.03999900817871,
      "font_name": "Batang",
      "bbox": [
        239.27999877929688,
        70.6376953125,
        355.9197692871094,
        90.67768859863281
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.19999694824219,
        127.45945739746094,
        482.6399841308594,
        143.42039489746094
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정번호",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.19999694824219,
        127.45945739746094,
        482.6399841308594,
        143.42039489746094
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.19999694824219,
        127.45945739746094,
        482.6399841308594,
        143.42039489746094
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요내용",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.19999694824219,
        127.45945739746094,
        482.6399841308594,
        143.42039489746094
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        158.14430236816406,
        469.67999267578125,
        172.828369140625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        158.14430236816406,
        469.67999267578125,
        172.828369140625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2022. 7. 14.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        158.14430236816406,
        469.67999267578125,
        172.828369140625
      ],
      "page_num": 4,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제정",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        158.14430236816406,
        469.67999267578125,
        172.828369140625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        191.86428833007812,
        469.67999267578125,
        206.54835510253906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        191.86428833007812,
        469.67999267578125,
        206.54835510253906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2024. 6. 26.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        191.86428833007812,
        469.67999267578125,
        206.54835510253906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개정",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.19999694824219,
        191.86428833007812,
        469.67999267578125,
        206.54835510253906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅰ. 서론 ··························································································· 1",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        69.95999908447266,
        136.05995178222656,
        519.90478515625,
        152.01995849609375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 목적",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        164.760009765625,
        514.951904296875,
        181.59396362304688
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        164.760009765625,
        514.951904296875,
        181.59396362304688
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 배경",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        192.9600067138672,
        514.951904296875,
        209.79396057128906
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        192.9600067138672,
        514.951904296875,
        209.79396057128906
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅱ. 불순물 위험평가 ····································································· 2",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        69.95999908447266,
        243.21994018554688,
        519.90478515625,
        259.179931640625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 개요",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        272.03997802734375,
        514.951904296875,
        288.8739318847656
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        272.03997802734375,
        514.951904296875,
        288.8739318847656
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 불순물 발생가능성 평가",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        300.239990234375,
        514.951904296875,
        317.0739440917969
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        300.239990234375,
        514.951904296875,
        317.0739440917969
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 발생가능성 평가",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        328.4399719238281,
        514.951904296875,
        345.27392578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        328.4399719238281,
        514.951904296875,
        345.27392578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 니트로사민류 불순물 발생원인",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        356.6399841308594,
        514.951904296875,
        373.47393798828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        356.6399841308594,
        514.951904296875,
        373.47393798828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 불순물 시험검사",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        384.8399963378906,
        514.9515380859375,
        401.6739501953125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        384.8399963378906,
        514.9515380859375,
        401.6739501953125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 1일 섭취 허용량 설정",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        413.03997802734375,
        514.9515380859375,
        429.8739318847656
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        413.03997802734375,
        514.9515380859375,
        429.8739318847656
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 일반 원칙",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        441.239990234375,
        514.9515380859375,
        458.0739440917969
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        441.239990234375,
        514.9515380859375,
        458.0739440917969
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 니트로사민류 불순물의 1일 섭취 허용량 설정",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        469.4399719238281,
        514.9515380859375,
        486.27392578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        469.4399719238281,
        514.9515380859375,
        486.27392578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 초과발암위해도를 이용한 인체영향평가",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        497.6399841308594,
        514.9515380859375,
        514.4739379882812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        497.6399841308594,
        514.9515380859375,
        514.4739379882812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅲ. 불순물 검출 시 조치방안 ··················································· 30",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        69.95999908447266,
        547.8999633789062,
        519.9039916992188,
        563.8599243164062
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 제약사 조치",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        576.6000366210938,
        514.9515380859375,
        593.4339599609375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        576.6000366210938,
        514.9515380859375,
        593.4339599609375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 신속 보고",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        604.7999877929688,
        514.9515380859375,
        621.6339111328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        604.7999877929688,
        514.9515380859375,
        621.6339111328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 검출 수준에 따른 단계별 조치",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        633.0,
        514.9515380859375,
        649.8339233398438
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        633.0,
        514.9515380859375,
        649.8339233398438
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 불순물 함유 우려 의약품의 제조공정 검증",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        661.2000122070312,
        514.9515380859375,
        678.033935546875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "32",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        661.2000122070312,
        514.9515380859375,
        678.033935546875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 허가사항 변경 등",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.5199966430664,
        689.4000244140625,
        514.9515380859375,
        706.2339477539062
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "41",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        92.5199966430664,
        689.4000244140625,
        514.9515380859375,
        706.2339477539062
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 식약처 조치",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        78.47999572753906,
        717.5999755859375,
        514.9515380859375,
        734.4338989257812
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "42",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        78.47999572753906,
        717.5999755859375,
        514.9515380859375,
        734.4338989257812
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목  차",
      "font_size": 24.0,
      "font_name": "H2hdrM",
      "bbox": [
        252.95999145507812,
        78.75843811035156,
        331.1999816894531,
        102.75843811035156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 6,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ. 질의응답 ··············································································· 45",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        75.0,
        104.97996520996094,
        520.6253051757812,
        120.9399642944336
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ. 참고문헌 ··············································································· 60",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        75.0,
        155.73995971679688,
        520.6253051757812,
        171.69996643066406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부록 1. 발암 잠재력 분류 접근법",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        79.55999755859375,
        203.48402404785156,
        308.8800048828125,
        218.48402404785156
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부록 2. 강화된 복귀돌연변이 시험 조건",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        79.55999755859375,
        233.48402404785156,
        353.8800048828125,
        248.48402404785156
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부록 3. 한시적 허용기준 적용방안",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        79.55999755859375,
        263.4840087890625,
        316.32000732421875,
        278.4840087890625
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 1 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 7,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        67.43999481201172,
        82.46882629394531,
        150.36000061035156,
        100.46882629394531
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서론",
      "font_size": 18.0,
      "font_name": "HYwulB",
      "bbox": [
        67.43999481201172,
        82.46882629394531,
        150.36000061035156,
        100.46882629394531
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        161.13995361328125,
        128.8800048828125,
        177.09996032714844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        161.13995361328125,
        128.8800048828125,
        177.09996032714844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 가이드라인은 원료의약품 및 완제의약품 제조‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        206.2799835205078,
        371.760009765625,
        221.8319854736328
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수입업체가 시판중인 의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        371.6399841308594,
        208.1024932861328,
        538.4404907226562,
        221.771240234375
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중 변이원성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        228.3599853515625,
        148.07998657226562,
        243.9119873046875
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        148.0800018310547,
        228.3599853515625,
        538.4405517578125,
        243.89903259277344
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        252.2624969482422,
        545.0404663085938,
        265.9312438964844
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 안내하기 위한 것이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        272.6400146484375,
        248.2540740966797,
        288.1790466308594
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        332.25994873046875,
        128.8800048828125,
        348.2199401855469
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배경",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        332.25994873046875,
        128.8800048828125,
        348.2199401855469
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        372.6224670410156,
        538.4405517578125,
        392.0990295410156
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(이하 ‵니트로사민류‵라 한다.)이 검출되고, 최근 새로운 변이원성 불순물**이 검",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        397.55999755859375,
        538.4400024414062,
        414.17901611328125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다.)뿐만 아니라, 미국 FDA",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        420.7200012207031,
        538.4307861328125,
        436.259033203125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        442.9200134277344,
        538.4400024414062,
        458.45904541015625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순물‵이라 한다.)의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        465.0,
        545.0389404296875,
        480.5390319824219
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        487.0799865722656,
        544.92041015625,
        502.6190185546875
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소시키거나 예방하도록 필요한 조치를 취하고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        509.2799987792969,
        384.4540710449219,
        524.8190307617188
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        80.63999938964844,
        535.4400024414062,
        538.4400024414062,
        549.8400268554688
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추정물질이고, ICH M7(R1) class 1에 해당하는 물질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        92.75999450683594,
        555.8399658203125,
        376.1999816894531,
        570.239990234375
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** AZBT 불순물, NDSRI 등",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        74.63999938964844,
        580.3200073242188,
        223.1999969482422,
        594.7200317382812
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 식약처는 원료의약품 및 완제의약품 제조‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        620.7599487304688,
        365.8800048828125,
        636.3119506835938
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수입업체(이하 ‵제약사‵라 한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.1199951171875,
        620.7599487304688,
        538.4400024414062,
        636.2990112304688
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.)가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        642.8399658203125,
        545.041015625,
        658.3790283203125
      ],
      "page_num": 7,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        665.0399780273438,
        544.9204711914062,
        680.5790405273438
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        687.1199340820312,
        538.4405517578125,
        702.6589965820312
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        711.0224609375,
        538.4403076171875,
        724.6912231445312
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사민류를 중심으로 안내하고자 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        731.3999633789062,
        289.2940673828125,
        746.9390258789062
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        67.43999481201172,
        85.46882629394531,
        249.36000061035156,
        103.46882629394531
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물 위험평가",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        67.43999481201172,
        85.46882629394531,
        249.36000061035156,
        103.46882629394531
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        160.17994689941406,
        306.75482177734375,
        180.09996032714844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개요",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        160.17994689941406,
        306.75482177734375,
        180.09996032714844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        213.2624969482422,
        544.9199829101562,
        226.93124389648438
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        235.46249389648438,
        544.92041015625,
        249.13124084472656
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예정이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        255.71998596191406,
        123.69407653808594,
        271.259033203125
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        299.9024658203125,
        545.0404663085938,
        313.57122802734375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        321.98248291015625,
        545.0404663085938,
        335.6512451171875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        344.0624694824219,
        545.041015625,
        357.7312316894531
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        364.44000244140625,
        98.85408020019531,
        379.9790344238281
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        406.67999267578125,
        545.041015625,
        422.2190246582031
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        430.7024841308594,
        545.041015625,
        444.3712463378906
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        450.9599914550781,
        545.0404663085938,
        466.4990234375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 조치를 이행하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        473.0400085449219,
        248.2540740966797,
        488.57904052734375
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        532.7799682617188,
        306.75482177734375,
        552.699951171875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물 발생가능성 평가",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        532.7799682617188,
        306.75482177734375,
        552.699951171875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 발생가능성 평가",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        576.5640258789062,
        202.1999969482422,
        591.5640258789062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        622.3424682617188,
        545.041015625,
        636.01123046875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정과 보관조건 등에 따라 제조‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        642.5999755859375,
        294.4800109863281,
        658.1519775390625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리 되어 유통되고 있음을 확인하고",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        294.3599853515625,
        644.4224853515625,
        538.4407348632812,
        658.0912475585938
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증해야 할 의무가 있음을 인지하여야 한다. 활용가능한 모든 새로운 정보를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        664.7999877929688,
        544.9204711914062,
        680.3390502929688
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        686.8799438476562,
        538.4400024414062,
        702.4190063476562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        710.782470703125,
        538.4400024414062,
        724.4512329101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        732.9824829101562,
        545.0404663085938,
        746.6512451171875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        747.47998046875,
        426.0940856933594,
        768.779052734375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        73.91999816894531,
        482.1340637207031,
        89.45903778076172
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        102.0,
        538.4384155273438,
        117.5390396118164
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.47999572753906,
        124.07999420166016,
        538.4397583007812,
        139.61903381347656
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성물)을 포함하여 발생가능성 평가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.47999572753906,
        146.2799835205078,
        316.5602722167969,
        161.81903076171875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        89.04000091552734,
        174.3599853515625,
        95.52000427246094,
        189.9119873046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.5999984741211,
        174.3599853515625,
        538.4405517578125,
        189.89903259277344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물질, 유연물질 및 분해생성물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.9199981689453,
        196.4399871826172,
        363.4804992675781,
        211.97903442382812
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        89.04000091552734,
        224.63998413085938,
        95.52000427246094,
        240.19198608398438
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.1199951171875,
        224.63998413085938,
        538.4400024414062,
        240.1790313720703
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되는 분해생성물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        183.59999084472656,
        248.54249572753906,
        281.04052734375,
        262.21124267578125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        285.3600158691406,
        405.8399963378906,
        300.9120178222656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암성시험에 관한 데",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        405.8399963378906,
        287.1824951171875,
        538.4400024414062,
        300.85125732421875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이터베이스 또는 문헌검색을 실시",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.27999877929688,
        309.2624816894531,
        321.24053955078125,
        322.9312438964844
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        333.6000061035156,
        474.1199951171875,
        349.1390380859375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3) In vitro 또는 In vivo 시험",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        359.760009765625,
        278.5205383300781,
        375.2990417480469
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변이원성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        402.0,
        132.95999145507812,
        417.552001953125
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        132.83999633789062,
        403.8224792480469,
        538.4391479492188,
        417.4912414550781
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        424.20001220703125,
        538.439453125,
        439.7390441894531
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        446.2799987792969,
        538.43896484375,
        461.81903076171875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 박테리아 변이원성시험을 직접 실시할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        468.3599853515625,
        391.174072265625,
        483.8990173339844
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        512.54248046875,
        545.0404663085938,
        526.2112426757812
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        532.7999877929688,
        538.43994140625,
        548.3519897460938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        554.9999389648438,
        544.9204711914062,
        570.5390014648438
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5개 등급으로 분류할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        577.0799560546875,
        254.73406982421875,
        592.6190185546875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        70.73460388183594,
        461.03997802734375,
        87.97241973876953
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        87.1199951171875,
        105.85945129394531,
        461.3999938964844,
        137.42039489746094
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(class)",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        87.1199951171875,
        105.85945129394531,
        461.3999938964844,
        137.42039489746094
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        87.1199951171875,
        105.85945129394531,
        461.3999938964844,
        137.42039489746094
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 방법",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        87.1199951171875,
        105.85945129394531,
        461.3999938964844,
        137.42039489746094
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.5999984741211,
        147.77459716796875,
        520.5567626953125,
        179.8924102783203
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변이원성과 발암성 확인 물질",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        102.5999984741211,
        147.77459716796875,
        520.5567626953125,
        179.8924102783203
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화합물-특이적 허용한계 수준",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        102.5999984741211,
        147.77459716796875,
        520.5567626953125,
        179.8924102783203
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 그 이하로 관리",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        102.5999984741211,
        147.77459716796875,
        520.5567626953125,
        179.8924102783203
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.5999984741211,
        216.49945068359375,
        109.5550765991211,
        232.46038818359375
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변이원성은 확인되고 발암성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        191.81460571289062,
        331.3087463378906,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미확인 물질",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        191.81460571289062,
        331.3087463378906,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(박테리아 변이원성 양성 및",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        191.81460571289062,
        331.3087463378906,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설치류 발암성 유발 데이터 없음)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        191.81460571289062,
        331.3087463378906,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적 허용한계 또는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        191.81460571289062,
        495.2279052734375,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여기간에 따른 조정된",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        191.81460571289062,
        495.2279052734375,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용한계",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        191.81460571289062,
        495.2279052734375,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(일반적 혹은 조정된 TTC)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        191.81460571289062,
        495.2279052734375,
        256.9324035644531
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.5999984741211,
        325.3394470214844,
        109.5550765991211,
        341.3003845214844
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조적 경고(structural alert)가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        309.65460205078125,
        334.3167724609375,
        356.89239501953125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으나, 원료의약품 구조와 관련",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        309.65460205078125,
        334.3167724609375,
        356.89239501953125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없는 것(변이원성 데이터 없음)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        309.65460205078125,
        334.3167724609375,
        356.89239501953125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적 허용한계 또는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여기간에 따른 조정된",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용한계로 관리하거나(일반적",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혹은 조정된 TTC),",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박테리아 변이원성 시험결과에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 class2 또는 class5로 분류",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 변이원성 양성 : class2",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 변이원성 음성 : class5",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        268.8546142578125,
        528.2373046875,
        397.58038330078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.5999984741211,
        428.0594482421875,
        109.5550765991211,
        444.0203857421875
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조적 경고 있으나, 검사된",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        412.3746032714844,
        331.436767578125,
        459.6123962402344
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품 등에 동일한 구조적",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        412.3746032714844,
        331.436767578125,
        459.6123962402344
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경고가 있고 비-변이원성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        412.3746032714844,
        331.436767578125,
        459.6123962402344
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비-변이원성 불순물로 관리",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        427.3746032714844,
        502.91998291015625,
        444.6123962402344
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.5999984741211,
        489.97943115234375,
        109.5550765991211,
        505.94036865234375
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조적 경고가 없거나,",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        474.29461669921875,
        311.9972839355469,
        521.4124145507812
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변이원성이 없음을 입증하는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        474.29461669921875,
        311.9972839355469,
        521.4124145507812
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "충분한 데이터 있음",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        138.47999572753906,
        474.29461669921875,
        311.9972839355469,
        521.4124145507812
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비-변이원성 불순물로 관리",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        341.7599792480469,
        489.29461669921875,
        502.91998291015625,
        506.53240966796875
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 5 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 니트로사민류 불순물 발생원인",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        80.7240219116211,
        299.6399841308594,
        95.7240219116211
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        126.5999984741211,
        538.4400024414062,
        142.1390380859375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다. 현",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        148.67999267578125,
        538.4400024414062,
        164.2190399169922
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        172.70249938964844,
        538.4400024414062,
        186.37124633789062
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        192.95999145507812,
        538.4400024414062,
        208.49903869628906
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        215.0399932861328,
        88.91999816894531,
        230.5919952392578
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        88.91999816894531,
        215.0399932861328,
        538.4400024414062,
        230.57904052734375
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        237.239990234375,
        538.4400024414062,
        252.77903747558594
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함하여 현재까지 발표된 위험 요소는 아래와 같다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        259.32000732421875,
        371.73406982421875,
        274.8590393066406
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 원료의약품",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.63999938964844,
        299.3999938964844,
        173.2213134765625,
        316.23394775390625
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        329.3999938964844,
        538.4405517578125,
        344.93902587890625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.83999633789062,
        351.6000061035156,
        523.4405517578125,
        367.7677001953125
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        377.6400146484375,
        545.0396118164062,
        393.1790466308594
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민을 형성한다. 만약 아질산을 잔류 아지드(사용 예: 테트라졸",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        399.8399963378906,
        544.9204711914062,
        415.3790283203125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        421.9200134277344,
        545.0404663085938,
        437.45904541015625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능성은 증가할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.95999908447266,
        444.0,
        248.01406860351562,
        459.5390319824219
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 1. 니트로사민 생성 과정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        210.83999633789062,
        580.7999877929688,
        384.35968017578125,
        596.3390502929688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        632.9999389648438,
        538.4400024414062,
        648.5390014648438
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 수 있으므로 생성 가능성을 배제할 수 없다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.91999816894531,
        655.199951171875,
        383.49407958984375,
        670.739013671875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        683.2799682617188,
        537.9594116210938,
        698.8190307617188
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다. 원료의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        709.43994140625,
        538.4405517578125,
        724.97900390625
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.83999633789062,
        731.5199584960938,
        538.4400024414062,
        747.0590209960938
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기를 포함하고 있을 수 있다. 3차 및 4차 아민은 시약 또는 촉매로서",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.83999633789062,
        753.5999755859375,
        545.0408325195312,
        769.1390380859375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투입될 수 있다. 모든 형태의 아민은 아질산 또는 니트로소화제와 반응",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.83999633789062,
        68.87999725341797,
        538.4403076171875,
        84.41903686523438
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 니트로사민을 형성할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.83999633789062,
        90.95999908447266,
        315.3340759277344,
        106.49903869628906
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        117.12000274658203,
        538.4405517578125,
        132.65904235839844
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다. 예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.79999542236328,
        139.1999969482422,
        544.9210205078125,
        154.73904418945312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.79999542236328,
        161.39999389648438,
        545.0404663085938,
        176.9390411376953
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다.(그림 2)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.79999542236328,
        183.47999572753906,
        538.5432739257812,
        199.01904296875
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.79999542236328,
        205.5599822998047,
        538.5584716796875,
        221.09902954101562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.79999542236328,
        227.75999450683594,
        488.0140686035156,
        243.29904174804688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 2. NDMA 생성 과정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        214.9199981689453,
        394.79998779296875,
        380.2796936035156,
        410.3390197753906
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2차 아민은 아미드 용매의 불순물로 존재할 수 있다. 대표적으로 DMF 내",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        447.1199951171875,
        538.4400024414062,
        462.6590270996094
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.0,
        469.20001220703125,
        538.4400024414062,
        484.7390441894531
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성할 수 있다. 3차 아민, 예를 들어 triethylamine 및 diisopropylethyla",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        102.0,
        491.2799987792969,
        538.4154052734375,
        506.81903076171875
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        102.0,
        513.47998046875,
        538.5357666015625,
        529.01904296875
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.0,
        535.5599365234375,
        538.44091796875,
        551.0989990234375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.0,
        557.6399536132812,
        544.9199829101562,
        573.1790161132812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        102.0,
        579.8399658203125,
        538.4729614257812,
        595.3790283203125
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "monium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.0,
        601.9199829101562,
        544.9204711914062,
        617.4590454101562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함유할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        102.0,
        623.9999389648438,
        196.174072265625,
        639.5390014648438
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        650.1599731445312,
        544.9188842773438,
        665.6990356445312
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.07999420166016,
        672.239990234375,
        538.4405517578125,
        687.779052734375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아민기를 포함한 그 외 시약 등을 평가하도록 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        103.07999420166016,
        694.43994140625,
        421.0540771484375,
        709.97900390625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 2. 니트로사민류 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        83.21460723876953,
        235.56053161621094,
        100.45242309570312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.87999725341797,
        116.65945434570312,
        482.5199890136719,
        132.62039184570312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성과정",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.87999725341797,
        116.65945434570312,
        482.5199890136719,
        132.62039184570312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원인",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.87999725341797,
        116.65945434570312,
        482.5199890136719,
        132.62039184570312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NDMA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        88.08000183105469,
        147.46429443359375,
        121.62728881835938,
        162.1483612060547
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· DMF의 가수분해",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        138.58428955078125,
        503.2008972167969,
        153.2683563232422
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는 분해(온도)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        156.2242889404297,
        508.9237365722656,
        170.90835571289062
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NDEA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        90.23999786376953,
        206.9842987060547,
        119.46733093261719,
        221.66836547851562
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 3차 아민인 DIPEA의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        180.58428955078125,
        521.3212280273438,
        195.2683563232422
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탈알킬화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        198.2242889404297,
        459.47967529296875,
        212.90835571289062
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· TEA의 4차 암모늄",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        215.74429321289062,
        510.0408935546875,
        230.42835998535156
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "염산염의 가수분해",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        233.38429260253906,
        508.9196472167969,
        248.068359375
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIPNA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        88.55999755859375,
        265.06427001953125,
        121.26603698730469,
        279.74835205078125
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 3차 아민인 DIPEA의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        256.3042907714844,
        521.3212280273438,
        270.9883728027344
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탈알킬화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        273.94427490234375,
        459.47967529296875,
        288.62835693359375
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EIPNA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        89.63999938964844,
        302.0242614746094,
        120.18661499023438,
        316.7083435058594
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 3차 아민인 DIPEA의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        293.2642822265625,
        521.3212280273438,
        307.9483642578125
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탈알킬화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        310.7842712402344,
        459.47967529296875,
        325.4683532714844
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NMBA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        88.79999542236328,
        340.3042907714844,
        120.90655517578125,
        354.9883728027344
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· NMP의 가수분해",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        331.5442810058594,
        504.5209045410156,
        346.2283630371094
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및/또는 분해(온도)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        349.18426513671875,
        508.9237365722656,
        363.86834716796875
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NMPA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        88.91999816894531,
        380.38427734375,
        120.90733337402344,
        395.068359375
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 3차 아민인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        371.5042724609375,
        474.76092529296875,
        386.1883544921875
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N,N-DMA의 탈알킬화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        414.55145263671875,
        389.144287109375,
        524.879638671875,
        403.828369140625
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDBA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        89.87999725341797,
        439.06427001953125,
        119.82713317871094,
        453.74835205078125
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 2차 아민인 DBA의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        412.6642761230469,
        512.8012084960938,
        427.3483581542969
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로소화 및/또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        415.44000244140625,
        430.30426025390625,
        517.120849609375,
        444.98834228515625
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3차 아민인 TBA의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        407.5199890136719,
        447.82427978515625,
        509.6812438964844,
        462.50836181640625
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탈알킬화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        414.239990234375,
        465.4642639160156,
        458.2796630859375,
        480.1483459472656
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 원료의약품의 구조로부터 아질산 발생",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        510.9599914550781,
        333.719970703125,
        526.4990234375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        537.1199951171875,
        545.03857421875,
        552.6590576171875
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.31999969482422,
        559.199951171875,
        545.0391235351562,
        574.739013671875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.31999969482422,
        581.2799682617188,
        188.8540802001953,
        596.8190307617188
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        609.47998046875,
        475.5605163574219,
        625.01904296875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다. 원료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        635.5199584960938,
        538.4402465820312,
        651.0590209960938
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.07999420166016,
        657.719970703125,
        523.0540161132812,
        673.259033203125
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        95.5199966430664,
        683.7599487304688,
        102.0,
        699.3119506835938
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.5999984741211,
        683.7599487304688,
        538.4402465820312,
        699.2990112304688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다. 아질산 불순물은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.5999984741211,
        705.9599609375,
        538.43896484375,
        721.4990234375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.5999984741211,
        728.0399780273438,
        538.4400024414062,
        743.5790405273438
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        750.1199340820312,
        439.8940734863281,
        765.6589965820312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        95.5199966430664,
        71.87999725341797,
        102.0,
        87.43199920654297
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다.(예: 톨루엔)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.47999572753906,
        71.87999725341797,
        535.062744140625,
        87.41903686523438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        95.5199966430664,
        98.04000091552734,
        102.0,
        113.59200286865234
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.63999938964844,
        99.86250305175781,
        544.9202880859375,
        113.53125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조하는 과정에서 교차오염의 가능성이 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        110.63999938964844,
        120.12000274658203,
        389.37408447265625,
        135.65904235839844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 회수한 용매, 촉매 및 시약의 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        148.1999969482422,
        310.91998291015625,
        163.73904418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        174.3599853515625,
        538.4400024414062,
        189.89903259277344
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 니트로사민 발생 위험에 노출될 수 있다. 또한, 회수 공정에 퀜칭",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.55999755859375,
        196.4399871826172,
        544.9204711914062,
        211.97903442382812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다.(잔류 아지드를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.55999755859375,
        218.63998413085938,
        544.9204711914062,
        234.1790313720703
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분해하기 위해 아질산 사용)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.55999755859375,
        240.71998596191406,
        267.3427429199219,
        256.259033203125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        266.8800048828125,
        538.439453125,
        282.4190368652344
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        290.782470703125,
        545.041015625,
        304.45123291015625
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노출될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.95999908447266,
        311.0400085449219,
        194.1340789794922,
        326.57904052734375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        337.20001220703125,
        538.4391479492188,
        352.7390441894531
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은 경우 오염원에 노출될 가능성이 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.31999969482422,
        359.2799987792969,
        356.97406005859375,
        374.81903076171875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 퀜칭(Quenching) 공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        387.4800109863281,
        237.1199951171875,
        403.01904296875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        413.5199890136719,
        544.9204711914062,
        429.05902099609375
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.19999694824219,
        435.7200012207031,
        545.041015625,
        451.259033203125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.19999694824219,
        459.6224670410156,
        544.9207763671875,
        473.2912292480469
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정이 없을 경우 그 이후 단계로 이행될 수 있다. 퀜칭공정이 주 반응물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.19999694824219,
        479.8800048828125,
        538.43896484375,
        495.4190368652344
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.19999694824219,
        503.9024658203125,
        538.4405517578125,
        517.5712280273438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 니트로사민 생성 위험성을 가지고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.19999694824219,
        524.1599731445312,
        369.8140869140625,
        539.6990356445312
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사) 공정 최적화·관리의 미흡",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        552.239990234375,
        260.760009765625,
        567.7919921875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        578.3999633789062,
        544.9204711914062,
        593.9390258789062
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        101.4000015258789,
        600.47998046875,
        449.0140686035156,
        616.01904296875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아) 산화제 존재",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        628.6799926757812,
        177.8405303955078,
        644.2190551757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        654.719970703125,
        538.4400024414062,
        670.259033203125
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시킬 수 있다. Dimethylamine에서 전환된 히드록실아민은 산화되어 알카",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.79999542236328,
        676.9199829101562,
        538.4400024414062,
        692.4590454101562
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.79999542236328,
        698.9999389648438,
        538.5348510742188,
        714.5390014648438
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mine과 반응하여 니트로사민이 생성될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        100.79999542236328,
        721.0799560546875,
        386.49407958984375,
        736.6190185546875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.4903564453125,
        311.7449951171875,
        813.4503173828125
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 완제의약품",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.63999938964844,
        71.63999938964844,
        173.2213134765625,
        88.47396087646484
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 3. 완제의약품 중 니트로사민 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        166.67999267578125,
        261.0,
        428.3996887207031,
        276.5390319824219
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 완제의약품의 제조공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        313.55999755859375,
        242.76052856445312,
        329.0990295410156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        339.7200012207031,
        545.041015625,
        355.259033203125
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        361.79998779296875,
        538.43896484375,
        377.3390197753906
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 알려져 있다. 이러한 니트로소화 반응에 취약한 아민들은 제조공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        383.8800048828125,
        538.4407348632812,
        399.4190368652344
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다. 주성분 아민기의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        406.0799865722656,
        545.041015625,
        421.6190185546875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.95999908447266,
        428.1600036621094,
        538.534423828125,
        443.69903564453125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        450.239990234375,
        544.91943359375,
        465.7790222167969
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다. 이러한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        472.44000244140625,
        544.9204711914062,
        487.9790344238281
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        494.5199890136719,
        538.4400024414062,
        510.05902099609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        516.5999755859375,
        538.4400024414062,
        532.1390380859375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.95999908447266,
        538.7999877929688,
        498.4540710449219,
        554.3390502929688
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 원료의약품의 분해 또는 산화과정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        566.8799438476562,
        307.8005065917969,
        582.4190063476562
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        593.0399780273438,
        544.9199829101562,
        608.5790405273438
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        616.9424438476562,
        538.439453125,
        630.6112060546875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로사민이 생성될 수 있다.(예: 라니티딘) 이러한 의약품은 높은 온도 및",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        637.199951171875,
        544.9199829101562,
        652.739013671875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        661.2224731445312,
        545.0404663085938,
        674.8912353515625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        681.47998046875,
        538.4400024414062,
        697.01904296875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        703.5599365234375,
        538.4400024414062,
        719.0989990234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 인하여 생성될 수 있다. 이러한 발생원인은 이와 같은 작용기를 포함",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.95999908447266,
        725.7599487304688,
        538.4400024414062,
        741.2990112304688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        99.95999908447266,
        747.8399658203125,
        479.97406005859375,
        763.3790283203125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 첨가제 등의 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        73.91999816894531,
        210.24000549316406,
        89.45903778076172
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        99.95999908447266,
        538.4400024414062,
        115.49903869628906
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        122.15999603271484,
        538.4407348632812,
        137.69903564453125
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동안 니트로사민의 생성으로 이어질 수 있다. 첨가제 중 아질산의 수치",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        144.239990234375,
        538.4400024414062,
        159.77903747558594
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        166.3199920654297,
        544.9199829101562,
        181.85903930664062
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를 고려하여 선택하도록 한다. 아질산 수치가 낮은 첨가제의 선택은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        188.51998901367188,
        544.9204711914062,
        204.0590362548828
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다. 또한, 아질산",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        210.59999084472656,
        545.0404663085938,
        226.1390380859375
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        232.67999267578125,
        538.4400024414062,
        248.2190399169922
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스테인, PABA) 활용을 고려할 수 있다. 또한 완제의약품의 제조원은 용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        254.87998962402344,
        538.4400024414062,
        270.4190368652344
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.27999877929688,
        278.782470703125,
        544.9183959960938,
        292.45123291015625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        101.27999877929688,
        299.0400085449219,
        130.174072265625,
        314.57904052734375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 직접용기(포장재)를 통한 오염",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        327.239990234375,
        283.91998291015625,
        342.7790222167969
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        353.2799987792969,
        545.041015625,
        368.81903076171875
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결합하여 니트로사민이 생성될 수 있다. 예를 들어 알루미늄 호일을 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.5999984741211,
        375.4800109863281,
        538.439453125,
        391.01904296875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.5999984741211,
        397.55999755859375,
        538.4405517578125,
        413.0990295410156
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.5999984741211,
        421.46246337890625,
        538.4400024414062,
        435.1312255859375
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.5999984741211,
        441.8399963378906,
        538.4400024414062,
        457.3790283203125
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        102.5999984741211,
        463.91998291015625,
        535.0540161132812,
        479.4590148925781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 3. 완제의약품의 포장재질 중 발생가능한 니트로사민",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        69.5999984741211,
        509.9346008300781,
        404.5210266113281,
        527.1724243164062
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.5199966430664,
        542.2642822265625,
        426.76092529296875,
        564.1483154296875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NOx 공급원",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.5199966430664,
        542.2642822265625,
        426.76092529296875,
        564.1483154296875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Amine 공급원",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.5199966430664,
        542.2642822265625,
        426.76092529296875,
        564.1483154296875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NOx와 반응하는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.5199966430664,
        542.2642822265625,
        426.76092529296875,
        564.1483154296875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Amine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        365.6399841308594,
        549.4642944335938,
        513.4796142578125,
        571.3483276367188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 공급원",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        365.6399841308594,
        549.4642944335938,
        513.4796142578125,
        571.3483276367188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로셀룰로오스",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.1999969482422,
        580.3043212890625,
        239.1589813232422,
        594.9883422851562
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(호일 내)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        172.55999755859375,
        597.9442749023438,
        217.8037567138672,
        612.6282958984375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프린트잉크",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        260.1600036621094,
        580.3043212890625,
        315.23968505859375,
        594.9883422851562
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(호일 내)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        265.0799865722656,
        597.9442749023438,
        310.32373046875,
        612.6282958984375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "호일/프린트잉크",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        442.55999755859375,
        589.184326171875,
        523.9196166992188,
        603.8683471679688
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로셀룰로오스",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.1999969482422,
        626.38427734375,
        239.1589813232422,
        641.0682983398438
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(호일 내)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        172.55999755859375,
        644.0242919921875,
        217.8037567138672,
        658.7083129882812
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프린트잉크",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        260.1600036621094,
        626.38427734375,
        315.23968505859375,
        641.0682983398438
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(호일 내)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        265.0799865722656,
        644.0242919921875,
        310.32373046875,
        658.7083129882812
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "호일/프린트잉크",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        442.55999755859375,
        635.2642822265625,
        523.9196166992188,
        649.9483032226562
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 이온교환 수지를 사용하는 정제 공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        707.6399536132812,
        327.239990234375,
        723.1790161132812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        733.7999877929688,
        545.0404663085938,
        749.3390502929688
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        757.7024536132812,
        544.9199829101562,
        771.3712158203125
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        68.87999725341797,
        544.9202270507812,
        84.41903686523438
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        90.95999908447266,
        538.4400024414062,
        106.49903869628906
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다. 또한, 용수의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        113.15999603271484,
        544.9193725585938,
        128.69903564453125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        135.239990234375,
        545.0404663085938,
        150.77903747558594
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다. 수지를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        157.3199920654297,
        544.9204711914062,
        172.85903930664062
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.75999450683594,
        181.34249877929688,
        544.9199829101562,
        195.01124572753906
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능성이 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        101.75999450683594,
        201.59999084472656,
        189.45407104492188,
        217.1390380859375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        270.4599609375,
        306.75482177734375,
        290.37994384765625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 시험검사",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        270.4599609375,
        306.75482177734375,
        290.37994384765625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        323.54248046875,
        538.4400024414062,
        337.21124267578125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        343.79998779296875,
        544.9204711914062,
        359.3390197753906
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하여야 한다. 시험검사는 환자가 직접 복용하는 완제의약품을 대상으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        365.8800048828125,
        544.9204711914062,
        381.4190368652344
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        388.0799865722656,
        538.4400024414062,
        403.6190185546875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        411.98248291015625,
        538.4405517578125,
        425.6512451171875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사도 함께 실시하여야 한다. 이러한 경우에는 원료의약품이나 그 중간체에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        432.239990234375,
        544.9207763671875,
        447.7790222167969
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        456.2624816894531,
        538.4400024414062,
        469.9312438964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 활용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        476.5199890136719,
        196.65408325195312,
        492.05902099609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        518.8799438476562,
        538.439453125,
        534.4190063476562
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        542.782470703125,
        538.4400024414062,
        556.4512329101562
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        563.0399780273438,
        538.4397583007812,
        578.5790405273438
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        585.239990234375,
        477.4540710449219,
        600.779052734375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.47999572753906,
        639.47998046875,
        538.4400024414062,
        655.01904296875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.23999786376953,
        661.5599365234375,
        544.919677734375,
        677.0989990234375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용량(Maximum daily dose, mg/일)으로 나누어 산출한다. 상세한 내용은 「4.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.23999786376953,
        683.6399536132812,
        538.4142456054688,
        699.1919555664062
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량 설정」을 참고한다. 시험법 개발시 불순물의 정량한계(LOQ)는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.23999786376953,
        705.8399658203125,
        545.0404663085938,
        721.3919677734375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」",
      "font_size": 12.960000038146973,
      "font_name": "T14",
      "bbox": [
        69.23999786376953,
        727.9199829101562,
        538.4400024414062,
        743.4719848632812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다. 정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.23999786376953,
        749.9999389648438,
        538.4400024414062,
        765.5390014648438
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다.(예: LC",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.23999786376953,
        68.87999725341797,
        538.3628540039062,
        84.41903686523438
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 LC-MS/MS)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.23999786376953,
        90.95999908447266,
        170.50460815429688,
        106.49903869628906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        133.3199920654297,
        538.4140625,
        148.85903930664062
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        155.39999389648438,
        544.9202880859375,
        170.9390411376953
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        177.59999084472656,
        544.9202880859375,
        193.1390380859375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        199.67999267578125,
        172.41407775878906,
        215.2190399169922
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        242.0399932861328,
        538.4400024414062,
        257.57904052734375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        265.9424743652344,
        544.9199829101562,
        279.6112365722656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        288.0224914550781,
        538.4400024414062,
        301.6912536621094
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이션을 실시할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        308.3999938964844,
        222.21408081054688,
        323.93902587890625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        350.6400146484375,
        538.4400024414062,
        366.1920166015625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        372.8399963378906,
        545.041015625,
        388.3919982910156
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        394.9200134277344,
        98.85408020019531,
        410.45904541015625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        453.0224914550781,
        545.0404663085938,
        466.6912536621094
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        473.2799987792969,
        538.5325317382812,
        488.81903076171875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        495.3599853515625,
        463.7740783691406,
        510.8990173339844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        551.6399536132812,
        462.6940612792969,
        567.1790161132812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 13 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 불순물 신규 시험법 개발 절차 >",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        182.75999450683594,
        70.39916229248047,
        412.6981201171875,
        89.07345581054688
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분 및 불순물의",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        100.43999481201172,
        134.89944458007812,
        208.44000244140625,
        150.86038208007812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성 검토",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        127.43999481201172,
        154.09945678710938,
        181.44000244140625,
        170.06039428710938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 물리·화학적 특성 고려",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        121.99974060058594,
        442.0799865722656,
        149.2873077392578
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예) 용해도, 분자량, Log P, boiling point 등",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        121.99974060058594,
        442.0799865722656,
        149.2873077392578
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 보관 조건(휘발성, 표준액 안정성 등) 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        152.95974731445312,
        452.8795166015625,
        166.2073211669922
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 내부표준물질 적절성 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        169.99974060058594,
        380.3999938964844,
        183.247314453125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▼",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        147.47999572753906,
        191.0943603515625,
        161.51998901367188,
        205.9021759033203
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전처리법 고려",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        116.5199966430664,
        254.77944946289062,
        192.47999572753906,
        270.7403869628906
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물의 특성 고려",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        211.99974060058594,
        523.0621948242188,
        252.13528442382812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) NDMA의 경우 휘발성 있음",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        211.99974060058594,
        523.0621948242188,
        252.13528442382812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "→ 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움)",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        211.99974060058594,
        523.0621948242188,
        252.13528442382812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주성분, 첨가제, 제형 특성 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        255.5597381591797,
        454.0799865722656,
        282.8473205566406
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 메트포르민 : 서방화 첨가제 산처리시 겔화",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        255.5597381591797,
        454.0799865722656,
        282.8473205566406
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 희석 및 추출 용매에 따른 감도 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        286.5197448730469,
        430.4399719238281,
        313.80731201171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 메탄올과 물 혼합시 감도 상승",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        286.5197448730469,
        430.4399719238281,
        313.80731201171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▼",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        147.47999572753906,
        321.6543884277344,
        161.51998901367188,
        336.4621887207031
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석 장비 선택",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        112.43999481201172,
        398.0594482421875,
        196.44000244140625,
        414.0203857421875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주성분의 휘발성 및 열안정성 고려(LC or GC)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        342.55975341796875,
        498.1027526855469,
        369.727294921875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)]",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        342.55975341796875,
        498.1027526855469,
        369.727294921875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        373.5197448730469,
        521.7599487304688,
        386.7673034667969
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(LC or LC-MS/MS 등)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        260.5199890136719,
        387.55975341796875,
        360.63470458984375,
        400.80731201171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        401.479736328125,
        526.3640747070312,
        414.727294921875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        277.67999267578125,
        415.7245788574219,
        522.1196899414062,
        427.6952819824219
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 질량분석시 불순물 특성을 고려한 이온화 방법 선정",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        431.1197509765625,
        488.6399230957031,
        469.8152770996094
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) NDMA, NDEA 등 저분자량 불순물 → APCI mode",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        431.1197509765625,
        488.6399230957031,
        469.8152770996094
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDSRI 등 고분자량 불순물 → ESI mode",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        431.1197509765625,
        488.6399230957031,
        469.8152770996094
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▼",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        147.47999572753906,
        477.8943786621094,
        161.51998901367188,
        492.7021789550781
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석조건 검토",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        115.43999481201172,
        527.41943359375,
        193.44000244140625,
        543.38037109375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        498.15789794921875,
        512.2799682617188,
        524.7752685546875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        498.15789794921875,
        512.2799682617188,
        524.7752685546875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        528.3197021484375,
        490.79998779296875,
        541.5673217773438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        545.23974609375,
        526.7011108398438,
        558.4873657226562
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 주성분으로 인한 영향 최소화 필요",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        260.8800048828125,
        559.2797241210938,
        445.79998779296875,
        572.52734375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▼",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        147.47999572753906,
        580.3743896484375,
        161.51998901367188,
        595.1821899414062
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험방법 밸리데이션",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.43999481201172,
        630.0194091796875,
        211.44000244140625,
        645.9803466796875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 잔류용매 및 시약 등과의 특이성 확인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        601.2797241210938,
        522.5999755859375,
        627.3753051757812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        601.2797241210938,
        522.5999755859375,
        627.3753051757812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        630.7997436523438,
        526.7015991210938,
        644.04736328125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미치는지 확인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        260.5199890136719,
        644.8397216796875,
        325.7995300292969,
        658.0873413085938
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 「의약품등 시험방법 밸리데이션 가이드라인」 적용",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        250.4399871826172,
        661.8796997070312,
        491.8799743652344,
        675.1273193359375
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        710.3597412109375,
        542.0610961914062,
        723.6073608398438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        71.87999725341797,
        724.3997192382812,
        541.9419555664062,
        765.6073608398438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        71.87999725341797,
        724.3997192382812,
        541.9419555664062,
        765.6073608398438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        71.87999725341797,
        724.3997192382812,
        541.9419555664062,
        765.6073608398438
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 14 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        306.75482177734375,
        108.33995819091797
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량 설정",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        306.75482177734375,
        108.33995819091797
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 일반 원칙",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        132.3240203857422,
        157.1999969482422,
        147.3240203857422
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        171.74249267578125,
        538.4400024414062,
        185.41123962402344
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        191.0399932861328,
        544.9204711914062,
        207.65904235839844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        214.19998168945312,
        493.7740783691406,
        229.73902893066406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)`",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        74.63999938964844,
        240.47999572753906,
        536.2319946289062,
        254.87998962402344
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        268.5637512207031,
        545.0404663085938,
        294.8990478515625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        303.2624816894531,
        538.4400024414062,
        316.9312438964844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        323.5199890136719,
        538.4395751953125,
        340.57122802734375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        345.7200012207031,
        538.5341186523438,
        361.259033203125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일 섭취 허용량을 1,500 ng/day로 설정할 수 있다. 식약처는 아지도 불순물(예:",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        367.79998779296875,
        538.5340576171875,
        383.3390197753906
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AZBT)에 대하여 TTC 개념을 적용한 바 있다.",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        389.8800048828125,
        348.3600158691406,
        405.4190368652344
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* TD50 :종양 발생률이 50%인 용량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        80.63999938964844,
        416.1600036621094,
        271.44000244140625,
        431.9999694824219
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50",
      "font_size": 7.679999828338623,
      "font_name": "T12",
      "bbox": [
        74.63999938964844,
        440.5199890136719,
        538.5596313476562,
        455.4960021972656
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        90.95999908447266,
        460.91998291015625,
        535.0800170898438,
        475.3199768066406
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        499.8000183105469,
        545.0404663085938,
        515.3390502929688
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        521.9999389648438,
        538.4400024414062,
        537.5390014648438
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으며, 니트로사민류도 이에 속한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        544.0799560546875,
        277.5340881347656,
        559.6190185546875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        582.8399658203125,
        545.0407104492188,
        598.3790283203125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        604.9199829101562,
        538.439697265625,
        620.4590454101562
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        626.9999389648438,
        545.041015625,
        642.5390014648438
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        649.199951171875,
        391.174072265625,
        664.739013671875
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<투여기간에 따른 불순물 1일 섭취 허용량>",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        166.3199920654297,
        682.3199462890625,
        428.9207763671875,
        697.8590087890625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여 기간",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        113.39999389648438,
        715.0994262695312,
        529.3200073242188,
        731.0603637695312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "≤ 1달",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        113.39999389648438,
        715.0994262695312,
        529.3200073242188,
        731.0603637695312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "> 1 – 12달",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        113.39999389648438,
        715.0994262695312,
        529.3200073242188,
        731.0603637695312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "> 1 - 10년",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        113.39999389648438,
        715.0994262695312,
        529.3200073242188,
        731.0603637695312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "> 10년 ~ 평생",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        113.39999389648438,
        715.0994262695312,
        529.3200073242188,
        731.0603637695312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취량 [μg/day]",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        743.179443359375,
        499.458740234375,
        759.140380859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "120",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        743.179443359375,
        499.458740234375,
        759.140380859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        743.179443359375,
        499.458740234375,
        759.140380859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        743.179443359375,
        499.458740234375,
        759.140380859375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.5",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.23999786376953,
        743.179443359375,
        499.458740234375,
        759.140380859375
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 15 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 니트로사민류 불순물의 1일 섭취 허용량 설정",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        80.7240219116211,
        398.3999938964844,
        95.7240219116211
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.95999908447266,
        140.54249572753906,
        538.439697265625,
        154.21124267578125
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        160.79998779296875,
        545.0399169921875,
        176.3390350341797
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        182.99998474121094,
        167.37408447265625,
        198.53903198242188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        212.0399932861328,
        538.43896484375,
        227.57904052734375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        234.239990234375,
        538.4404907226562,
        249.77903747558594
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법으로 설정할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        256.32000732421875,
        219.45407104492188,
        271.8590393066406
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        300.6000061035156,
        517.9204711914062,
        316.1390380859375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        328.79998779296875,
        538.4395751953125,
        344.96771240234375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "견고성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        328.79998779296875,
        538.4395751953125,
        344.96771240234375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        350.8800048828125,
        538.5432739257812,
        367.0476989746094
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "departure)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        372.9599914550781,
        544.9204711914062,
        388.4990234375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량을 산출할 수 있다. 이때 TD50은 발암성시험 데이터베이스",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        395.1600036621094,
        538.4410400390625,
        411.32769775390625
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        417.239990234375,
        538.5340576171875,
        432.7790222167969
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        439.32000732421875,
        400.174072265625,
        454.8590393066406
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        677.3999633789062,
        538.439453125,
        692.9390258789062
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        699.47998046875,
        521.134033203125,
        715.01904296875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 예시: NDMA의 1일 섭취 허용량 계산>",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.27999877929688,
        484.30426025390625,
        298.4817810058594,
        498.98834228515625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        70.19999694824219,
        509.0242614746094,
        533.2013549804688,
        524.0712280273438
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        70.19999694824219,
        528.8242797851562,
        496.800048828125,
        543.8712158203125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        70.19999694824219,
        551.6243286132812,
        497.8012390136719,
        566.6712036132812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        175.8000030517578,
        571.42431640625,
        427.9581298828125,
        586.1083374023438
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        70.19999694824219,
        594.2243041992188,
        393.88134765625,
        608.9083251953125
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        113.63999938964844,
        614.0242919921875,
        493.8404846191406,
        628.7083129882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ð NDMA 1일 섭취 허용량 : 96 ng/day",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        204.0,
        633.8242797851562,
        399.6382141113281,
        648.50830078125
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 16 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.039999961853027,
      "font_name": "Wingdings-Regular",
      "bbox": [
        91.19999694824219,
        78.22429656982422,
        243.11964416503906,
        92.90835571289062
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성별·용량 당 50 개체 미만",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        78.22429656982422,
        243.11964416503906,
        92.90835571289062
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.039999961853027,
      "font_name": "Wingdings-Regular",
      "bbox": [
        91.19999694824219,
        94.78429412841797,
        190.79998779296875,
        109.46835327148438
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3가지 용량 미만",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        94.78429412841797,
        190.79998779296875,
        109.46835327148438
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.039999961853027,
      "font_name": "Wingdings-Regular",
      "bbox": [
        91.19999694824219,
        111.22429656982422,
        199.60125732421875,
        125.90835571289062
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시 대조군 부재",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        111.22429656982422,
        199.60125732421875,
        125.90835571289062
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.039999961853027,
      "font_name": "Wingdings-Regular",
      "bbox": [
        91.19999694824219,
        127.7843017578125,
        245.3207244873047,
        142.46836853027344
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간헐적인 투여(주5회 미만)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        127.7843017578125,
        245.3207244873047,
        142.46836853027344
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.039999961853027,
      "font_name": "Wingdings-Regular",
      "bbox": [
        91.19999694824219,
        144.34429931640625,
        238.00057983398438,
        159.0283660888672
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평생 보다 짧은 투여기간",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        144.34429931640625,
        238.00057983398438,
        159.0283660888672
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        187.3199920654297,
        530.4004516601562,
        202.85903930664062
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        217.34249877929688,
        538.4407348632812,
        231.01124572753906
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음의 방법으로 1일 섭취허용량을 설정할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        237.59999084472656,
        378.5740661621094,
        253.1390380859375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        283.79998779296875,
        530.7593994140625,
        299.3390197753906
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.47999572753906,
        305.8800048828125,
        454.0799865722656,
        322.0476989746094
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        332.0400085449219,
        530.7340087890625,
        347.57904052734375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA)을 활용하여 기준 설정 [부록 1]",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        97.19999694824219,
        354.1199951171875,
        328.4227294921875,
        369.6590270996094
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        380.2799987792969,
        530.75927734375,
        395.81903076171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.5 μg/day로 설정. 양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2]",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        402.3599853515625,
        501.10296630859375,
        417.8990173339844
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        428.5199890136719,
        530.7599487304688,
        444.05902099609375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비변이원성으로 관리. 양성인 경우 ➊ 또는 ➋에 따라 기준 설정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.47999572753906,
        450.6000061035156,
        489.48052978515625,
        466.1390380859375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        507.9599914550781,
        538.44091796875,
        523.4990234375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        531.8624877929688,
        117.47999572753906,
        545.53125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        558.239990234375,
        545.0404663085938,
        573.779052734375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        580.3199462890625,
        544.91943359375,
        596.4876708984375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용량을 설정할 수 있다. 이 방법으로 1일 섭취 허용량을 설정한 경우에는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        602.3999633789062,
        544.9204711914062,
        617.9390258789062
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        624.5999755859375,
        417.5740661621094,
        640.1390380859375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        652.6799926757812,
        538.439453125,
        668.2190551757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        674.7599487304688,
        544.9204711914062,
        690.2990112304688
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        696.9599609375,
        545.041015625,
        712.4990234375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        719.0399780273438,
        470.85406494140625,
        734.5790405273438
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        747.1199340820312,
        538.4400024414062,
        762.6589965820312
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        70.70249938964844,
        544.9204711914062,
        84.37124633789062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        90.95999908447266,
        545.0404663085938,
        106.49903869628906
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        113.15999603271484,
        463.0540771484375,
        128.69903564453125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        196.67999267578125,
        148.42430114746094,
        511.1915588378906,
        163.10836791992188
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CAS no.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        196.67999267578125,
        148.42430114746094,
        511.1915588378906,
        163.10836791992188
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AI(ng/day)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        196.67999267578125,
        148.42430114746094,
        511.1915588378906,
        163.10836791992188
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-nitrosodi-methylamine(NDMA)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        169.7843017578125,
        494.56097412109375,
        184.46836853027344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "62-75-9",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        169.7843017578125,
        494.56097412109375,
        184.46836853027344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        169.7843017578125,
        494.56097412109375,
        184.46836853027344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        84.0,
        191.144287109375,
        493.7603454589844,
        205.82835388183594
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "64091-91-4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        84.0,
        191.144287109375,
        493.7603454589844,
        205.82835388183594
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        84.0,
        191.144287109375,
        493.7603454589844,
        205.82835388183594
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso morpholine (NMOR)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        212.38429260253906,
        493.7603454589844,
        227.068359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "59-89-2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        212.38429260253906,
        493.7603454589844,
        227.068359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "127",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        212.38429260253906,
        493.7603454589844,
        227.068359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso piperidine (NPIP)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        233.74429321289062,
        500.5614929199219,
        248.42835998535156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100-75-4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        233.74429321289062,
        500.5614929199219,
        248.42835998535156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1300",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        233.74429321289062,
        500.5614929199219,
        248.42835998535156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso pyrrolidine (NPYR)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        254.9842987060547,
        496.7606201171875,
        269.6683654785156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "930-55-2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        254.9842987060547,
        496.7606201171875,
        269.6683654785156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1700",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        83.11143493652344,
        254.9842987060547,
        496.7606201171875,
        269.6683654785156
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        69.5999984741211,
        306.1199951171875,
        529.1830444335938,
        321.6590270996094
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        334.20001220703125,
        544.91943359375,
        349.7390441894531
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        356.2799987792969,
        545.041015625,
        371.81903076171875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        377.3999938964844,
        531.2140502929688,
        394.01904296875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        405.61944580078125,
        530.2799682617188,
        421.58038330078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근법은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CPDB(Carcinogenic",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Potency",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Database)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LCDB(Lhasa",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.47999572753906,
        435.0,
        538.5340576171875,
        450.5390319824219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Carcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        457.0799865722656,
        538.4402465820312,
        472.6190185546875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        479.1600036621094,
        538.4400024414062,
        494.69903564453125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관계(SAR) 개념을 기반으로 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        501.3600158691406,
        269.85406494140625,
        516.8990478515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        531.262451171875,
        545.0404663085938,
        544.9312133789062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        551.5199584960938,
        538.4397583007812,
        567.0590209960938
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라고 가정*한다. 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        572.6399536132812,
        538.4423828125,
        589.259033203125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        597.6224975585938,
        538.4390258789062,
        611.291259765625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 미칠 것으로 예상된다. 따라서, 니트로사민류 불순물의 변이원성 및 발암",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        617.8799438476562,
        538.4402465820312,
        633.4190063476562
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        640.0799560546875,
        493.0540771484375,
        655.6190185546875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        667.2194213867188,
        542.7787475585938,
        683.1803588867188
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다. 이후 활성화된",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.5999984741211,
        687.6194458007812,
        542.7787475585938,
        703.5803833007812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.5999984741211,
        708.0194091796875,
        542.6587524414062,
        723.9803466796875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.5999984741211,
        728.41943359375,
        542.6587524414062,
        744.38037109375
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 알려져 있다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        84.5999984741211,
        748.8194580078125,
        202.69874572753906,
        764.7803955078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        76.91999816894531,
        544.9199829101562,
        92.45903778076172
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        99.0,
        461.37408447265625,
        114.5390396118164
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        127.07999420166016,
        538.439453125,
        142.61903381347656
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 상세한 방법은 부록 1을 참고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        149.2799835205078,
        291.93408203125,
        164.81903076171875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        69.5999984741211,
        193.5599822998047,
        409.5437927246094,
        209.09902954101562
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.72000122070312,
        221.63998413085938,
        538.4402465820312,
        237.1790313720703
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        245.66249084472656,
        538.4404907226562,
        259.33123779296875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항을 제공한다. N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        265.9200134277344,
        544.9202270507812,
        281.45904541015625
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        288.0,
        538.4400024414062,
        303.5390319824219
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        310.20001220703125,
        538.5218505859375,
        325.7390441894531
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        332.2799987792969,
        466.6540832519531,
        347.81903076171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.72000122070312,
        360.3599853515625,
        544.920654296875,
        375.8990173339844
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        88.43999481201172,
        382.55999755859375,
        544.9218139648438,
        398.0990295410156
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        88.43999481201172,
        404.6399841308594,
        440.97406005859375,
        420.17901611328125
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        432.7200012207031,
        544.92041015625,
        448.259033203125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ames 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        454.91998291015625,
        545.0407104492188,
        470.4590148925781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업데이트 될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        477.0,
        194.0140838623047,
        492.5390319824219
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        505.0799865722656,
        544.9199829101562,
        520.6190185546875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        527.2799682617188,
        545.0414428710938,
        542.8190307617188
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "471호를 따라야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        549.3599853515625,
        194.0140838623047,
        564.8990478515625
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➍ 생체 내(in vivo) 변이원성 시험",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        593.6399536132812,
        265.1999206542969,
        609.1790161132812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.72000122070312,
        621.8399658203125,
        544.9205932617188,
        637.3790283203125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        645.7424926757812,
        544.9187622070312,
        659.4112548828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.95999908447266,
        665.9999389648438,
        393.6940612792969,
        681.5390014648438
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.0,
        715.3199462890625,
        538.542724609375,
        730.8590087890625
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.0,
        739.3424682617188,
        538.4396362304688,
        753.01123046875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.0,
        68.87999725341797,
        538.44091796875,
        84.41903686523438
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.0,
        90.95999908447266,
        444.3600158691406,
        106.51200103759766
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외 규제기관에서",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        444.1199951171875,
        92.78250122070312,
        544.9223022460938,
        106.45124816894531
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.0,
        113.15999603271484,
        545.0409545898438,
        128.69903564453125
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용량을 따른 것이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.0,
        135.239990234375,
        197.0140838623047,
        150.77903747558594
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.0,
        168.3599853515625,
        538.4400024414062,
        183.89903259277344
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.0,
        190.4399871826172,
        445.8940734863281,
        205.97903442382812
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 20 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        102.23999786376953,
        77.47915649414062,
        493.2181091308594,
        96.15345001220703
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조-활성 상관관계 평가를",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        147.59999084472656,
        310.4845886230469,
        244.9646453857422,
        322.4552917480469
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통한 섭취 허용량 설정이 가능한가 ?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        131.0399932861328,
        324.88458251953125,
        258.4196472167969,
        336.85528564453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        411.3599853515625,
        181.96458435058594,
        451.3199768066406,
        194.232177734375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(불확실성 계수 미적용)",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        383.6399841308594,
        196.3645782470703,
        479.0221862792969,
        208.3352813720703
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50을 설정하기에 충분한",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        150.36000061035156,
        181.72457885742188,
        242.20376586914062,
        193.99217224121094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암성 연구 결과가 존재하는가?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        139.9199981689453,
        196.1245880126953,
        249.53964233398438,
        208.0952911376953
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수로",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        361.3199768066406,
        554.6845703125,
        411.48028564453125,
        566.6552734375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취 허용량 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        355.79998779296875,
        569.0845947265625,
        417.1199951171875,
        581.0552978515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 공통 적용 기준",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        140.75999450683594,
        554.444580078125,
        250.79969787597656,
        566.415283203125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(26.5 ng/일) 적용",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        162.72000122070312,
        568.8446044921875,
        232.00405883789062,
        580.8153076171875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        319.91998291015625,
        180.04458618164062,
        328.91998291015625,
        192.01528930664062
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        206.51998901367188,
        253.24459838867188,
        233.51998901367188,
        265.2153015136719
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        207.1199951171875,
        507.76458740234375,
        234.1199951171875,
        519.7352905273438
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        140.52000427246094,
        435.0445861816406,
        352.1999816894531,
        448.6952819824219
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암 잠재력 분류 접근법(CPCA)",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        140.52000427246094,
        435.0445861816406,
        352.1999816894531,
        448.6952819824219
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용 대상에 해당하는가 ?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        150.36000061035156,
        451.12457275390625,
        240.41964721679688,
        463.09527587890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        206.75999450683594,
        379.9645690917969,
        233.75999450683594,
        391.9352722167969
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        319.91998291015625,
        309.0445861816406,
        328.91998291015625,
        321.0152893066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Read-across 등을 이용한 구조-활성",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        371.03997802734375,
        295.9645690917969,
        498.2840576171875,
        307.9352722167969
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관관계 방법을 이용 유사 구조의",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        372.47998046875,
        310.3645935058594,
        496.8443298339844,
        322.3352966308594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50 으로",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        415.67999267578125,
        324.76458740234375,
        453.64434814453125,
        337.03216552734375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취 허용량 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        402.47998046875,
        339.1645812988281,
        463.79998779296875,
        351.1352844238281
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 21 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        71.87999725341797,
        510.0005187988281,
        87.41903686523438
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        99.95999908447266,
        538.4405517578125,
        115.49903869628906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(LTL)의 적용은 신중하게 접근하여야 한다. 상기 절차에 따라 설정된 1일",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        122.15999603271484,
        545.0404663085938,
        137.69903564453125
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        146.0625,
        545.0394287109375,
        159.7312469482422
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다. 식약처는 ① 허용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        166.3199920654297,
        538.439453125,
        181.8719940185547
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        188.51998901367188,
        538.439453125,
        204.07199096679688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        210.59999084472656,
        538.4400024414062,
        226.15199279785156
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "별 사례별로 적용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        232.67999267578125,
        253.0540771484375,
        248.2190399169922
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 니트로사민류 불순물의 기준설정 현황",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        273.0,
        320.7599792480469,
        288.5390319824219
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.23999786376953,
        301.20001220703125,
        538.44091796875,
        316.7390441894531
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목록이다. 이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        323.2799987792969,
        538.4410400390625,
        339.44769287109375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "read-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        345.3599853515625,
        538.4402465820312,
        360.8990173339844
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        369.3824768066406,
        538.4391479492188,
        383.0512390136719
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취허용량을 설정하였다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        389.6400146484375,
        264.93408203125,
        405.1790466308594
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.04000091552734,
        417.7200012207031,
        538.4407958984375,
        433.259033203125
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        439.9200134277344,
        538.4403076171875,
        455.45904541015625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        462.0,
        494.1340637207031,
        477.5390319824219
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 4. 니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        71.63999938964844,
        505.1346130371094,
        478.0397033691406,
        522.3724365234375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연번",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        532.904296875,
        381.20770263671875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        532.904296875,
        381.20770263671875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생성분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        532.904296875,
        381.20770263671875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        532.904296875,
        381.20770263671875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        532.904296875,
        381.20770263671875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.0,
        532.904296875,
        451.8406066894531,
        547.5883178710938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        540.1043090820312,
        506.7596435546875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        540.1043090820312,
        506.7596435546875,
        561.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosodi-ethylamine, NDEA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        565.3043212890625,
        498.088134765625,
        579.9883422851562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        583.42431640625,
        257.6786804199219,
        604.7083129882812
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosoethylisopropylamine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        583.42431640625,
        257.6786804199219,
        604.7083129882812
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EIPNA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질NDEA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.1999969482422,
        584.8397216796875,
        535.6998291015625,
        611.308349609375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        613.184326171875,
        250.23899841308594,
        634.4683227539062
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosodiisopropylamine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        613.184326171875,
        250.23899841308594,
        634.4683227539062
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DIPNA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질NDEA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        614.5997314453125,
        535.6998291015625,
        641.0682983398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        643.0642700195312,
        249.6370391845703,
        664.3483276367188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-di-n-butylamine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        643.0642700195312,
        249.6370391845703,
        664.3483276367188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDBA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질NDEA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        163.55999755859375,
        644.479736328125,
        535.6998291015625,
        670.9483032226562
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosodipropylamine, NDPA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질NDEA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        673.2797241210938,
        535.6998291015625,
        698.52734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        700.5443115234375,
        246.51800537109375,
        721.8283081054688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosodi-methylamine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        700.5443115234375,
        246.51800537109375,
        721.8283081054688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDMA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        161.75999450683594,
        707.144287109375,
        497.76513671875,
        728.4283447265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        161.75999450683594,
        707.144287109375,
        497.76513671875,
        728.4283447265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        161.75999450683594,
        707.144287109375,
        497.76513671875,
        728.4283447265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        161.75999450683594,
        707.144287109375,
        497.76513671875,
        728.4283447265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        161.75999450683594,
        707.144287109375,
        497.76513671875,
        728.4283447265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        730.42431640625,
        263.2012634277344,
        751.7083129882812
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-methyl-4-aminobutyric",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        730.42431640625,
        263.2012634277344,
        751.7083129882812
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "acid, NMBA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NDMA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        731.8397216796875,
        535.6998291015625,
        758.3082885742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 22 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생성분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.0,
        72.34429931640625,
        451.8406066894531,
        87.02835845947266
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        103.3042984008789,
        256.5951232910156,
        124.5883560180664
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1-Methyl-4-nitrosopiperazine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        103.3042984008789,
        256.5951232910156,
        124.5883560180664
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MeNP(MNP)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NDMA",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        147.47999572753906,
        104.71974182128906,
        535.6998291015625,
        131.18836975097656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosomorpholine, NMOR",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "127",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        72.1199951171875,
        134.62429809570312,
        497.76513671875,
        149.30836486816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-piperidine, NPIP",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,300",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        155.38429260253906,
        497.76513671875,
        170.068359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-pyrrolidine, NPYR",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,700",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        177.34429931640625,
        497.76513671875,
        192.0283660888672
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2-nitroso-octahydrocyclopenta(c)pyrrole",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "글리클라지드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,700",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NPYR1)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        196.99974060058594,
        535.3408203125,
        222.247314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-nebivolol, NNEB",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네비보롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.26429748535156,
        497.76513671875,
        238.9483642578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl-nintedanib",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "닌테다닙",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        240.9442901611328,
        497.76513671875,
        255.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-dabigatran etexilate",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다비가트란",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AMES 음성",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        257.624267578125,
        521.4000244140625,
        272.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desloratadine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데스로라타딘",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        274.3042907714844,
        497.76513671875,
        288.9883728027344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-desmethyl-desvenlafaxine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데스벤라팍신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        290.8642883300781,
        497.76513671875,
        305.5483703613281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-dorzolamide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도르졸라미드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        307.5442810058594,
        497.76513671875,
        322.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-nordoxepin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "독세핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        324.2242736816406,
        497.76513671875,
        338.9083557128906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-desmethyl-N-nitroso-doxycycline",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "독시사이클린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        340.9042663574219,
        497.76513671875,
        355.5883483886719
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-methyl-2-[1-phenyl",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-1-(2-pyridinyl)methoxy]ethanamine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "독실아민",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        357.4642639160156,
        497.76513671875,
        385.3483581542969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-duloxetine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "둘록세틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NNK2)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        387.67974853515625,
        535.3408203125,
        412.92730712890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "23",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-diclofenac",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디클로페낙",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        414.94427490234375,
        497.76513671875,
        429.62835693359375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "24",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ranolazine impurity 1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라놀라진",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        431.624267578125,
        497.76513671875,
        446.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ramipril",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라미프릴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        448.30426025390625,
        497.76513671875,
        462.98834228515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-labetalol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라베타롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        464.9842834472656,
        497.76513671875,
        479.6683654785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-rasagiline",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라사길린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        481.5442810058594,
        497.76513671875,
        496.2283630371094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-levofloxacin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "레보플록사신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        498.2242736816406,
        497.76513671875,
        512.9083251953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-2,6-pipecoloxilidide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로피바카인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        514.904296875,
        497.76513671875,
        529.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "30",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        557.9843139648438,
        81.2000961303711,
        572.6683349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-folinic acid:",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        123.47999572753906,
        531.5842895507812,
        237.52072143554688,
        546.268310546875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-[4-[[(2-amino-5-formyl-3,4,5,6",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.91999816894531,
        544.7843017578125,
        259.1545715332031,
        585.8683471679688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ",7,8-hexahydro-4-oxo-6-pteridin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.91999816894531,
        544.7843017578125,
        259.1545715332031,
        585.8683471679688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "yl)methyl]nitrosoamino]benzoyl]",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.91999816894531,
        544.7843017578125,
        259.1545715332031,
        585.8683471679688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-L-glutamic acid",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        137.0399932861328,
        584.38427734375,
        220.00628662109375,
        599.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "류코보린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        286.0799865722656,
        557.9843139648438,
        497.76513671875,
        572.6683349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        286.0799865722656,
        557.9843139648438,
        497.76513671875,
        572.6683349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        286.0799865722656,
        557.9843139648438,
        497.76513671875,
        572.6683349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        286.0799865722656,
        557.9843139648438,
        497.76513671875,
        572.6683349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "31",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desethyllidocaine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리도카인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        600.9442749023438,
        497.76513671875,
        615.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-rivaroxaban amide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리바록사반",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        617.6243286132812,
        497.76513671875,
        632.308349609375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "33",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        634.3043212890625,
        237.27955627441406,
        655.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-rivaroxaban",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        634.3043212890625,
        237.27955627441406,
        655.5883178710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "open-ring acid",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        140.87998962402344,
        640.904296875,
        497.76513671875,
        662.1882934570312
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리바록사반",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        140.87998962402344,
        640.904296875,
        497.76513671875,
        662.1882934570312
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        140.87998962402344,
        640.904296875,
        497.76513671875,
        662.1882934570312
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        140.87998962402344,
        640.904296875,
        497.76513671875,
        662.1882934570312
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        140.87998962402344,
        640.904296875,
        497.76513671875,
        662.1882934570312
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        664.184326171875,
        240.5197296142578,
        685.4683227539062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-desmethyl",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        664.184326171875,
        240.5197296142578,
        685.4683227539062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "rivastigmine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        670.7843017578125,
        497.76513671875,
        692.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리바스티그민",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        670.7843017578125,
        497.76513671875,
        692.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        670.7843017578125,
        497.76513671875,
        692.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        670.7843017578125,
        497.76513671875,
        692.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        148.44000244140625,
        670.7843017578125,
        497.76513671875,
        692.0682983398438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "35",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ribociclib impurity 1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리보시클립",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        693.9442749023438,
        497.76513671875,
        708.6282958984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-lisinopril",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리시노프릴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        710.624267578125,
        497.76513671875,
        725.3082885742188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "37",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-meropenem",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메로페넴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        727.3043212890625,
        497.76513671875,
        741.9883422851562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "38",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-nitroso-metoprolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "메토프롤롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        743.9843139648438,
        497.76513671875,
        758.6683349609375
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 23 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생성분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.0,
        72.34429931640625,
        451.8406066894531,
        87.02835845947266
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "39",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-methylphenidate, NMPH",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메틸페니데이트",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,300",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NPIP3)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        104.71974182128906,
        535.6998291015625,
        129.96731567382812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-moxifloxacin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목시플록사신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        133.18429565429688,
        497.76513671875,
        147.8683624267578
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-mirabegron",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미라베그론",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        149.86428833007812,
        497.76513671875,
        164.54835510253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-mirtazapine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미르타자핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        166.54429626464844,
        497.76513671875,
        181.22836303710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "43",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-varenicline, NNV",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바레니클린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        188.62429809570312,
        497.0085754394531,
        203.30836486816406
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "44",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-ethyl-valacyclovir",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발라시클로비르",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        210.8242950439453,
        497.76513671875,
        225.50836181640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "45",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-methyl-valacyclovir",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발라시클로비르",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        227.38429260253906,
        497.76513671875,
        242.068359375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "46",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-betahistine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베타히스틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        244.0642852783203,
        497.76513671875,
        258.74835205078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "47",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-betaxolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베탁솔롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        260.7442626953125,
        497.76513671875,
        275.4283447265625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "48",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-vortioxetine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보티옥세틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        277.4242858886719,
        497.76513671875,
        292.1083679199219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "49",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-bupropion",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부프로피온",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        293.9842834472656,
        497.76513671875,
        308.6683654785156
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-bisoprolol, NBP",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비소프롤롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        310.6642761230469,
        497.76513671875,
        325.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "51",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-vildagliptin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "빌다글립틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        327.3442687988281,
        497.76513671875,
        342.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "52",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-salbutamol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "살부타몰",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        344.0242614746094,
        497.76513671875,
        358.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "53",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-celiprolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "셀리프롤롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        360.58428955078125,
        497.76513671875,
        375.26837158203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "54",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-sotalol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소타롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        377.2642822265625,
        497.76513671875,
        391.9483642578125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "55",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        407.144287109375,
        81.2000961303711,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3-[2-(N-nitroso-N-methyl)amino",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.91999816894531,
        393.94427490234375,
        259.2113037109375,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ")ethyl]-N-methyl-1H-indole-5-m",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.91999816894531,
        393.94427490234375,
        259.2113037109375,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ethanesulfonamide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        131.0399932861328,
        420.3442687988281,
        225.98684692382812,
        435.0283508300781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수마프립탄",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        407.144287109375,
        497.76513671875,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        407.144287109375,
        497.76513671875,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        407.144287109375,
        497.76513671875,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        407.144287109375,
        497.76513671875,
        421.828369140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "56",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-pseudoephedrine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "슈도에페드린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        437.0242614746094,
        497.76513671875,
        451.7083435058594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "57",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-cinacalcet",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시나칼세트",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        453.5842590332031,
        497.76513671875,
        468.2683410644531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "58",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        483.4642639160156,
        81.2000961303711,
        498.1483459472656
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7-nitroso-3-(trifluoromethyl)-5,6,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        470.2642822265625,
        262.3607177734375,
        498.1483459472656
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7,8-tetrahydro[1,2,4]triazolo-[4,3- a]",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        470.2642822265625,
        262.3607177734375,
        498.1483459472656
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pyrazine, NTTP",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        140.52000427246094,
        496.6642761230469,
        216.5417938232422,
        511.3483581542969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시타글립틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        478.2797546386719,
        534.9817504882812,
        503.5273132324219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        478.2797546386719,
        534.9817504882812,
        503.5273132324219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "37",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        478.2797546386719,
        534.9817504882812,
        503.5273132324219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        478.2797546386719,
        534.9817504882812,
        503.5273132324219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NTHP4)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        478.2797546386719,
        534.9817504882812,
        503.5273132324219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "59",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl citalopram",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시탈로프람",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        513.3442993164062,
        497.76513671875,
        528.0283203125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ciprofloxacin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시프로플록사신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        530.0242919921875,
        497.76513671875,
        544.7083129882812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl-sildenafil",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실데나필",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        546.5842895507812,
        497.76513671875,
        561.268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "62",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-cilazapril",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실라자프릴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        563.2642822265625,
        497.76513671875,
        577.9483032226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "63",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        579.9442749023438,
        258.609375,
        601.2283325195312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1-(2,3-dichlorophenyl)-4-nitroso",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        579.9442749023438,
        258.609375,
        601.2283325195312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "piperazine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        152.75999450683594,
        586.5443115234375,
        497.76513671875,
        607.8283081054688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아리피프라졸",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        152.75999450683594,
        586.5443115234375,
        497.76513671875,
        607.8283081054688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        152.75999450683594,
        586.5443115234375,
        497.76513671875,
        607.8283081054688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        152.75999450683594,
        586.5443115234375,
        497.76513671875,
        607.8283081054688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        152.75999450683594,
        586.5443115234375,
        497.76513671875,
        607.8283081054688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "64",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl-azelastine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아젤라스틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.8242797851562,
        497.76513671875,
        624.50830078125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        637.904296875,
        369.4481201171875,
        652.5883178710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-azaerythromycin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        637.904296875,
        369.4481201171875,
        652.5883178710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아지스로마이신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        637.904296875,
        369.4481201171875,
        652.5883178710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        637.904296875,
        369.4481201171875,
        652.5883178710938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ICH",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        412.3199768066406,
        626.7197265625,
        432.1419982910156,
        639.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3A/Q3B에",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        638.7197265625,
        450.3815612792969,
        663.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 관리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        638.7197265625,
        450.3815612792969,
        663.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비변이원성 불순물",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        459.239990234375,
        638.7197265625,
        532.2006225585938,
        651.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "66",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        677.6243286132812,
        369.4481201171875,
        692.308349609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethylazithromycin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        677.6243286132812,
        369.4481201171875,
        692.308349609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아지스로마이신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        677.6243286132812,
        369.4481201171875,
        692.308349609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        677.6243286132812,
        369.4481201171875,
        692.308349609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ICH",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        412.3199768066406,
        666.439697265625,
        432.1419982910156,
        679.6873168945312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3A/Q3B에",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        678.439697265625,
        450.3815612792969,
        703.6873168945312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 관리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        678.439697265625,
        450.3815612792969,
        703.6873168945312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비변이원성 불순물",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        459.239990234375,
        678.439697265625,
        532.2006225585938,
        691.6873168945312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "67",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-atenolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아테놀롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        705.7042846679688,
        497.76513671875,
        720.3883056640625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "68",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-Atomoxetine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아토목세틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100.0",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NNK2)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        722.7197265625,
        535.3408203125,
        747.9673461914062
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "69",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3-amino-N-nitrosopiperidine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알로글립틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        749.9843139648438,
        497.76513671875,
        764.6683349609375
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생성분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.0,
        72.34429931640625,
        451.8406066894531,
        87.02835845947266
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ambroxol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암브록솔",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AMES 음성",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        103.3042984008789,
        521.4000244140625,
        117.98835754394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "71",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-enalapril",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에날라프릴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        119.98429870605469,
        497.76513671875,
        134.66836547851562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "72",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-esmolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에스몰롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        136.66429138183594,
        497.76513671875,
        151.34835815429688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "73",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-folic acid, NFA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "엽산/폴산",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        153.34429931640625,
        497.76513671875,
        168.0283660888672
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "74",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        174.2242889404297,
        257.376953125,
        195.50836181640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-desmethylorphena",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        174.2242889404297,
        257.376953125,
        195.50836181640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "drine, NMOA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        144.72000122070312,
        180.8242950439453,
        497.76513671875,
        202.10836791992188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오르페나드린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        144.72000122070312,
        180.8242950439453,
        497.76513671875,
        202.10836791992188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        144.72000122070312,
        180.8242950439453,
        497.76513671875,
        202.10836791992188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        144.72000122070312,
        180.8242950439453,
        497.76513671875,
        202.10836791992188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        144.72000122070312,
        180.8242950439453,
        497.76513671875,
        202.10836791992188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-imatinib",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이매티닙",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        208.18429565429688,
        497.76513671875,
        222.8683624267578
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "76",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.86428833007812,
        258.5354919433594,
        246.1483612060547
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ethylenediamine-triac",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        224.86428833007812,
        258.5354919433594,
        246.1483612060547
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "etic acid",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        156.83999633789062,
        238.06430053710938,
        204.04061889648438,
        252.7483673095703
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이소소르비드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        276.1199951171875,
        226.2797393798828,
        339.62060546875,
        239.52731323242188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모노니트레이트",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        231.46429443359375,
        497.76513671875,
        251.52731323242188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        231.46429443359375,
        497.76513671875,
        251.52731323242188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        231.46429443359375,
        497.76513671875,
        251.52731323242188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        231.46429443359375,
        497.76513671875,
        251.52731323242188
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "77",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        255.07972717285156,
        339.62060546875,
        274.9483642578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-iminodiacetic acid",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        255.07972717285156,
        339.62060546875,
        274.9483642578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이소소르비드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        255.07972717285156,
        339.62060546875,
        274.9483642578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모노니트레이트",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        260.2642822265625,
        497.76513671875,
        280.3273010253906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        260.2642822265625,
        497.76513671875,
        280.3273010253906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        260.2642822265625,
        497.76513671875,
        280.3273010253906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        260.2642822265625,
        497.76513671875,
        280.3273010253906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "78",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Indapamide Impurity A",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인다파미드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        282.3442687988281,
        497.76513671875,
        297.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "79",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ketamine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "케타민",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        299.0242614746094,
        497.76513671875,
        313.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        328.9042663574219,
        81.2000961303711,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-aryl piperazine /",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        105.23999786376953,
        315.70428466796875,
        255.75897216796875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desalkylquetiapine,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        105.23999786376953,
        315.70428466796875,
        255.75897216796875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDAQ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        162.47999572753906,
        342.1042785644531,
        194.53945922851562,
        356.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쿠에티아핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        328.9042663574219,
        497.76513671875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        328.9042663574219,
        497.76513671875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        328.9042663574219,
        497.76513671875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        281.0400085449219,
        328.9042663574219,
        497.76513671875,
        343.5883483886719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "81",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        358.7842712402344,
        251.80104064941406,
        380.068359375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso Quetiapine HEEP",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        358.7842712402344,
        251.80104064941406,
        380.068359375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Impurity",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        157.8000030517578,
        365.38427734375,
        521.4000244140625,
        386.6683654785156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쿠에티아핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        157.8000030517578,
        365.38427734375,
        521.4000244140625,
        386.6683654785156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        157.8000030517578,
        365.38427734375,
        521.4000244140625,
        386.6683654785156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        157.8000030517578,
        365.38427734375,
        521.4000244140625,
        386.6683654785156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AMES 음성",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        157.8000030517578,
        365.38427734375,
        521.4000244140625,
        386.6683654785156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "82",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        388.5442810058594,
        240.5197296142578,
        409.828369140625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-N-desmethyl",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        388.5442810058594,
        240.5197296142578,
        409.828369140625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "clarithromycin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        143.39999389648438,
        401.7442626953125,
        213.6223907470703,
        416.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "클래리트로마이",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        271.0799865722656,
        389.9597473144531,
        341.0390319824219,
        403.2073059082031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        301.0799865722656,
        395.144287109375,
        497.76513671875,
        415.2073059082031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        301.0799865722656,
        395.144287109375,
        497.76513671875,
        415.2073059082031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        301.0799865722656,
        395.144287109375,
        497.76513671875,
        415.2073059082031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        301.0799865722656,
        395.144287109375,
        497.76513671875,
        415.2073059082031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "83",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-cloazpine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "클로자핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        418.4242858886719,
        497.76513671875,
        433.1083679199219
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "84",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-tigecycline",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "타이가사이클린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        435.1042785644531,
        497.76513671875,
        449.7883605957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "85",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-tamsulosin",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐스로신",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        451.7842712402344,
        497.76513671875,
        466.4683532714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "86",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl terbinafine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "테르비나핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        468.3442687988281,
        497.76513671875,
        483.0283508300781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "87",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-terbinafine impurity A",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "테르비나핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        485.0242614746094,
        497.76513671875,
        499.7083435058594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "88",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-tetracaine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "테트라카인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        501.7042541503906,
        497.76513671875,
        516.3883056640625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "89",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        518.38427734375,
        234.0402069091797,
        539.6683349609375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-desmethyl",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        518.38427734375,
        234.0402069091797,
        539.6683349609375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "trimebutine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        524.9843139648438,
        497.76513671875,
        546.268310546875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트리메부틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        524.9843139648438,
        497.76513671875,
        546.268310546875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        524.9843139648438,
        497.76513671875,
        546.268310546875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        524.9843139648438,
        497.76513671875,
        546.268310546875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        524.9843139648438,
        497.76513671875,
        546.268310546875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "90",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-trimetazidine, NTMZ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트리메타지딘",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        548.144287109375,
        497.76513671875,
        562.8283081054688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "91",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-ticagrelor",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "티카그렐러",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        564.8242797851562,
        497.76513671875,
        579.50830078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "92",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-paroxetine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파록세틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,300",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NPIP3)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        581.8397216796875,
        534.9815673828125,
        607.0873413085938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "93",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-phenylephrine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "페닐레프린",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        609.1043090820312,
        497.76513671875,
        623.788330078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "94",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-perindopril",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "페린도프릴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        625.7843017578125,
        497.76513671875,
        640.4683227539062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-felodipine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "펠로디핀",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        642.4642944335938,
        497.76513671875,
        657.1483154296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        670.5443115234375,
        369.4481201171875,
        685.2283325195312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-calcium folinate",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        670.5443115234375,
        369.4481201171875,
        685.2283325195312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폴리네이트칼슘",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        670.5443115234375,
        369.4481201171875,
        685.2283325195312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        670.5443115234375,
        369.4481201171875,
        685.2283325195312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ICH",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        412.3199768066406,
        659.3597412109375,
        432.1419982910156,
        672.6073608398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3A/Q3B에",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        671.3597412109375,
        450.3815612792969,
        696.6073608398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 관리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        671.3597412109375,
        450.3815612792969,
        696.6073608398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비변이원성 불순물",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        459.239990234375,
        671.3597412109375,
        532.2006225585938,
        684.6073608398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "97",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-furosemide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "푸로세미드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        698.7443237304688,
        497.76513671875,
        713.4283447265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "98",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-pramipexole",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프라미펙솔",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        715.42431640625,
        497.76513671875,
        730.1083374023438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "99",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-nitroso-frovatriptan/(3R)-2,3,4,9-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tetrahydro-3-(N-methyl(nitroso)am",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로바트립탄",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "400",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        735.9442749023438,
        497.76513671875,
        763.8283081054688
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) NPYR : N-nitroso-pyrrolidine",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        64.91999816894531,
        228.47998046875,
        205.94342041015625,
        240.43199157714844
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        64.91999816894531,
        243.47998046875,
        329.5419921875,
        255.43199157714844
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) NPIP : N-nitroso-piperidine",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        64.91999816894531,
        258.4800109863281,
        199.1005401611328,
        270.4320068359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        64.91999816894531,
        273.4800109863281,
        270.3786926269531,
        285.4320068359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        305.0400085449219,
        538.4400024414062,
        320.57904052734375
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        327.239990234375,
        545.040771484375,
        342.7790222167969
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나누었을 때 계산될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        349.32000732421875,
        259.8940734863281,
        364.8590393066406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        389.6400146484375,
        450.72052001953125,
        405.1790466308594
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        417.7200012207031,
        538.4402465820312,
        433.259033203125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        435.98248291015625,
        544.9204711914062,
        455.45904541015625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        462.0,
        443.1340637207031,
        477.5390319824219
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        490.0799865722656,
        538.43994140625,
        505.6190185546875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        512.2799682617188,
        473.73406982421875,
        527.8190307617188
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.5999984741211,
        545.3999633789062,
        544.4400024414062,
        559.7879638671875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        112.19999694824219,
        565.7999877929688,
        460.416015625,
        580.18798828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        615.3599853515625,
        538.43896484375,
        630.8990478515625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        637.43994140625,
        544.9199829101562,
        652.97900390625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류를 계산할 때 포함되지 않을 수 있다. 그러나 니트로사민류의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        659.6399536132812,
        545.0415649414062,
        675.1790161132812
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        681.719970703125,
        538.4385375976562,
        697.259033203125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        703.7999877929688,
        544.9199829101562,
        719.3390502929688
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        722.0625,
        538.4402465820312,
        741.5390014648438
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        748.0799560546875,
        157.29408264160156,
        763.6190185546875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생성분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CPCA",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.08000183105469,
        72.34429931640625,
        381.20770263671875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.0,
        72.34429931640625,
        451.8406066894531,
        87.02835845947266
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.9599914550781,
        79.54429626464844,
        506.7596435546875,
        101.42835235595703
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ino)-1H-carbazole-6-carboxamide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.07999420166016,
        104.26429748535156,
        256.9479064941406,
        118.94835662841797
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-propanolol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로프라놀롤",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        121.904296875,
        497.76513671875,
        136.58836364746094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "101",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-flecainide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플레카이니드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        138.58428955078125,
        497.76513671875,
        153.2683563232422
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "102",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-fluoxetine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플루옥세틴",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SAR/read-across,",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질 NNK2)",
      "font_size": 6.359999656677246,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        155.59974670410156,
        535.341552734375,
        180.84732055664062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "103",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        189.19973754882812,
        341.0390319824219,
        209.068359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-hydrochlorothiazide",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        189.19973754882812,
        341.0390319824219,
        209.068359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "히드로클로로티",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        66.0,
        189.19973754882812,
        341.0390319824219,
        209.068359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아지드",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        291.1199951171875,
        194.38429260253906,
        369.4481201171875,
        214.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        291.1199951171875,
        194.38429260253906,
        369.4481201171875,
        214.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ICH",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        412.3199768066406,
        183.19973754882812,
        432.1419982910156,
        196.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3A/Q3B에",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        195.19973754882812,
        450.3815612792969,
        220.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 관리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        394.0799865722656,
        195.19973754882812,
        450.3815612792969,
        220.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비변이원성 불순물",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        459.239990234375,
        195.19973754882812,
        532.2006225585938,
        208.4473114013672
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 26 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        384.95941162109375,
        104.37995910644531
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과발암위해도를 이용한 인체영향평가",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        384.95941162109375,
        104.37995910644531
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        141.50250244140625,
        538.4402465820312,
        155.17124938964844
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        163.70249938964844,
        538.4404907226562,
        177.37124633789062
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        183.95999145507812,
        538.4407348632812,
        199.49903869628906
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해도 산출 기반의 인체영향평가 방식을 활용한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        206.0399932861328,
        378.2140808105469,
        221.57904052734375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "< 초과발암위해도를 이용한 인체영향평가 방법 >",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        63.119998931884766,
        257.2799987792969,
        358.24078369140625,
        272.81903076171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        282.4800109863281,
        538.439697265625,
        298.01904296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.72000122070312,
        298.79998779296875,
        538.4405517578125,
        320.0990295410156
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        81.72000122070312,
        326.6400146484375,
        110.97407531738281,
        342.1790466308594
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        351.8399963378906,
        538.4140625,
        367.3919982910156
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        81.47999572753906,
        373.9200134277344,
        435.5740661621094,
        389.4720153808594
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① (1단계) 노출평가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        413.2799987792969,
        195.1205291748047,
        428.8320007324219
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        439.32000732421875,
        538.4405517578125,
        454.8590393066406
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        94.68000030517578,
        461.5199890136719,
        527.3740234375,
        477.05902099609375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        487.55999755859375,
        538.4400024414062,
        503.0990295410156
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        94.31999969482422,
        509.7599792480469,
        136.53407287597656,
        525.2990112304688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        535.7999877929688,
        544.9197387695312,
        551.3390502929688
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        557.9999389648438,
        545.0415649414062,
        573.5390014648438
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다. 건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        580.0799560546875,
        538.4400024414062,
        595.6190185546875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.27999877929688,
        602.1599731445312,
        538.4140625,
        617.6990356445312
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.27999877929688,
        624.3599853515625,
        449.2540588378906,
        639.8990478515625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        650.3999633789062,
        538.4400024414062,
        665.9519653320312
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.36000061035156,
        672.5999755859375,
        514.174072265625,
        688.1390380859375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        698.6399536132812,
        533.4940185546875,
        714.1790161132812
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        724.0642700195312,
        542.3212280273438,
        738.748291015625
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        99.5999984741211,
        742.7843017578125,
        542.4412231445312,
        757.4683227539062
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        99.5999984741211,
        68.14429473876953,
        542.3212280273438,
        82.82835388183594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이를 줄일 필요가 있다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        99.5999984741211,
        88.54429626464844,
        227.17498779296875,
        103.22835540771484
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        113.75999450683594,
        545.0404663085938,
        129.2990264892578
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        135.83999633789062,
        538.43896484375,
        151.37904357910156
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        159.74249267578125,
        544.9199829101562,
        173.41123962402344
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.27999877929688,
        180.1199951171875,
        452.37408447265625,
        195.65904235839844
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        206.1599884033203,
        538.4298706054688,
        221.69903564453125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터의 처리 방법은 다음을 고려한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        93.5999984741211,
        228.3599853515625,
        330.6940612792969,
        243.89903259277344
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        275.8994445800781,
        533.7787475585938,
        291.8603820800781
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제시한다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        105.47999572753906,
        296.2994384765625,
        159.85874938964844,
        312.2603759765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        320.6594543457031,
        533.7787475585938,
        336.6203918457031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등 통계적 수치를 산출하는 것이 유의하지 않다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        106.68000030517578,
        341.0594482421875,
        370.54498291015625,
        357.0203857421875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        365.41943359375,
        533.7787475585938,
        381.38037109375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        105.5999984741211,
        385.8194580078125,
        533.7787475585938,
        401.7803955078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하한값과 상한값으로 제시할 수 있다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        105.5999984741211,
        406.2194519042969,
        310.06500244140625,
        422.1803894042969
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        430.6994323730469,
        529.5693359375,
        446.6603698730469
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        105.95999908447266,
        451.0994567871094,
        436.30499267578125,
        467.0603942871094
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        475.4594421386719,
        525.7050170898438,
        491.4203796386719
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.04000091552734,
        499.8194580078125,
        533.7787475585938,
        515.7803955078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        105.5999984741211,
        520.2194213867188,
        527.1449584960938,
        536.1803588867188
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② (2단계) 변이원성/발암성 불순물 특성 파악",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        579.9599609375,
        348.3599853515625,
        595.511962890625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ICH M7(R1) 가이드라인에서는 변이원성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.55999755859375,
        605.9999389648438,
        350.3999938964844,
        621.5519409179688
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암성 불순물을 5개 등급으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        350.3999938964844,
        605.9999389648438,
        545.041015625,
        621.5390014648438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.4000015258789,
        628.199951171875,
        538.4403076171875,
        643.739013671875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.4000015258789,
        650.2799682617188,
        538.4405517578125,
        665.8190307617188
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해도를 산출하여 평가하도록 권장한다. 상세한 내용은 ‘ 1일 섭취 허",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.4000015258789,
        672.3599853515625,
        538.4400024414062,
        687.8990478515625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량 설정’ 부분을 참고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.4000015258789,
        694.5599365234375,
        268.174072265625,
        710.0989990234375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 28 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ (3단계) 개인별 초과발암위해도 산출",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        71.87999725341797,
        312.1205139160156,
        87.43199920654297
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        98.04000091552734,
        538.439453125,
        113.57904052734375
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        94.31999969482422,
        120.12000274658203,
        480.93408203125,
        135.65904235839844
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        145.1999969482422,
        544.9205932617188,
        161.81903076171875
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초과발암위해가 있는 것으로 간주한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.27999877929688,
        168.3599853515625,
        330.8140869140625,
        183.89903259277344
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과발암위해도 (명/10만명) =",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        75.1199951171875,
        232.30429077148438,
        226.9755401611328,
        246.9883575439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-5 × 1일 노출량* (㎍/day)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        310.0799865722656,
        220.65428161621094,
        451.4429626464844,
        235.82835388183594
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일))",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        246.239990234375,
        243.46429443359375,
        515.1632080078125,
        258.1483459472656
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day)",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        69.1199951171875,
        275.8800048828125,
        423.37200927734375,
        290.2799987792969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        63.119998931884766,
        297.2242736816406,
        529.0800170898438,
        311.9083557128906
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        157.67999267578125,
        315.0797424316406,
        485.6746826171875,
        328.3273010253906
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        69.0,
        346.67999267578125,
        529.0800170898438,
        362.03997802734375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        86.63999938964844,
        366.8399963378906,
        426.1199951171875,
        381.239990234375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출",
      "font_size": 11.039999961853027,
      "font_name": "T12",
      "bbox": [
        75.1199951171875,
        392.8799743652344,
        509.0400085449219,
        406.12799072265625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다. 복합제의 경우, 해당 복합제",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        79.31999969482422,
        418.0397644042969,
        532.7013549804688,
        431.2873229980469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량에서 정하는 최대용량을 적용할 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        130.44000244140625,
        435.55975341796875,
        336.9787292480469,
        448.80731201171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        63.119998931884766,
        456.55975341796875,
        532.7008666992188,
        469.80731201171875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다. 복용기간은 질환 및 의약품의 특성을 고려할 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        139.1999969482422,
        472.5197448730469,
        399.6187438964844,
        485.7673034667969
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생",
      "font_size": 11.039999961853027,
      "font_name": "T12",
      "bbox": [
        75.1199951171875,
        494.8642578125,
        529.1995849609375,
        509.54833984375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량",
      "font_size": 11.039999961853027,
      "font_name": "T12",
      "bbox": [
        84.83999633789062,
        514.9199829101562,
        529.2000122070312,
        528.16796875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(식약처가 마련한 잠정기준 등을 대입)",
      "font_size": 11.039999961853027,
      "font_name": "T12",
      "bbox": [
        84.83999633789062,
        532.5599975585938,
        278.022216796875,
        545.8079833984375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시. 초과발암위해도를 이용한 인체영향평가 사례",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        60.0,
        592.199951171875,
        381.47998046875,
        607.751953125
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 14.039999961853027,
      "font_name": "HYwulM",
      "bbox": [
        101.4000015258789,
        80.94808959960938,
        129.47999572753906,
        94.98808288574219
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인체영향평가 사례 : NDMA 검출 메트포르민",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        87.36000061035156,
        118.39915466308594,
        385.20135498046875,
        137.07345581054688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.08000183105469,
        155.39999389648438,
        538.0800170898438,
        170.9390411376953
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.27999877929688,
        179.1599884033203,
        538.0800170898438,
        194.69903564453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2020.12.31.)까지 복용하는 것으로 가정하여 산출",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.27999877929688,
        201.3599853515625,
        401.4005126953125,
        216.89903259277344
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "< 초과발암위해도 >",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        244.1999969482422,
        231.53460693359375,
        364.28131103515625,
        248.7724151611328
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ㆍR =",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        111.95999908447266,
        275.8994445800781,
        145.68820190429688,
        291.8603820800781
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-5 X NDMA 1일 노출량 (㎍/일)",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        238.0800018310547,
        265.1212158203125,
        423.1762390136719,
        281.6603698730469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI (0.096 ㎍/일) X (25,550일/복용기간(일))",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        213.47999572753906,
        286.2194519042969,
        495.13873291015625,
        303.9803771972656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* AI : NDMA 1일 섭취 허용량",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        81.5999984741211,
        322.0994567871094,
        268.1999816894531,
        345.2603759765625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단위",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        125.5199966430664,
        368.5997619628906,
        495.3599853515625,
        381.8473205566406
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의미",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        125.5199966430664,
        368.5997619628906,
        495.3599853515625,
        381.8473205566406
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        125.5199966430664,
        368.5997619628906,
        495.3599853515625,
        381.8473205566406
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과발암위해도",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        100.55999755859375,
        405.55975341796875,
        170.51904296875,
        418.80731201171875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        192.36000061035156,
        391.5197448730469,
        444.7415466308594,
        432.727294921875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제제 복용으로 인해 100,000명 중 추가 발암 발생 가능",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        192.36000061035156,
        391.5197448730469,
        444.7415466308594,
        432.727294921875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성이 있는 수치는 나타냄",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        192.36000061035156,
        391.5197448730469,
        444.7415466308594,
        432.727294921875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명/10만",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.0,
        405.55975341796875,
        502.91998291015625,
        418.80731201171875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "복용기간",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        115.55999755859375,
        440.5997619628906,
        444.14154052734375,
        461.7673034667969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품별 허가 이후기간~2020년 12월 31일까지 복용 가정",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        115.55999755859375,
        440.5997619628906,
        444.14154052734375,
        461.7673034667969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(일) / 25,550 일",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        192.36000061035156,
        456.55975341796875,
        267.239990234375,
        469.80731201171875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "967 ∼ 8,774 일",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        454.79998779296875,
        448.5197448730469,
        516.0,
        461.7673034667969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI (㎍/day)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        110.27999877929688,
        480.0797424316406,
        515.1478881835938,
        493.3273010253906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하루 중 NDMA 섭취 허용량",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.27999877929688,
        480.0797424316406,
        515.1478881835938,
        493.3273010253906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.096 ㎍/day",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.27999877929688,
        480.0797424316406,
        515.1478881835938,
        493.3273010253906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1일 노출량 (㎍/day)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        90.47999572753906,
        506.9597473144531,
        352.31951904296875,
        520.2073364257812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품 복용을 통한 일일 최대노출량",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        90.47999572753906,
        506.9597473144531,
        352.31951904296875,
        520.2073364257812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.08000183105469,
        540.1199951171875,
        538.0789794921875,
        555.6590576171875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        563.8799438476562,
        544.6804809570312,
        579.4190063476562
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매우 낮은 수준임",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        587.782470703125,
        213.0,
        601.4512329101562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하)",
      "font_size": 12.0,
      "font_name": "T16",
      "bbox": [
        104.75999450683594,
        608.2799682617188,
        524.8919677734375,
        622.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDMA 분석결과 *",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        99.95999908447266,
        634.9996948242188,
        175.71104431152344,
        648.247314453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ppm)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        124.43999481201172,
        647.479736328125,
        151.23428344726562,
        660.7273559570312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "복용기간",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        226.3199920654297,
        634.9996948242188,
        266.2795104980469,
        648.247314453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(일)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        238.3199920654297,
        641.2396850585938,
        505.31903076171875,
        660.7273559570312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대복용량 (mg/일)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        238.3199920654297,
        641.2396850585938,
        505.31903076171875,
        660.7273559570312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과발암위해도",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        238.3199920654297,
        641.2396850585938,
        505.31903076171875,
        660.7273559570312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.010∼0.609",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.15999603271484,
        665.5997314453125,
        479.7257385253906,
        685.3273315429688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "967 ∼ 8,774",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.15999603271484,
        665.5997314453125,
        479.7257385253906,
        685.3273315429688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,000~2,550",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.15999603271484,
        665.5997314453125,
        479.7257385253906,
        685.3273315429688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.21",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        110.15999603271484,
        665.5997314453125,
        479.7257385253906,
        685.3273315429688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(95% CI 0.12~0.30)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        425.8800048828125,
        678.5596923828125,
        514.954833984375,
        691.8073120117188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 제품별 1~9 배치 검출결과의 중앙값",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        94.07999420166016,
        706.4400024414062,
        303.8399963378906,
        720.8400268554688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 30 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        67.43999481201172,
        85.46882629394531,
        321.3599853515625,
        103.46882629394531
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 검출 시 조치방안",
      "font_size": 18.0,
      "font_name": "HYwulB",
      "bbox": [
        67.43999481201172,
        85.46882629394531,
        321.3599853515625,
        103.46882629394531
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        162.33995056152344,
        184.9199981689453,
        178.29995727539062
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제약사 조치",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        162.33995056152344,
        184.9199981689453,
        178.29995727539062
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 신속 보고",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        206.1240234375,
        157.1999969482422,
        221.1240234375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        249.8625030517578,
        538.4400024414062,
        263.53125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다. 발생가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        270.239990234375,
        544.9204711914062,
        285.7790222167969
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        292.32000732421875,
        538.43896484375,
        307.8590393066406
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        314.3999938964844,
        538.4402465820312,
        329.93902587890625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        338.4224853515625,
        544.9204711914062,
        352.09124755859375
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계산과정도 함께 제시하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        358.67999267578125,
        274.2940673828125,
        374.2190246582031
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 검출 수준에 따른 단계적 조치",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        419.7239990234375,
        299.6399841308594,
        434.7239990234375
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약사는 식약처가 마련‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        461.6399841308594,
        223.3199920654297,
        477.1919860839844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.3199920654297,
        461.6399841308594,
        538.4400024414062,
        477.17901611328125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        485.54248046875,
        545.0415649414062,
        499.21124267578125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        505.9200134277344,
        538.4404907226562,
        521.4590454101562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 관련 사항을 식약처에 제출하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        527.9999389648438,
        330.4540710449219,
        543.5390014648438
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        580.199951171875,
        417.2140808105469,
        595.739013671875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (수준 1)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        76.08000183105469,
        617.8799438476562,
        142.18270874023438,
        633.4190063476562
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        89.04000091552734,
        642.8945922851562,
        490.7740783691406,
        660.1324462890625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        668.9345703125,
        526.5604858398438,
        686.1724243164062
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        695.0946044921875,
        544.9204711914062,
        712.3324584960938
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.39999389648438,
        720.1424560546875,
        468.239990234375,
        733.8112182617188
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 31 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ (수준 2)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        76.08000183105469,
        70.91999816894531,
        142.18270874023438,
        86.45903778076172
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "√ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        95.81460571289062,
        461.5205078125,
        113.05242156982422
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        121.974609375,
        544.9204711914062,
        139.21241760253906
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저감화하거나 규격에 기준을 설정하여 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.39999389648438,
        147.0225067138672,
        370.79998779296875,
        160.69125366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        170.214599609375,
        538.4405517578125,
        187.45240783691406
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.39999389648438,
        195.2624969482422,
        468.239990234375,
        208.93124389648438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (수준 3)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        76.08000183105469,
        232.07998657226562,
        142.18270874023438,
        247.61903381347656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        257.0946044921875,
        538.4404907226562,
        274.3323974609375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 제품을 선정*하여 주기적으로 시험검사",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.87999725341797,
        279.3599853515625,
        374.5205383300781,
        295.8112487792969
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        98.63999938964844,
        306.6000061035156,
        415.0799865722656,
        321.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        329.6946105957031,
        545.041015625,
        346.9324035644531
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 사항을 제품표준서에 반영하여 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.75999450683594,
        354.86248779296875,
        351.5999755859375,
        368.53125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        391.67999267578125,
        401.9999694824219,
        407.2190246582031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "< 불순물 검출 수준에 따른 단계별 조치사항 >",
      "font_size": 12.960000038146973,
      "font_name": "T16",
      "bbox": [
        150.72000122070312,
        425.760009765625,
        443.7427062988281,
        441.31201171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구분",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.08000183105469,
        468.0194396972656,
        211.21875,
        499.58038330078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 불순물",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.08000183105469,
        468.0194396972656,
        211.21875,
        499.58038330078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출 수준",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.08000183105469,
        468.0194396972656,
        211.21875,
        499.58038330078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치사항",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        356.3999938964844,
        452.5394287109375,
        404.3999938964844,
        468.5003662109375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회수",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        256.44000244140625,
        486.1394348144531,
        280.44000244140625,
        502.1003723144531
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가변경",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        337.32000732421875,
        471.61944580078125,
        385.3199768066406,
        487.58038330078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(저감화 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.3999938964844,
        487.4242858886719,
        393.23968505859375,
        516.50830078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준설정)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.3999938964844,
        487.4242858886719,
        393.23968505859375,
        516.50830078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출하 시 시험검사",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        425.2799987792969,
        486.1394348144531,
        521.280029296875,
        502.1003723144531
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수준1",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        529.5951538085938,
        367.79998779296875,
        545.0682983398438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준 초과",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        529.5951538085938,
        367.79998779296875,
        545.0682983398438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        77.04000091552734,
        529.5951538085938,
        367.79998779296875,
        545.0682983398438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        77.04000091552734,
        529.5951538085938,
        367.79998779296875,
        545.0682983398438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(식약처 검토)",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        333.9599914550781,
        541.6799926757812,
        388.5689697265625,
        552.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        466.67999267578125,
        524.55517578125,
        479.6399841308594,
        537.51513671875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(저감화 또는",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        444.239990234375,
        536.0399780273438,
        502.0799865722656,
        547.9920043945312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준설정 완료시까지)",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        429.239990234375,
        547.0800170898438,
        517.208984375,
        557.8800048828125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수준2",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        562.3043212890625,
        220.0010223388672,
        584.6683349609375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준의 30% 초과",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        562.3043212890625,
        220.0010223388672,
        584.6683349609375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~ 기준 이내",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        142.55999755859375,
        568.7151489257812,
        367.79998779296875,
        592.4683227539062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.55999755859375,
        568.7151489257812,
        367.79998779296875,
        592.4683227539062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(식약처 검토)",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        333.9599914550781,
        580.2000122070312,
        388.5689697265625,
        591.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        466.67999267578125,
        563.1951904296875,
        479.6399841308594,
        576.1551513671875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(저감화 또는",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        444.239990234375,
        574.6799926757812,
        502.0799865722656,
        586.6320190429688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준설정 완료시까지)",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        429.239990234375,
        585.719970703125,
        517.208984375,
        596.5199584960938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수준3",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        598.0642700195312,
        219.5217742919922,
        620.4283447265625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준의 10% 초과",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        598.0642700195312,
        219.5217742919922,
        620.4283447265625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~ 30% 이하",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        142.9199981689453,
        604.4751586914062,
        479.6399841308594,
        628.2283325195312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "✓",
      "font_size": 12.960000038146973,
      "font_name": "Haansoft Batang",
      "bbox": [
        142.9199981689453,
        604.4751586914062,
        479.6399841308594,
        628.2283325195312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(자체주기적관리)",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        444.0,
        615.9599609375,
        502.448974609375,
        626.7599487304688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수준4",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        637.3043212890625,
        400.67950439453125,
        653.8873291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준의 10% 이하",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        637.3043212890625,
        400.67950439453125,
        653.8873291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘불검출’로 인정하여 업체 자율관리",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        77.04000091552734,
        637.3043212890625,
        400.67950439453125,
        653.8873291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5",
      "font_size": 8.279999732971191,
      "font_name": "T12",
      "bbox": [
        63.119998931884766,
        670.199951171875,
        538.3804321289062,
        686.8319702148438
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요",
      "font_size": 12.960000038146973,
      "font_name": "T16",
      "bbox": [
        74.5199966430664,
        687.5999755859375,
        524.6400756835938,
        708.9119873046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        720.5999755859375,
        538.439697265625,
        736.1519775390625
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요",
      "font_size": 12.960000038146973,
      "font_name": "T16",
      "bbox": [
        72.95999908447266,
        737.0399780273438,
        527.0405883789062,
        758.23193359375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 32 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 불순물 함유 우려 의약품의 제조공정 검증",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        80.7240219116211,
        382.0799865722656,
        95.7240219116211
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        124.46249389648438,
        538.4405517578125,
        138.13124084472656
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        146.54249572753906,
        538.4405517578125,
        160.21124267578125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        168.62249755859375,
        538.4400024414062,
        182.29124450683594
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "험적으로 입증하는 것이다. 따라서, 의약품 제조공정에서 니트로사민류의 발생원",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        188.99998474121094,
        538.4400024414062,
        204.53903198242188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        211.07998657226562,
        544.9199829101562,
        226.61903381347656
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        233.1599884033203,
        538.4400024414062,
        248.69903564453125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        257.1824951171875,
        538.4400024414062,
        270.85125732421875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 평가하는 것이다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        277.44000244140625,
        189.81407165527344,
        292.9790344238281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 니트로사민류 제조공정 검증 시 고려사항",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.55999755859375,
        317.5199890136719,
        361.20068359375,
        334.35394287109375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        347.4224853515625,
        538.4405517578125,
        361.09124755859375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        367.67999267578125,
        137.7340850830078,
        383.2190246582031
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 원료의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        395.760009765625,
        177.84104919433594,
        411.2990417480469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        421.9200134277344,
        545.0404663085938,
        438.08770751953125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.83999633789062,
        444.0,
        487.9027099609375,
        459.5390319824219
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.5199966430664,
        471.1199951171875,
        538.4127197265625,
        486.6590270996094
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.1199951171875,
        493.32000732421875,
        537.2405395507812,
        508.8590393066406
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        95.5199966430664,
        520.43994140625,
        538.4127197265625,
        535.97900390625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tributylamine 등이 있음",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.39999389648438,
        542.5199584960938,
        251.27999877929688,
        558.0590209960938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        569.6399536132812,
        545.0404663085938,
        585.1790161132812
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.75999450683594,
        591.719970703125,
        497.8799743652344,
        607.259033203125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        618.8399658203125,
        516.7205200195312,
        634.3919677734375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        645.9599609375,
        509.03997802734375,
        661.4990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        673.0799560546875,
        538.4400024414062,
        688.6319580078125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "능성 있음",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.04000091552734,
        697.1024780273438,
        168.47999572753906,
        710.771240234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        722.3999633789062,
        496.0799865722656,
        737.9390258789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        749.5199584960938,
        545.0404663085938,
        765.0719604492188
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 33 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는 판매자로부터 제공받는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.68000030517578,
        70.70249938964844,
        343.5605163574219,
        84.37124633789062
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 출발물질 혹은 중간체의 오염가능성이 있음",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        96.0,
        366.2405090332031,
        111.5390396118164
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        123.12000274658203,
        538.4405517578125,
        138.6719970703125
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.43999481201172,
        147.0225067138672,
        473.27996826171875,
        160.69125366210938
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ 기타 생성 가능 원인에 대한 평가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        172.3199920654297,
        309.8399963378906,
        187.8719940185547
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 생산라인 공유에 따른 교차오염 등",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        199.4399871826172,
        314.15997314453125,
        214.97903442382812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 완제의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        228.59999084472656,
        177.84104919433594,
        244.1390380859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        254.75999450683594,
        538.4405517578125,
        270.31201171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        276.8399963378906,
        544.9188842773438,
        292.3790283203125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작업을 수행하는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        300.74249267578125,
        244.0805206298828,
        314.4112548828125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        326.0400085449219,
        538.4405517578125,
        341.5920104980469
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.5999984741211,
        348.239990234375,
        538.4400024414062,
        363.7790222167969
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 생성될 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.5999984741211,
        372.1424865722656,
        212.52000427246094,
        385.8112487792969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 완제의약품 포장과정에서 불순물 발생 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        397.44000244140625,
        387.9605407714844,
        412.99200439453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        424.55999755859375,
        538.4400024414062,
        440.0990295410156
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합에 따른 생성 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.79999542236328,
        448.46246337890625,
        249.72052001953125,
        462.1312255859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.04000091552734,
        473.760009765625,
        538.4405517578125,
        489.31201171875
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        495.9599914550781,
        545.041015625,
        511.4990234375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사구조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        518.0399780273438,
        538.5325317382812,
        533.5790405273438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        518.0399780273438,
        538.5325317382812,
        533.5790405273438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물(Nitrosamine",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.47999572753906,
        518.0399780273438,
        538.5325317382812,
        533.5790405273438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "drug",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.47999572753906,
        518.0399780273438,
        538.5325317382812,
        533.5790405273438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "substance-related",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        108.47999572753906,
        518.0399780273438,
        538.5325317382812,
        533.5790405273438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "impurities, NDSRIs) 발생 가능성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        540.1199951171875,
        319.3205261230469,
        555.6590576171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의약품 중 니트로사민류 발생 원인 분석",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        581.280029296875,
        353.760009765625,
        598.1139526367188
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        611.0625,
        538.4388427734375,
        624.7312622070312
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석한 결과, 추정되는 생성원인은 다음과 같다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        76.08000183105469,
        631.43994140625,
        361.8940734863281,
        646.97900390625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        659.5199584960938,
        438.1199951171875,
        675.0719604492188
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사르탄류 중 NDMA 및 NDEA 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.5999755859375,
        359.5205078125,
        700.1390380859375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        708.719970703125,
        538.4404907226562,
        724.259033203125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        730.9199829101562,
        538.4379272460938,
        746.4590454101562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        752.9999389648438,
        538.4405517578125,
        768.5390014648438
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        68.87999725341797,
        538.4402465820312,
        84.41903686523438
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        90.95999908447266,
        545.0404663085938,
        106.49903869628906
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성되는 것으로 추정되고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        113.15999603271484,
        288.3340759277344,
        128.69903564453125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 4. 사르탄류 중 NDMA 및 NDEA 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.63999938964844,
        375.239990234375,
        443.5196838378906,
        390.7790222167969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        426.4800109863281,
        465.36053466796875,
        442.01904296875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        450.6000061035156,
        538.4400024414062,
        466.1390380859375
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        472.67999267578125,
        538.439697265625,
        488.2190246582031
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        496.5824890136719,
        545.041015625,
        510.2512512207031
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        516.9599609375,
        125.97407531738281,
        532.4990234375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 35 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        349.4739990234375,
        126.97732543945312,
        359.82427978515625,
        133.72976684570312
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NH",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        325.0190124511719,
        151.5473175048828,
        333.1033630371094,
        157.45947265625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        212.59300231933594,
        199.99432373046875,
        216.97064208984375,
        205.90647888183594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OH",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        267.53302001953125,
        143.2313232421875,
        305.0303649902344,
        149.1434783935547
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OH",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        267.53302001953125,
        143.2313232421875,
        305.0303649902344,
        149.1434783935547
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H3C",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        233.22900390625,
        161.06031799316406,
        243.6583709716797,
        167.87576293945312
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        241.33599853515625,
        185.75631713867188,
        245.71363830566406,
        191.66847229003906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        268.2030029296875,
        207.93231201171875,
        272.58062744140625,
        213.84446716308594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OH",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        296.61102294921875,
        196.27731323242188,
        305.0303649902344,
        202.18946838378906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        338.68701171875,
        184.68531799316406,
        358.89837646484375,
        190.59747314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        338.68701171875,
        184.68531799316406,
        358.89837646484375,
        190.59747314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H3C",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        237.31600952148438,
        209.9483184814453,
        247.67837524414062,
        216.70077514648438
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        210.51600646972656,
        156.71331787109375,
        214.89364624023438,
        162.62547302246094
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        248.57200622558594,
        142.2233123779297,
        258.9222412109375,
        148.97576904296875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H3COOC",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        196.64700317382812,
        129.62332153320312,
        219.73936462402344,
        136.3757781982422
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        267.6669921875,
        121.24431610107422,
        278.01727294921875,
        127.99676513671875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HO",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        236.177001953125,
        106.31331634521484,
        244.57464599609375,
        112.22547912597656
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        270.41400146484375,
        83.50731658935547,
        314.86724853515625,
        91.96076202392578
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        270.41400146484375,
        83.50731658935547,
        314.86724853515625,
        91.96076202392578
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OH",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        281.20098876953125,
        116.96031188964844,
        289.620361328125,
        122.87247467041016
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        314.1650085449219,
        122.75631713867188,
        318.5426330566406,
        128.66847229003906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        385.25201416015625,
        184.68531799316406,
        406.52325439453125,
        191.5007781982422
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH3",
      "font_size": 4.028091907501221,
      "font_name": "ArialMT",
      "bbox": [
        385.25201416015625,
        184.68531799316406,
        406.52325439453125,
        191.5007781982422
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        256.21002197265625,
        84.95631408691406,
        292.2333679199219,
        93.45147705078125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        256.21002197265625,
        84.95631408691406,
        292.2333679199219,
        93.45147705078125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        244.8870086669922,
        92.39031219482422,
        248.9513702392578,
        98.30247497558594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        260.364013671875,
        132.5213165283203,
        264.4283752441406,
        138.4334716796875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        234.10000610351562,
        116.51931762695312,
        238.16436767578125,
        122.43148040771484
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H3C",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        188.406005859375,
        156.71331787109375,
        198.76837158203125,
        163.4657745361328
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        325.822998046875,
        195.26931762695312,
        329.8873596191406,
        201.1814727783203
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        246.96400451660156,
        155.3273162841797,
        251.0283660888672,
        161.23947143554688
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H",
      "font_size": 5.4574151039123535,
      "font_name": "ArialMT",
      "bbox": [
        215.27301025390625,
        143.2943115234375,
        219.33737182617188,
        149.2064666748047
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 5. 리팜피신의 구조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        224.87998962402344,
        222.62249755859375,
        371.27996826171875,
        236.29124450683594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 6. 리팜피신 중 MeNP 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        185.87998962402344,
        358.4624938964844,
        411.239990234375,
        372.1312561035156
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        385.0799865722656,
        466.5605163574219,
        400.6190185546875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        409.20001220703125,
        538.4913940429688,
        424.7390441894531
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "amine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        431.2799987792969,
        538.439453125,
        446.81903076171875
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        453.3599853515625,
        463.6540832519531,
        468.8990173339844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 36 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 7. 몬테루카스트의 구조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        235.1999969482422,
        203.42250061035156,
        407.6399841308594,
        217.09124755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 8. 몬테루카스트 중 NDPA 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.59999084472656,
        360.1424865722656,
        447.3599853515625,
        373.8112487792969
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 완제의약품 제조공정 유래 불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        438.239990234375,
        307.8005065917969,
        453.7790222167969
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 메트포르민 중 NDMA 발생원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        463.32000732421875,
        314.1605224609375,
        478.8590393066406
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        487.44000244140625,
        538.4407348632812,
        502.9790344238281
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        509.6399841308594,
        538.4400024414062,
        525.1790161132812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염에 노출되어 NDMA 생성되는 것으로 추정되고 있다. 또한, 열 또는 압",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        531.719970703125,
        538.4400024414062,
        547.259033203125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "력이 발생하는 과정이 포함된 과립‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        96.72000122070312,
        553.7999877929688,
        317.5199890136719,
        569.3519897460938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "코팅‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        317.6399841308594,
        553.7999877929688,
        350.0400085449219,
        569.3519897460938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건조 등 제조공정 조건에 따른",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        350.1600036621094,
        555.6224975585938,
        544.9199829101562,
        569.291259765625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향도 있을 것으로 추정되고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        575.9999389648438,
        307.8940734863281,
        591.5390014648438
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 37 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 9. 메트포르민의 구조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.87998962402344,
        196.22250366210938,
        378.239990234375,
        209.89125061035156
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 10. 메트포르민 중 NDMA의 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        168.1199951171875,
        345.2624816894531,
        429.1205139160156,
        358.9312438964844
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 원료의약품의 분해산물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        406.20001220703125,
        242.76052856445312,
        421.7390441894531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 라니티딘, 니자티딘 중 NDMA 발생원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        431.2799987792969,
        362.8805236816406,
        446.81903076171875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        457.22247314453125,
        538.439453125,
        470.8912353515625
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        477.4800109863281,
        544.9199829101562,
        493.01904296875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분해‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        96.72000122070312,
        499.6800231933594,
        129.239990234375,
        515.2319946289062
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결합하여 NDMA가 생성되는 것으로 추정되고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        129.239990234375,
        499.6800231933594,
        442.0540771484375,
        515.2190551757812
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 11. 라니티딘과 니자티딘의 구조 및 NDMA 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.59999084472656,
        706.7024536132812,
        487.5599670410156,
        720.3712158203125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 38 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs)",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        82.55999755859375,
        73.91999816894531,
        534.5835571289062,
        89.45903778076172
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.27999877929688,
        98.78250122070312,
        538.4400024414062,
        112.45124816894531
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        119.15999603271484,
        544.9208984375,
        134.69903564453125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        141.239990234375,
        538.4400024414062,
        156.77903747558594
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 추정되고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        96.72000122070312,
        163.3199920654297,
        216.93408203125,
        178.85903930664062
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 5. 발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        198.2946014404297,
        494.8768005371094,
        215.53240966796875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        146.75999450683594,
        232.18429565429688,
        525.4797973632812,
        246.8683624267578
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생 가능한 주성분 유사구조 니트로사민 불순물",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        146.75999450683594,
        232.18429565429688,
        525.4797973632812,
        246.8683624267578
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바레니클린(varenicline)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        330.94427490234375,
        464.9074401855469,
        345.62835693359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-varenicline",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        117.0,
        330.94427490234375,
        464.9074401855469,
        345.62835693359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "살부타몰(salbutamol)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        121.55999755859375,
        452.8642578125,
        465.7966613769531,
        467.54833984375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-salbutamol",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        121.55999755859375,
        452.8642578125,
        465.7966613769531,
        467.54833984375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라사길린(rasagiline)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        125.39999389648438,
        590.0242919921875,
        462.0256652832031,
        604.7083129882812
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-rasagiline",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        125.39999389648438,
        590.0242919921875,
        462.0256652832031,
        604.7083129882812
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트리메타지딘(trimetazidine)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        105.47999572753906,
        713.0242919921875,
        470.9045715332031,
        727.7083129882812
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso-trimetazidine",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        105.47999572753906,
        713.0242919921875,
        470.9045715332031,
        727.7083129882812
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 39 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 의약품 중 니트로사민류 제조공정 검증",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.63999938964844,
        85.91999816894531,
        348.24066162109375,
        102.75395965576172
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.27999877929688,
        110.87999725341797,
        545.041015625,
        126.41903686523438
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        132.95999145507812,
        538.4400024414062,
        148.49903869628906
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준 이하로 관리됨을 입증하는 것을 목적으로 한다. 이러한 제조공정 검증",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        155.1599884033203,
        538.4400024414062,
        170.69903564453125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        177.239990234375,
        538.4405517578125,
        192.7919921875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        199.3199920654297,
        538.4405517578125,
        214.8719940185547
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        221.51998901367188,
        545.0404663085938,
        237.0590362548828
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다. 또한, 불순",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        243.59999084472656,
        538.4400024414062,
        259.1390380859375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        265.67999267578125,
        538.4227294921875,
        281.2190246582031
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        287.8800048828125,
        538.4400024414062,
        303.4190368652344
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        309.9599914550781,
        544.9199829101562,
        325.5119934082031
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        332.0400085449219,
        538.4405517578125,
        347.57904052734375
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        354.239990234375,
        145.41407775878906,
        369.7790222167969
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        404.9024658203125,
        544.9204711914062,
        418.57122802734375
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        425.1600036621094,
        538.4405517578125,
        440.69903564453125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.55999755859375,
        447.239990234375,
        544.9204711914062,
        462.7790222167969
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        82.55999755859375,
        469.44000244140625,
        436.6540832519531,
        484.9790344238281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        504.3824462890625,
        538.4400024414062,
        518.0512084960938
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        524.6399536132812,
        538.4400024414062,
        540.1790161132812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        546.719970703125,
        99.93408203125,
        562.259033203125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        590.9024658203125,
        538.4405517578125,
        604.5712280273438
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        611.1599731445312,
        538.4400024414062,
        626.6990356445312
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다. 또한, 해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        633.3599853515625,
        538.4400024414062,
        648.8990478515625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        657.262451171875,
        544.9204711914062,
        670.9312133789062
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        677.5199584960938,
        538.4400024414062,
        693.0590209960938
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        701.54248046875,
        538.4400024414062,
        715.2112426757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음을 입증하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        721.7999877929688,
        216.93408203125,
        737.3390502929688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 40 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        68.87999725341797,
        538.4400024414062,
        84.41903686523438
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        90.95999908447266,
        544.9204711914062,
        106.49903869628906
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        113.15999603271484,
        538.4400024414062,
        128.69903564453125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정을 중점으로 제조공정 검증을 수행하여야 한다. 원료의약품의 발생 원인",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        135.239990234375,
        538.439453125,
        150.77903747558594
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        159.1425018310547,
        545.0404663085938,
        172.81124877929688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        179.51998901367188,
        132.45407104492188,
        195.0590362548828
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        225.50250244140625,
        538.4400024414062,
        239.17124938964844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        245.87998962402344,
        538.4402465820312,
        261.4190368652344
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        267.9599914550781,
        545.041015625,
        283.4990234375
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        83.75999450683594,
        290.0400085449219,
        535.2940673828125,
        305.57904052734375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 41 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 허가사항 변경 등",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        80.7240219116211,
        222.59999084472656,
        96.1312484741211
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        124.56000518798828,
        544.9199829101562,
        140.0990447998047
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "책임을 진다. 따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        146.75999450683594,
        538.439453125,
        162.31199645996094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        168.83999633789062,
        538.439453125,
        184.37904357910156
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        192.74249267578125,
        538.4400024414062,
        206.41123962402344
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 등 전주기 안전관리에 노력을 기울여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        213.1199951171875,
        371.73406982421875,
        228.65904235839844
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제약사는 신규 품목허가‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        253.4399871826172,
        223.07998657226562,
        268.99200439453125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신고‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        223.0800018310547,
        253.4399871826172,
        255.59999084472656,
        268.99200439453125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등록 시 의약품 허가‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        255.59999084472656,
        253.4399871826172,
        391.55999755859375,
        268.99200439453125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심사 자료로서 유전독성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        391.55999755859375,
        255.2624969482422,
        545.041015625,
        268.9312438964844
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        277.34246826171875,
        538.4388427734375,
        291.01123046875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 이미 허가‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        297.6000061035156,
        174.1199951171875,
        313.1520080566406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신고‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        174.239990234375,
        297.6000061035156,
        206.87998962402344,
        313.1520080566406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등록된 품목도 불순물의 생성 및 오염 위험을 최소화",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        207.0,
        299.4224853515625,
        538.4403076171875,
        313.09124755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        321.6224670410156,
        538.43994140625,
        335.2912292480469
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, 제조방법‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        341.8800048828125,
        161.99998474121094,
        357.4320068359375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        161.87998962402344,
        343.7024841308594,
        538.4400024414062,
        357.3712463378906
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        363.9599914550781,
        438.8140563964844,
        379.4990234375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품 또는 완제의약품의 조성, 합성‧",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        69.5999984741211,
        408.3599853515625,
        323.1600036621094,
        423.9119873046875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조공정, 포장재, 제조원, 규격 변경",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        323.03997802734375,
        408.3599853515625,
        538.4402465820312,
        423.8990173339844
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        430.44000244140625,
        538.4400024414062,
        445.9790344238281
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        452.5199890136719,
        538.4400024414062,
        468.05902099609375
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        474.7200012207031,
        404.1340637207031,
        490.259033203125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.83999633789062,
        518.9999389648438,
        538.4140625,
        534.5390014648438
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.83999633789062,
        541.0799560546875,
        544.9204711914062,
        556.6190185546875
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.83999633789062,
        563.2799682617188,
        118.5340805053711,
        578.8190307617188
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 42 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        184.9199981689453,
        104.37995910644531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처 조치",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        67.19999694824219,
        88.41995239257812,
        184.9199981689453,
        104.37995910644531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        141.50250244140625,
        544.9204711914062,
        155.17124938964844
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        161.87998962402344,
        544.9204711914062,
        177.41903686523438
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        183.95999145507812,
        538.5340576171875,
        199.49903869628906
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        207.8625030517578,
        544.9199829101562,
        221.53125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        228.239990234375,
        536.134033203125,
        243.77903747558594
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        274.34246826171875,
        538.4400024414062,
        288.01123046875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        296.4224853515625,
        544.9204711914062,
        310.09124755859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요청할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        316.79998779296875,
        163.77407836914062,
        332.3390197753906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 불순물 종류 및 발생 원인 조사 결과",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        349.9200134277344,
        322.9205322265625,
        365.4720153808594
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        378.0,
        443.1610412597656,
        393.552001953125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 분석결과 및 배치수, 배치선정의 타당성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        406.0799865722656,
        332.6399841308594,
        421.6319885253906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 기준 및 시험방법의 적정성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        434.2799987792969,
        258.0005187988281,
        449.8320007324219
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 상기 기준에 따른 시험검사 결과의 적정성",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        462.3599853515625,
        348.96051025390625,
        477.9119873046875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 시험검사 결과에 따른 예방 및 시정조치 계획 등",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        490.44000244140625,
        387.8399963378906,
        505.99200439453125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        534.8399658203125,
        538.4400024414062,
        550.3790283203125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        556.9199829101562,
        538.4140625,
        572.4590454101562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        578.9999389648438,
        527.614013671875,
        594.5390014648438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        719.6399536132812,
        538.4400024414062,
        735.1790161132812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 한시적 기준을 설정할 수 있다. 상기 절차에 따라 설정한 1일 섭취 허용량",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        741.719970703125,
        538.4404907226562,
        757.259033203125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업체 제출 근거자료 및",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        91.19999694824219,
        632.5997314453125,
        199.70155334472656,
        645.8473510742188
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해외 규제기관 정보",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        648.5596923828125,
        192.2610626220703,
        661.8073120117188
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        133.8000030517578,
        664.6397094726562,
        153.72000122070312,
        677.8873291015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중앙약사심의위원회",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        406.44000244140625,
        648.5596923828125,
        496.4385681152344,
        661.8073120117188
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준설정자문위원회 자문",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        237.59999084472656,
        639.6796875,
        357.5995178222656,
        652.9273071289062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(정기 및 수시)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        264.6000061035156,
        655.6397094726562,
        330.63470458984375,
        668.8873291015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 43 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        70.70249938964844,
        545.0408325195312,
        84.37124633789062
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        90.95999908447266,
        538.4400024414062,
        106.49903869628906
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        114.98249816894531,
        538.4400024414062,
        128.6512451171875
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        135.239990234375,
        544.9202880859375,
        150.77903747558594
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        157.3199920654297,
        544.9200439453125,
        172.85903930664062
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        179.51998901367188,
        119.25408172607422,
        195.0590362548828
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        221.75999450683594,
        538.4449462890625,
        237.92771911621094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        243.95997619628906,
        544.9204711914062,
        259.4990234375
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        266.0400085449219,
        544.9204711914062,
        281.57904052734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출하허용기준을 설정한 바 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        288.1199951171875,
        261.2140808105469,
        303.6590270996094
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        332.5199890136719,
        544.9204711914062,
        348.05902099609375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        356.4224853515625,
        544.9199829101562,
        370.09124755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        376.67999267578125,
        545.0399169921875,
        392.2190246582031
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        400.7024841308594,
        545.0409545898438,
        414.3712463378906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출하도록 요청하고 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        420.9599914550781,
        226.174072265625,
        436.4990234375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        465.239990234375,
        538.439453125,
        480.7790222167969
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        487.44000244140625,
        417.0940856933594,
        502.9790344238281
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 배치 간 변동성 자료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        515.5199584960938,
        225.4805145263672,
        531.0719604492188
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 안정성시험 자료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        543.5999755859375,
        192.9600067138672,
        559.1519775390625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 불순물 발생원인 및 공정변수 평가 자료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        571.7999877929688,
        335.8799743652344,
        587.3519897460938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 시험방법 및 밸리데이션 자료",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        599.8799438476562,
        270.9599914550781,
        615.4319458007812
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 예방 및 시정조치 등",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.08000183105469,
        627.9599609375,
        219.0,
        643.511962890625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        672.3599853515625,
        544.9195556640625,
        687.8990478515625
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.5999984741211,
        694.43994140625,
        538.439697265625,
        709.97900390625
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        716.5199584960938,
        538.4227294921875,
        732.0590209960938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        69.5999984741211,
        738.719970703125,
        521.134033203125,
        754.259033203125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 44 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 의약품 중 불순물 안전관리 절차(예) >",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        165.36000061035156,
        70.39916229248047,
        430.0981140136719,
        89.07345581054688
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        72.95999908447266,
        85.46882629394531,
        191.87998962402344,
        103.46882629394531
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질의응답",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        72.95999908447266,
        85.46882629394531,
        191.87998962402344,
        103.46882629394531
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 17.03999900817871,
      "font_name": "Haansoft Batang",
      "bbox": [
        69.83999633789062,
        145.93289184570312,
        324.16522216796875,
        162.97288513183594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        69.83999633789062,
        145.93289184570312,
        324.16522216796875,
        162.97288513183594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)은 무엇인가요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        232.44749450683594,
        319.19622802734375,
        245.10374450683594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q1",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        194.9591522216797,
        122.61766815185547,
        213.63345336914062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A1. 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        300.4800109863281,
        523.7999877929688,
        316.01904296875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 불순물(이하 ‘니트로사민류’라 한다.)에서 관찰되는 변이원성과",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        324.36749267578125,
        523.7999877929688,
        337.02374267578125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        344.7674865722656,
        517.7999877929688,
        357.4237365722656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        365.16748046875,
        523.7999877929688,
        377.82373046875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        385.5675048828125,
        523.7999877929688,
        398.2237548828125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        405.9674987792969,
        410.7599792480469,
        418.6237487792969
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        516.9674682617188,
        528.239990234375,
        529.6237182617188
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량을 설정할 수 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        536.16748046875,
        252.2362518310547,
        548.82373046875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q2",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        475.7591247558594,
        122.61766815185547,
        494.4334411621094
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A2. 니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        602.9999389648438,
        517.7999877929688,
        618.5390014648438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        627.0075073242188,
        517.7999877929688,
        639.6637573242188
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        647.407470703125,
        523.9199829101562,
        660.063720703125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정할 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        667.8074951171875,
        209.87998962402344,
        680.4637451171875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        690.1275024414062,
        517.7999877929688,
        702.7837524414062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        710.5274658203125,
        523.7999877929688,
        723.1837158203125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        730.927490234375,
        436.1943664550781,
        743.583740234375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 46 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        123.84750366210938,
        530.760009765625,
        136.50375366210938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.01952362060547,
        143.04750061035156,
        390.3562316894531,
        155.70375061035156
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        106.31999969482422,
        79.27915954589844,
        125.01692199707031,
        97.95345306396484
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A3. 발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        221.39999389648438,
        523.7999877929688,
        236.9390411376953
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        245.28749084472656,
        523.9199829101562,
        257.9437255859375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        265.6875,
        523.7999877929688,
        278.34375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        90.6595230102539,
        286.0874938964844,
        523.7999877929688,
        298.7437438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        306.48748779296875,
        523.7999877929688,
        319.14373779296875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상이합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        326.8874816894531,
        153.474365234375,
        339.5437316894531
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        460.4474792480469,
        518.63623046875,
        473.1037292480469
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q4",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        416.8391418457031,
        122.61766815185547,
        435.5134582519531
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A4. 두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        537.1199951171875,
        523.7999877929688,
        552.6590576171875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.75999450683594,
        561.1275024414062,
        523.7999877929688,
        573.7837524414062
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량을 결정하게 됩니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.75999450683594,
        581.5274658203125,
        263.9943542480469,
        594.1837158203125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        603.8474731445312,
        517.7999877929688,
        616.5037231445312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        90.83999633789062,
        624.2474975585938,
        183.71437072753906,
        636.9037475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 47 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        119.88749694824219,
        528.239990234375,
        132.5437469482422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        139.08749389648438,
        494.8762512207031,
        151.74374389648438
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q5",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        78.67916107177734,
        122.61766815185547,
        97.35345458984375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A5. 비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        251.3999786376953,
        523.7999877929688,
        266.93902587890625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2021, Developmenting Structure-Activity Relationships for N-Nitrosamine",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        275.2875061035156,
        523.7999877929688,
        287.9437561035156
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        295.6875,
        523.7999877929688,
        308.34375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        316.0874938964844,
        523.7999877929688,
        328.7437438964844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        336.48748779296875,
        517.9199829101562,
        349.14373779296875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도체, halogen, aromatic system 등이 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        356.8874816894531,
        355.79998779296875,
        369.5437316894531
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 48 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        128.64749145507812,
        528.3599853515625,
        141.30374145507812
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게 하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        147.84750366210938,
        152.87625122070312,
        160.50375366210938
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q6",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        87.55915832519531,
        122.61766815185547,
        106.23345184326172
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A6. 잠재력 점수 계산식 및 계산과정은 아래와 같습니다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        66.83999633789062,
        263.1600036621094,
        362.0159912109375,
        278.69903564453125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        72.36000061035156,
        287.3999938964844,
        476.5199890136719,
        301.7879943847656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "= 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일)",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        146.63999938964844,
        309.8399963378906,
        384.7439880371094,
        324.2279968261719
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소의 개수",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        122.5199966430664,
        338.7794494628906,
        488.03997802734375,
        354.7403869628906
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        122.5199966430664,
        338.7794494628906,
        488.03997802734375,
        354.7403869628906
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "빨간색으로 표시된 구조 특징",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        122.5199966430664,
        338.7794494628906,
        488.03997802734375,
        354.7403869628906
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 1",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        150.83999633789062,
        390.85943603515625,
        281.63507080078125,
        406.82037353515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        150.83999633789062,
        390.85943603515625,
        281.63507080078125,
        406.82037353515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비활성화 구조 특성",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        107.75999450683594,
        446.7794494628906,
        215.75999450683594,
        462.7403869628906
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형 N-니트로소기의 양쪽에 ≥5 인",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.47999572753906,
        473.41943359375,
        251.2987518310547,
        546.9804077148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연속된 비수소 원자(고리형 또는",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.47999572753906,
        473.41943359375,
        251.2987518310547,
        546.9804077148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형) 사슬. 각 사슬에서 4개",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.47999572753906,
        473.41943359375,
        251.2987518310547,
        546.9804077148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이하의 원자가 동일한 고리에 있을",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.47999572753906,
        473.41943359375,
        251.2987518310547,
        546.9804077148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수 있음",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.47999572753906,
        473.41943359375,
        251.2987518310547,
        546.9804077148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        270.47998046875,
        502.21942138671875,
        285.8350830078125,
        518.1803588867188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활성화 구조 특성",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        113.75999450683594,
        560.8994140625,
        281.63507080078125,
        576.8603515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        113.75999450683594,
        560.8994140625,
        281.63507080078125,
        576.8603515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력점수= 3 + 1 + 0 = 4",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.75999450683594,
        587.5394287109375,
        500.5199890136719,
        603.5003662109375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 분류 4",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.75999450683594,
        587.5394287109375,
        500.5199890136719,
        603.5003662109375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.75999450683594,
        587.5394287109375,
        500.5199890136719,
        603.5003662109375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        72.1199951171875,
        627.3599853515625,
        523.7999877929688,
        641.7479858398438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        82.08000183105469,
        649.447509765625,
        385.3143615722656,
        662.103759765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 상세 내용은 [부록 1]을 참고하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        670.2000122070312,
        327.71435546875,
        684.5880126953125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 49 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 17.03999900817871,
      "font_name": "Haansoft Batang",
      "bbox": [
        72.23999786376953,
        77.89289093017578,
        261.1199951171875,
        94.9328842163086
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1일 섭취허용량 설정",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        72.23999786376953,
        77.89289093017578,
        261.1199951171875,
        94.9328842163086
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        70.49952697753906,
        171.6074981689453,
        528.239990234375,
        184.2637481689453
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다. 이렇게 CPCA를 적용할 수 없는",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        190.8074951171875,
        528.239990234375,
        203.4637451171875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 어떻게 1일 섭취 허용량을 설정하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        210.0074920654297,
        313.9162292480469,
        222.6637420654297
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q7",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        131.23916625976562,
        122.61766815185547,
        149.91346740722656
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A7. 니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        68.76000213623047,
        270.0,
        526.4400024414062,
        285.5390319824219
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.55999755859375,
        293.16748046875,
        532.4400024414062,
        305.82373046875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.55999755859375,
        312.9674987792969,
        532.4400024414062,
        325.6237487792969
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.55999755859375,
        332.7674865722656,
        546.756103515625,
        351.61920166015625
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조-활성 상관관계 평가를",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        162.59999084472656,
        490.6045837402344,
        259.9646301269531,
        502.5752868652344
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통한 섭취 허용량 설정이 가능한가 ?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        146.0399932861328,
        505.00457763671875,
        273.4196472167969,
        516.9752807617188
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        412.44000244140625,
        397.7245788574219,
        452.5199890136719,
        409.9921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(불확실성 계수 미적용)",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        384.7200012207031,
        412.12457275390625,
        480.22216796875,
        424.09527587890625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50을 설정하기에 충분한",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        165.36000061035156,
        397.6045837402344,
        257.2037658691406,
        409.8721618652344
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암성 연구 결과가 존재하는가?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        154.9199981689453,
        412.00457763671875,
        264.5396423339844,
        423.97528076171875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수로",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        365.1600036621094,
        667.0045776367188,
        415.3202819824219,
        678.9752807617188
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취 허용량 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        359.5199890136719,
        681.4046020507812,
        420.84027099609375,
        693.3753051757812
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 공통 적용",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        165.83999633789062,
        666.7645874023438,
        258.7637634277344,
        678.7352905273438
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준(26.5 ng/일) 적용",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        169.55999755859375,
        681.16455078125,
        255.04405212402344,
        693.13525390625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        327.3599853515625,
        399.5245666503906,
        336.3599853515625,
        411.4952697753906
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        220.0800018310547,
        451.6045837402344,
        247.0800018310547,
        463.5752868652344
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        220.55999755859375,
        635.444580078125,
        247.55999755859375,
        647.415283203125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        155.51998901367188,
        581.6845703125,
        358.32000732421875,
        595.0952758789062
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발암 잠재력 분류 접근법(CPCA)",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        155.51998901367188,
        581.6845703125,
        358.32000732421875,
        595.0952758789062
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용 대상에 해당하는가 ?",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        165.36000061035156,
        596.0845947265625,
        255.41964721679688,
        608.0552978515625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        220.1999969482422,
        543.16455078125,
        247.1999969482422,
        555.13525390625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        327.3599853515625,
        492.64459228515625,
        336.3599853515625,
        504.61529541015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Read-across 등을 이용한 구조-활성",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        372.1199951171875,
        476.0845642089844,
        499.3640441894531,
        488.0552673339844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상관관계 방법을 이용 유사 구조의",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        373.55999755859375,
        490.4845886230469,
        497.9243469238281,
        502.4552917480469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TD50 으로",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        416.7599792480469,
        504.88458251953125,
        454.7243347167969,
        517.1522216796875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취 허용량 계산",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        403.55999755859375,
        519.2846069335938,
        464.8800048828125,
        531.2553100585938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의",
      "font_size": 9.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        719.8992309570312,
        380.2799987792969,
        732.0
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 50 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        119.88749694824219,
        528.239990234375,
        132.5437469482422
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준이 재설정될 수 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        139.08749389648438,
        246.95623779296875,
        151.74374389648438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q8",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        78.67916107177734,
        122.61766815185547,
        97.35345458984375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A8. 기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        201.3599853515625,
        523.7999877929688,
        216.89903259277344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        225.24749755859375,
        523.7999877929688,
        237.90374755859375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500 ng/일로 섭취허용량이 재설정 되었습니다. 또한, CPCA로 도출된 섭취허용량",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        245.64749145507812,
        523.9199829101562,
        258.3037414550781
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        266.0474853515625,
        523.7999877929688,
        278.7037353515625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        286.4474792480469,
        143.87437438964844,
        299.1037292480469
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        414.60748291015625,
        528.3599853515625,
        427.26373291015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        433.8074951171875,
        413.7562561035156,
        446.4637451171875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q9",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.79999542236328,
        373.3991394042969,
        122.61766815185547,
        392.0734558105469
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A9. N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        511.0799865722656,
        523.7999877929688,
        526.6190185546875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        535.0874633789062,
        523.9199829101562,
        547.7437133789062
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알려진 바가 거의 없습니다. 따라서, 제시된 강화된 Ames 시험(Enhanced Ames test,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        555.4874877929688,
        523.7999877929688,
        568.1437377929688
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EAT) 조건으로 수행하는 것을 권고합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        575.8875122070312,
        324.239990234375,
        588.5437622070312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        598.2074584960938,
        523.7999877929688,
        610.8637084960938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        618.6074829101562,
        523.7999877929688,
        631.2637329101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "될 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.72000122070312,
        639.0075073242188,
        182.2743682861328,
        651.6637573242188
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 상세 내용은 [부록 2]를 참고하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        661.447509765625,
        342.8343811035156,
        674.103759765625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        128.64749145507812,
        528.239990234375,
        141.30374145507812
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "총 니트로사민류 기준에 포함하여 관리하여야 하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        147.84750366210938,
        364.5562438964844,
        160.50375366210938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q10",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        87.55915832519531,
        126.4575424194336,
        106.23345184326172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A10. 변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        206.75999450683594,
        523.7999877929688,
        222.29904174804688
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "총 니트로사민류 기준에 포함되지 않아도 됩니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.68000030517578,
        230.64749145507812,
        357.9599914550781,
        243.30374145507812
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        345.0074768066406,
        522.239990234375,
        357.6637268066406
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은 무엇이 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        364.2074890136719,
        170.03623962402344,
        376.8637390136719
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q11",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        307.3991394042969,
        126.4575424194336,
        326.0734558105469
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A11. 구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        445.67999267578125,
        523.7999877929688,
        461.2190246582031
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.43999481201172,
        469.5674743652344,
        523.9199829101562,
        482.2237243652344
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.43999481201172,
        489.9674987792969,
        523.7999877929688,
        502.6237487792969
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등이 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.43999481201172,
        510.36749267578125,
        178.67437744140625,
        523.0237426757812
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다. NDSRIs의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        532.8074951171875,
        523.9199829101562,
        545.4637451171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.83999633789062,
        553.2074584960938,
        523.7999877929688,
        565.8637084960938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.83999633789062,
        573.6074829101562,
        523.7999877929688,
        586.2637329101562
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.83999633789062,
        594.0075073242188,
        502.0799865722656,
        606.6637573242188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        197.0399932861328,
        621.0075073242188,
        498.8699951171875,
        633.6637573242188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CAS no.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        197.0399932861328,
        621.0075073242188,
        498.8699951171875,
        633.6637573242188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI(ng/일)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        197.0399932861328,
        621.0075073242188,
        498.8699951171875,
        633.6637573242188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitrosodi-methylamine(NDMA)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        636.6074829101562,
        481.3199768066406,
        649.2637329101562
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "62-75-9",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        636.6074829101562,
        481.3199768066406,
        649.2637329101562
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        636.6074829101562,
        481.3199768066406,
        649.2637329101562
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        652.3275146484375,
        484.3199768066406,
        664.9837646484375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "64091-91-4",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        652.3275146484375,
        484.3199768066406,
        664.9837646484375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        652.3275146484375,
        484.3199768066406,
        664.9837646484375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso morpholine (NMOR)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        667.927490234375,
        484.3199768066406,
        680.583740234375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "59-89-2",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        667.927490234375,
        484.3199768066406,
        680.583740234375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "127",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        667.927490234375,
        484.3199768066406,
        680.583740234375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso piperidine (NPIP)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        683.6474609375,
        493.3199768066406,
        696.3037109375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100-75-4",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        683.6474609375,
        493.3199768066406,
        696.3037109375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1300",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        683.6474609375,
        493.3199768066406,
        696.3037109375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-nitroso pyrrolidine (NPYR)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        699.2474975585938,
        487.3199768066406,
        711.9037475585938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "930-55-2",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        699.2474975585938,
        487.3199768066406,
        711.9037475585938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1700",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.97952270507812,
        699.2474975585938,
        487.3199768066406,
        711.9037475585938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        141.4875030517578,
        522.3599853515625,
        154.1437530517578
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        160.6875,
        111.71624755859375,
        173.34375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q12",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        100.27915954589844,
        126.4575424194336,
        118.95345306396484
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A12. 원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        230.51998901367188,
        496.55999755859375,
        246.0590362548828
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        256.4474792480469,
        517.7999877929688,
        269.1037292480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준으로 설정할 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.5199966430664,
        276.8475036621094,
        249.3543701171875,
        289.5037536621094
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        299.16748046875,
        523.7999877929688,
        311.82373046875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        319.5675048828125,
        523.7999877929688,
        332.2237548828125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합이 10-5 이하가 되도록 관리되어야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.27999877929688,
        338.3999938964844,
        323.15435791015625,
        352.6237487792969
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        489.9674987792969,
        450.83624267578125,
        502.6237487792969
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q13",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        439.2791442871094,
        126.4575424194336,
        457.9534606933594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A13. 의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        568.3199462890625,
        517.8300170898438,
        583.8590087890625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        592.2074584960938,
        442.1943664550781,
        604.8637084960938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 53 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 17.03999900817871,
      "font_name": "Haansoft Batang",
      "bbox": [
        69.83999633789062,
        77.89289093017578,
        272.3999938964844,
        94.9328842163086
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한시적 허용기준 적용",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        69.83999633789062,
        77.89289093017578,
        272.3999938964844,
        94.9328842163086
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류의 한시적 허용기준 어떻게 정하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        172.8074951171875,
        349.9162292480469,
        185.4637451171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q14",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        129.19915771484375,
        126.4575424194336,
        147.8734588623047
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A14. 식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        266.2799987792969,
        523.7999877929688,
        280.5037536621094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        286.67999267578125,
        523.7999877929688,
        300.90374755859375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        308.6474914550781,
        517.7999877929688,
        321.3037414550781
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준을 설정합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        329.0474853515625,
        202.19436645507812,
        341.7037353515625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        351.36749267578125,
        517.7999877929688,
        364.02374267578125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        371.7674865722656,
        523.7999877929688,
        384.4237365722656
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        392.16748046875,
        523.7999877929688,
        404.82373046875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        412.5675048828125,
        178.19436645507812,
        425.2237548828125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        444.9674987792969,
        517.7999877929688,
        457.6237487792969
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.36000061035156,
        464.16748046875,
        132.59437561035156,
        476.82373046875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        556.6875,
        522.239990234375,
        569.34375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용이 가능한가요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        575.8875122070312,
        178.43624877929688,
        588.5437622070312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q15",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        512.119140625,
        126.4575424194336,
        530.7933959960938
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A15. 의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        646.43994140625,
        523.7999877929688,
        661.97900390625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        670.447509765625,
        517.7999877929688,
        683.103759765625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상 투여하는 의약품 또한 적용 대상임을 알려드립니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        690.8474731445312,
        386.8800048828125,
        703.5037231445312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        713.16748046875,
        383.7543640136719,
        725.82373046875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 54 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        142.32749938964844,
        522.239990234375,
        171.78375244140625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준 적용을 제안할 수 있나요? 보고와 함께 제출해야 하는 자료는 무엇인가요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        142.32749938964844,
        522.239990234375,
        171.78375244140625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q16",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        99.91915893554688,
        126.4575424194336,
        118.59345245361328
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A16. Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        244.9199981689453,
        523.7999877929688,
        260.45904541015625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.79999542236328,
        267.3599853515625,
        523.7999877929688,
        281.583740234375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.79999542236328,
        287.7599792480469,
        504.7200012207031,
        301.9837341308594
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.83999633789062,
        309.94427490234375,
        521.6813354492188,
        324.62835693359375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        98.5199966430664,
        329.5042724609375,
        457.44000244140625,
        344.1883544921875
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.83999633789062,
        351.1042785644531,
        517.8004150390625,
        365.7883605957031
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간을 분석한 자료",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        97.19999694824219,
        370.6642761230469,
        196.19964599609375,
        385.3483581542969
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        526.927490234375,
        517.1962280273438,
        539.583740234375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q17",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        476.119140625,
        126.4575424194336,
        494.79345703125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A17. 니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        606.8399658203125,
        523.7999877929688,
        622.3790283203125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.15999603271484,
        630.7274780273438,
        523.7999877929688,
        643.3837280273438
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알려드립니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.15999603271484,
        651.1275024414062,
        168.3543701171875,
        663.7837524414062
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 55 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        142.32749938964844,
        430.6762390136719,
        154.98374938964844
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q18",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        95.71916198730469,
        126.4575424194336,
        114.3934555053711
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A18. 원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        219.95999145507812,
        523.7999877929688,
        235.49903869628906
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.15999603271484,
        243.8474884033203,
        529.7999877929688,
        256.50372314453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가 및 관리전략을 수립하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.15999603271484,
        264.24749755859375,
        329.3943786621094,
        276.90374755859375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 56 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 17.03999900817871,
      "font_name": "Haansoft Batang",
      "bbox": [
        69.83999633789062,
        77.89289093017578,
        357.9599914550781,
        94.9328842163086
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 위험평가, 보고 및 조치방안",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        69.83999633789062,
        77.89289093017578,
        357.9599914550781,
        94.9328842163086
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        177.6074981689453,
        528.239990234375,
        190.2637481689453
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        196.8074951171875,
        528.239990234375,
        209.4637451171875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수행하여야 하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        216.0074920654297,
        176.396240234375,
        228.6637420654297
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q19",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        137.23915100097656,
        126.4575424194336,
        155.9134521484375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A19. 의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        292.44000244140625,
        530.1599731445312,
        307.9790344238281
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        316.3274841308594,
        470.7543640136719,
        328.9837341308594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        338.7674865722656,
        530.1599731445312,
        351.4237365722656
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.47999572753906,
        359.16748046875,
        530.0399780273438,
        371.82373046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수집·검토하고,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.47999572753906,
        379.5675048828125,
        174.83436584472656,
        392.2237548828125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        400.4474792480469,
        530.0399780273438,
        414.6637268066406
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.95999908447266,
        420.6000061035156,
        530.1599731445312,
        436.1390380859375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.95999908447266,
        442.927490234375,
        530.0399780273438,
        457.14373779296875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따른 단계별 조치를 해야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.95999908447266,
        464.8874816894531,
        264.474365234375,
        477.5437316894531
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        487.3274841308594,
        489.5999755859375,
        499.9837341308594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "새로운 불순물 정보 확인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        74.4000015258789,
        522.8242797851562,
        200.87998962402344,
        537.50830078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▶",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        208.44000244140625,
        559.8294677734375,
        224.40000915527344,
        581.0575561523438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물 평가 및 시험",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        244.4399871826172,
        522.8242797851562,
        348.9599914550781,
        537.50830078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "▶",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        370.3199768066406,
        559.8294677734375,
        386.27996826171875,
        581.0575561523438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단계별 조치",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        426.8399963378906,
        522.8242797851562,
        487.44000244140625,
        537.50830078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 국내·외 규제기관 발표 및",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        72.83999633789062,
        539.7197265625,
        205.47988891601562,
        552.9673461914062
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련 문헌 조사 등 불순물",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.08000183105469,
        552.7997436523438,
        205.4798126220703,
        579.00732421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모니터링(상시)",
      "font_size": 9.828072547912598,
      "font_name": "MalgunGothic",
      "bbox": [
        85.08000183105469,
        552.7997436523438,
        205.4798126220703,
        579.00732421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 발생가능성 평가(인지일로부터",
      "font_size": 9.828072547912598,
      "font_name": "MalgunGothic",
      "bbox": [
        230.51998901367188,
        539.7197265625,
        366.2894287109375,
        552.9673461914062
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3개월이내)",
      "font_size": 9.828072547912598,
      "font_name": "MalgunGothic",
      "bbox": [
        242.63999938964844,
        552.7997436523438,
        288.7948303222656,
        566.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 위해 발견 시 신속하게 시험",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        230.51998901367188,
        565.7597045898438,
        362.2686767578125,
        579.00732421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사 실시",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        242.63999938964844,
        578.7197265625,
        284.86822509765625,
        591.9673461914062
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 초과 검출 시 식약처 보고(기준 미정",
      "font_size": 8.499602317810059,
      "font_name": "MalgunGothicBold",
      "bbox": [
        230.51998901367188,
        592.0045776367188,
        365.58197021484375,
        603.9752807617188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물은 검출 시 보고)",
      "font_size": 8.499602317810059,
      "font_name": "MalgunGothicBold",
      "bbox": [
        248.87998962402344,
        603.6445922851562,
        327.71295166015625,
        615.6152954101562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•검출수준에 따른 단계별 조치",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.8399963378906,
        539.7197265625,
        523.5999755859375,
        566.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•공정개선 등 저감화 조치 또는",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        393.8399963378906,
        539.7197265625,
        523.5999755859375,
        566.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준설정 등 허가변경 후속",
      "font_size": 9.461679458618164,
      "font_name": "MalgunGothicBold",
      "bbox": [
        402.47998046875,
        565.7597045898438,
        523.8497924804688,
        605.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치(인지일로부터 2년 이내,",
      "font_size": 9.828072547912598,
      "font_name": "MalgunGothic",
      "bbox": [
        402.47998046875,
        565.7597045898438,
        523.8497924804688,
        605.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요시 연장)",
      "font_size": 9.828072547912598,
      "font_name": "MalgunGothic",
      "bbox": [
        402.47998046875,
        565.7597045898438,
        523.8497924804688,
        605.04736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【관련문서】",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        653.407470703125,
        135.239990234375,
        666.063720703125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.43999481201172,
        674.0399780273438,
        530.1599731445312,
        689.5790405273438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘검출 수준에 따른 단계적 조치’ 참고",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.75999450683594,
        696.1199340820312,
        290.8800048828125,
        711.6589965820312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 57 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        121.20750427246094,
        492.59625244140625,
        133.86375427246094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q20",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        77.59915924072266,
        126.4575424194336,
        96.27345275878906
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A20. 새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        196.91998291015625,
        517.7999877929688,
        212.4590301513672
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.27999877929688,
        220.927490234375,
        499.4343566894531,
        233.583740234375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        243.24749755859375,
        517.7999877929688,
        255.90374755859375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        263.6474914550781,
        523.7999877929688,
        276.3037414550781
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        284.0474853515625,
        130.55438232421875,
        296.7037353515625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        306.48748779296875,
        523.7999877929688,
        319.14373779296875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        326.8874816894531,
        509.03436279296875,
        339.5437316894531
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        468.0074768066406,
        519.2362670898438,
        480.6637268066406
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q21",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        424.3991394042969,
        126.4575424194336,
        443.0734558105469
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A21. 위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        551.9999389648438,
        523.7999877929688,
        567.5390014648438
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수립하여 실시할 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.79999542236328,
        575.8875122070312,
        269.0400085449219,
        588.5437622070312
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        598.3275146484375,
        523.7999877929688,
        610.9837646484375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.63999938964844,
        618.7274780273438,
        516.3543701171875,
        631.3837280273438
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 58 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        121.08749389648438,
        528.3599853515625,
        150.5437469482422
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항을 식약처에 보고해야 하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        121.08749389648438,
        528.3599853515625,
        150.5437469482422
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q22",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        78.67916107177734,
        126.4575424194336,
        97.35345458984375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A22. 니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        223.8074951171875,
        523.7999877929688,
        236.4637451171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우, 식약처 보고 대상은 아닙니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        96.95999908447266,
        244.20748901367188,
        295.4343566894531,
        256.8637390136719
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        266.6474914550781,
        523.7999877929688,
        279.3037414550781
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        287.0474853515625,
        517.6743774414062,
        299.7037353515625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        66.83999633789062,
        306.82427978515625,
        497.1600036621094,
        321.50836181640625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        330.12750244140625,
        517.7999877929688,
        342.78375244140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "책임자의 책임하에 문서화하고 보관하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        350.5274963378906,
        383.03436279296875,
        363.1837463378906
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        464.6474914550781,
        431.2762451171875,
        477.3037414550781
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q23",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        421.03912353515625,
        126.4575424194336,
        439.71343994140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        557.6400146484375,
        523.7999877929688,
        571.0237426757812
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        578.7675170898438,
        523.7999877929688,
        591.4237670898438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처에 신속히 보고하도록 하였으나,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        599.16748046875,
        305.03436279296875,
        611.82373046875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        619.7999877929688,
        523.7999877929688,
        635.3390502929688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        643.6875,
        523.9199829101562,
        656.34375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등 필요한 조치를 진행하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        664.0874633789062,
        299.03436279296875,
        676.7437133789062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        686.5274658203125,
        523.9199829101562,
        699.1837158203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        706.927490234375,
        491.03436279296875,
        719.583740234375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 59 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.27999877929688,
        124.44749450683594,
        435.1162414550781,
        137.10374450683594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q24",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.95999908447266,
        78.07916259765625,
        126.4575424194336,
        96.75345611572266
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A24. 니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        220.8074951171875,
        523.7999877929688,
        233.4637451171875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.72000122070312,
        241.20748901367188,
        517.7996215820312,
        253.86373901367188
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.72000122070312,
        261.60748291015625,
        517.7999877929688,
        274.26373291015625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며,",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        102.72000122070312,
        282.00750732421875,
        135.95999145507812,
        294.66375732421875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        304.3274841308594,
        523.7999877929688,
        316.9837341308594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등 조치 계획에 관한 자료를 첨부하여야 합니다.",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.31999969482422,
        324.72747802734375,
        369.71435546875,
        337.38372802734375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        345.5999755859375,
        523.3200073242188,
        359.82373046875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.43999481201172,
        366.0,
        523.7999877929688,
        380.2237548828125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.43999481201172,
        387.9674987792969,
        523.3200073242188,
        400.6237487792969
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.43999481201172,
        406.79998779296875,
        523.7999877929688,
        421.02374267578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        100.43999481201172,
        428.7674865722656,
        124.43999481201172,
        441.4237365722656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.83999633789062,
        451.2074890136719,
        523.7999877929688,
        463.8637390136719
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.87999725341797,
        471.60748291015625,
        513.1199951171875,
        484.26373291015625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 60 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅴ",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        72.95999908447266,
        85.46882629394531,
        191.87998962402344,
        103.46882629394531
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참고문헌",
      "font_size": 18.0,
      "font_name": "H2hdrM",
      "bbox": [
        72.95999908447266,
        85.46882629394531,
        191.87998962402344,
        103.46882629394531
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) Control of nitrosamine impurities in human drugs, Guidance for industry,",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        156.9824981689453,
        545.041259765625,
        170.6512451171875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA (2021.2)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.95999908447266,
        180.3824920654297,
        163.650634765625,
        194.05123901367188
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) USP <1469> Nitrosamine impurities",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        206.78250122070312,
        291.87548828125,
        220.4512481689453
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) Assessment report, Procedure under Article 5(3) of regulation EC (No)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        233.1824951171875,
        545.0399780273438,
        246.8512420654297
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "726/2004, Nitrosamine impurities in human medicinal products, Procedure",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.75999450683594,
        256.5824890136719,
        544.9188842773438,
        270.2512512207031
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "number: EMA/H/A-5(3)/1490, EMA, (2020.6.25)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        89.75999450683594,
        279.98248291015625,
        361.4109191894531,
        293.6512451171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) Questions and answer for marketing authorisation holder/applicants on the",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        306.3824768066406,
        544.9203491210938,
        320.0512390136719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.47999572753906,
        329.782470703125,
        544.9198608398438,
        343.45123291015625
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "on nitrosamine impurities in human medicinal products (2024.1.15.)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.47999572753906,
        353.1824645996094,
        483.690673828125,
        366.8512268066406
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        379.5824890136719,
        544.9205932617188,
        393.2512512207031
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-Related Impurities Guidance for Industry (2023.8)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.47999572753906,
        402.98248291015625,
        385.0506286621094,
        416.6512451171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) Assessment and control of DNA reactive (mutagenic) Impurities in",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        429.3824768066406,
        544.9205322265625,
        443.0512390136719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pharmaceuticals to limit potential carcinogenic risk M7(R1), ICH",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.0,
        452.782470703125,
        545.0408325195312,
        466.45123291015625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(International Council for Harmonisation of technical requirements for",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.0,
        476.1824645996094,
        544.9192504882812,
        489.8512268066406
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pharmaceuticals for human use). (2017)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.0,
        499.5824890136719,
        333.8406982421875,
        513.251220703125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        525.9824829101562,
        445.7699890136719,
        539.6512451171875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        552.3824462890625,
        521.3704833984375,
        566.0512084960938
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        578.782470703125,
        538.4400024414062,
        592.4512329101562
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물역학위해관리학회지, 2021:13:10-16.",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        602.1824951171875,
        308.894775390625,
        615.8512573242188
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 61 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 도입배경",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        121.88401794433594,
        135.95999145507812,
        136.88401794433594
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        156.0,
        538.4400024414062,
        173.98500061035156
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.36000061035156,
        179.82937622070312,
        537.8399658203125,
        195.64968872070312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        208.1999969482422,
        545.9400024414062,
        226.18499755859375
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        84.47999572753906,
        232.1493682861328,
        493.3199768066406,
        247.9696807861328
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 정의 및 원리",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        277.8840026855469,
        165.95999145507812,
        292.8840026855469
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        315.7200012207031,
        545.9400024414062,
        333.7049865722656
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.1199951171875,
        341.8293762207031,
        538.5599975585938,
        357.6496887207031
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측되는 발암잠재력으로 분류하는 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        93.1199951171875,
        365.8293762207031,
        370.55999755859375,
        381.6496887207031
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        397.3199768066406,
        538.5599975585938,
        415.3049621582031
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        84.23999786376953,
        421.3199768066406,
        538.5599975585938,
        439.3049621582031
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성 관계(SAR) 개념을 기반으로 함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        84.23999786376953,
        445.3199768066406,
        318.7200012207031,
        463.3049621582031
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        485.3999938964844,
        538.4400024414062,
        503.3849792480469
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.04000091552734,
        511.50933837890625,
        536.760009765625,
        527.3296508789062
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        543.0,
        538.5599975585938,
        560.9849853515625
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.55999755859375,
        569.109375,
        545.9400024414062,
        584.9296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.55999755859375,
        593.109375,
        476.2799987792969,
        608.9296875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        631.5093383789062,
        545.9400024414062,
        647.3296508789062
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조적 특징을 기반으로 예측치를 산출",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        104.5199966430664,
        655.5093383789062,
        374.8800048828125,
        671.3296508789062
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이",
      "font_size": 12.960000038146973,
      "font_name": "T16",
      "bbox": [
        82.55999755859375,
        682.43994140625,
        537.8411865234375,
        697.991943359375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발전하고 자료가 추가됨에 따라 변경될 수 있음",
      "font_size": 12.960000038146973,
      "font_name": "T16",
      "bbox": [
        94.79999542236328,
        703.3199462890625,
        392.1600341796875,
        718.8719482421875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부록 1  발암 잠재력 분류 접근법",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        62.87999725341797,
        78.20401763916016,
        298.91998291015625,
        93.20401763916016
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 62 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 적용범위",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        70.6440200805664,
        135.95999145507812,
        85.6440200805664
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        108.5999984741211,
        533.4829711914062,
        126.58499908447266
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        142.1999969482422,
        531.1199951171875,
        160.18499755859375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        175.8000030517578,
        536.5199584960938,
        193.78500366210938
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        210.95999145507812,
        397.67999267578125,
        228.95999145507812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (적용대상)",
      "font_size": 15.0,
      "font_name": "T13",
      "bbox": [
        64.08000183105469,
        250.00457763671875,
        538.4400024414062,
        268.90496826171875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        250.00457763671875,
        538.4400024414062,
        268.90496826171875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.79999542236328,
        277.02935791015625,
        538.4400024414062,
        292.84967041015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물**",
      "font_size": 9.59999942779541,
      "font_name": "T7",
      "bbox": [
        91.79999542236328,
        297.7200012207031,
        522.124755859375,
        317.3134460449219
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        79.31999969482422,
        328.1999816894531,
        399.3599853515625,
        342.5999755859375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** nitrosated indole 등 제외",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        76.08000183105469,
        348.239990234375,
        218.27999877929688,
        362.6399841308594
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 일반원칙",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        393.92401123046875,
        135.95999145507812,
        408.92401123046875
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ (고려사항)",
      "font_size": 15.0,
      "font_name": "T13",
      "bbox": [
        64.08000183105469,
        429.7115783691406,
        546.0599975585938,
        449.7449645996094
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①두 개의 N-니트로소기를 포함하는 니트로사민류의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        429.7115783691406,
        546.0599975585938,
        449.7449645996094
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        457.79998779296875,
        544.9197998046875,
        473.6896667480469
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        91.55999755859375,
        477.7115783691406,
        545.9400024414062,
        497.7449645996094
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "②α-탄소와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        477.7115783691406,
        545.9400024414062,
        497.7449645996094
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        505.869384765625,
        484.44000244140625,
        521.689697265625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요",
      "font_size": 12.0,
      "font_name": "T16",
      "bbox": [
        79.31999969482422,
        533.0399780273438,
        448.67999267578125,
        547.4400024414062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조",
      "font_size": 12.0,
      "font_name": "T16",
      "bbox": [
        56.63999938964844,
        568.2000122070312,
        342.1199951171875,
        582.6000366210938
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        68.5199966430664,
        456.47998046875,
        86.50499725341797
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        488.8994445800781,
        542.6587524414062,
        521.660400390625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        488.8994445800781,
        542.6587524414062,
        521.660400390625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI)",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        90.95999908447266,
        522.4994506835938,
        492.65625,
        538.4603881835938
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        555.9599609375,
        538.4400024414062,
        573.9449462890625
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.27999877929688,
        579.9599609375,
        545.9400024414062,
        597.9449462890625
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조 특성 점수(표 3)의 합계로 산출함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        92.27999877929688,
        605.9999389648438,
        351.7200012207031,
        621.8896484375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        82.55999755859375,
        628.3199462890625,
        538.4403076171875,
        643.8719482421875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수는 아래의 계산식에 따라 계산해야 함. 니트로사민류에 표 2 및 3의 구",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        93.83999633789062,
        649.0799560546875,
        538.4400024414062,
        664.6319580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        93.83999633789062,
        669.8399658203125,
        432.1199951171875,
        685.3919677734375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.55999755859375,
        699.5345458984375,
        533.5609741210938,
        716.7723999023438
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.55999755859375,
        719.0946044921875,
        533.5612182617188,
        736.3324584960938
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 점수 합계)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        100.55999755859375,
        738.9442749023438,
        173.8837432861328,
        753.6282958984375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.19999694824219,
        95.93460845947266,
        107.75677490234375,
        113.17242431640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.68000030517578,
        111.53460693359375,
        96.5999984741211,
        128.7724151611328
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        111.95999908447266,
        95.93460845947266,
        173.63876342773438,
        113.17242431640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ng/일)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        122.63999938964844,
        103.73460388183594,
        367.4405212402344,
        128.7724151611328
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        122.63999938964844,
        103.73460388183594,
        367.4405212402344,
        128.7724151611328
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        150.2946014404297,
        153.07180786132812,
        167.53240966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26.5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        150.2946014404297,
        153.07180786132812,
        167.53240966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함.*",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        127.12124633789062,
        536.1787109375,
        190.46038818359375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        127.12124633789062,
        536.1787109375,
        190.46038818359375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        127.12124633789062,
        536.1787109375,
        190.46038818359375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호하는 것으로 간주됨",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        127.12124633789062,
        536.1787109375,
        190.46038818359375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        227.57460021972656,
        151.63262939453125,
        244.81240844726562
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        227.57460021972656,
        151.63262939453125,
        244.81240844726562
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량은 각각 96ng/일와 100ng/일임. 분류 2로 분류된",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖는 것으로 예측됨",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        189.37945556640625,
        536.2987670898438,
        283.34039306640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        304.8546142578125,
        151.63262939453125,
        322.0924072265625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "400",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        304.8546142578125,
        151.63262939453125,
        322.0924072265625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        282.1394348144531,
        536.1787109375,
        344.900390625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        282.1394348144531,
        536.1787109375,
        344.900390625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        282.1394348144531,
        536.1787109375,
        344.900390625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 설정됨",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        282.1394348144531,
        536.1787109375,
        344.900390625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        374.214599609375,
        156.55184936523438,
        391.452392578125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        374.214599609375,
        156.55184936523438,
        391.452392578125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4로",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류된",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류는",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-하이드록실화를",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        343.8194580078125,
        536.2987670898438,
        359.7803955078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        359.41943359375,
        536.1787109375,
        422.1803894042969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        359.41943359375,
        536.1787109375,
        422.1803894042969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선호되기 때문에 발암잠재력이 낮을 것으로 예측됨. 섭취허용량",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        359.41943359375,
        536.1787109375,
        422.1803894042969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500ng/일은 ICH M7에 따라 TTC로 설정됨.**",
      "font_size": 7.679999828338623,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        359.41943359375,
        536.1787109375,
        422.1803894042969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        443.6946105957031,
        156.55184936523438,
        460.9324035644531
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,500",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        80.04000091552734,
        443.6946105957031,
        156.55184936523438,
        460.9324035644531
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        421.0994567871094,
        536.2987670898438,
        483.8603820800781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "α-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        421.0994567871094,
        536.2987670898438,
        483.8603820800781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        421.0994567871094,
        536.2987670898438,
        483.8603820800781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.**",
      "font_size": 7.679999828338623,
      "font_name": "MalgunGothic",
      "bbox": [
        179.1599884033203,
        421.0994567871094,
        536.2987670898438,
        483.8603820800781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 64 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        77.6946029663086,
        530.2803955078125,
        94.93241882324219
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 α-탄소 상의 수소 원자 개수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        84.72000122070312,
        112.97460174560547,
        264.8399353027344,
        130.21241760253906
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가장 작은 수부터 나열)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        113.75999450683594,
        122.33460998535156,
        518.52001953125,
        148.828369140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        113.75999450683594,
        122.33460998535156,
        518.52001953125,
        148.828369140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        113.75999450683594,
        122.33460998535156,
        518.52001953125,
        148.828369140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        183.53460693359375,
        184.0181121826172,
        200.7724151611328
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3*",
      "font_size": 8.279999732971191,
      "font_name": "MalgunGothic",
      "bbox": [
        477.239990234375,
        182.98822021484375,
        487.9573974609375,
        200.7724151611328
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0, 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        257.2146301269531,
        184.0181121826172,
        274.4524230957031
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        479.03997802734375,
        257.2146301269531,
        486.1781005859375,
        274.4524230957031
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        330.8946228027344,
        184.0181121826172,
        348.1324157714844
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        479.03997802734375,
        330.8946228027344,
        486.1781005859375,
        348.1324157714844
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1, 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        404.5746154785156,
        184.0181121826172,
        421.8124084472656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        479.03997802734375,
        404.5746154785156,
        486.1781005859375,
        421.8124084472656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        478.2546081542969,
        184.0181121826172,
        495.4924011230469
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        479.03997802734375,
        478.2546081542969,
        486.1781005859375,
        495.4924011230469
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        160.3199920654297,
        551.9345703125,
        184.0181121826172,
        569.1724243164062
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        479.03997802734375,
        551.9345703125,
        486.1781005859375,
        569.1724243164062
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨. Methylene α-탄소가",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        78.1199951171875,
        609.4994506835938,
        531.2587280273438,
        625.4603881835938
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ethyl기의 일부인 경우 2점을 적용해야함",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        89.5199966430664,
        627.2594604492188,
        314.5199890136719,
        643.2203979492188
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 65 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 2. 비활성화 구조 특성 및 관련 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        72.77460479736328,
        294.0005187988281,
        90.01242065429688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        93.94429779052734,
        542.3212280273438,
        108.62835693359375
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합산해야 함. 표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        62.15999984741211,
        110.5042953491211,
        542.3213500976562,
        158.1883544921875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        62.15999984741211,
        110.5042953491211,
        542.3213500976562,
        158.1883544921875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        62.15999984741211,
        110.5042953491211,
        542.3213500976562,
        158.1883544921875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        114.72000122070312,
        168.77459716796875,
        523.5567626953125,
        204.13241577148438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        114.72000122070312,
        168.77459716796875,
        523.5567626953125,
        204.13241577148438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 비활성화",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        114.72000122070312,
        168.77459716796875,
        523.5567626953125,
        204.13241577148438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조 특성 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        114.72000122070312,
        168.77459716796875,
        523.5567626953125,
        204.13241577148438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분자 상 모든 위치에 존재하는 카르복실산기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        228.53460693359375,
        269.1573486328125,
        245.7724151611328
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        228.53460693359375,
        484.9786071777344,
        245.7724151611328
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피롤리딘 고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        283.734619140625,
        234.23980712890625,
        300.972412109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        283.734619140625,
        484.9786071777344,
        300.972412109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하나 이상의 황 원자를 포함하는 6원",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        326.3346252441406,
        278.7562255859375,
        361.8124084472656
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        326.3346252441406,
        278.7562255859375,
        361.8124084472656
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        335.4546203613281,
        484.9786071777344,
        352.6924133300781
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5원 또는 6원 고리의 N-니트로소기*",
      "font_size": 8.279999732971191,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        386.6282043457031,
        244.59738159179688,
        404.41241455078125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        387.17462158203125,
        484.9786071777344,
        404.41241455078125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모르폴린 고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        439.0146179199219,
        234.23980712890625,
        456.2524108886719
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        439.0146179199219,
        484.9786071777344,
        456.2524108886719
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7원 고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        490.734619140625,
        205.91981506347656,
        507.972412109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        490.734619140625,
        484.9786071777344,
        507.972412109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형 N-니트로소기의 양쪽에 ≥5 인",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        544.4945678710938,
        278.8768310546875,
        616.3324584960938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연속된 비수소 원자(고리형 또는 비고리형)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        544.4945678710938,
        278.8768310546875,
        616.3324584960938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사슬. 각 사슬에서 4개 이하의 원자가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        544.4945678710938,
        278.8768310546875,
        616.3324584960938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동일한 고리에 있을 수 있음",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        544.4945678710938,
        278.8768310546875,
        616.3324584960938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        571.7345581054688,
        484.9786071777344,
        588.972412109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기(고리형 또는 비고리형)의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        648.174560546875,
        278.8762512207031,
        683.6524047851562
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽에서만 α-탄소에 결합된 전자 끄는 기**",
      "font_size": 8.279999732971191,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        648.174560546875,
        278.8762512207031,
        683.6524047851562
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        657.2945556640625,
        484.9786071777344,
        674.5324096679688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기(고리형 또는 비고리형)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        711.5345458984375,
        278.8768310546875,
        747.012451171875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양쪽에서 α-탄소에 결합된 전자 끄는 기**",
      "font_size": 8.279999732971191,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        711.5345458984375,
        278.8768310546875,
        747.012451171875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        720.6546020507812,
        484.9786071777344,
        737.8924560546875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 66 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-니트로소기(고리형 또는 비고리형)의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        82.97460174560547,
        278.8762512207031,
        118.3324203491211
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽에서만 β-탄소***에 결합된 하이드록실기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        82.97460174560547,
        278.8762512207031,
        118.3324203491211
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        92.0946044921875,
        484.9786071777344,
        109.3324203491211
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기(고리형 또는 비고리형)의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        156.53460693359375,
        278.8762512207031,
        191.8924102783203
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양쪽에서 β-탄소***에 결합된 하이드록실기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.95690155029297,
        156.53460693359375,
        278.8762512207031,
        191.8924102783203
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        468.5999755859375,
        165.65460205078125,
        484.9786071777344,
        182.8924102783203
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        63.84000015258789,
        223.06430053710938,
        525.1611938476562,
        237.7483673095703
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고리(모두 별도로 계산)로 되어있는 예는 제외됨",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        87.23999786376953,
        239.0242919921875,
        330.35968017578125,
        253.70835876464844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨. 추가적인 전자 끄는 기 예시는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        63.84000015258789,
        260.0242919921875,
        525.1611938476562,
        274.7083740234375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        86.15999603271484,
        275.9842834472656,
        525.2811889648438,
        322.5883483886719
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        86.15999603271484,
        275.9842834472656,
        525.2811889648438,
        322.5883483886719
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "\"β-carbon electron withdrawing groups\"라고 부름",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        86.15999603271484,
        275.9842834472656,
        525.2811889648438,
        322.5883483886719
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "*** β-탄소가 sp3 혼성 상태에 있어야 함",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        63.84000015258789,
        328.2942810058594,
        268.67999267578125,
        343.4683532714844
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 67 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 3. 활성화 구조 특성 및 관련 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        77.6946029663086,
        280.91998291015625,
        94.93241882324219
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        98.98429870605469,
        542.4412231445312,
        113.6683578491211
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합산해야 함. 표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음. 다음 예는 예시일 뿐",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        62.15999984741211,
        115.4242935180664,
        538.43994140625,
        130.1083526611328
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이며 모든 것을 포괄하지는 않음",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        62.15999984741211,
        131.9842987060547,
        217.68017578125,
        146.66836547851562
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.7199935913086,
        162.1746063232422,
        516.3567504882812,
        188.53240966796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.7199935913086,
        162.1746063232422,
        516.3567504882812,
        188.53240966796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 활성화",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.7199935913086,
        162.1746063232422,
        516.3567504882812,
        188.53240966796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조 특성 점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        432.5999755859375,
        180.4145965576172,
        519.5999145507812,
        197.65240478515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-탄소에 결합된 아릴기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        203.81460571289062,
        211.800537109375,
        221.0524139404297
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(즉, N-니트로소기의 벤질 또는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        223.25460815429688,
        272.63677978515625,
        240.49241638183594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유사-벤질 치환기)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        242.81459045410156,
        175.06874084472656,
        260.0523986816406
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        469.91998291015625,
        223.25460815429688,
        482.3380126953125,
        240.49241638183594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "β-탄소에 결합된 메틸기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        277.734619140625,
        210.8405303955078,
        294.972412109375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(고리형 또는 비고리형)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        297.29461669921875,
        206.26873779296875,
        314.53240966796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        469.91998291015625,
        287.5746154785156,
        482.3380126953125,
        304.8124084472656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 68 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.55999755859375,
        74.81460571289062,
        440.7599792480469,
        92.05242156982422
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.7168960571289,
        119.214599609375,
        255.59677124023438,
        136.45240783691406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        139.974609375,
        215.1398468017578,
        157.21241760253906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        119.214599609375,
        391.1514587402344,
        138.73240661621094
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        119.214599609375,
        391.1514587402344,
        138.73240661621094
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        139.974609375,
        453.9599914550781,
        157.21241760253906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        171.239990234375,
        159.78404235839844,
        203.1599884033203,
        187.71568298339844
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.7168960571289,
        191.45460510253906,
        280.19622802734375,
        208.69241333007812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        212.214599609375,
        280.19677734375,
        229.45240783691406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        233.0946044921875,
        248.1398468017578,
        250.33241271972656
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        201.8946075439453,
        391.1514587402344,
        221.41241455078125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        201.8946075439453,
        391.1514587402344,
        221.41241455078125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        222.65460205078125,
        453.9599914550781,
        239.8924102783203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        171.239990234375,
        252.78402709960938,
        203.1599884033203,
        280.7156677246094
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.7168960571289,
        284.4546203613281,
        280.19622802734375,
        301.6924133300781
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        305.3346252441406,
        149.4298858642578,
        322.5724182128906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        284.4546203613281,
        391.1514587402344,
        303.972412109375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        284.4546203613281,
        391.1514587402344,
        303.972412109375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        305.3346252441406,
        453.9599914550781,
        322.5724182128906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        325.0240478515625,
        228.1199951171875,
        352.9556884765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        356.6946105957031,
        233.671875,
        373.9324035644531
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        377.5746154785156,
        198.93984985351562,
        394.8124084472656
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        356.6946105957031,
        391.1514587402344,
        376.21240234375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        356.6946105957031,
        391.1514587402344,
        376.21240234375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        377.5746154785156,
        453.9599914550781,
        394.8124084472656
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        397.2640380859375,
        228.1199951171875,
        425.1956787109375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        428.9346008300781,
        391.1514587402344,
        456.6123962402344
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        428.9346008300781,
        391.1514587402344,
        456.6123962402344
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        428.9346008300781,
        391.1514587402344,
        456.6123962402344
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        449.8146057128906,
        446.7599792480469,
        467.0523986816406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        469.6240234375,
        228.1199951171875,
        497.5556640625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        501.2945861816406,
        391.1514587402344,
        528.8524169921875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        501.2945861816406,
        391.1514587402344,
        528.8524169921875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        501.2945861816406,
        391.1514587402344,
        528.8524169921875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        522.0545654296875,
        446.7599792480469,
        539.2924194335938
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        541.864013671875,
        228.1199951171875,
        569.795654296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        573.5346069335938,
        391.1514587402344,
        601.0924072265625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        573.5346069335938,
        391.1514587402344,
        601.0924072265625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        573.5346069335938,
        391.1514587402344,
        601.0924072265625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        594.2945556640625,
        449.6399841308594,
        611.5324096679688
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        64.55999755859375,
        630.174560546875,
        502.43951416015625,
        647.4124145507812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 69 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 검토사례",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        56.63999938964844,
        77.7240219116211,
        135.95999145507812,
        92.7240219116211
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 1] N-Nitroso-felodipine",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.55999755859375,
        107.41944885253906,
        225.837646484375,
        123.38038635253906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 분류 5",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        277.44000244140625,
        178.45944213867188,
        500.2799987792969,
        194.42037963867188
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        277.44000244140625,
        178.45944213867188,
        500.2799987792969,
        194.42037963867188
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.7168960571289,
        259.49462890625,
        255.59677124023438,
        276.732421875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        280.3746032714844,
        215.1398468017578,
        297.6123962402344
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        259.49462890625,
        391.1514587402344,
        279.0124206542969
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        259.49462890625,
        391.1514587402344,
        279.0124206542969
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        351.239990234375,
        280.3746032714844,
        453.9599914550781,
        297.6123962402344
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        171.239990234375,
        300.06402587890625,
        203.1599884033203,
        327.99566650390625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.7168960571289,
        331.734619140625,
        280.19622802734375,
        348.972412109375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        352.6146240234375,
        280.19677734375,
        369.8524169921875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        373.3746032714844,
        248.2410888671875,
        390.6123962402344
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        293.8800048828125,
        342.17462158203125,
        390.7781066894531,
        361.6924133300781
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        293.8800048828125,
        342.17462158203125,
        390.7781066894531,
        361.6924133300781
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        362.9346008300781,
        453.9599914550781,
        380.1723937988281
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        171.239990234375,
        393.18402099609375,
        203.1599884033203,
        421.11566162109375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.7168960571289,
        424.8546142578125,
        280.19622802734375,
        442.0924072265625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        445.6146240234375,
        149.2659454345703,
        462.8524169921875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        424.8546142578125,
        390.7781066894531,
        444.3724060058594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        306.8399963378906,
        424.8546142578125,
        390.7781066894531,
        444.3724060058594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        445.6146240234375,
        453.9599914550781,
        462.8524169921875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        465.4240417480469,
        228.1199951171875,
        493.3556823730469
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        497.0946044921875,
        233.11500549316406,
        514.3323974609375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        517.8545532226562,
        199.0410919189453,
        535.0924072265625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        306.8399963378906,
        497.0946044921875,
        390.7781066894531,
        516.6124267578125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        306.8399963378906,
        497.0946044921875,
        390.7781066894531,
        516.6124267578125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        517.8545532226562,
        453.9599914550781,
        535.0924072265625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        537.6640014648438,
        228.1199951171875,
        565.5956420898438
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        569.3345947265625,
        390.7781066894531,
        597.012451171875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        569.3345947265625,
        390.7781066894531,
        597.012451171875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        569.3345947265625,
        390.7781066894531,
        597.012451171875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        590.0946044921875,
        446.7599792480469,
        607.3324584960938
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        609.904052734375,
        228.1199951171875,
        637.835693359375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        641.5745849609375,
        390.7781066894531,
        669.25244140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        641.5745849609375,
        390.7781066894531,
        669.25244140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        641.5745849609375,
        390.7781066894531,
        669.25244140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        662.3345947265625,
        446.7599792480469,
        679.5724487304688
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        682.14404296875,
        228.1199951171875,
        710.07568359375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        713.8145751953125,
        390.7781066894531,
        741.492431640625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        98.75999450683594,
        713.8145751953125,
        390.7781066894531,
        741.492431640625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        98.75999450683594,
        713.8145751953125,
        390.7781066894531,
        741.492431640625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        351.239990234375,
        734.694580078125,
        449.6399841308594,
        751.9324340820312
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 70 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 2] N-Nitroso-enalapril",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.119998931884766,
        76.4594497680664,
        216.77296447753906,
        92.4203872680664
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재력 분류 5",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.0,
        142.09945678710938,
        498.8399963378906,
        158.06039428710938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.0,
        142.09945678710938,
        498.8399963378906,
        158.06039428710938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        227.69459533691406,
        254.15676879882812,
        244.93240356445312
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        248.57460021972656,
        213.69984436035156,
        265.8124084472656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        227.69459533691406,
        389.3381042480469,
        247.21241760253906
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        227.69459533691406,
        389.3381042480469,
        247.21241760253906
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        248.57460021972656,
        452.5199890136719,
        265.8124084472656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        268.384033203125,
        201.72000122070312,
        296.315673828125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        300.05462646484375,
        278.7562255859375,
        317.29241943359375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        320.8146057128906,
        278.75677490234375,
        338.0523986816406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        341.5746154785156,
        246.69984436035156,
        358.8124084472656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        310.3746032714844,
        389.7114562988281,
        329.89239501953125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        310.3746032714844,
        389.7114562988281,
        329.89239501953125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        349.79998779296875,
        331.2546081542969,
        452.5199890136719,
        348.4924011230469
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        361.384033203125,
        201.72000122070312,
        389.315673828125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        96.27690124511719,
        393.05462646484375,
        278.7562255859375,
        410.29241943359375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        413.8146057128906,
        147.82594299316406,
        431.0523986816406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        393.05462646484375,
        389.3381042480469,
        412.5724182128906
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        393.05462646484375,
        389.3381042480469,
        412.5724182128906
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        413.8146057128906,
        452.5199890136719,
        431.0523986816406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        433.6240234375,
        226.67999267578125,
        461.5556640625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        465.29461669921875,
        231.6750030517578,
        482.53240966796875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        486.05462646484375,
        197.60108947753906,
        503.29241943359375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        465.29461669921875,
        389.3381042480469,
        484.8124084472656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        465.29461669921875,
        389.3381042480469,
        484.8124084472656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        486.05462646484375,
        452.5199890136719,
        503.29241943359375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        505.864013671875,
        226.67999267578125,
        533.795654296875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        537.5346069335938,
        389.3381042480469,
        565.2124633789062
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        537.5346069335938,
        389.3381042480469,
        565.2124633789062
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        537.5346069335938,
        389.3381042480469,
        565.2124633789062
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        558.2945556640625,
        445.3199768066406,
        575.5324096679688
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        578.10400390625,
        226.67999267578125,
        606.03564453125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        609.7745971679688,
        389.3381042480469,
        637.4524536132812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        609.7745971679688,
        389.3381042480469,
        637.4524536132812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        609.7745971679688,
        389.3381042480469,
        637.4524536132812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        630.6546020507812,
        445.3199768066406,
        647.8924560546875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        650.3440551757812,
        226.67999267578125,
        678.2756958007812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        682.0145874023438,
        389.3381042480469,
        709.6924438476562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        682.0145874023438,
        389.3381042480469,
        709.6924438476562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        682.0145874023438,
        389.3381042480469,
        709.6924438476562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        702.8945922851562,
        448.1999816894531,
        720.1324462890625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 71 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 3] N-Nitroso-ketamine",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.119998931884766,
        76.4594497680664,
        220.31765747070312,
        92.4203872680664
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재력 분류 5",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.0,
        139.69944763183594,
        498.8399963378906,
        155.66038513183594
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.0,
        139.69944763183594,
        498.8399963378906,
        155.66038513183594
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        222.77459716796875,
        254.15676879882812,
        240.0124053955078
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        243.5345916748047,
        213.69984436035156,
        260.77239990234375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        222.77459716796875,
        389.3381042480469,
        242.2924041748047
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        222.77459716796875,
        389.3381042480469,
        242.2924041748047
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        243.5345916748047,
        452.5199890136719,
        260.77239990234375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        263.3440246582031,
        201.72000122070312,
        291.2756652832031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        295.0146179199219,
        278.7562255859375,
        312.2524108886719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        315.7746276855469,
        278.75677490234375,
        333.0124206542969
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        336.65460205078125,
        246.69984436035156,
        353.89239501953125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        305.4546203613281,
        389.3381042480469,
        324.972412109375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        305.4546203613281,
        389.3381042480469,
        324.972412109375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        326.2146301269531,
        452.5199890136719,
        343.4524230957031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        356.3440246582031,
        201.72000122070312,
        384.2756652832031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        388.0146179199219,
        278.7562255859375,
        405.2524108886719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        408.8946228027344,
        147.98988342285156,
        426.1324157714844
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        388.0146179199219,
        389.7114562988281,
        407.53240966796875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        388.0146179199219,
        389.7114562988281,
        407.53240966796875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        349.79998779296875,
        408.8946228027344,
        452.5199890136719,
        426.1324157714844
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        428.58404541015625,
        226.67999267578125,
        456.51568603515625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        460.2546081542969,
        231.6750030517578,
        477.4924011230469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        481.1346130371094,
        197.60108947753906,
        498.3724060058594
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        460.2546081542969,
        389.3381042480469,
        479.77239990234375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        460.2546081542969,
        389.3381042480469,
        479.77239990234375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        481.1346130371094,
        452.5199890136719,
        498.3724060058594
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        500.82403564453125,
        226.67999267578125,
        528.7556762695312
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        532.4945678710938,
        389.3381042480469,
        560.1724243164062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        532.4945678710938,
        389.3381042480469,
        560.1724243164062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        532.4945678710938,
        389.3381042480469,
        560.1724243164062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        553.3745727539062,
        445.3199768066406,
        570.6124267578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        573.1840209960938,
        226.67999267578125,
        601.1156616210938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        604.8545532226562,
        389.3381042480469,
        632.4124145507812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        604.8545532226562,
        389.3381042480469,
        632.4124145507812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        604.8545532226562,
        389.3381042480469,
        632.4124145507812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        625.6145629882812,
        445.3199768066406,
        642.8524169921875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        645.4240112304688,
        226.67999267578125,
        673.3556518554688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        677.0946044921875,
        389.3381042480469,
        704.6524047851562
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        677.0946044921875,
        389.3381042480469,
        704.6524047851562
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        677.0946044921875,
        389.3381042480469,
        704.6524047851562
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        697.8545532226562,
        448.1999816894531,
        715.0924072265625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 72 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 4] N-Nitroso-nebivolol",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.119998931884766,
        76.4594497680664,
        220.25296020507812,
        92.4203872680664
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "α-수소의 개수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "빨간색으로 표시된 구조 특징",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        139.8000030517578,
        145.25460815429688,
        271.75146484375,
        162.49241638183594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        139.8000030517578,
        145.25460815429688,
        271.75146484375,
        162.49241638183594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        93.1199951171875,
        193.25460815429688,
        210.0,
        210.49241638183594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기(고리형 또는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.35690307617188,
        224.0946044921875,
        241.4362335205078,
        272.53240966796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형)의 양쪽에서 β-탄소***에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.35690307617188,
        224.0946044921875,
        241.4362335205078,
        272.53240966796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결합된 하이드록실기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        67.35690307617188,
        224.0946044921875,
        241.4362335205078,
        272.53240966796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        259.67999267578125,
        239.69459533691406,
        276.3114318847656,
        256.9324035644531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형 N-니트로소기의 양쪽에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        290.2146301269531,
        241.43638610839844,
        369.8524169921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≥5 인 연속된 비수소 원자(고리형",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        290.2146301269531,
        241.43638610839844,
        369.8524169921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 비고리형) 사슬.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        290.2146301269531,
        241.43638610839844,
        369.8524169921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 사슬에서 4개 이하의 원자가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        290.2146301269531,
        241.43638610839844,
        369.8524169921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동일한 고리에 있을 수 있음",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        290.2146301269531,
        241.43638610839844,
        369.8524169921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        259.67999267578125,
        321.41461181640625,
        276.3114318847656,
        338.65240478515625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        384.29461669921875,
        271.75146484375,
        401.53240966796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        384.29461669921875,
        271.75146484375,
        401.53240966796875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력점수= 1 + 2 + 1 = 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        78.0,
        411.05462646484375,
        502.79998779296875,
        428.29241943359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        78.0,
        411.05462646484375,
        502.79998779296875,
        428.29241943359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        78.0,
        411.05462646484375,
        502.79998779296875,
        428.29241943359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "*** β-탄소가 sp3 혼성 상태에 있어야함",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        439.8942565917969,
        256.07965087890625,
        455.1883544921875
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 73 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        96.29460144042969,
        254.15676879882812,
        113.53241729736328
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        117.05461120605469,
        213.69984436035156,
        134.29241943359375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        117.05461120605469,
        452.5199890136719,
        134.29241943359375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        136.86404418945312,
        201.72000122070312,
        164.79568481445312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        168.53460693359375,
        278.7562255859375,
        185.7724151611328
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        189.2946014404297,
        278.75677490234375,
        206.53240966796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        210.1746063232422,
        246.69984436035156,
        227.41241455078125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        199.73460388183594,
        452.5199890136719,
        216.972412109375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        229.86404418945312,
        201.72000122070312,
        257.7956848144531
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        261.53460693359375,
        278.7562255859375,
        278.77239990234375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        282.41461181640625,
        147.98988342285156,
        299.65240478515625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        282.41461181640625,
        452.5199890136719,
        299.65240478515625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        302.2240295410156,
        226.67999267578125,
        330.1556701660156
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        333.8946228027344,
        232.23187255859375,
        351.1324157714844
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        354.65460205078125,
        197.49984741210938,
        371.89239501953125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.7114562988281,
        353.41241455078125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.7114562988281,
        353.41241455078125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        349.79998779296875,
        354.65460205078125,
        452.5199890136719,
        371.89239501953125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        374.4640197753906,
        226.67999267578125,
        402.3956604003906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        426.8946228027344,
        445.3199768066406,
        444.1324157714844
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        446.70404052734375,
        226.67999267578125,
        474.63568115234375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        499.1346130371094,
        445.3199768066406,
        516.3724365234375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        518.9440307617188,
        226.67999267578125,
        546.8756713867188
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        571.3745727539062,
        448.1999816894531,
        588.6124267578125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 74 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 5] N-Nitroso-meropenem",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.119998931884766,
        76.4594497680664,
        236.92007446289062,
        92.4203872680664
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "α-수소의 개수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "빨간색으로 표시된 구조 특징",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        139.8000030517578,
        149.93460083007812,
        271.75146484375,
        167.1724090576172
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        139.8000030517578,
        149.93460083007812,
        271.75146484375,
        167.1724090576172
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        93.1199951171875,
        202.73460388183594,
        210.0,
        219.972412109375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분자 상 모든 위치에 존재하는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        244.0146026611328,
        276.3114318847656,
        276.8524169921875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "카르복실산기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        244.0146026611328,
        276.3114318847656,
        276.8524169921875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.4000015258789,
        244.0146026611328,
        276.3114318847656,
        276.8524169921875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피롤리딘 고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        325.49462890625,
        276.3114318847656,
        342.732421875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.4000015258789,
        325.49462890625,
        276.3114318847656,
        342.732421875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로소기(고리형 또는",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        383.5746154785156,
        221.8800048828125,
        432.0124206542969
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고리형)의 한쪽에서만",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        383.5746154785156,
        221.8800048828125,
        432.0124206542969
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-탄소에 결합된 전자 끄는 기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        383.5746154785156,
        221.8800048828125,
        432.0124206542969
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        259.67999267578125,
        399.17462158203125,
        276.3114318847656,
        416.41241455078125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        451.2546081542969,
        271.75146484375,
        468.4924011230469
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        451.2546081542969,
        271.75146484375,
        468.4924011230469
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력점수= 3 + 3 + 3 + 1 = 10",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.3599967956543,
        477.8946228027344,
        502.79998779296875,
        495.1324157714844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재력 분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.3599967956543,
        477.8946228027344,
        502.79998779296875,
        495.1324157714844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.3599967956543,
        477.8946228027344,
        502.79998779296875,
        495.1324157714844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 75 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        96.29460144042969,
        254.15676879882812,
        113.53241729736328
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        117.05461120605469,
        213.69984436035156,
        134.29241943359375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        117.05461120605469,
        452.5199890136719,
        134.29241943359375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        136.86404418945312,
        201.72000122070312,
        164.79568481445312
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        168.53460693359375,
        278.7562255859375,
        185.7724151611328
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        189.2946014404297,
        278.75677490234375,
        206.53240966796875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        210.1746063232422,
        246.69984436035156,
        227.41241455078125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        199.73460388183594,
        452.5199890136719,
        216.972412109375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        229.86404418945312,
        201.72000122070312,
        257.7956848144531
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        261.53460693359375,
        278.7562255859375,
        278.77239990234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        282.41461181640625,
        147.98988342285156,
        299.65240478515625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        282.41461181640625,
        452.5199890136719,
        299.65240478515625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        302.2240295410156,
        226.67999267578125,
        330.1556701660156
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        333.8946228027344,
        232.23187255859375,
        351.1324157714844
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        354.65460205078125,
        197.49984741210938,
        371.89239501953125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.7114562988281,
        353.41241455078125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.7114562988281,
        353.41241455078125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        349.79998779296875,
        354.65460205078125,
        452.5199890136719,
        371.89239501953125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        374.4640197753906,
        226.67999267578125,
        402.3956604003906
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.3381042480469,
        433.6924133300781
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        426.8946228027344,
        445.3199768066406,
        444.1324157714844
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        446.70404052734375,
        226.67999267578125,
        474.63568115234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        499.1346130371094,
        445.3199768066406,
        516.3724365234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        518.9440307617188,
        226.67999267578125,
        546.8756713867188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        571.3745727539062,
        448.1999816894531,
        588.6124267578125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 76 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시 6] N-Nitroso-desloratadine",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.119998931884766,
        76.4594497680664,
        244.19764709472656,
        92.4203872680664
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "α-수소의 개수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "빨간색으로 표시된 구조 특징",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.07999420166016,
        100.97460174560547,
        491.6399841308594,
        118.21241760253906
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        139.8000030517578,
        157.0146026611328,
        271.75146484375,
        174.25241088867188
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        139.8000030517578,
        157.0146026611328,
        271.75146484375,
        174.25241088867188
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        93.1199951171875,
        216.8946075439453,
        210.0,
        234.13241577148438
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5원 또는 6원 고리의 N-니트로소기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        68.4000015258789,
        273.05462646484375,
        276.3114318847656,
        290.29241943359375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "+2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.4000015258789,
        273.05462646484375,
        276.3114318847656,
        290.29241943359375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활성화 구조 특성",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        332.2146301269531,
        271.75146484375,
        349.4524230957031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        99.5999984741211,
        332.2146301269531,
        271.75146484375,
        349.4524230957031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수 = 1 + 2 = 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.68000030517578,
        358.8546142578125,
        499.1999816894531,
        376.0924072265625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.68000030517578,
        358.8546142578125,
        499.1999816894531,
        376.0924072265625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.68000030517578,
        358.8546142578125,
        499.1999816894531,
        376.0924072265625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 77 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N-니트로사민의 α-탄소에",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        96.29460144042969,
        254.15676879882812,
        113.53241729736328
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수소가 존재하는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        117.05461120605469,
        213.69984436035156,
        134.29241943359375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        96.29460144042969,
        389.3381042480469,
        115.81242370605469
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        117.05461120605469,
        452.5199890136719,
        134.29241943359375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        136.86404418945312,
        201.72000122070312,
        164.79568481445312
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민이 N-니트로소기의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        168.53460693359375,
        278.7562255859375,
        185.7724151611328
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한쪽 또는 양쪽에 둘 이상의",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        189.2946014404297,
        278.75677490234375,
        206.53240966796875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α-수소를 가지고 있는가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        210.1746063232422,
        246.69984436035156,
        227.41241455078125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아니오",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        292.44000244140625,
        178.974609375,
        389.3381042480469,
        198.49241638183594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        199.73460388183594,
        452.5199890136719,
        216.972412109375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓예",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        169.8000030517578,
        229.86404418945312,
        201.72000122070312,
        257.7956848144531
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N-니트로사민에 3차 α-탄소가",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        96.27690124511719,
        261.53460693359375,
        278.7562255859375,
        278.77239990234375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는가?*",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        282.41461181640625,
        147.98988342285156,
        299.65240478515625
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 5",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        261.53460693359375,
        389.3381042480469,
        281.0523986816406
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        282.41461181640625,
        452.5199890136719,
        299.65240478515625
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        302.2240295410156,
        226.67999267578125,
        330.1556701660156
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수를 산출한다.",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        333.8946228027344,
        232.23187255859375,
        351.1324157714844
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수가 ≥4 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        354.65460205078125,
        197.49984741210938,
        371.89239501953125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.3381042480469,
        353.41241455078125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 4",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        305.5199890136719,
        333.8946228027344,
        389.3381042480469,
        353.41241455078125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 1500 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        354.65460205078125,
        452.5199890136719,
        371.89239501953125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        374.4640197753906,
        226.67999267578125,
        402.3956604003906
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 3 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.7114562988281,
        433.6924133300781
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.7114562988281,
        433.6924133300781
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 3",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        406.1346130371094,
        389.7114562988281,
        433.6924133300781
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 400 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        349.79998779296875,
        426.8946228027344,
        445.3199768066406,
        444.1324157714844
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        446.70404052734375,
        226.67999267578125,
        474.63568115234375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 = 2 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 2",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        478.3746032714844,
        389.3381042480469,
        505.9324035644531
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 100 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        499.1346130371094,
        445.3199768066406,
        516.3724365234375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "↓아니오",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        518.9440307617188,
        226.67999267578125,
        546.8756713867188
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재력 점수가 ≤ 1 인가?",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분류 1",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        97.31999969482422,
        550.6145629882812,
        389.3381042480469,
        578.1724243164062
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AI = 26.5 ng/일",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        349.79998779296875,
        571.3745727539062,
        448.1999816894531,
        588.6124267578125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 78 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        119.52000427246094,
        535.9199829101562,
        137.68406677246094
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        64.08000183105469,
        159.47999572753906,
        538.4849853515625,
        177.46499633789062
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WP2 uvrA (pKM101) 포함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.23999786376953,
        183.47999572753906,
        272.7599792480469,
        201.46499633789062
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장)",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        64.08000183105469,
        223.55999755859375,
        506.2627258300781,
        241.5449981689453
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        265.55999755859375,
        538.4400024414062,
        281.4496765136719
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함. 랫드와 햄스터의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.47999572753906,
        287.5199890136719,
        538.4400024414062,
        305.5049743652344
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "S9은 개체에 cytochrome",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        87.47999572753906,
        311.5199890136719,
        538.5340576171875,
        329.5049743652344
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P450",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        87.47999572753906,
        311.5199890136719,
        538.5340576171875,
        329.5049743652344
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효소유도제로 처리된 후(예:",
      "font_size": 12.960000038146973,
      "font_name": "T7",
      "bbox": [
        87.47999572753906,
        311.5199890136719,
        538.5340576171875,
        329.5049743652344
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Phenobarbital과 β-naphthoflavone) 분리되어야 함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        87.47999572753906,
        337.55999755859375,
        400.79998779296875,
        353.4496765136719
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        375.47998046875,
        546.0599975585938,
        393.4649658203125
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        88.79999542236328,
        399.47998046875,
        538.5599975585938,
        417.4649658203125
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 수 있음",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        88.79999542236328,
        425.58935546875,
        163.8000030517578,
        441.40966796875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        82.55999755859375,
        452.6399841308594,
        538.4408569335938,
        468.1919860839844
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        95.87999725341797,
        473.3999938964844,
        538.439697265625,
        488.9519958496094
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양을 포함해야함",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        95.87999725341797,
        494.2799987792969,
        193.32052612304688,
        509.8320007324219
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        530.760009765625,
        538.4400024414062,
        548.7449951171875
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.75999450683594,
        554.760009765625,
        545.9400024414062,
        572.7449951171875
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두 가지 니트로사민류도 양성 대조군으로 포함되어야 함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.75999450683594,
        580.869384765625,
        478.79998779296875,
        596.689697265625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        71.63999938964844,
        612.3599853515625,
        538.5599365234375,
        630.3599853515625
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        84.1199951171875,
        636.3599853515625,
        533.625,
        654.3599853515625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        82.55999755859375,
        665.3999633789062,
        538.4400024414062,
        680.9519653320312
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        94.31999969482422,
        686.2799682617188,
        538.4405517578125,
        701.8319702148438
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        94.31999969482422,
        707.0399780273438,
        538.5081787109375,
        722.5919799804688
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        94.31999969482422,
        727.7999877929688,
        538.4404296875,
        743.3519897460938
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨",
      "font_size": 12.960000038146973,
      "font_name": "T12",
      "bbox": [
        94.31999969482422,
        748.679931640625,
        536.0400390625,
        764.23193359375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        62.87999725341797,
        78.20401763916016,
        434.47509765625,
        93.20401763916016
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 79 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ (적용원칙)",
      "font_size": 15.0,
      "font_name": "T13",
      "bbox": [
        64.08000183105469,
        118.60458374023438,
        538.4400024414062,
        137.5050048828125
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①허용기준(1일 섭취허용량) 설정 가능 여부,",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        64.08000183105469,
        118.60458374023438,
        538.4400024414062,
        137.5050048828125
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "②불순물 검출",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        118.60458374023438,
        538.4400024414062,
        137.5050048828125
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수준, ③의료적 필요성 및 공급 부족 우려,",
      "font_size": 15.0,
      "font_name": "T7",
      "bbox": [
        91.55999755859375,
        142.3199920654297,
        545.9400024414062,
        161.50498962402344
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "④해외 규제기관 동향",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        142.3199920654297,
        545.9400024414062,
        161.50498962402344
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 종합적으로 검토하여 개별 사례별로 적용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        169.62936401367188,
        414.0,
        185.44967651367188
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        207.47999572753906,
        516.47998046875,
        225.46499633789062
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        247.55999755859375,
        478.91998291015625,
        265.54498291015625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.08000183105469,
        287.5199890136719,
        538.5599975585938,
        305.5049743652344
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.68000030517578,
        311.5199890136719,
        537.719970703125,
        329.5049743652344
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구분",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.79999542236328,
        374.41943359375,
        456.5950622558594,
        390.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방안 1",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.79999542236328,
        374.41943359375,
        456.5950622558594,
        390.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방안 2",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.79999542236328,
        374.41943359375,
        456.5950622558594,
        390.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개요",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.79999542236328,
        392.5394592285156,
        312.9787292480469,
        417.5003662109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류 공통 한시적",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.79999542236328,
        392.5394592285156,
        312.9787292480469,
        417.5003662109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준 적용",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        197.75999450683594,
        410.5394287109375,
        275.7599792480469,
        426.5003662109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준(AI) 초과 검출된",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        368.7599792480469,
        392.5394592285156,
        511.3387451171875,
        408.5003967285156
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니트로사민류는 LTL* 개념 적용",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        352.32000732421875,
        409.96124267578125,
        523.5599975585938,
        426.5003662109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용대상",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        73.79999542236328,
        461.41943359375,
        121.79999542236328,
        477.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 해당 불순물 특이적 허용기준",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        425.41943359375,
        336.3787536621094,
        441.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정 불가하고,",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        162.0,
        443.41943359375,
        242.625,
        459.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 불순물 검출수준이 니트로사민류",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        461.41943359375,
        336.3787536621094,
        477.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계열 특이적 공통기준(26.5ng/일)",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        159.47999572753906,
        479.41943359375,
        336.3787536621094,
        513.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과한 경우",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        159.47999572753906,
        479.41943359375,
        336.3787536621094,
        513.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 허용기준이 있으나, 검출량이",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        425.41943359375,
        537.6187133789062,
        441.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준을 초과하는 의약품으로,",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        365.1600036621094,
        443.41943359375,
        532.3049926757812,
        459.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 저감화 등 시정·예방조치(CAPA)",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        461.41943359375,
        537.6187133789062,
        477.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간이 3년 이내",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        360.7200012207031,
        479.41943359375,
        451.3199768066406,
        495.38037109375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용기간",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        73.79999542236328,
        512.179443359375,
        306.3599853515625,
        536.1803588867188
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12개월 이내 한시적 적용",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        73.79999542236328,
        512.179443359375,
        306.3599853515625,
        536.1803588867188
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 기간 연장 필요 시 별도 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        162.1199951171875,
        530.7197265625,
        311.2799987792969,
        543.9673461914062
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3년 이내 한시적 적용",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        377.6399841308594,
        512.179443359375,
        498.239990234375,
        528.140380859375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 기간 연장 필요 시 별도 검토",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        365.7599792480469,
        530.7197265625,
        509.9999694824219,
        543.9673461914062
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한시적",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        73.79999542236328,
        581.2994384765625,
        262.08001708984375,
        615.2603759765625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        73.79999542236328,
        581.2994384765625,
        262.08001708984375,
        615.2603759765625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "178ng/일",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        73.79999542236328,
        581.2994384765625,
        262.08001708984375,
        615.2603759765625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불순물별 별도 설정",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        383.8800048828125,
        543.0194702148438,
        491.8799743652344,
        558.9804077148438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료기간",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        354.47998046875,
        563.0399780273438,
        449.9999694824219,
        582.552001953125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12개월",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        354.47998046875,
        563.0399780273438,
        449.9999694824219,
        582.552001953125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이내",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        425.03997802734375,
        578.0399780273438,
        445.0794982910156,
        589.9920043945312
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12개월",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        483.47998046875,
        563.0399780273438,
        513.4795532226562,
        574.9920043945312
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초과",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        488.5199890136719,
        578.0399780273438,
        508.4399719238281,
        589.9920043945312
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한시적",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        359.5199890136719,
        590.8799438476562,
        389.3999938964844,
        602.8319702148438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용기준",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        354.47998046875,
        598.3199462890625,
        517.1300659179688,
        617.8319702148438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.3 × AI",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        354.47998046875,
        598.3199462890625,
        517.1300659179688,
        617.8319702148438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6.7 × AI",
      "font_size": 9.960000038146973,
      "font_name": "T12",
      "bbox": [
        354.47998046875,
        598.3199462890625,
        517.1300659179688,
        617.8319702148438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단, 한시적 허용기준은 1,500ng/일 초과 불가",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        625.2797241210938,
        533.400390625,
        638.52734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(허용기준(AI) > 1,500ng/일인 경우 예외)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        640.2797241210938,
        514.1146850585938,
        653.52734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치사항",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        73.79999542236328,
        687.9794311523438,
        121.79999542236328,
        703.9403686523438
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•12개월 이내 한시적 허용기준 이내",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        652.5794677734375,
        334.458740234375,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품만 출하 허용",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        652.5794677734375,
        334.458740234375,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•12개월 이내 저감화 완료",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        652.5794677734375,
        334.458740234375,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(조치 지시 후 1개월 이내 저감화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        141.239990234375,
        652.5794677734375,
        334.458740234375,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 제출 포함)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.59999084472656,
        724.664306640625,
        230.8837432861328,
        739.3483276367188
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•한시적 허용기준 이내 제품만 출하",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        652.5794677734375,
        535.5787353515625,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        652.5794677734375,
        535.5787353515625,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "•3년 이내 저감화 완료",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        652.5794677734375,
        535.5787353515625,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(조치 지시 후 1개월 이내 저감화",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        342.47998046875,
        652.5794677734375,
        535.5787353515625,
        722.5403442382812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 제출 포함)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        351.8399963378906,
        724.664306640625,
        432.12371826171875,
        739.3483276367188
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "< 한시적 허용기준 적용 기준 >",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        194.63999938964844,
        346.7591247558594,
        408.256591796875,
        365.4334411621094
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        747.7394409179688,
        326.0437316894531,
        763.7003784179688
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부록 3  한시적 허용기준 적용방안",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        62.87999725341797,
        78.20401763916016,
        307.0799865722656,
        93.20401763916016
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 80 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        67.939453125,
        357.47998046875,
        83.900390625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 81 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 82 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.4903564453125,
        314.625,
        813.4503173828125
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서)",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        63.3599967956543,
        283.5399475097656,
        537.3245849609375,
        299.49993896484375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        329.1951599121094,
        157.08059692382812,
        342.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        329.1951599121094,
        157.08059692382812,
        342.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        329.1951599121094,
        157.08059692382812,
        342.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        352.59515380859375,
        157.08059692382812,
        365.5551452636719
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        352.59515380859375,
        157.08059692382812,
        365.5551452636719
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        352.59515380859375,
        157.08059692382812,
        365.5551452636719
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        375.9951477050781,
        157.08059692382812,
        388.95513916015625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        446.19512939453125,
        157.08187866210938,
        459.1551208496094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        446.19512939453125,
        157.08187866210938,
        459.1551208496094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        446.19512939453125,
        157.08187866210938,
        459.1551208496094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        446.19512939453125,
        157.08187866210938,
        459.1551208496094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        609.9951782226562,
        157.0800018310547,
        622.9551391601562
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        609.9951782226562,
        157.0800018310547,
        622.9551391601562
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        72.1199951171875,
        609.9951782226562,
        157.0800018310547,
        622.9551391601562
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2024년  6월  26일",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        329.1951599121094,
        304.0757751464844,
        342.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식 품 의 약 품 안 전 처 장   오  유  경",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        352.59515380859375,
        389.7599792480469,
        365.5551452636719
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 약 품 안 전 국 장       김  상  봉",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        375.9951477050781,
        389.7599792480469,
        388.95513916015625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 약 품 심 사 부 장       김  영  림",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        399.3951416015625,
        389.7599792480469,
        412.3551330566406
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 료 제 품 연 구 부 장     손  수  정",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        422.7951354980469,
        389.7599792480469,
        435.755126953125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 약 품 관 리 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        446.19512939453125,
        266.037109375,
        459.1551208496094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문 은 희 , 박 희 영 , 이 종 규",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        469.59515380859375,
        336.95880126953125,
        482.5551452636719
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 약 품 규 격 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        492.9951477050781,
        266.037109375,
        505.95513916015625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박 상 애 , 우 선 욱 , 김 민 경",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        516.3951416015625,
        336.95880126953125,
        529.3551025390625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 약 품 연 구 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        174.59999084472656,
        539.795166015625,
        264.9571228027344,
        552.755126953125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김 판 순 , 안 일 영",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        563.1951904296875,
        278.27880859375,
        576.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        609.9951782226562,
        498.237060546875,
        622.9551391601562
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Tel. : 043-719-2654  /  Fax. : 043-719-2650",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        633.3951416015625,
        537.1640014648438,
        646.3551025390625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        656.795166015625,
        529.1970825195312,
        669.755126953125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Tel. : 043-719-2997  /  Fax. : 043-719-2950",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        680.1951904296875,
        537.1640014648438,
        693.1551513671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        703.5951538085938,
        541.8009643554688,
        716.5551147460938
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Tel. : 043-719-4618  /  Fax. : 043-719-4600",
      "font_size": 12.960000038146973,
      "font_name": "Batang",
      "bbox": [
        175.67999267578125,
        726.9951782226562,
        537.1640014648438,
        739.9551391601562
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    }
  ],
  "markdown_content": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024. 6.\n가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n**[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다. | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요? | ‧ |\n| 수 있다. | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다. | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다. | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다. | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까? | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다. | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다. 이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024. 6. 26. | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2. 배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가? | 물질, 유연물질 및 분해생성물 | 그림 9. 메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다. | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다. | (2020.12.31.)까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다. | 부록 1. 발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7. 몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요? | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가? | α-수소를 가지고 있는가? | α-수소를 가지고 있는가? | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다. 이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다. | 하는 등 전주기 안전관리에 노력을 기울여야 한다. | 수행하여야 하나요? | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다. | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5. 리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요? | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다. | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다. | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다. | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2. 강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다. | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가? | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다. | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ. 불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다. | 1,500 ng/일로 섭취허용량이 재설정 되었습니다. 또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다. | 수소가 존재하는가? | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가? | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다. | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다. | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다. | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3. 완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3. 한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다. | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7. 니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1. 개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다. | 을 평가하는 것이다. | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다. | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가?* | 있는가?* | 있는가?* | 수소가 존재하는가? | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다. | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다. | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬. | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다. | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다. | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다. | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다. 이미 허가‧ | 1) 원료의약품 | 2. 불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다. | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가?* | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다. | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다. | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다. | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다. | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다. | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다. | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다.)에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다. | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다. | 통한 섭취 허용량 설정이 가능한가 ? | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다. | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가. 발생가능성 평가 | 2 | 기준을 설정합니다. | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가? | 잠재력 점수를 산출한다. | 잠재력 점수를 산출한다. | 잠재력 점수를 산출한다. | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다. | α-수소를 가지고 있는가? | 등 통계적 수치를 산출하는 것이 유의하지 않다. | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10. 메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다. | 책임자의 책임하에 문서화하고 보관하시기 바랍니다. | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다. | on nitrosamine impurities in human medicinal products (2024.1.15.) | 나. 니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다. | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가? | 점수가 ≥4 인가? | 점수가 ≥4 인가? | 잠재력 점수를 산출한다. | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다. | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다. | ↓예 | 그림 6. 리팜피신 중 MeNP 발생 원인 | 그림 8. 몬테루카스트 중 NDPA 발생 원인 |\n| 한다. | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다. | 은 무엇이 있나요? | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다. | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다. | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다. | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가? | Q9 | 그림 4. 사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가? | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3. 불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다. | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다. | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다. | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2. NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정. 양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다. | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다. | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다. | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가?* | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가? | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4. 1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다. | 있는가?* | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다. | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다. 복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까? | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요? | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다. | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다. | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가. 일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가?* | 가능성은 증가할 수 있다. | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리. 양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다. | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ? | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다. | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요? | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다. | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다. | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다. | 잠재력 점수를 산출한다. | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요? | 랍니다. | 따른 단계별 조치를 해야 합니다. | 잠재력 점수를 산출한다. | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요? | 대한 박테리아 변이원성시험을 직접 실시할 수 있다. | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다. | 나. 니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다. | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다. | 등에 활용할 수 있다. | 업데이트 될 수 있다. | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬. 각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다. | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다. 복용기간은 질환 및 의약품의 특성을 고려할 수 있다. | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가? | 잠재력 점수가 = 2 인가? | 예 | 분류 2 | 잠재력 점수가 = 2 인가? | 예 | 분류 2 | 잠재력 점수가 = 2 인가? | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다. | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가? | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요? | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다. | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다. | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까? (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다. | 5. 초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use). (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가? | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다. | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4. 니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ? | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다. | 표 3. 완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다. | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다. | 하거나, | 등이 있습니다. | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다. | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다. | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가? | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다. | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요? | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다. | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다. | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요? | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가? | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다. | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다. | • 안정성시험 자료 | 다. | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다. | Ⅲ. 불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다. | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다. | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다. 따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다. | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다. | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요? | EAT) 조건으로 수행하는 것을 권고합니다. | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다. | 민원인을 구속하는 내용이 있습니까? | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n상기 사항에 대하여 확인하였음.\n\n2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다. 또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022. 7. 14.\n제정\n\n<!-- PAGE_5 -->\n#### Ⅰ. 서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1. 목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1. 제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가. 신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나. 검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다. 불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라. 허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2. 식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ. 질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ. 참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다.)이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다.)뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다.)의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다.)가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n- - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가. 발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다. 활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n- - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n- - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다. 따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임. 분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20. 새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5. 발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8. 기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가. 신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10. 변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3. 발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18. 원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24. 니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22. 니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12. 원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다. |\n| 다. 의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16. Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다. 또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5. 비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다. 또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨. 추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6. 잠재력 점수 계산식 및 계산과정은 아래와 같습니다. | A14. 식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2. 정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n- - 4 -\n표 1. ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나. 니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다. 현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다. 만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1. 니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다. 원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다. 3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다. 모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n- - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다. 예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다.(그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다. 대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다. 3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다. 예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n- - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n- - 7 -\n표 2. 니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다. 원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다. 아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n- - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다.(예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다. 또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다.(잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다. 이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다. 퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다. Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n- - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다. 이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다. 주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다. 이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다.(예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다. 또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다. 이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n- - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다. 첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다. 아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다. 또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다. 예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n**[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ?**\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다. 예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다. 또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다. 수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다. 시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다. 이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다. 발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다. 상세한 내용은 「4.\n\n1일 섭취 허용량 설정」을 참고한다. 시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다. 정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다.(예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가? | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다. | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no. | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n- - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가. 일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다. 식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n<투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나. 니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다. 이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n- ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\nð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다. 이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n니트로사민류\n\nCAS no.\n\nAI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다. 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다. 따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n* 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다. 이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n- - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n항을 제공한다. N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다. 상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다. 식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다. 이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4. 두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬. 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21. 위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13. 의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다. | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다. | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다. | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다. | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다. |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16. | 식약처에 신속히 보고하도록 하였으나, |\n| A2. 니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17. 니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가? | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨. Methylene α-탄소가 | 잠재력 점수가 = 2 인가? | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다. | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다. | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다. | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다. | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다. | 잠재력 점수가 = 2 인가? | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15. 의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다. | ↓아니오 | 알려드립니다. | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다. | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다. | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다. | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다. | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다. | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다. |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다. | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다. | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다. | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11. 라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다. | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가? | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다. | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다. | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다. | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다. | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다. | 수소가 존재하는가? | 수소가 존재하는가? | 수소가 존재하는가? | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요? | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요? | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다. | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요? | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요? | 허용기준이 재설정될 수 있나요? | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요? 보고와 함께 제출해야 하는 자료는 무엇인가요? | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요? | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가? | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요? | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요? | 총 니트로사민류 기준에 포함하여 관리하여야 하나요? | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요? |\n**으로 추정되고 있다.**\n| A19. 의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다. |\n| A1. 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11. 구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9. N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다. NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다. 그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n- - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다. 건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다. 상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시. 초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다. 발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나. 검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다. 불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다. 또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다. 이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다. 또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다. 원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라. 허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다. 따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음. | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함. 랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨. 섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다. 상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1. 도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3. 적용범위\n\n<!-- PAGE_68 -->\n##### 4. 일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함. 니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함.*\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.**\n\n- - 64 -\n표 1. 각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2. 비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. 표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3. 활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. 표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음. 다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5. 검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel. : 043-719-2654  /  Fax. : 043-719-2650**\n**Tel. : 043-719-2997  /  Fax. : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel. : 043-719-4618  /  Fax. : 043-719-4600\n",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 129,
        "word_count": 26,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024.  6.\n 가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다. ",
        "original_sentence": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "6.\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024.  6.\n 가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요? ",
        "original_sentence": "6.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 141,
        "word_count": 27,
        "page_number": 2,
        "window_text": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024.  6.\n 가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다. ",
        "original_sentence": "가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "**[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 332,
        "word_count": 82,
        "page_number": 4,
        "window_text": "<!-- PAGE_1 -->\n# 의약품 중 변이원성‧발암성 불순물\n\n<!-- PAGE_1 -->\n# 안전관리 가이드라인 [민원인안내서]\n\n<!-- PAGE_1 -->\n## - 불순물 중“니트로사민류”를 중심으로 -\n\n- 2024.  6.\n 가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다. ",
        "original_sentence": "**[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "| N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 239,
        "word_count": 51,
        "page_number": 13,
        "window_text": "6.\n 가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다. ",
        "original_sentence": "| N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요? "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| ‧ |\n| 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 9,
        "window_text": "가이드라인 등록번호\n\n[ 안내서-1209-02 ]\n\n<!-- PAGE_2 -->\n### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n의약품 중 변이원성·발암성 불순물 안전관리 가이드라인 (민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다. ",
        "original_sentence": "| ‧ |\n| 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "| 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 4,
        "window_text": "**[표 시작]**\n\n| 42 | N-nitroso-mirtazapine | 미르타자핀 | 3 | 400 | - | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| N-니트로소기의 α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류는 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | ⑥ 기타 생성 가능 원인에 대한 평가 | 등을 종합적으로 검토하여 개별 사례별로 적용 | 초과발암위해가 있는 것으로 간주한다.  | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 4,
        "window_text": "| N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | N-니트로사민이 N-니트로소기의 | 비활성화 구조 특성 | 예시 | 개별 비활성화 | 구조 특성 점수 | - 내부표준물질 적절성 검토 |\n| 11 | N-nitroso-pyrrolidine, NPYR | - | - | 1,700 | - | 74 | N-nitroso-N-desmethylorphena | 니트로사민류의 한시적 허용기준 어떻게 정하나요?  | ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다. ",
        "original_sentence": "| FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 180,
        "word_count": 57,
        "page_number": 4,
        "window_text": "| ‧ |\n| 수 있다.  | 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다. ",
        "original_sentence": "| drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 86,
        "word_count": 19,
        "page_number": 4,
        "window_text": "| 2019년 식약처 지시에 따라 “니트로사민류 불순물 자체조사”를 수행하였어도 | 수 있다.  | FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024. ",
        "original_sentence": "| 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "| 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 81,
        "word_count": 28,
        "page_number": 4,
        "window_text": "| FDA (2021.2) | 불순물의 실제 농도에 대한 대표성 있는 분석값이 필요하다.  | drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6. ",
        "original_sentence": "| 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 90,
        "word_count": 20,
        "page_number": 4,
        "window_text": "| drine, NMOA | 오르페나드린 | 1 | 26.5 | - | TD50을 설정하기에 충분한 | 잠재력 분류 5 | AI = 1500 ng/일 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 | 예 | · 3차 아민인 DIPEA의 | TD50 계산 | 구조 특성 점수 |\n| 설정하여야 한다.  | 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6.  26. ",
        "original_sentence": "| 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 186,
        "word_count": 39,
        "page_number": 4,
        "window_text": "| 2) 발암성시험 데이터가 불충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | WP2 uvrA (pKM101) 포함 | 지침서ㆍ안내서가 있습니까?  | 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6.  26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2. ",
        "original_sentence": "이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "6. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 1,
        "window_text": "| 0, 2 | O | N | N | N | CH3 | ICH | 3* |\n| 경우, 이를 종합적으로 검토하여 별도의 기준으로 설정할 수 있다.  | 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6.  26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가? ",
        "original_sentence": "6. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "26. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 4,
        "window_text": "| 43 | N-nitroso-varenicline, NNV | 바레니클린 | 3 | 400 | - | 발암잠재력 분류 접근법(CPCA)을 적용할 수 없습니다.  이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6.  26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9. ",
        "original_sentence": "26. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 230,
        "word_count": 60,
        "page_number": 4,
        "window_text": "이렇게 CPCA를 적용할 수 없는 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | 한쪽 또는 양쪽에 둘 이상의 | N-니트로사민이 N-니트로소기의 | 2 | 1 | 2024.  6.  26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다. ",
        "original_sentence": "| 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 4,
        "window_text": "6.  26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다. ",
        "original_sentence": "배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 물질, 유연물질 및 분해생성물 | 그림 9. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 9,
        "window_text": "26.  | 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31.",
        "original_sentence": "| 물질, 유연물질 및 분해생성물 | 그림 9. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 90,
        "word_count": 26,
        "page_number": 10,
        "window_text": "| 개정 | 변이원성은 확인되고 발암성 | 미확인 물질 | (박테리아 변이원성 양성 및 | 설치류 발암성 유발 데이터 없음) | ▼ | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계 | (일반적 혹은 조정된 TTC) |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) | NDSRIs 등 신규 불순물 정보 수집하여, 불순물 발생가능성평가, 시험검사 및 조치를 | 2.  배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다. ",
        "original_sentence": "메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 17,
        "window_text": "배경 | 1 | 비활성화 구조 특성 | Q1 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | 발암성 연구 결과가 존재하는가?  | 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1. ",
        "original_sentence": "| - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| (2020.12.31.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 14,
        "word_count": 2,
        "page_number": 4,
        "window_text": "| 물질, 유연물질 및 분해생성물 | 그림 9.  메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7. ",
        "original_sentence": "| (2020.12.31."
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": ")까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 189,
        "word_count": 52,
        "page_number": 26,
        "window_text": "메트포르민의 구조 | 아지드 | - | OH | H | (불확실성 계수 미적용) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| 실시하여야 한다.  | - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요? ",
        "original_sentence": ")까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 부록 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 4,
        "window_text": "| - 생산라인 공유에 따른 교차오염 등 | 가능성이 있다.  | (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가? ",
        "original_sentence": "| 부록 1. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 42,
        "word_count": 13,
        "page_number": 13,
        "window_text": "| (2020.12.31. )까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가? ",
        "original_sentence": "발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 151,
        "word_count": 34,
        "page_number": 10,
        "window_text": ")까지 복용하는 것으로 가정하여 산출 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | O | 아니오 | 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | 탈알킬화 |\n| α-탄소에 결합된 아릴기 | 위해도 산출 기반의 인체영향평가 방식을 활용한다.  | 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가? ",
        "original_sentence": "몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요? "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 94,
        "word_count": 19,
        "page_number": 27,
        "window_text": "| 부록 1.  발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다. ",
        "original_sentence": "| ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 27,
        "window_text": "발암 잠재력 분류 접근법 | NDEA | 비활성화 구조 특성 | 그림 7.  몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다. ",
        "original_sentence": "| α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 27,
        "window_text": "몬테루카스트의 구조 |\n| 44 | N-nitroso-N-ethyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 75 | N-nitroso-imatinib | 이매티닙 | 5 | 1,500 | - | 경우 어떻게 1일 섭취 허용량을 설정하나요?  | ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다. ",
        "original_sentence": "| α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 120,
        "word_count": 36,
        "page_number": 10,
        "window_text": "| ⇒ ‘발암잠재력 분류 접근법(CPCA)’ 적용 가능 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요? ",
        "original_sentence": "| 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 39,
        "word_count": 8,
        "page_number": 2,
        "window_text": "| α-수소를 가지고 있는가?  | α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다. ",
        "original_sentence": "이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "| 하는 등 전주기 안전관리에 노력을 기울여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| α-수소를 가지고 있는가?  | 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5. ",
        "original_sentence": "| 하는 등 전주기 안전관리에 노력을 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 수행하여야 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 58,
        "window_text": "| 한쪽 또는 양쪽에 둘 이상의 | H3C | - 불순물의 특성 고려 | 예) NDMA의 경우 휘발성 있음 | → 메탄올에 녹여서 전처리(농축 과정이 포함되는 SPE, LLE 어려움) | O |\n| 조‧ | 한다.  이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요? ",
        "original_sentence": "| 수행하여야 하나요? "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 77,
        "word_count": 22,
        "page_number": 4,
        "window_text": "이와 관련한 자세한 사항은 ICH M7(R1) 가이드라인을 참고한다.  | 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다. ",
        "original_sentence": "| 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 288,
        "word_count": 60,
        "page_number": 4,
        "window_text": "| 하는 등 전주기 안전관리에 노력을 기울여야 한다.  | 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다. ",
        "original_sentence": "| 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 4,
        "window_text": "| 수행하여야 하나요?  | 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다. ",
        "original_sentence": "리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요? "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 112,
        "word_count": 31,
        "page_number": 4,
        "window_text": "| 비활성화 구조 특성 | 2 | · TEA의 4차 암모늄 |\n| 하고, 발생 우려가 있는 경우 신속하게 시험·검사를 실시하여야 합니다.  | 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2. ",
        "original_sentence": "| 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "| N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| 10-5 × 1일 노출량* (㎍/day) |\n| (즉, N-니트로소기의 벤질 또는 | 13 | N-nitroso-nebivolol, NNEB | 네비보롤 | 4 | 1,500 | - | 45 | N-nitroso-N-methyl-valacyclovir | 발라시클로비르 | 3 | 400 | - | 76 | N-nitroso-ethylenediamine-triac | ‧ | 및 N-nitroso-atenolol의 경우 CPCA를 적용하여 분류 5 및 4로 분류되어 | N-니트로사민의 α-탄소에 | 그림 5.  리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다. ",
        "original_sentence": "| N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "| amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 12,
        "window_text": "리팜피신의 구조 | 이소소르비드 | 아니오 | 분류 5 | AI = 1500 ng/일 | -1 |\n| 분자 상 모든 위치에 존재하는 카르복실산기 | 중 변이원성‧ | 발암잠재력 분류 접근법(CPCA)은 무엇인가요?  | 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가? ",
        "original_sentence": "| amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "| 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 119,
        "word_count": 38,
        "page_number": 13,
        "window_text": "| 초과발암위해도 (명/10만명) = | ❍ (수준 3) | 2 | 100 | 나) 완제의약품 | 접근법을 도입한 바, 국내 도입을 위한 기준설정 방안 마련 | 데이터의 처리 방법은 다음을 고려한다.  | N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다. ",
        "original_sentence": "| 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 23,
        "window_text": "| N-니트로사민의 α-탄소에 | 총 니트로사민류 기준에 포함되지 않아도 됩니다.  | amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ. ",
        "original_sentence": "강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 4,
        "window_text": "| amide도 유사한 반응과정을 거쳐 니트로사민을 생성할 수 있다.  | 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다. ",
        "original_sentence": "| N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "| 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 104,
        "word_count": 24,
        "page_number": 4,
        "window_text": "| 원료의약품 | 발생 가능한 주성분 유사구조 니트로사민 불순물 | ↓예 | ↓예 | ↓예 | < 초과발암위해도 > | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | +3 |\n| 부록 2.  강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다. ",
        "original_sentence": "| 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 210,
        "word_count": 52,
        "page_number": 14,
        "window_text": "강화된 복귀돌연변이 시험 조건 | 별 사례별로 적용할 수 있다.  | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다. ",
        "original_sentence": "| 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 124,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| N-nitroso piperidine (NPIP) | 100-75-4 | 1300 | α-수소를 가지고 있는가?  | 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가? ",
        "original_sentence": "불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "| 1,500 ng/일로 섭취허용량이 재설정 되었습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 32,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| 염산염의 가수분해 |\n| 14 | N-nitroso-desmethyl-nintedanib | 닌테다닙 | 3 | 400 | - | 다음의 방법으로 1일 섭취허용량을 설정할 수 있다.  | 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가? ",
        "original_sentence": "| 1,500 ng/일로 섭취허용량이 재설정 되었습니다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 27,
        "window_text": "| 고리(모두 별도로 계산)로 되어있는 예는 제외됨 | 분해하기 위해 아질산 사용) | 없는 니트로사민류가 검출된 경우에는 식약처 의약품통합정보시스템(의약품 | etic acid | +2 |\n| 유사-벤질 치환기) | 분자 상 모든 위치에 존재하는 | 카르복실산기 | +3 | 46 | N-nitroso-betahistine | 베타히스틴 | 1 | 26.5 | - | Ⅱ.  불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다. ",
        "original_sentence": "또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "| 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 74,
        "window_text": "불순물 위험평가 ····································································· 2 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정합니다.  | 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다. ",
        "original_sentence": "| 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 116,
        "word_count": 24,
        "page_number": 4,
        "window_text": "| 1,500 ng/일로 섭취허용량이 재설정 되었습니다.  또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다. ",
        "original_sentence": "| 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "| (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 157,
        "word_count": 22,
        "page_number": 1,
        "window_text": "또한, CPCA로 도출된 섭취허용량 | 경우, 식약처 보고 대상은 아닙니다.  | 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3. ",
        "original_sentence": "| (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 수소가 존재하는가?  | 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3. ",
        "original_sentence": "| 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 322,
        "word_count": 82,
        "page_number": 4,
        "window_text": "| 허용기준 적용이 불가하며, 설정(확립)된 허용기준을 적용하여 니트로사민류 | 1일 섭취 허용량 (㎍/day)  × (25,550일/복용기간(일)) | AI = 1500 ng/일 |\n| 수소가 존재하는가?  | (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다. ",
        "original_sentence": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 130,
        "word_count": 27,
        "page_number": 10,
        "window_text": "| (사유 :                                                                 ) | 되는 분해생성물 | AI = 1500 ng/일 |\n| 77 | N-nitroso-iminodiacetic acid | 이소소르비드 | 예정이다.  | 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7. ",
        "original_sentence": "| N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 102,
        "word_count": 37,
        "page_number": 4,
        "window_text": "| 제약사는 신규 품목허가‧ | 방법으로 설정할 수 있다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1. ",
        "original_sentence": "완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 237,
        "word_count": 57,
        "page_number": 13,
        "window_text": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 전처리법 고려 | 0, 3 | ↓예 | 아니오 | 신고‧ | - 주성분, 첨가제, 제형 특성 검토 | 예) 메트포르민 : 서방화 첨가제 산처리시 겔화 | 등록 시 의약품 허가‧ | · 3차 아민인 DIPEA의 | 2 |\n| 15 | N-nitroso-dabigatran etexilate | 다비가트란 | - | 1,500 | AMES 음성 | 47 | N-nitroso-betaxolol | 베탁솔롤 | 4 | 1,500 | - | 함하여 현재까지 발표된 위험 요소는 아래와 같다.  | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다. ",
        "original_sentence": "한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 40,
        "word_count": 12,
        "page_number": 4,
        "window_text": "| N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민에 3차 α-탄소가 | N-니트로사민의 α-탄소에 | 안전나라)의 전자민원창구(민원사무명: 의약품 불순물 자료 검토)를 통해 보고 | 그림 3.  완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다. ",
        "original_sentence": "| ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 4,
        "window_text": "완제의약품 중 니트로사민 발생 원인 | 모노니트레이트 | 4 | 1,500 | - | 아니오 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 | 예 | 분류 5 |\n| 부록 3.  한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다. ",
        "original_sentence": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 387,
        "word_count": 95,
        "page_number": 2,
        "window_text": "한시적 허용기준 적용방안 | DIPNA | (제조방법 변경, 기준 및 시험방법에 불순물 시험 추가 등) 등 후속조치를 해야 | α-탄소가 헤테로원자에 직접적으로 이중 결합된 니트로사민류인 N-nitrosamides, | 및 구조적 특징의 분석 등은 과학이 발전하고 자료가 추가됨에 따라 변경될 수 | 환자에게 미치는 영향(대체약, 의료적 필요성 등) 등을 분석한 자료* 및 투여 | 평가 및 관리전략을 수립하시기 바랍니다.  | ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가?",
        "original_sentence": "개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 을 평가하는 것이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 23,
        "window_text": "| ↓예 | 10-5 X NDMA 1일 노출량 (㎍/일) |\n| A7.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가?",
        "original_sentence": "| 을 평가하는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 320,
        "word_count": 45,
        "page_number": 10,
        "window_text": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발암 | 1.  개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가? * | 있는가?",
        "original_sentence": "| 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 137,
        "word_count": 31,
        "page_number": 13,
        "window_text": "개요 | 2 | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | ↓예 | 일반적 허용한계 또는 | 투여기간에 따른 조정된 | 허용한계로 관리하거나(일반적 | 혹은 조정된 TTC), | 박테리아 변이원성 시험결과에 | 따라 class2 또는 class5로 분류 | * 변이원성 양성 : class2 | * 변이원성 음성 : class5 |\n| 5원 또는 6원 고리의 N-니트로소기 | +2 | 16 | N-nitroso-desloratadine | 데스로라타딘 | 3 | 400 | - | 48 | N-nitroso-vortioxetine | 보티옥세틴 | 3 | 400 | - | * 1일 노출량 (㎍/day) = 오염도(ppm) × 1일 최대복용량 (mg/day) | 사항을 안내하기 위한 것이다.  | 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가? * | 있는가? * | 수소가 존재하는가? ",
        "original_sentence": "| ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "* | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 을 평가하는 것이다.  | 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가? * | 있는가? * | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다. ",
        "original_sentence": "* | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "* | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 4) 니트로사민류 불순물의 기준설정 현황 | Cross KP and Ponting DJ, 2021, Developmenting Structure-Activity Relationships for | N-Nitrosamine Activity, Comput Toxicol, 20:100186에 설명된 것에 국한되며, 여기서는 | \"β-carbon electron withdrawing groups\"라고 부름 | 2021, Developmenting Structure-Activity Relationships for N-Nitrosamine | 기준으로 설정할 수 있습니다.  | ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가? * | 있는가? * | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다. ",
        "original_sentence": "* | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "* | 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 74,
        "window_text": "| ㆍR = | 탈알킬화 |\n| β-탄소에 결합된 메틸기 | 78 | Indapamide Impurity A | 인다파미드 | 5 | 1,500 | - | number: EMA/H/A-5(3)/1490, EMA, (2020.6.25) | 있는가? * | 있는가? * | 있는가? * | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "* | 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "| 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 303,
        "word_count": 72,
        "page_number": 4,
        "window_text": "* | 있는가? * | 있는가? * | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬. ",
        "original_sentence": "| 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 26,
        "window_text": "* | 있는가? * | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다. ",
        "original_sentence": "| 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 109,
        "word_count": 26,
        "page_number": 2,
        "window_text": "* | 수소가 존재하는가?  | 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다. ",
        "original_sentence": "| 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "| AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 159,
        "word_count": 44,
        "page_number": 4,
        "window_text": "| 하며, | 있는 제품을 선정*하여 주기적으로 시험검사 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 | □ 예 | ■ 아니오 |\n| 피롤리딘 고리의 N-니트로소기 | ⦁잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수 + 활성화 구조특성 점수 | ➊ 구조-활성 상관관계(SAR)를 고려한 read-across 접근법을 활용하여 견고한 | N-nitrosoureas, N-nitrosoguanidines과 헤테로 방향족 고리 내의 니트로사민류인 | 합니다.  | 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다. ",
        "original_sentence": "| AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 126,
        "word_count": 29,
        "page_number": 4,
        "window_text": "| 제조·수입자 점검(예: GMP 실태조사, 수입자 감시 등) 시 검토될 수 있으니, | 있습니다.  | 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다. ",
        "original_sentence": "| 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 4,
        "window_text": "| 가능 여부, ②불순물 검출 수준, ③의료적 필요성 및 공급 부족 우려, ④해외 | N-니트로사민에 3차 α-탄소가 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2. ",
        "original_sentence": "| 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 209,
        "word_count": 47,
        "page_number": 4,
        "window_text": "| AI (0.096 ㎍/일) X (25,550일/복용기간(일)) | - 희석 및 추출 용매에 따른 감도 검토 | 예) 메탄올과 물 혼합시 감도 상승 | 예 | 분류 5 | +3 |\n| 비고리형 N-니트로소기의 양쪽에 | ≥5 인 연속된 비수소 원자(고리형 | 또는 비고리형) 사슬.  | 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다. ",
        "original_sentence": "| -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 146,
        "word_count": 36,
        "page_number": 10,
        "window_text": "| 각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 | 17 | N-nitroso-N-desmethyl-desvenlafaxine | 데스벤라팍신 | 1 | 26.5 | - | 출하허용기준을 설정한 바 있다.  | 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가?",
        "original_sentence": "| Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "이미 허가‧ | 1) 원료의약품 | 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 23,
        "word_count": 7,
        "page_number": 4,
        "window_text": "| 기간을 1년 미만으로 설정한 경우 그 근거자료**를 제출하시기 바랍니다.  | -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다. ",
        "original_sentence": "이미 허가‧ | 1) 원료의약품 | 2. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 4,
        "window_text": "| -1 |\n| (고리형 또는 비고리형) | 49 | N-nitroso-bupropion | 부프로피온 | 5 | 1,500 | - | Activity, Comput Toxicol, 20:100186)에 수재된 강한 전자 끄는 기와 약한 전자 | 결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 | N-니트로사민이 N-니트로소기의 | 제시한다.  | Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다. ",
        "original_sentence": "불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 241,
        "word_count": 56,
        "page_number": 9,
        "window_text": "| Read-across 등을 이용한 구조-활성 | · 3차 아민인 DIPEA의 |\n| 79 | N-nitroso-ketamine | 케타민 | 5 | 1,500 | - | 1) 발암성시험 데이터가 충분한 니트로사민류 불순물의 1일 섭취 허용량 설정 | 한다.  이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다. ",
        "original_sentence": "| 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "* | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 166,
        "word_count": 44,
        "page_number": 4,
        "window_text": "이미 허가‧ | 1) 원료의약품 | 2.  불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다. ",
        "original_sentence": "* | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 37,
        "window_text": "불순물 발생가능성 평가 | 2 | EIPNA | 사민류*, ②헤테로 방향족 고리 내의 니트로사민류가 아닌 화합물** | N-니트로사민이 N-니트로소기의 | ↓아니오 | ↓아니오 | ↓아니오 | 한다.  | 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 205,
        "word_count": 57,
        "page_number": 9,
        "window_text": "| 작업을 수행하는 경우 | ↓예 | 신고‧ |\n| ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA) | 등록대상 | 3 | 400 | nitrosated indole 등은 돌연변이 유발 및 발암성을 일으키는 대사 메커니즘이 | 발암 결과가 있는 참조물질의 TD50값을 이용하여 기준 설정 | * 미리 선택한 배치 또는 미리 정해진 기간마다 시험실시 | 있는가? * | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다. ",
        "original_sentence": "| 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 190,
        "word_count": 44,
        "page_number": 15,
        "window_text": "* | Q11 | 아니오 | 분류 5 | AI = 1500 ng/일 |\n| 18 | N-nitroso-dorzolamide | 도르졸라미드 | 2 | 100 | - | 50 | N-nitroso-bisoprolol, NBP | 비소프롤롤 | 4 | 1,500 | - | 데이션을 실시할 수 있다.  | 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다. ",
        "original_sentence": "| 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 256,
        "word_count": 60,
        "page_number": 27,
        "window_text": "| 규제기관 동향 등을 종합적으로 검토하여 개별 불순물 사례별로 한시적 허용 | 노출될 수 있다.  | 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다.",
        "original_sentence": "| N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 195,
        "word_count": 53,
        "page_number": 2,
        "window_text": "| 이터베이스 또는 문헌검색을 실시 | 구조적 경고(structural alert)가 | 있으나, 원료의약품 구조와 관련 | 없는 것(변이원성 데이터 없음) | = 3점 + 1점 + 0점 = 4점 (분류 4 : 1500 ng/일) | 구조-활성 상관관계 평가를 | 아니오 | 분류 5 | 예 | 상관관계 방법을 이용 유사 구조의 | 탈알킬화 |\n| 요청할 수 있다.  | 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 2,
        "window_text": "| 가) 완제의약품의 제조공정 | 끄는 기를 말하며, 강한 전자 끄는 기에는 trifluoromethyl, nitrile, cationic | 불가 및 발암잠재력 분류 접근법(CPCA)을 적용할 수 없는 경우, 아래의 흐름도에 따라 | 한쪽 또는 양쪽에 둘 이상의 | 발생가능성 평가, 시험 및 조치하는 안전관리 체계를 운영하여야 합니다.  | N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다. ",
        "original_sentence": "| 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 니트로사민류 불순물(이하 ‘니트로사민류’라 한다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 29,
        "word_count": 5,
        "page_number": 8,
        "window_text": "| N-nitroso-aryl piperazine / | N-nitroso-desalkylquetiapine, | 분석한 결과 또는 제약업체에서 제출한 시험 결과값을 활용할 수 있다) |\n| 1) 니트로사민류 제조공정 검증 시 고려사항 | * AI : NDMA 1일 섭취 허용량 | 불순물 관리 기준을 설정할 수 있으며, 이는 검출된 모든 니트로사민류의 발암 위해의 | 한쪽 또는 양쪽에 둘 이상의 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ? ",
        "original_sentence": "| 니트로사민류 불순물(이하 ‘니트로사민류’라 한다."
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": ")에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 2,
        "window_text": "| □ 예 | ■ 아니오 | ▼ | +1 |\n| 피롤리딘 고리의 N-니트로소기 | +3 | 19 | N-nitroso-nordoxepin | 독세핀 | 1 | 26.5 | - | 51 | N-nitroso-vildagliptin | 빌다글립틴 | 5 | 1,500 | - | 하나 이상의 황 원자를 포함하는 6원 | 고리의 N-니트로소기 | 한다.  | 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다. ",
        "original_sentence": ")에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "| ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 40,
        "word_count": 12,
        "page_number": 10,
        "window_text": "| 여부 | 라) 직접용기(포장재)를 통한 오염 | 상이합니다.  | 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가. ",
        "original_sentence": "| ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| 통한 섭취 허용량 설정이 가능한가 ? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 23,
        "word_count": 7,
        "page_number": 23,
        "window_text": "| 니트로사민류 불순물(이하 ‘니트로사민류’라 한다. )에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다. ",
        "original_sentence": "| 통한 섭취 허용량 설정이 가능한가 ? "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "| AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 83,
        "word_count": 20,
        "page_number": 4,
        "window_text": ")에서 관찰되는 변이원성과 | 사항으로 타당한 사유가 있는 경우에는 이를 연장하여 조치할 수 있습니다.  | ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가? ",
        "original_sentence": "| AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 141,
        "word_count": 23,
        "page_number": 23,
        "window_text": "| ↓아니오 | 3 | 등 조치 계획에 관한 자료를 첨부하여야 합니다.  | 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다. ",
        "original_sentence": "| 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "발생가능성 평가 | 2 | 기준을 설정합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 4,
        "window_text": "| 통한 섭취 허용량 설정이 가능한가 ?  | AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다. ",
        "original_sentence": "발생가능성 평가 | 2 | 기준을 설정합니다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 342,
        "word_count": 74,
        "page_number": 13,
        "window_text": "| AI = 1500 ng/일 | TD50 으로 |\n| 80 | 시험(Enhanced Ames test, EAT) 조건으로 수행하는 것을 권고한다.  | 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다. ",
        "original_sentence": "| N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| 발 | 행 | 일 | ➋ 발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, | * N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines 등 제외 | 가.  발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다. ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "발생가능성 평가 | 2 | 기준을 설정합니다.  | N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가? ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| N-니트로사민이 N-니트로소기의 | 예측되는 부족량, 출하중지할 경우 예상되는 중지 기간 및 재개일자 등 | 활성화 구조 특성 | 0 | 바레니클린(varenicline) | N-nitroso-varenicline | 1, 2 | 2024년  6월  26일 | 쿠에티아핀 | 3 | 400 | - | AI = 1500 ng/일 | · NMP의 가수분해 | 3 |\n| - 2) 구조-활성 상관관계(structure-activity-relationship, SAR) 평가 | nitrogen, S=O 치환기 등이 있으며, 약한 전자 끄는 기에는 carbonyl/carboxyl 유 | α-수소를 가지고 있는가?  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다. ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 195,
        "word_count": 47,
        "page_number": 4,
        "window_text": "| 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10. ",
        "original_sentence": "| 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 27,
        "window_text": "| 잠재력 점수를 산출한다.  | 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다. ",
        "original_sentence": "| α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "| 등 통계적 수치를 산출하는 것이 유의하지 않다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 23,
        "window_text": "| 잠재력 점수를 산출한다.  | 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다. ",
        "original_sentence": "| 등 통계적 수치를 산출하는 것이 유의하지 않다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 274,
        "word_count": 73,
        "page_number": 26,
        "window_text": "| 예 | 분류 4 | 예 | 분류 4 | 예 | 분류 4 | +3 |\n| 20 | N-desmethyl-N-nitroso-doxycycline | 독시사이클린 | 3 | 400 | - | 하고, 제조방법‧ | Phenobarbital과 β-naphthoflavone) 분리되어야 함 | NMBA | 합이 10-5 이하가 되도록 관리되어야 합니다.  | α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
        "original_sentence": "| α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 188,
        "word_count": 52,
        "page_number": 13,
        "window_text": "| α-수소를 가지고 있는가?  | 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다. ",
        "original_sentence": "메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| 책임자의 책임하에 문서화하고 보관하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 45,
        "window_text": "| 등 통계적 수치를 산출하는 것이 유의하지 않다.  | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.) ",
        "original_sentence": "| 책임자의 책임하에 문서화하고 보관하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 4,
        "window_text": "| α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | NDAQ | 아니오 | 분류 5 | 섭취 허용량 계산 |\n| 52 | N-nitroso-salbutamol | 살부타몰 | 5 | 1,500 | - | ※ 초과발암위해도 : 1일 노출량을 1일 섭취 허용량*으로 나눈 값으로, 불순물 함유 의 | 구조-활성 상관관계 평가를 통하여 섭취 허용량을 설정하고자 하는 경우 고려할 사항 | 강력한 발암 원인을 대사 활성의 α-하이드록실화 메커니즘으로 가정하여, 니트로 | 그림 10.  메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나. ",
        "original_sentence": "| 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 148,
        "word_count": 33,
        "page_number": 2,
        "window_text": "메트포르민 중 NDMA의 발생 원인 | < 한시적 허용기준 적용 기준 > | - 주성분의 휘발성 및 열안정성 고려(LC or GC) | 예) 라니티딘이 열에 노출시 불순물 생성[GC(X) → LC(O)] |\n| • 불순물 종류 및 발생 원인 조사 결과 | ** nitrosated indole 등 제외 | 나누었을 때 계산될 수 있다.  | 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| on nitrosamine impurities in human medicinal products (2024.1.15.) ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 69,
        "word_count": 9,
        "page_number": 1,
        "window_text": "| 책임자의 책임하에 문서화하고 보관하시기 바랍니다.  | 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가? ",
        "original_sentence": "| on nitrosamine impurities in human medicinal products (2024.1.15.) "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 트륨(NaNO2) 혹은 다른 아질산염(같은 공정 혹은 다른 공정에서) 존재 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가? ",
        "original_sentence": "| 나. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 5,
        "window_text": "| □ 예 | ■ 아니오 | 및/또는 분해(온도) |\n| 21 | N-nitroso-N-methyl-2-[1-phenyl | -1-(2-pyridinyl)methoxy]ethanamine | 독실아민 | 1 | 26.5 | - | 발 | 행 | 인 | 여야 한다.  | on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 점수가 ≥4 인가? ",
        "original_sentence": "니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 40,
        "word_count": 11,
        "page_number": 4,
        "window_text": "| on nitrosamine impurities in human medicinal products (2024.1.15.)  | 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 잠재력 점수를 산출한다. ",
        "original_sentence": "| CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 10,
        "window_text": "| 나.  니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다. ",
        "original_sentence": "| 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 10,
        "window_text": "니트로사민류 불순물 발생원인 | 5 | 도체, halogen, aromatic system 등이 있습니다.  | CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다. ",
        "original_sentence": "| 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| CPCA)을 활용하여 기준 설정 [부록 1] | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6. ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 247,
        "word_count": 71,
        "page_number": 2,
        "window_text": "| 점수가 ≥4 인가?  | 점수가 ≥4 인가?  | 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8. ",
        "original_sentence": "| 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 152,
        "word_count": 48,
        "page_number": 4,
        "window_text": "| 점수가 ≥4 인가?  | 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다. ",
        "original_sentence": "| - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| ↓예 | 그림 6. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 13,
        "word_count": 5,
        "page_number": 26,
        "window_text": "| 잠재력 점수를 산출한다.  | 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다. ",
        "original_sentence": "| ↓예 | 그림 6. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "리팜피신 중 MeNP 발생 원인 | 그림 8. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 26,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 한쪽 또는 양쪽에 둘 이상의 | 관련 사항을 제품표준서에 반영하여 관리 | ↓예 | 식 품 의 약 품 안 전 처 장   오  유  경 | 예 | 분류 4 | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 53 | N-nitroso-celiprolol | 셀리프롤롤 | 5 | 1,500 | - | 81 | N-nitroso Quetiapine HEEP | 계산과정도 함께 제시하여야 한다.  | - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요? ",
        "original_sentence": "리팜피신 중 MeNP 발생 원인 | 그림 8. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "몬테루카스트 중 NDPA 발생 원인 |\n| 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| - 3) In vitro 또는 In vivo 시험 | 잠재력 점수 = 1 + 2 = 3 | 잠재력 분류 3 | AI = 400 ng/일 | 해외 규제기관 지침 및 발표, 관련 문헌 등을 통해 발생가능한 최신 불순물 정보를 | 않은 경우 오염원에 노출될 가능성이 있다.  | ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다. ",
        "original_sentence": "몬테루카스트 중 NDPA 발생 원인 |\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 8,
        "window_text": "| ↓예 | 그림 6.  리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다. ",
        "original_sentence": "| 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "| 은 무엇이 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 23,
        "window_text": "리팜피신 중 MeNP 발생 원인 | 그림 8.  몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다. ",
        "original_sentence": "| 은 무엇이 있나요? "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 227,
        "word_count": 56,
        "page_number": 4,
        "window_text": "몬테루카스트 중 NDPA 발생 원인 |\n| 한다.  | 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가? ",
        "original_sentence": "| 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 186,
        "word_count": 51,
        "page_number": 23,
        "window_text": "| 허가(신고) 등을 통해 관련 자료의 적정성을 검토받아야 한다.  | 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4. ",
        "original_sentence": "| 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 58,
        "word_count": 18,
        "page_number": 4,
        "window_text": "| 은 무엇이 있나요?  | 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가? ",
        "original_sentence": "| 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 57,
        "word_count": 18,
        "page_number": 2,
        "window_text": "| 약품 복용으로 인해 100,000명 중 추가 발암 가능성이 있는 정도 | 사민류의 변이원성 및 발암성을 증가 또는 감소시키거나, 다른 생물학적 경로로 | 예측되는 발암잠재력으로 분류하는 방법 | 검출량(ng/일 및 ppm)), ②발생원인(추정원인 포함), 니트로사민류 저감화 등 | Impurity | 쿠에티아핀 | - | 1,500 | AMES 음성 | AI = 1500 ng/일 |\n| 여야 한다.  | 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3. ",
        "original_sentence": "| 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가? "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| Q9 | 그림 4. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 13,
        "word_count": 5,
        "page_number": 10,
        "window_text": "| 기준을 적용하며, 적용이 확정된 후 제약사는 한시적 허용기준에 적합한 | 기간을 분석한 자료 | 이 생성될 가능성 | 단위 | 의미 | 비고 | · 3차 아민인 |\n| 54 | N-nitroso-sotalol | 소타롤 | 4 | 1,500 | - | 발암잠재력에 따라 5가지로 분류*하여 1일 섭취 허용량을 설정하는 방법이다.  | 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| Q9 | 그림 4. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 218,
        "word_count": 57,
        "page_number": 13,
        "window_text": "| 편 집 위 원 장 | 4 | 1,500 | ③ 초과발암위해도 산출을 통한 위해평가 단계로 실시한다.  | 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다. ",
        "original_sentence": "사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 106,
        "word_count": 28,
        "page_number": 4,
        "window_text": "| 구분 | 방안 1 | 방안 2 | ↓아니오 | ↓아니오 | ↓아니오 | α-수소를 가지고 있는가?  | Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다. ",
        "original_sentence": "| 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 171,
        "word_count": 37,
        "page_number": 4,
        "window_text": "| Q9 | 그림 4.  사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다. ",
        "original_sentence": "불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 2,
        "window_text": "사르탄류 중 NDMA 및 NDEA 발생 원인 | 의 약 품 안 전 국 장       김  상  봉 | - 불순물의 섭취허용량 및 관리수준을 고려한 분석 장비 선정 |\n| ➌ 강화된 복귀돌연변이 시험(Enhanced Ames test, EAT) 결과 음성인 경우 기준을 | • 섭취 허용량, 1일 최대복용량, 잠정관리기준, 업체관리기준 | NMPA | 수집·검토하고, | 점수가 ≥4 인가?  | 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2. ",
        "original_sentence": "| □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "| ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 4,
        "window_text": "| 아니오 | AI = 1500 ng/일 |\n| N-니트로소기(고리형 또는 | 비고리형)의 한쪽에서만 | α-탄소에 결합된 전자 끄는 기 | 5원 또는 6원 고리의 N-니트로소기* | 3.  불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정. ",
        "original_sentence": "| ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 272,
        "word_count": 74,
        "page_number": 10,
        "window_text": "불순물 시험검사 | 11 | 바) 퀜칭(Quenching) 공정 | ❍ 몬테루카스트 중 N-nitrosodipropylamine(NDPA) 발생원인 | 니트로사민 제거를 증가시키는 구조적 특성에 대한 평가를 기반으로 예측되는 | 활성화 구조 특성 | 0 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다. ",
        "original_sentence": "| N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 219,
        "word_count": 43,
        "page_number": 4,
        "window_text": "| □ 예 | ■ 아니오 | +2 |\n| 82 | N-nitroso-N-desmethyl | AZBT)에 대하여 TTC 개념을 적용한 바 있다.  | ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다. ",
        "original_sentence": "| * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 125,
        "word_count": 36,
        "page_number": 4,
        "window_text": "| ❍ (수준 4) 불검출된 것으로 간주하여 시험 생략 가능 | 1일 섭취허용량을 설정하였다.  | N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 306,
        "word_count": 77,
        "page_number": 4,
        "window_text": "| N-니트로사민에 3차 α-탄소가 | 제품만을 출하하여야 하며, 정해진 기한 내 불순물을 저감화 등 적절한 조치를 | 전략, 유익성·위해성 평가 결과 등이 포함된 조사 보고서(조사 진행 중인 경우 | 2, 1 | 3 | 일일 섭취 허용량을 노출량으로 나눈 값으로 메트포르민 | 제제 복용으로 인해 100,000명 중 추가 발암 발생 가능 | 성이 있는 수치는 나타냄 | (LC or LC-MS/MS 등) | 클래리트로마이 | 예 | 분류 5 | N,N-DMA의 탈알킬화 |\n| 한다.  | * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 32,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| * 1일 최대복용량, 복용기간 : 시나리오 기반 또는 실제사용데이터(RWD) 이용하여 산출 | 가) 원료의약품 | 개요 | 니트로사민류 공통 한시적 | ③ 완제의약품 포장과정에서 불순물 발생 가능성 | N-니트로사민에 3차 α-탄소가 | 3-[2-(N-nitroso-N-methyl)amino | )ethyl]-N-methyl-1H-indole-5-m | ↓아니오 | ↓예 | 그림 2.  NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "| 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "| 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 10,
        "window_text": "NDMA 생성 과정 | 신 | 4 | 1,500 | - | 예 | 분류 5 | 허용기준(AI) 초과 검출된 |\n| 기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 기술하는 | 1.5 μg/day로 설정.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다. ",
        "original_sentence": "| 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 10,
        "window_text": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 [부록 2] | 분석 장비 선택 | clarithromycin | TD50을 설정하기에 충분한 | 의 약 품 심 사 부 장       김  영  림 | 예) 이르베사르탄 중 NDMA 1일 섭취 허용량(0.32 ppm) 이하 | +1 | 예 | TD50 계산 |\n| 55 | • 분석결과 및 배치수, 배치선정의 타당성 | 다) 원료의약품의 분해산물 | -Related Impurities Guidance for Industry (2023.8) | 있는 것으로 알려진 니트로사민류 2가지를 포함하도록 한다.  | 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가?",
        "original_sentence": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 10,
        "window_text": "| 발암잠재력에 따라 니트로사민류를 분류하는 방법입니다.  | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가? ",
        "original_sentence": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "| 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 90,
        "word_count": 26,
        "page_number": 10,
        "window_text": "| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4. ",
        "original_sentence": "| 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 127,
        "word_count": 42,
        "page_number": 4,
        "window_text": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다. ",
        "original_sentence": "| 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "* | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 75,
        "word_count": 20,
        "page_number": 10,
        "window_text": "| 예 | 분류 3 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가?",
        "original_sentence": "* | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "| 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 173,
        "word_count": 42,
        "page_number": 4,
        "window_text": "| 예 | 분류 3 | 중간조사 보고서로 제출), 향후 조치 계획, ③유통현황 및 회수 영향 등 관련 | 초과발암위해도 | 하한값과 상한값으로 제시할 수 있다.  | 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다. ",
        "original_sentence": "| 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 55,
        "word_count": 16,
        "page_number": 4,
        "window_text": "| 1, 3 | 수마프립탄 | 1 | 26.5 | - | 명/10만 | 3 |\n| 원료의약품 또는 완제의약품의 조성, 합성‧ | 잠재력점수= 1 + 2 + 1 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 | 있는가? * | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다. ",
        "original_sentence": "1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 1,
        "window_text": "* | 구조적 경고 있으나, 검사된 | 원료의약품 등에 동일한 구조적 | 경고가 있고 비-변이원성 | 발암성 연구 결과가 존재하는가?  | 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "| 있는가?"
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "* | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 203,
        "word_count": 57,
        "page_number": 2,
        "window_text": "| 허용기준 적용 | AI = 1500 ng/일 | 니트로사민류는 LTL* 개념 적용 | (불확실성 계수 미적용) |\n| 23 | N-nitroso-diclofenac | 디클로페낙 | 5 | 1,500 | - | 니트로사민류의 일반 Ames 시험(OECD 471 가이드라인의 박테리아 복귀 돌연변이 | 4.  1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까? ",
        "original_sentence": "* | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 2,
        "window_text": "1일 섭취 허용량 설정 | 14 | * TD50 :종양 발생률이 50%인 용량 | 하여야 합니다.  | 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요? ",
        "original_sentence": "| · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 507,
        "word_count": 135,
        "page_number": 3,
        "window_text": "| 있는가? * | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다. ",
        "original_sentence": "복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 33,
        "word_count": 12,
        "page_number": 2,
        "window_text": "* | Q4 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 관리(예: LOQ ≤ 0.032 ppm)를 위한 LC-MS/MS 분석법 선택 | AI = 1500 ng/일 | · 2차 아민인 DBA의 | □ 예 | ■ 아니오 |\n| 83 | N-nitroso-cloazpine | 클로자핀 | 5 | 1,500 | - | 제출하도록 요청하고 있다.  | · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다. ",
        "original_sentence": "| 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 270,
        "word_count": 65,
        "page_number": 13,
        "window_text": "| · 복용량 : 허가사항 용법·용량에서 정하는 1일 최대 용량을 적용할 수 있다.  복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가. ",
        "original_sentence": "| - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요? "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 23,
        "window_text": "복합제의 경우, 해당 복합제 | 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 생성의 잠재적 원인과 발생가능성 등을 평가하고, ➁발생가능성 ‘있음’으로 평가되면 | Q23 | ethanesulfonamide |\n| 할 수 있음 | N-니트로사민에 3차 α-탄소가 | Q21 | ① 해당 불순물 특이적 허용기준 | < 불순물 검출 수준에 따른 단계별 조치사항 > | 의 료 제 품 연 구 부 장     손  수  정 | 예 | 분류 5 | 비-변이원성 불순물로 관리 | AI = 400 ng/일 | AI = 400 ng/일 | AI = 400 ng/일 |\n| 24 | N-nitroso-ranolazine impurity 1 | 라놀라진 | 3 | 400 | - | ➍ 생체 내(in vivo) 변이원성 시험 결과 음성(비변이원성)인 경우 ICH Q3A/B 따라 | ▪ 불검출 데이터의 비율이 60% 이하인 경우에는 해당 데이터에 검출한계의 1/2 | ↓아니오 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가?",
        "original_sentence": "| • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 26,
        "window_text": "| 예 | 분류 3 | 자료 | 4 | 정리한 자료입니까?  | - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다. ",
        "original_sentence": "| 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 35,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| - 질량분석시 불순물 특성을 고려한 이온화 방법 선정 | 예) NDMA, NDEA 등 저분자량 불순물 → APCI mode | NDSRI 등 고분자량 불순물 → ESI mode | 니트로소화 및/또는 |\n| 56 | N-nitroso-pseudoephedrine | 슈도에페드린 | 4 | 1,500 | - | 84 | N-nitroso-tigecycline | 타이가사이클린 | 5 | 1,500 | - | 시험) 결과 음성인 경우, 1.5 μg/일로 기준이 설정 가능한가요?  | • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 192,
        "word_count": 55,
        "page_number": 4,
        "window_text": "| • 기준 및 시험방법의 적정성 | ↓아니오 | 용법·용량에서 정하는 최대용량을 적용할 수 있다.  | 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가?"
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "* | 가능성은 증가할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 11,
        "window_text": "| 예 | 발암 잠재력 분류 접근법(CPCA) |\n| 모르폴린 고리의 N-니트로소기 | 가장 견고하고 낮은 값(보수적 접근)을 사용할 수 있다.  | 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리. ",
        "original_sentence": "* | 가능성은 증가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 105,
        "word_count": 27,
        "page_number": 38,
        "window_text": "| 나) 완제의약품 제조공정 유래 불순물 | NDBA | 가.  일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다. ",
        "original_sentence": "| 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 2,
        "window_text": "일반 원칙 | 14 | Q13 | 복용기간 | 제품별 허가 이후기간~2020년 12월 31일까지 복용 가정 | +1 |\n| 편 | 집 | 위 | 원 | 5 | 1,500 | 성 관계(SAR) 개념을 기반으로 함 | 시험·검사를 실시하여야 하며, ➂검출량과 허용기준을 비교하여 불순물 검출 수준에 | ↓아니오 | ↓아니오 | ↓아니오 | 있는가? * | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ? ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "| 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 178,
        "word_count": 47,
        "page_number": 4,
        "window_text": "* | 가능성은 증가할 수 있다.  | 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다. ",
        "original_sentence": "| 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 78,
        "word_count": 23,
        "page_number": 4,
        "window_text": "| 비활성화 구조 특성 | 다른 아질산염을 사용하는 경우(같은 공정 혹은 다른 공정에서) | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요? ",
        "original_sentence": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 32,
        "word_count": 10,
        "page_number": 26,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다. ",
        "original_sentence": "| 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ? "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 140,
        "word_count": 37,
        "page_number": 4,
        "window_text": "| 설정 불가하고, | 의 약 품 관 리 과 | AI = 1500 ng/일 | 허용기준을 초과하는 의약품으로, |\n| 25 | N-nitroso-ramipril | 라미프릴 | 5 | 1,500 | - | 85 | N-nitroso-tamsulosin | 탐스로신 | 4 | 1,500 | - | 비변이원성으로 관리.  양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다. ",
        "original_sentence": "| 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 120,
        "word_count": 22,
        "page_number": 27,
        "window_text": "양성인 경우 ➊ 또는 ➋에 따라 기준 설정 | 활성화 구조 특성 | 0 | (혹은 정량한계의 1/2)값을 적용하여 통계값을 구할 수 있다.  | 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다. ",
        "original_sentence": "| 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요? "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 74,
        "word_count": 21,
        "page_number": 48,
        "window_text": "| 합에 따른 생성 가능성 | 적용 대상에 해당하는가 ?  | 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다. ",
        "original_sentence": "| 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "| 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 8,
        "window_text": "| 아니오 | AI = 400 ng/일 | 3차 아민인 TBA의 | 967 ∼ 8,774 일 |\n| 57 | N-nitroso-cinacalcet | 시나칼세트 | 3 | 400 | - | 불순물이 반응하여 NDPA가 생성되는 것으로 추정되고 있다.  | 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요? ",
        "original_sentence": "| 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 53,
        "word_count": 8,
        "page_number": 10,
        "window_text": "| 살부타몰(salbutamol) | N-nitroso-salbutamol | (일) / 25,550 일 | 조치사항 |\n| 2개의 N-니트로소기를 함유한 NDSRIs의 경우 CPCA를 적용하여 어떻게 분류하나요?  | 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다. ",
        "original_sentence": "| (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| 적용대상 | • 상기 기준에 따른 시험검사 결과의 적정성 | 로사민류 불순물 기준 설정 현황’에서 최신사항을 확인 할 수 있다.  | 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다.  | 따른 단계별 조치를 해야 합니다. ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 121,
        "word_count": 31,
        "page_number": 4,
        "window_text": "| 개별 허용한도 외 총 허용기준을 설정하여 관리하여야 한다.  | (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다.  | 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다. ",
        "original_sentence": "| ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요? "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| 랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 45,
        "window_text": "| (susceptible population)을 정의하고, 이들에서의 노출 양상을 제시한다.  | 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다.  | 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요? ",
        "original_sentence": "| 랍니다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "| 따른 단계별 조치를 해야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 45,
        "window_text": "| 잠재력 점수를 산출한다.  | ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다.  | 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다. ",
        "original_sentence": "| 따른 단계별 조치를 해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "| 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| ② 불순물 검출수준이 니트로사민류 | 예 | 분류 4 |\n| 26 | N-nitroso-labetalol | 라베타롤 | 4 | 1,500 | - | 니트로사민류 시험·검사 결과는 모두 식약처에 보고해야 하나요?  | 랍니다.  | 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다. ",
        "original_sentence": "| 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "| ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 138,
        "word_count": 34,
        "page_number": 10,
        "window_text": "| 랍니다.  | 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나. ",
        "original_sentence": "| ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "| 대한 박테리아 변이원성시험을 직접 실시할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 따른 단계별 조치를 해야 합니다.  | 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다. ",
        "original_sentence": "| 대한 박테리아 변이원성시험을 직접 실시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 56,
        "word_count": 16,
        "page_number": 2,
        "window_text": "| 잠재력 점수를 산출한다.  | ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다. ",
        "original_sentence": "| 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "| 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| ↓아니오 | 예 | 분류 4 | 탈알킬화 |\n| 86 | N-nitroso-desmethyl terbinafine | 테르비나핀 | 1 | 26.5 | - | 니트로사민류 시험·검사할 제품이 다수일 때는 우선순위를 부여하여 수행할 수 있나요?  | 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다. ",
        "original_sentence": "| 나. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 265,
        "word_count": 58,
        "page_number": 4,
        "window_text": "| 대한 박테리아 변이원성시험을 직접 실시할 수 있다.  | 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다.  | 업데이트 될 수 있다. ",
        "original_sentence": "니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "| 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 8,
        "window_text": "| 구분 | 개별 불순물 | 검출 수준 | 등을 통하여 추가적인 조치가 불필요함을 입증하여야 한다.  | 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다.  | 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬. ",
        "original_sentence": "| 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 등에 활용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 17,
        "window_text": "| 나.  니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다.  | 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다. ",
        "original_sentence": "| 등에 활용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| 업데이트 될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 23,
        "window_text": "니트로사민류 불순물의 1일 섭취 허용량 설정 | 15 | 7-nitroso-3-(trifluoromethyl)-5,6, | 7,8-tetrahydro[1,2,4]triazolo-[4,3- a] | 할 N-니트로소기 주변 구조적 환경요소는 치환 정도, 입체적 부피, 전자적 | ↓아니오 | 관한 자료(SAR/Read across 또는 CPCA 기준설정 근거자료 포함) 등 관련 자료 | 문 은 희 , 박 희 영 , 이 종 규 | 허가변경 |\n| 있는 조치를 이행하여야 한다.  | 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다.  | 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다. ",
        "original_sentence": "| 업데이트 될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 5,
        "window_text": "| 관된 품목의 불순물 안전관리에 활용할 수 있도록 한다.  | 등에 활용할 수 있다.  | 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다. ",
        "original_sentence": "| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 84,
        "word_count": 24,
        "page_number": 10,
        "window_text": "| 등에 활용할 수 있다.  | 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가? ",
        "original_sentence": "각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "| Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 64,
        "word_count": 19,
        "page_number": 4,
        "window_text": "| 업데이트 될 수 있다.  | 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "| Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "복용기간은 질환 및 의약품의 특성을 고려할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 23,
        "window_text": "| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 | 비고리형) 사슬.  각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "복용기간은 질환 및 의약품의 특성을 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 4,
        "window_text": "각 사슬에서 4개 | 이하의 원자가 동일한 고리에 있을 | 수 있음 | ▪ 분석 결과 모두 검출한계 이상으로 정량된 경우에는 실제 통계값을 사용한다.  | Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "| Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| Q17 | Q2 | 구조적 경고가 없거나, | 변이원성이 없음을 입증하는 | 충분한 데이터 있음 | 수 있다.  복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다. ",
        "original_sentence": "| 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 4,
        "window_text": "복용기간은 질환 및 의약품의 특성을 고려할 수 있다.  | Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가? ",
        "original_sentence": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 4,
        "window_text": "| Read-across 등을 이용한 구조-활성 |\n| 27 | N-nitroso-rasagiline | 라사길린 | 2 | 100 | - | 점수가 ≥4 인가?  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요? ",
        "original_sentence": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 296,
        "word_count": 82,
        "page_number": 4,
        "window_text": "| 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다. ",
        "original_sentence": "| 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 4,
        "window_text": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다. ",
        "original_sentence": "| < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "| 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 111,
        "word_count": 30,
        "page_number": 4,
        "window_text": "| 예 | 분류 2 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "| • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 188,
        "word_count": 50,
        "page_number": 23,
        "window_text": "| 예 | 분류 2 | AI (㎍/day) | 하루 중 NDMA 섭취 허용량 | 0.096 ㎍/day | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | ▼ | 계열 특이적 공통기준(26.5ng/일) | 초과한 경우 | 2, 2 | AI = 1500 ng/일 | 기간이 3년 이내 | □ 예(☞지침서) | ■ 아니오 | 1 |\n| 58 | 87 | N-nitroso-terbinafine impurity A | 테르비나핀 | 1 | 26.5 | - | 사례에 따른 주요 보완사항은 표 6에서 기술한 바와 같다.  | < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다. ",
        "original_sentence": "| • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "| * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 4,
        "window_text": "| < 예시: NDMA의 1일 섭취 허용량 계산> | 점수가 ≥4 인가?  | 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5. ",
        "original_sentence": "| * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "| pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 39,
        "word_count": 8,
        "page_number": 23,
        "window_text": "| 회수 | (저감화 또는 | 기준설정) | AI = 1500 ng/일 | 출하 시 시험검사 |\n| 7원 고리의 N-니트로소기 | 식약처에서 설정한 니트로사민류 허용기준은 어디서 확인할 수 있나요?  | • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use). ",
        "original_sentence": "| pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "(공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 166,
        "word_count": 45,
        "page_number": 4,
        "window_text": "| • 시험검사 결과에 따른 예방 및 시정조치 계획 등 | 영향, 대사 활성화 가능성, 생성된 대사산물의 안정성/반응성 및 전체 분자량 | 5 | 구조-활성 상관관계 평가를 | 비-변이원성 불순물로 관리 | 상관관계 방법을 이용 유사 구조의 | +1 |\n| DAN 등)를 통한 분석방법(예: LC, LC-MS/MS)을 활용할 수 있다.  | * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "(공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "| 5. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "| * 1일 섭취 허용량(㎍/day) : 사람이 매일 평생(70년, 25,550일) 동안 섭취할 때 자연발생 | 양을 포함해야함 | 잠재력 점수를 산출한다.  | pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다. ",
        "original_sentence": "| 5. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use). ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 59,
        "word_count": 10,
        "page_number": 4,
        "window_text": "| pyrazine, NTTP | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4. ",
        "original_sentence": "초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use). "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "(2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 4,
        "window_text": "(공무원용) | 의 약 품 규 격 과 | 예 | 분류 4 | 예 |\n| 28 | N-nitroso-levofloxacin | 레보플록사신 | 4 | 1,500 | - | 88 | N-nitroso-tetracaine | 테트라카인 | 3 | 400 | - | 관계(SAR) 개념을 기반으로 한다.  | 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ? ",
        "original_sentence": "(2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 4,
        "window_text": "| 5.  초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다. ",
        "original_sentence": "| 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "| - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 128,
        "word_count": 41,
        "page_number": 19,
        "window_text": "초과발암위해도를 이용한 인체영향평가 | 26 | pharmaceuticals for human use).  (2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3. ",
        "original_sentence": "| - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 140,
        "word_count": 33,
        "page_number": 4,
        "window_text": "(2017) | 분해‧ | ↓아니오 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다. ",
        "original_sentence": "니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ? "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "| TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 4,
        "window_text": "| 예 | 분류 2 | 결합하여 NDMA가 생성되는 것으로 추정되고 있다.  | - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다. ",
        "original_sentence": "| TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 표 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 10,
        "window_text": "| - 주성분 및 불순물 특성을 고려한 칼럼* 및 이동상 선정 | 예) 라니티딘은 고정상에 의존적 → 칼럼 선정 중요 | +1 | AI = 100 ng/일 | AI = 100 ng/일 | AI = 100 ng/일 |\n| 표 4.  니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다. ",
        "original_sentence": "| 표 3. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 95,
        "word_count": 17,
        "page_number": 13,
        "window_text": "니트로사민류 개별 불순물의 1일 섭취 허용량 설정(2024.6.21) | 1일 노출량 (㎍/day) | 제품 복용을 통한 일일 최대노출량 | β-탄소는 아래와 같이 N-니트로소기를 기준으로 정해짐 | ↓아니오 | 통한 섭취 허용량 설정이 가능한가 ?  | TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다. ",
        "original_sentence": "완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "| 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 63,
        "word_count": 18,
        "page_number": 4,
        "window_text": "| TD50 으로 |\n| 감소시키거나 예방하도록 필요한 조치를 취하고 있다.  | 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다. ",
        "original_sentence": "| 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "| 하거나, | 등이 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 23,
        "window_text": "| 표 3.  완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가? ",
        "original_sentence": "| 하거나, | 등이 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "| Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 311,
        "word_count": 76,
        "page_number": 2,
        "window_text": "완제의약품의 포장재질 중 발생가능한 니트로사민 | ① NDMA의 CPDB 랫드 발암성시험의 TD50(종양발생율이 1/2 되는 용량)은 0.0959 mg/kg/day이다.  | 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다. ",
        "original_sentence": "| Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 80,
        "word_count": 23,
        "page_number": 27,
        "window_text": "| 적용기간 | 12개월 이내 한시적 적용 | 허용량을 총 허용기준으로 설정하는 것이 한가지 예가 될 수 있다.  | 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요? ",
        "original_sentence": "| 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 69,
        "window_text": "| 하거나, | 등이 있습니다.  | Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다. ",
        "original_sentence": "| 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가? "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "| KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 54,
        "word_count": 10,
        "page_number": 22,
        "window_text": "| Q15 | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 아니오 | 3년 이내 한시적 적용 |\n| 29 | N-nitroso-2,6-pipecoloxilidide | 로피바카인 | 4 | 1,500 | - | 59 | N-nitroso-desmethyl citalopram | 시탈로프람 | 1 | 26.5 | - | 모든 니트로사민류(NDSRIs 포함)를 발암잠재력 분류 접근법(CPCA)을 적용하여 | • 배치 간 변동성 자료 | 적인 발암가능성에 더하여 10만분의 1 확률로 암이 더 발생할 수 있는 1일 섭취 허용량 | 있다.  | 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
        "original_sentence": "| KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "| AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 113,
        "word_count": 30,
        "page_number": 4,
        "window_text": "| 박 상 애 , 우 선 욱 , 김 민 경 |\n| 89 | N-nitroso-desmethyl | 구분 | 의약품관리과로 문의하시기 바랍니다.  | 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다. ",
        "original_sentence": "| AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "| 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 13,
        "window_text": "| 발암성 위험 또는 기타 독성 영향을 초래하는 연구되지 않은 화학물질의 AI) | ↓아니오 | ↓아니오 | ↓아니오 | 점수가 ≥4 인가?  | KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "| 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "| 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 2,
        "window_text": "| KM방법(kaplan-Meier method) 등 통계적 방법을 활용하여 처리할 수도 있다.  | AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요? ",
        "original_sentence": "| 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "(민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 158,
        "word_count": 41,
        "page_number": 4,
        "window_text": "| AI = 100 ng/일 | AI = 1500 ng/일 | 섭취 허용량 계산 | ■예(☞안내서) | □ 아니오 |\n| 완제의약품의 규격에 니트로사민류의 한시적 허용기준을 설정하여 관리할 수 있나요?  | 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가? ",
        "original_sentence": "(민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "| * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 106,
        "word_count": 31,
        "page_number": 88,
        "window_text": "| 새로운 불순물 정보 확인 | 에는 니트로사민 생성 위험성을 가지고 있다.  | 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다. ",
        "original_sentence": "| * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 133,
        "word_count": 38,
        "page_number": 10,
        "window_text": "| 분석조건 검토 | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다. ",
        "original_sentence": "| 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 211,
        "word_count": 56,
        "page_number": 23,
        "window_text": "(민원인용) | trimebutine | 트리메부틴 | 5 | 1,500 | - | 불순물 평가 및 시험 | 단계별 조치 | ✓ |\n| 60 | N-nitroso-ciprofloxacin | 시프로플록사신 | 4 | 1,500 | - | 하고 관련 사항을 식약처에 제출하여야 한다.  | * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다. ",
        "original_sentence": "| * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "| 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 65,
        "word_count": 18,
        "page_number": 10,
        "window_text": "| * 랫드와 마우스 시험 결과 중 보다 보수적인 랫드의 조화평균(harmonic mean) TD50을 사용 | 수준1 | 기준 초과 | ✓ | ✓ | 활용 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다. ",
        "original_sentence": "| 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "| impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 210,
        "word_count": 52,
        "page_number": 39,
        "window_text": "| 예 | 분류 3 | N-nitroso-folinic acid: | * 기간 연장 필요 시 별도 검토 | - 불순물은 주성분/첨가제의 RT가 겹치지 않게 분리 | * 기간 연장 필요 시 별도 검토 |\n| 섭취허용량을 설정할 수 있나요?  | * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ. ",
        "original_sentence": "| impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "| • 안정성시험 자료 | 다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 45,
        "window_text": "| * 세 개 이상의 N-니트로소기를 포함하는 경우 식약처에 문의 필요 | (식약처가 마련한 잠정기준 등을 대입) | 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민감도에 대해서는 | 섭취허용량 | (저감화 또는 |\n| • 국내·외 규제기관 발표 및 | 니트로사민 | NOx 공급원 | Amine 공급원 | NOx와 반응하는 | 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다. ",
        "original_sentence": "| • 안정성시험 자료 | 다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "| N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 291,
        "word_count": 51,
        "page_number": 4,
        "window_text": "| 예 | 분류 3 | ↓아니오 | ↓아니오 | (예: 건조공정)을 거치는 경우 니트로사민이 생성될 가능성이 있다.  | impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다. ",
        "original_sentence": "| N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "| Ⅲ. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| impurities, NDSRIs) 발생 가능성 | 의 약 품 연 구 과 | • 발생가능성 평가(인지일로부터 | (식약처 검토) | •검출수준에 따른 단계별 조치 | •공정개선 등 저감화 조치 또는 | (ng/일) | 비고 |\n| 61 | N-nitroso-desmethyl-sildenafil | 실데나필 | 3 | 400 | - | 으며, 니트로사민류도 이에 속한다.  | • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "| Ⅲ. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 85,
        "word_count": 10,
        "page_number": 5,
        "window_text": "| • 안정성시험 자료 | 다.  | N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 4,
        "window_text": "| N-[4-[[(2-amino-5-formyl-3,4,5,6 | ,7,8-hexahydro-4-oxo-6-pteridin | yl)methyl]nitrosoamino]benzoyl] | tributylamine 등이 있음 | 아니오 | - 불순물이 과량으로 존재하는 주성분보다 빨리 용리하게 | 불순물별 별도 설정 | 기준설정 완료시까지) |\n| 90 | N-nitroso-trimetazidine, NTMZ | 트리메타지딘 | 3 | 400 | - | 일반적으로 불순물 신규 시험법 개발을 위한 절차는 다음과 같다.  | Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "| ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "| 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 4,
        "window_text": "| Ⅲ.  불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다. ",
        "original_sentence": "| 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 4,
        "window_text": "불순물 검출 시 조치방안 ··················································· 30 | 471호를 따라야 한다.  | ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다. ",
        "original_sentence": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 29,
        "word_count": 11,
        "page_number": 4,
        "window_text": "| ② 랫드 TD50을 50,000으로 나누면 1/100,000의 비율로 종양을 발생하는 용량을 얻을 수 있다.  | 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다. ",
        "original_sentence": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "| 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 136,
        "word_count": 40,
        "page_number": 4,
        "window_text": "| 사) 공정 최적화·관리의 미흡 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요? ",
        "original_sentence": "| 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 525,
        "word_count": 145,
        "page_number": 23,
        "window_text": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다. ",
        "original_sentence": "따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "| 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 138,
        "word_count": 31,
        "page_number": 4,
        "window_text": "| 예 | 분류 1 | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다. ",
        "original_sentence": "| 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "| 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 247,
        "word_count": 72,
        "page_number": 4,
        "window_text": "| 예 | 분류 1 | 2, 3 | Amine | 주요 공급원 | 1 |\n| 투여 기간이 10년 이상인 의약품도 ‘한시적 허용기준 적용 방안2(LTL 접근법)’ | 관련 문헌 조사 등 불순물 | 모니터링(상시) | 알려진 바가 거의 없습니다.  따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요? "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| EAT) 조건으로 수행하는 것을 권고합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 45,
        "window_text": "따라서, 제시된 강화된 Ames 시험(Enhanced Ames test, | 추정물질이고, ICH M7(R1) class 1에 해당하는 물질 | 력이 발생하는 과정이 포함된 과립‧ | 구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진 | 니트로사민류 공통 적용 기준 | 3개월이내) | 코팅‧ | AI = 400 ng/일 | 잠재력 점수로 |\n| 30 | 수준2 | 기준의 30% 초과 | 가장 큰 그룹(즉, 가장 낮은 잠재력 점수가 있는 분류 그룹)이 전체 분자의 1일 | 활성화 구조 특성 | 0 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | ▶ | 하여 주성분으로 인한 영향 최소화 필요 | 류코보린 | 4 | 1,500 | - | AI = 400 ng/일 | ▶ | □ 예 | ■ 아니오 |\n| 62 | N-nitroso-cilazapril | 실라자프릴 | 5 | 1,500 | - | 91 | N-nitroso-ticagrelor | 티카그렐러 | 5 | 1,500 | - | 수 있다.  | 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
        "original_sentence": "| EAT) 조건으로 수행하는 것을 권고합니다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 23,
        "window_text": "| 1 | N-nitrosodi-ethylamine, NDEA | - | - | 26.5 | - | 나) 원료의약품의 분해 또는 산화과정 | 전화번호: 043-719-2654 | 총 1일 섭취 허용량은 26.5ng/일로 설정하고 관리하여야 한다.  | 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "| 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "| 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 2,
        "window_text": "| 김 판 순 , 안 일 영 | • 위해 발견 시 신속하게 시험 | 치료기간 | 12개월 | ✓ | 12개월 |\n| • 불순물 발생원인 및 공정변수 평가 자료 | (26.5 ng/일) 적용 | 0.0959 (mg/kg/day) / 50,000 = 0.00192 μg/kg/day | AI = 26.5 ng/일 | AI = 26.5 ng/일 | AI = 26.5 ng/일 | 섭취 허용량 계산 | +1 |\n| 기타 확인 | 적용이 가능한가요?  | EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n",
        "original_sentence": "| 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "| (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 37,
        "window_text": "| EAT) 조건으로 수행하는 것을 권고합니다.  | 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n",
        "original_sentence": "| (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| 참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의 | 수립하여 실시할 수 있습니다.  | 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 85,
        "word_count": 18,
        "page_number": 2,
        "window_text": "| 민원인을 구속하는 내용이 있습니까?  | (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다. ",
        "original_sentence": "지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "상기 사항에 대하여 확인하였음.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 2,
        "window_text": "| (저감화 또는 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
        "original_sentence": "상기 사항에 대하여 확인하였음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 263,
        "word_count": 53,
        "page_number": 3,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022. ",
        "original_sentence": "2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 120,
        "word_count": 23,
        "page_number": 3,
        "window_text": "지침서ㆍ안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 183,
        "word_count": 40,
        "page_number": 3,
        "window_text": "상기 사항에 대하여 확인하였음.\n\n 2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7.  14.\n",
        "original_sentence": "또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 92,
        "word_count": 21,
        "page_number": 3,
        "window_text": "2024 년  6 월  26 일\n\n담당자\n\n확  인(부서장)\n\n문 은 희\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의약품안전국\n\n팩스번호: 043-719-2650\n\n<!-- PAGE_3 -->\n###### 이 안내서는 의약품 중 변이원성・발암성 불순물, 특히 니트로사민류\n\n<!-- PAGE_3 -->\n###### 안전관리에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술한 것입니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7.  14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ. ",
        "original_sentence": "※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "7. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 4,
        "window_text": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### 기술방식(‘∼하여야 한다’ 등)에도 참고로만 활용하시기 바랍니다.  또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7.  14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1. ",
        "original_sentence": "7. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "14.\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 4,
        "window_text": "또한,\n\n<!-- PAGE_3 -->\n###### 본 안내서는 2024년 6월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를\n\n<!-- PAGE_3 -->\n###### 토대로 작성되었으며 이후 최신 개정 법규 내용 및 구체적인 사실관계\n\n<!-- PAGE_3 -->\n###### 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7.  14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1. ",
        "original_sentence": "14.\n"
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "제정\n\n<!-- PAGE_5 -->\n#### Ⅰ. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 5,
        "window_text": "※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알\n\n제·개정 이력\n\n연번\n\n제·개정번호\n\n승인일자\n\n주요내용\n\n1\n\n0\n\n- 2022.  7.  14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가. ",
        "original_sentence": "제정\n\n<!-- PAGE_5 -->\n#### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 124,
        "word_count": 8,
        "page_number": 5,
        "window_text": "7.  14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나. ",
        "original_sentence": "서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 56,
        "word_count": 11,
        "page_number": 5,
        "window_text": "14.\n 제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다. ",
        "original_sentence": "목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 61,
        "word_count": 12,
        "page_number": 5,
        "window_text": "제정\n\n<!-- PAGE_5 -->\n#### Ⅰ.  서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라. ",
        "original_sentence": "제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 5,
        "window_text": "서론 ··························································································· 1\n\n<!-- PAGE_5 -->\n###### 1.  목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2. ",
        "original_sentence": "신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 5,
        "window_text": "목적\n\n<!-- PAGE_5 -->\n###### 1\n\n<!-- PAGE_5 -->\n###### 1.  제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ. ",
        "original_sentence": "검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 77,
        "word_count": 16,
        "page_number": 5,
        "window_text": "제약사 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 가.  신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ. ",
        "original_sentence": "불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 5,
        "window_text": "신속 보고\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 나.  검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다.",
        "original_sentence": "허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 5,
        "window_text": "검출 수준에 따른 단계별 조치\n\n<!-- PAGE_5 -->\n###### 30\n\n<!-- PAGE_5 -->\n###### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다.",
        "original_sentence": "식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 113,
        "word_count": 8,
        "page_number": 6,
        "window_text": "불순물 함유 우려 의약품의 제조공정 검증\n\n<!-- PAGE_5 -->\n###### 32\n\n<!-- PAGE_5 -->\n###### 라.  허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다.",
        "original_sentence": "질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 425,
        "word_count": 76,
        "page_number": 7,
        "window_text": "허가사항 변경 등\n\n<!-- PAGE_5 -->\n###### 41\n\n<!-- PAGE_5 -->\n###### 2.  식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다.",
        "original_sentence": "참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다."
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": ")이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 23,
        "window_text": "식약처 조치\n\n<!-- PAGE_5 -->\n###### 42\n\n<!-- PAGE_5 -->\n# 목  차\n\n- - 6 -\n<!-- PAGE_6 -->\n#### Ⅳ.  질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n",
        "original_sentence": ")이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다."
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": ")뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 73,
        "word_count": 17,
        "page_number": 23,
        "window_text": "질의응답 ··············································································· 45\n\n<!-- PAGE_6 -->\n#### Ⅴ.  참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가. ",
        "original_sentence": ")뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다."
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": ")의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 203,
        "word_count": 46,
        "page_number": 4,
        "window_text": "참고문헌 ··············································································· 60\n\n- - 1 -\n<!-- PAGE_7 -->\n## Ⅰ\n\n<!-- PAGE_7 -->\n## 서론\n\n<!-- PAGE_7 -->\n#### 1\n\n<!-- PAGE_7 -->\n#### 목적\n\n이 가이드라인은 원료의약품 및 완제의약품 제조‧\n\n수입업체가 시판중인 의약품\n\n발암성 불순물을 검출하고, 이를 1일 섭취 허용량 이내로 감소시\n\n키거나 예방하기 위해 실시하여야 하는 안전관리 업무 수행 시 고려하여야 할\n\n<!-- PAGE_7 -->\n#### 2\n\n<!-- PAGE_7 -->\n#### 배경\n\n‵18년 고혈압약(발사르탄)을 시작으로 매년 의약품에서 니트로사민류* 불순물\n\n(이하 ‵니트로사민류‵라 한다. )이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다. ",
        "original_sentence": ")의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다."
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": ")가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 190,
        "word_count": 49,
        "page_number": 4,
        "window_text": ")이 검출되고, 최근 새로운 변이원성 불순물**이 검\n\n출됨에 따라 식품의약품안전처(이하 ‵식약처‵라 한다. )뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n",
        "original_sentence": ")가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "- - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 529,
        "word_count": 122,
        "page_number": 8,
        "window_text": ")뿐만 아니라, 미국 FDA\n\n와 유럽 EMA 등 해외 규제기관에서도 ‵변이원성 또는 발암성 불순물‵(이하 ‵불\n\n순물‵이라 한다. )의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n",
        "original_sentence": "- - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 121,
        "word_count": 27,
        "page_number": 8,
        "window_text": ")의 영향을 받는 원료의약품 및 완제의약품에 대한 위험평가를\n\n실시하고, 1일 섭취 허용량을 제시하는 등 의약품 중 불순물을 허용기준 이내로\n\n* (NDMA 등) 대표적인 NDMA는 WHO 국제 암연구소(IARC)가 지정한 인체 발암\n\n** AZBT 불순물, NDSRI 등\n\n이에 식약처는 원료의약품 및 완제의약품 제조‧\n\n수입업체(이하 ‵제약사‵라 한\n\n- 다. )가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다. ",
        "original_sentence": "발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 184,
        "word_count": 42,
        "page_number": 22,
        "window_text": ")가 불순물을 확인하고 1일 섭취 허용량을 초과하는 것을 방지하기 위해\n취해야 할 절차 및 1일 섭취 허용량을 초과한 의약품이 이미 유통 중인 경우\n\n제약사의 조치사항, 이와 관련한 식약처의 검토 절차 등 의약품의 품질 확보\n\n및 안정적 공급을 위해 제약사와 식약처가 협력해야 할 사항에 대해 니트로\n\n사민류를 중심으로 안내하고자 한다.\n\n - - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임. ",
        "original_sentence": "활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "- - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 8,
        "window_text": "- - 2 -\n<!-- PAGE_8 -->\n## Ⅱ\n\n<!-- PAGE_8 -->\n## 불순물 위험평가\n\n<!-- PAGE_8 -->\n#### 1\n\n<!-- PAGE_8 -->\n#### 개요\n\n식약처는 해외 규제기관 등과의 긴밀한 협력을 통해 의약품 중에 포함될 수\n\n있는 불순물에 대한 검토를 지속하고 필요시 제약사에 적절한 조치를 권고할\n\n식약처의 의약품 중 불순물 검토 등과는 별도로 제약사는 현재 활용 가능한\n\n과학기술 등을 이용하여 원료의약품 합성공정 및 완제의약품 제조공정 등을\n\n면밀히 검토하여 불순물 생성의 잠재적 원인과 발생가능성 등을 평가하여야\n\n또한, 1일 최대복용량, 치료기간, 적응증, 복용환자 수와 같은 개별 의약품의\n\n고유 특성을 고려하여 우선 순위를 정해 시험검사를 실시하고 필요한 경우\n\n제조공정 변경, 기준규격 설정 등 허가변경을 포함하여 불순물을 저감화할 수\n\n<!-- PAGE_8 -->\n#### 2\n\n<!-- PAGE_8 -->\n#### 불순물 발생가능성 평가\n\n<!-- PAGE_8 -->\n##### 가.  발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20. ",
        "original_sentence": "- - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "- - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 466,
        "word_count": 103,
        "page_number": 9,
        "window_text": "발생가능성 평가\n\n제약사는 자사의 원료의약품 및 완제의약품이 최신 과학기술 등에 부합하는\n\n제조공정과 보관조건 등에 따라 제조‧\n\n품질관리 되어 유통되고 있음을 확인하고\n\n입증해야 할 의무가 있음을 인지하여야 한다.  활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5. ",
        "original_sentence": "- - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 253,
        "word_count": 41,
        "page_number": 4,
        "window_text": "활용가능한 모든 새로운 정보를\n\n활용하여 원료의약품 합성공정 및 보관과정, 완제의약품의 제조공정 및 보관\n\n과정에서 발생할 가능성이 있는 모든 불순물을 확인하고 이러한 불순물에 대\n\n한 변이원성을 평가한 후 변이원성 또는 발암성이 확인되는 경우 발암 위해가\n\n10-5 (10만분의 1) 수준 이하로 관리되도록 조치하여야 한다.\n\n - - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8. ",
        "original_sentence": "따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 68,
        "word_count": 18,
        "page_number": 4,
        "window_text": "- - 3 -\n이를 위한 불순물 유전독성 평가는 아래와 같은 과정으로 실시한다.\n\n - - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가. ",
        "original_sentence": "분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 240,
        "word_count": 52,
        "page_number": 4,
        "window_text": "- - 원료의약품 및 완제의약품에 존재하는 실제 불순물뿐만 아니라 잠재적으로\n존재할 수 있는 불순물(존재가 합리적으로 예상되는 합성불순물과 분해\n\n생성물)을 포함하여 발생가능성 평가\n\n**[표 시작]**\n\n| - 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준설정 불가 시 | 은 원료의약품의 제조공정에 사용되는 시약·용매·출발물질·중간체·분해생성 | - 회수 원료물질을 사용하는 경우에는 잔류 아민(예: TEA, DIPEA)으로 인 | 원료의약품 : 원료의약품 합성공정에 사용되는 시약, 출발물질, 중간생성 |\n| --- | --- | --- | --- |\n| 및 유사 화학물질의 독성자료도 부족하여 이를 활용한 기준 설정 어려움 | 들의 초과발암위해도는 각 품목별로 허가(신고)일 이후부터 해당년도 말 |\n| 103 | N-nitroso-hydrochlorothiazide | 히드로클로로티 | 험적으로 입증하는 것이다.  따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10. ",
        "original_sentence": "새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 13,
        "window_text": "따라서, 의약품 제조공정에서 니트로사민류의 발생원 | 기준(1일 섭취허용량) 설정 가능 여부 ② 불순물 검출 수준 ③ 의료적 필요 | 섭취허용량 100ng/일에는 강력하고 확실한 시험을 거친 두 가지 | 니트로사민류 즉, N-nitrosodimethylamine(NDMA)과 4-(methylnitro | samino)-1-(3-pyridyl)-1-(butanone)(NNK)이 대표적으로 해당하며 | 섭취허용량은 각각 96ng/일와 100ng/일임.  분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3. ",
        "original_sentence": "발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 106,
        "word_count": 18,
        "page_number": 4,
        "window_text": "분류 2로 분류된 | 니트로사민류는 NDMA 및 NNK보다 높지 않은 발암잠재력을 | 갖는 것으로 예측됨 |\n| A20.  새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18. ",
        "original_sentence": "기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 4,
        "window_text": "새로운 니트로사민류 불순물 정보 입수일로부터 3개월 이내 발생가능성을 평가 | 12 | 2-nitroso-octahydrocyclopenta(c)pyrrole | 글리클라지드 | - | 1,700 | SAR/read-across, | 참조물질 NPYR1) | 약품의 제조 또는 보관과 관련된 위험 요인으로 분류할 수 있으며, 의약품 제 | 이 유통되는 동안에는 새로운 정보가 확인되면 위해평가 및 시험검사를 실시 |\n| 표 5.  발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24. ",
        "original_sentence": "신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 252,
        "word_count": 59,
        "page_number": 10,
        "window_text": "발생 가능한 원료의약품 유사구조 니트로사민 불순물 구조(예시) | A8.  기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22. ",
        "original_sentence": "변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 47,
        "word_count": 8,
        "page_number": 4,
        "window_text": "기존 니트로사민류 공통 허용기준(26.5 ng/일)을 적용하였던 N-nitroso-salbutamol | 물 또는 완제의약품의 제조용수·첨가제·분해생성물 등을 포함하여 니트로사 |\n| 가.  신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12. ",
        "original_sentence": "발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 4,
        "window_text": "신속 보고 | 2) USP <1469> Nitrosamine impurities | ❍ (적용대상) 의약품 공급 부족 가능성이 있는 경우에 한해 적용 | A10.  변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다. ",
        "original_sentence": "원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24. "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 189,
        "word_count": 44,
        "page_number": 13,
        "window_text": "변이원성 없음이 입증된 니트로사민류는 ICH Q3A 및 Q3B 가이드라인을 따르며, | - 대표성 있는 분석값으로 평균, 중앙값 등 통계값을 산출하는 경우 ’불검출‘ |\n| 니트로사민류는 ICH M7(R1) 가이드라인에서 제시된 바와 같이 강한 변이원성 | 성 및 공급 부족 우려 ④ 해외 규제기관 동향 등을 종합적으로 검토하여 개 |\n**품질(GMP, Good Manufacturing Practice) 측면과 관련된 위험 요소도 있**\n| A3.  발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다. ",
        "original_sentence": "니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 218,
        "word_count": 45,
        "page_number": 13,
        "window_text": "발암잠재력 분류 접근법(CPCA)은 니트로사민류에서 관찰되는 변이원성과 | A18.  원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16. ",
        "original_sentence": "니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 86,
        "word_count": 20,
        "page_number": 4,
        "window_text": "원칙적으로 신규 제조판매 또는 수입 품목허가·신고 신청 시에는 한시적 | A24.  니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다. ",
        "original_sentence": "원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "|\n| 다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 45,
        "window_text": "니트로사민류가 허용기준을 초과검출 또는 식약처에서 설정한 허용기준이 | OECD 시험 가이드라인 471호 ‘박테리아를 이용한 복귀돌연변이 시험’은 시험 |\n| * N-니트로소기가 피롤리딘 고리, 하나 이상의 황 원자를 포함하는 6원 고리 또는 모르폴린 | ❍ 방법 : 평판법이 아닌 전배양법으로 수행(전배양시간 30분 권장) | A22.  니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5. ",
        "original_sentence": "|\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 354,
        "word_count": 74,
        "page_number": 13,
        "window_text": "니트로사민류 발생가능성이 없거나 시험검사 결과 식약처 허용기준 이내인 | N-니트로소기(고리형 또는 | 비고리형)의 양쪽에서 β-탄소***에 | 결합된 하이드록실기 | 불순물이 원료의약품의 구조상 발생 가능한 자연가능한 분해산물인 경우 | 완제의약품 : 장기보존시험, 가속시험, 가혹시험 등 안정성시험 중에 생성 |\n| 1) NPYR : N-nitroso-pyrrolidine | A12.  원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다. ",
        "original_sentence": "의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 174,
        "word_count": 47,
        "page_number": 4,
        "window_text": "원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우, | 특정 의약품에 대한 불순물 가능성 평가 및 시험검사를 실시할 것을 지시한다.  |\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨. ",
        "original_sentence": "Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 143,
        "word_count": 38,
        "page_number": 13,
        "window_text": "|\n| 다.  의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6. ",
        "original_sentence": "또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 332,
        "word_count": 86,
        "page_number": 53,
        "window_text": "의약품 중 발생가능한 니트로사민류에 대하여 문헌에서 확인된 정보를 포 | 변동성을 분석하며, 사용(유효)기간 이내에 불순물의 경향성을 고찰하여 발생 가 | 이며 발암성을 나타내는 “cohort of concern”으로서 개별 섭취 허용량은 다음의 | 수치가 높은 경우, 아질산 제거제로 항산화제 등(예: 아스코르브산, 1-시 |\n| 참고로, 식약처와 해외 규제기관에서는 니트로사민류 등 불순물에 대한 분석 | * 평생(70년)동안 매일 섭취할 때 `무시 가능한 수준(발암 위해가 10만 명 중 1명 이하)` |\n| 2) NNK : 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone | A16.  Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다. ",
        "original_sentence": "비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 88,
        "window_text": "Q24에 언급된 자료 외 추가로, 회수·출하 중지 조치가 수급에 미치는 영향, | - 정보 입수일로부터 2년 이내 공정개선 등 저감화 조치, 허가(신고) 사항 변경 | 물질의 돌연변이 유발 가능성을 평가하기 위한 시험 수행에 대한 표준 권고사 | 미칠 수 있는 공정 및 공정변수에 대한 고찰을 수행하여야 한다.  또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14. ",
        "original_sentence": "또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 10,
        "window_text": "또한, 불순 | (예: 니자티딘 중 NDMA 등), 원료의약품의 합성에서부터 완제의약품의 제조 |\n| ❍ (적용대상) | ①N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 | ❍ (적용방안) 불순물 특성에 따라 방안 1 또는 방안 2 적용 | A5.  비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2. ",
        "original_sentence": "추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "잠재력 점수 계산식 및 계산과정은 아래와 같습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 23,
        "window_text": "비활성화 구조 특성으로서 전자 끄는 기는 문헌(Cross KP and Ponting DJ, | 제약사는 자체 위험평가와 시험검사를 통해 불순물 검출이 확인되는 경우 검 |\n| ① 아질산염 및 아민을 함유한 의약품 및 첨가제 성분이 용액 또는 현탁액 | < 초과발암위해도를 이용한 인체영향평가 방법 > | - 검출되는 니트로사민류의 개별 섭취허용량 중 가장 보수적인 섭취허용량을 총 허용 | 능한 불순물을 충분히 제거 또는 저감화하기 위한 예방 및 시정조치의 타당성 | √ 모든 시험검사 결과, 기준의 30% 이하로 일정하게 관리되는 경우 대표성 | 스테인, PABA) 활용을 고려할 수 있다.  또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n",
        "original_sentence": "잠재력 점수 계산식 및 계산과정은 아래와 같습니다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "| A14. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 4,
        "window_text": "또한 완제의약품의 제조원은 용 |\n| ** 카르복실산과 아릴(별도 계산), 케톤(상충되는 자료)은 제외됨.  추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1. ",
        "original_sentence": "| A14. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 464,
        "word_count": 113,
        "page_number": 4,
        "window_text": "추가적인 전자 끄는 기 예시는 | 3) NPIP : N-nitroso-piperidine |\n| ❍ S9의 종류 및 농도 : 대사활성계(S9) 없이 및 대사활성계(S9) 존재 | A6.  잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나. ",
        "original_sentence": "식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 401,
        "word_count": 91,
        "page_number": 4,
        "window_text": "잠재력 점수 계산식 및 계산과정은 아래와 같습니다.  | A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다. ",
        "original_sentence": "정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "- - 4 -\n표 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 13,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| A14.  식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다. ",
        "original_sentence": "- - 4 -\n표 1. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 145,
        "word_count": 35,
        "page_number": 11,
        "window_text": "식약처는 의약품 공급부족이 우려되는 경우 ①허용기준(1일 섭취허용량) 설정 | - 다만, 관련 문서 및 기록은 추후 식약처에서 자료 제출 요청 또는 의약품 등 | 물 발생원인에 따라 실제 생산한 원료 또는 완제의약품(연간 3개 배치 등) | - 원료의약품 합성공정에 사용한 회수 용매가 니트로사민 생성 또는 니트로 |\n| 3 | 불순물 시험검사 |\n| 4) NTHP : N-nitroso-1,2,3,6-tetrahydropyridine | 또는 발암성 불순물에 대한 품질관리기준을 설정하고 관리한 자료를 제출하여야 | 식약처는 제약사가 제출한 시험검사 결과 등과 관련하여 다음의 사항을 검토 | ▪ 불순물 시험결과에서 ‘불검출’로 처리 시 실제 검출한계값 또는 정량한계값을 | 탄소가 헤테로원자에 직접적으로 이중 결합되지 않는 니트로 |\n| - 평생보다 짧은 기간(LTL) 동안 특정 의약품을 복용했을 때 불순물로 인해 | 2.  정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1. ",
        "original_sentence": "ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 13,
        "window_text": "정의 및 원리 |\n| - 1) 발생 가능한 불순물 종류를 확정하여 변이원성‧ | 의약품 중 변이원성․발암성 불순물 안전관리 가이드라인 (민원인 안내서) | 발암성시험에 관한 데 |\n\n**[표 끝]**\n\n변이원성‧\n\n발암성에 관한 문헌자료 등이 없는 경우 컴퓨터를 이용하여 박테리아\n\n변이원성 시험 결과를 예측하는 (Q)SAR 방법 등을 이용할 수 있으며, 구조적\n\n경고(structural alert)를 근거로 적절한 관리방법을 적용하거나, 특정 불순물에\n\n의약품 중 불순물의 유전독성에 따른 관리방법을 설정하기 위해서는 불순물\n\n등급을 구분하는 것이 필요하며, 불순물 등급은 크게 불순물별로 변이원성‧\n\n발암성 정보수집, 변이원성 예측 또는 시험결과를 종합분석하여 표 1과 같이\n\n5개 등급으로 분류할 수 있다.\n\n - - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n",
        "original_sentence": "니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 147,
        "word_count": 35,
        "page_number": 11,
        "window_text": "- - 4 -\n표 1.  ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다. ",
        "original_sentence": "현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 75,
        "word_count": 17,
        "page_number": 26,
        "window_text": "ICH M7(R1) 가이드라인에 따른 불순물 등급 및 관리 방법\n\n등급\n\n(class)\n\n정의\n\n관리 방법\n\n1\n\n변이원성과 발암성 확인 물질\n\n화합물-특이적 허용한계 수준\n\n또는 그 이하로 관리\n\n- - 5 -\n<!-- PAGE_11 -->\n##### 나.  니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다. ",
        "original_sentence": "만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 13,
        "window_text": "니트로사민류 불순물 발생원인\n\n니트로사민류는 주로 아민과 니트로소화제(nitrosating agent)가 반응할 수 있\n\n는 조건에서 결합될 때 발생할 수 있지만, 그 외 경로로도 생성될 수 있다.  현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다. ",
        "original_sentence": "니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 85,
        "word_count": 24,
        "page_number": 4,
        "window_text": "현\n\n재까지 확인된 의약품에서의 니트로사민류 발생 원인은 원료의약품과 완제의\n\n가) 산성 반응조건에서 2차, 3차 아민 또는 4차 암모늄 존재 하에 아질산나\n\n- - 산성 조건에서 아질산염은 아질산을 형성할 수 있고, 이는 아민과 반응하여\n니트로사민을 형성한다.  만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n",
        "original_sentence": "나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 4,
        "window_text": "만약 아질산을 잔류 아지드(사용 예: 테트라졸\n\n환을 합성하는데 사용하는 시약)의 반응성을 종결하기 위해 사용한다면 발생\n\n그림 1.  니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다. ",
        "original_sentence": "원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 42,
        "word_count": 14,
        "page_number": 6,
        "window_text": "니트로사민 생성 과정\n\n- - 아질산염은 세척공정을 거친다고 하더라도 사용된 단계 그 이후로 이행\n될 수 있으므로 생성 가능성을 배제할 수 없다.\n\n 나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다.",
        "original_sentence": "3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 12,
        "window_text": "나) 니트로사민을 생성할 수 있는 2차, 3차 아민 및 4차 암모늄 아민의 공급원\n\n- - 아민류는 다양한 원인에 의하여 제조공정 중 존재할 수 있다.  원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다. ",
        "original_sentence": "모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "- - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 4,
        "window_text": "원료의약품\n(또는 원료의약품의 불순물), 중간체 또는 출발물질은 2차 또는 3차 아민\n\n기를 포함하고 있을 수 있다.  3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다. ",
        "original_sentence": "- - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 121,
        "word_count": 20,
        "page_number": 26,
        "window_text": "3차 및 4차 아민은 시약 또는 촉매로서\n\n- - 6 -\n투입될 수 있다.  모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다. ",
        "original_sentence": "예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다."
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "(그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 104,
        "word_count": 15,
        "page_number": 4,
        "window_text": "모든 형태의 아민은 아질산 또는 니트로소화제와 반응\n\n하여 니트로사민을 형성할 수 있다.\n\n - - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n",
        "original_sentence": "(그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 23,
        "window_text": "- - 아미드 용매는 특정 조건 하에서 분해되어 2차 아민의 공급원으로 작용\n할 수 있다.  예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n",
        "original_sentence": "대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 204,
        "word_count": 34,
        "page_number": 10,
        "window_text": "예를 들어 높은 반응온도 조건의 합성단계에서 유기용매로\n\n사용된 DMF(N,N-dimethylforamide)는 2차 아민인 Dimethylamine으로\n\n분해될 수 있고, 이는 아질산과 반응하여 NDMA를 생성한다. (그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2. ",
        "original_sentence": "3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 115,
        "word_count": 18,
        "page_number": 23,
        "window_text": "(그림 2)\n\n또한, N-methylpyrrolidone, N,N-dimethylacetamide 및 N,N-diethylacet\n\n2차 아민은 아미드 용매의 불순물로 존재할 수 있다.  대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n",
        "original_sentence": "예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "- - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 119,
        "word_count": 28,
        "page_number": 12,
        "window_text": "대표적으로 DMF 내\n\nDimethylamine이 유연물질로 존재할 경우 상기 반응과정에 따라 NDMA를\n\n생성할 수 있다.  3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다. ",
        "original_sentence": "- - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "- - 7 -\n표 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 13,
        "word_count": 6,
        "page_number": 4,
        "window_text": "3차 아민, 예를 들어 triethylamine 및 diisopropylethyla\n\nmine와 같은 경우 2차 아민(N,N-diethylamine (DEA), diisopropylamine,\n\nethylisopropylamine)을 함유하고 있을 수 있고, 4차 아민은 탈알킬화되\n\n어 유연물질 또는 분해생성물로서 2차 및 3차 아민을 함유하고 있을 수\n\n있다.  예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n",
        "original_sentence": "- - 7 -\n표 2. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 187,
        "word_count": 42,
        "page_number": 13,
        "window_text": "예를 들어 일반적인 상이동 촉매로서 사용되는 TBAB(Tetrabutylam\n\nmonium bromide)는 tributyl- (TBA) 및 dibutylamine (DBA) 불순물을\n\n함유할 수 있다.\n\n - - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다. ",
        "original_sentence": "니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 13,
        "window_text": "- - 아민 불순물은 공정에 따라 그 수준이 다를 수 있으므로 원료의약품\n제조원(API manufacturer) 별로 평가하며, 니트로사민을 생성할 수 있는\n\n아민기를 포함한 그 외 시약 등을 평가하도록 한다.\n\n - - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n",
        "original_sentence": "라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 13,
        "window_text": "- - 7 -\n표 2.  니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다.",
        "original_sentence": "원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 9,
        "window_text": "니트로사민류 발생 원인\n\n니트로사민\n\n생성과정\n\n원인\n\nNDMA\n\n· DMF의 가수분해\n\n및/또는 분해(온도)\n\n다) 원료의약품의 구조로부터 아질산 발생\n\n- - 같은 공정 혹은 다른 공정에서 2차 또는 3차 아민 존재 하에 히드록실아민의\n산화 또는 니트로-방향족 전구체로부터 아질산이 발생하는 경우 니트로사민이\n\n생성될 수 있다.\n\n 라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n",
        "original_sentence": "‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 85,
        "word_count": 22,
        "page_number": 13,
        "window_text": "라) 외부 업체로부터 오염된 원료(예: 용매, 시약, 촉매 등)의 사용\n\n- - 외부 업체로부터 공급받는 원료로부터 니트로사민이 도입될 수 있다.  원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다. ",
        "original_sentence": "아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "- - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 46,
        "word_count": 15,
        "page_number": 4,
        "window_text": "원료\n물질 공급과정에 대한 정보는 니트로사민 발생 예방에 중요한 요소이다.\n\n ‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다.",
        "original_sentence": "- - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "(예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 76,
        "word_count": 16,
        "page_number": 9,
        "window_text": "‧\n\n아질산나트륨은 일부 출발물질의 알려진 유연물질이며, 질산염 함유 원료\n\n(예: 질산칼륨)는 아질산을 유연물질로 함유할 수 있다.  아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다. ",
        "original_sentence": "(예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 50,
        "word_count": 14,
        "page_number": 13,
        "window_text": "아질산 불순물은\n\n다양한 경로(시약, 용매 등)로 유입될 수 있으며, 공정에 따라 그 수준\n\n은 다를 수 있으며, 원료 제조원 별로 평가하도록 한다.\n\n - - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다. ",
        "original_sentence": "마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 13,
        "window_text": "- - 8 -\n‧\n\n원료물질 중 불순물로서 2차 또는 3차 아민을 함유할 수 있다. (예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n",
        "original_sentence": "또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다."
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "(잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 139,
        "word_count": 33,
        "page_number": 13,
        "window_text": "(예: 톨루엔)\n\n‧\n\n출발물질 또는 위탁 제조원으로부터 공급받는 중간체는 해당 원료를\n\n제조하는 과정에서 교차오염의 가능성이 있다.\n\n 마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다. ",
        "original_sentence": "(잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 103,
        "word_count": 26,
        "page_number": 23,
        "window_text": "마) 회수한 용매, 촉매 및 시약의 사용\n\n하여 니트로사민 발생 위험에 노출될 수 있다.  또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n",
        "original_sentence": "이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 128,
        "word_count": 31,
        "page_number": 14,
        "window_text": "또한, 회수 공정에 퀜칭\n\n단계가 포함된 경우 니트로사민을 함유하고 있을 수 있다. (잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다. ",
        "original_sentence": "퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 13,
        "window_text": "(잔류 아지드를\n\n사민의 전구체를 함유하는 공정에서 사용된 경우 니트로사민 발생위험에\n\n- - 원료물질의 회수를 외부업체에 위탁할 경우나 설비의 세척공정이 적절하지\n- - 퀜칭 공정을 주 반응물에서 직접 수행할 경우 니트로사민 생성 위험성이\n있다.  이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다. ",
        "original_sentence": "아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 110,
        "word_count": 20,
        "page_number": 88,
        "window_text": "이는 아질산이 직접 잔류 아민과 반응하도록 하며, 적절한 제거\n\n또는 세척공정이 없거나 우려되는 특정 불순물을 효과적으로 제거하는\n\n공정이 없을 경우 그 이후 단계로 이행될 수 있다.  퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다. ",
        "original_sentence": "Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "- - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 138,
        "word_count": 32,
        "page_number": 15,
        "window_text": "퀜칭공정이 주 반응물\n\n외에서 수행될 경우라도 오염된 회수원료가 주 반응공정에 투입될 경우\n\n- - 반응온도, pH 또는 투입순서와 같은 공정이 최적화되어 있지 못하거나\n관리가 적절하지 못할 경우 니트로사민이 생성될 수 있다.\n\n 아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다.",
        "original_sentence": "- - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 23,
        "window_text": "아) 산화제 존재\n\n- - 산화제(과산화수소 등)가 존재하는 경우 아질산염 및 니트로사민을 생성\n시킬 수 있다.  Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다. ",
        "original_sentence": "이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 142,
        "word_count": 31,
        "page_number": 13,
        "window_text": "Dimethylamine에서 전환된 히드록실아민은 산화되어 알카\n\n리성 환경에서 고농도의 아질산염을 생성할 수 있으며, 이는 Dimethyla\n\nmine과 반응하여 니트로사민이 생성될 수 있다.\n\n - - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다. ",
        "original_sentence": "주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 186,
        "word_count": 44,
        "page_number": 15,
        "window_text": "- - 9 -\n<!-- PAGE_15 -->\n###### 2) 완제의약품\n\n- - 주성분의 아민기가 니트로소화 반응에 취약한 경우 N-니트로소 불순물을\n형성한다는 사례가 보고되었으며, 특히 2차 아민이 이러한 반응에 취약한\n\n것으로 알려져 있다.  이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n",
        "original_sentence": "이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다."
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "(예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 23,
        "window_text": "이러한 니트로소화 반응에 취약한 아민들은 제조공정\n\n또는 보관 중에 분해(예: 가수분해)되어 생성될 수 있다.  주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다. ",
        "original_sentence": "(예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 95,
        "word_count": 21,
        "page_number": 26,
        "window_text": "주성분 아민기의\n\n탈수소화 또는 탈알킬화를 유도하는 낮은 염기도(low basicity, 낮은 pKa\n\n값), 산성 염(예: HCl) 등에 의한 산성화, 아민류의 형태(예: 무정형), 수분\n\n존재 등은 니트로소화 반응에 영향을 주는 것으로 알려져 있다.  이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다. ",
        "original_sentence": "또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 62,
        "word_count": 17,
        "page_number": 13,
        "window_text": "이러한\n\n상태에서 아질산염 또는 아민을 함유한 원료(첨가제 등) 성분이 용액 또\n\n는 현탁액으로 존재(예: 습식 과립공정)하거나 고온에서 유지되는 작업\n\n- - 구조 자체의 반응성(예: 니트로알킬, 옥심 또는 기타 작용기의 존재) 또는\n외인성 니트로화제 존재에 의해 유도된 원료의약품의 분해로 인하여 니트\n\n로사민이 생성될 수 있다. (예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다. ",
        "original_sentence": "이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "- - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 130,
        "word_count": 32,
        "page_number": 4,
        "window_text": "(예: 라니티딘) 이러한 의약품은 높은 온도 및\n\n습도 조건에서 원료의약품의 분해가 촉진되어 니트로사민이 생성될 수\n\n있다.  또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다. ",
        "original_sentence": "- - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 75,
        "word_count": 20,
        "page_number": 88,
        "window_text": "또한, 원료의약품 또는 그 유연물질/분해생성물(예: 히드라존, 히드\n\n라지드)에 존재하는 히드라진 또는 기타 아민을 포함하는 작용기의 산화\n\n로 인하여 생성될 수 있다.  이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n",
        "original_sentence": "첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 13,
        "window_text": "이러한 발생원인은 이와 같은 작용기를 포함\n\n하는 원료 및 완제의약품의 제조 및 보관 중에 관찰될 수 있다.\n\n - - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ?",
        "original_sentence": "아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 111,
        "word_count": 25,
        "page_number": 13,
        "window_text": "- - 10 -\n다) 첨가제 등의 관리\n\n- - 아질산은 대표적인 니트로소화 불순물로서 일반적으로 사용되는 첨가제\n에서 보고되고 있으며, 아질산 불순물은 완제의약품 제조공정 및 사용기간\n\n동안 니트로사민의 생성으로 이어질 수 있다.  첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다. ",
        "original_sentence": "또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 184,
        "word_count": 43,
        "page_number": 26,
        "window_text": "첨가제 중 아질산의 수치\n\n는 첨가제 별, 공급업체 별, 동일 공급업체의 배치 별로 다양할 수 있어\n\n이를 고려하여 선택하도록 한다.  아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다. ",
        "original_sentence": "예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "**[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ?",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 16,
        "window_text": "아질산 수치가 낮은 첨가제의 선택은\n\n니트로사민 생성 위험을 낮출 수 있는 것으로 알려져 있다.  또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다. ",
        "original_sentence": "**[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ?"
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "**\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 231,
        "word_count": 59,
        "page_number": 16,
        "window_text": "또한, 아질산\n\n수 내에도 아질산 및 니트로사민이 함유되어 있을 수 있음을 인지하도록\n\n- - 직접용기 재질에 니트로셀룰로오스와 프린트잉크에 존재하는 아민류와\n결합하여 니트로사민이 생성될 수 있다.  예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다. ",
        "original_sentence": "**\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다. "
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 114,
        "word_count": 23,
        "page_number": 23,
        "window_text": "예를 들어 알루미늄 호일을 사용\n\n하는 블리스터 포장의 경우, 열을 가하여 접합하는 과정에서 니트로셀룰\n\n로오스로부터 산화질소가 발생하고 프린트잉크 또는 원료의약품에 존재\n\n할 수 있는 저분자 아민(예: DMA, DEA)과 반응하여 니트로사민을 생성\n\n할 수 있고, 이는 열 포장 동안 기화되어 제품을 오염시킬 가능성이 있다.\n\n **[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다. ",
        "original_sentence": "예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 106,
        "word_count": 18,
        "page_number": 26,
        "window_text": "**[표 시작]**\n\n| 니트로셀룰로오스 | 프린트잉크 |\n| --- | --- |\n**적용 대상에 해당하는가 ? **\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다. ",
        "original_sentence": "또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 137,
        "word_count": 30,
        "page_number": 17,
        "window_text": "**\n| (호일 내) | (호일 내) |\n| 니트로셀룰로오스 | 프린트잉크 |\n| 아니오 | 복용기간 |\n| (호일 내) | (호일 내) |\n\n**[표 끝]**\n\n호일/프린트잉크\n\n호일/프린트잉크\n\n마) 이온교환 수지를 사용하는 정제 공정\n\n- - 4차 암모늄 음이온 교환 수지(사용 예: 정제공정)에서 침출되는 아민과\n이동상에 존재하는 니트로화제가 반응하는 경우 니트로사민이 생성될 수\n\n- - 11 -\n있다.  예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n",
        "original_sentence": "수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 132,
        "word_count": 29,
        "page_number": 88,
        "window_text": "예시로 주사용수 생산 과정에서 용수를 소독하는데 사용된 잔류\n\n클로라민이 Demineralisation 공정에서 사용된 이온교환 수지로부터 침출\n\n된 디메틸아민과 반응하여 NDMA 생성이 있을 수 있다.  또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다. ",
        "original_sentence": "시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 159,
        "word_count": 36,
        "page_number": 13,
        "window_text": "또한, 용수의\n\n소독 과정(예: chlorination, chloro-amination, ozonation) 중 반응에 취약한\n\n아민류가 존재할 경우 부산물로 니트로사민을 생성할 수 있다.  수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n",
        "original_sentence": "이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 13,
        "window_text": "수지를\n\n사용하여 정제한 물을 사용하는 원료의약품 또는 완제의약품에도 위험\n\n불순물이 발생가능한 것으로 평가된 의약품의 경우에는 실제 불순물이 존재\n\n하는지, 존재한다면 검출 수준이 어느 정도 인지를 확인하기 위한 시험검사를\n\n실시하여야 한다.  시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다. ",
        "original_sentence": "발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 135,
        "word_count": 27,
        "page_number": 13,
        "window_text": "시험검사는 환자가 직접 복용하는 완제의약품을 대상으로\n\n수행하여야 하나, 발생가능성 평가 결과 불순물 생성의 잠재적인 원인이 원료\n\n의약품이거나 그 중간체인 경우에는 원료의약품이나 그 중간체에 대한 시험\n\n검사도 함께 실시하여야 한다.  이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다. ",
        "original_sentence": "의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "상세한 내용은 「4.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 10,
        "window_text": "이러한 경우에는 원료의약품이나 그 중간체에\n\n대한 시험검사 결과를 불순물 생성의 원인조사와 완제의약품의 제조공정 검증\n\n완제의약품 또는 원료의약품(출발물질, 중간체 등 포함)에 대한 불순물 시험검\n\n사 대상 배치 수는 발생가능성 평가를 통한 위험성에 비례하여 선정하여야 한\n\n- 다.  발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다.",
        "original_sentence": "상세한 내용은 「4.\n\n"
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "1일 섭취 허용량 설정」을 참고한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 4,
        "window_text": "발생원인 평가가 이루어졌고 모든 배치에서 불순물 수준이 일정할 것으\n로 예상되는 경우에는 대표성 있는 배치를 선정해 실시할 수 있다.\n\n 의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가? ",
        "original_sentence": "1일 섭취 허용량 설정」을 참고한다. "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 113,
        "word_count": 25,
        "page_number": 4,
        "window_text": "의약품 중 니트로사민류 불순물은 개별 니트로사민류의 기준(ppm) 이하로 관\n\n리해야 하며, 이는 각 불순물의 1일 섭취 허용량(ng/일)을 허가사항 중 1일 최대\n\n복용량(Maximum daily dose, mg/일)으로 나누어 산출한다.  상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 55,
        "word_count": 16,
        "page_number": 4,
        "window_text": "상세한 내용은 「4.\n\n 1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다. ",
        "original_sentence": "정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "(예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 712,
        "word_count": 179,
        "page_number": 19,
        "window_text": "1일 섭취 허용량 설정」을 참고한다.  시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no. ",
        "original_sentence": "(예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가? "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "| 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 45,
        "word_count": 18,
        "page_number": 4,
        "window_text": "시험법 개발시 불순물의 정량한계(LOQ)는\n\n1일 섭취 허용량 이하여야 하며, 「불순물 검출 수준에 따른 단계별 조치사항」\n\n에 따라 10% 이하 수준으로 정량한계를 설정하여 관리하는 것이 이상적이다.  정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n",
        "original_sentence": "| 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "| 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 184,
        "word_count": 53,
        "page_number": 4,
        "window_text": "정\n\n- - 12 -\n량한계 수준(ppm 또는 ppb)에 따라 적절한 분석 장비를 선정할 수 있다. (예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n",
        "original_sentence": "| 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "| monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 497,
        "word_count": 131,
        "page_number": 38,
        "window_text": "(예: LC\n\n또는 LC-MS/MS)\n\n대표성 있는 배치를 선정할 때는 출발물질, 중간물질, 원료의약품 및 제조원,\n\n완제의약품 및 제조원, 주요 변경사항 등을 고려하여 연간 3개 이상의 배치를\n\n선정하여야 하며, 연간 3개 배치 미만으로 생산하는 경우 모든 배치에 대해\n\n법을 개발하여 관련 웹사이트 등을 통해 참고용으로 공개하고 있으므로 이를\n\n활용하여 원료의약품 및 완제의약품에 적합한 분석법 개발하고 시험방법 밸리\n\n불순물 시험검사를 위해서는 충분히 민감한 분석법을 개발하고 「의약품등 시\n\n험방법 밸리데이션 가이드라인」 등을 통하여 분석법의 유효성을 검증하여야\n\n니트로사민 발생원인 평가와 관련하여 아민류 및 아질산류를 분석하기 위한\n\n방법으로 이온크로마토그래피법(예: IC-CD) 또는 유도체화(FMOC-Cl, Griess,\n\n- - 13 -\n<!-- PAGE_19 -->\n###### < 불순물 신규 시험법 개발 절차 >\n\n주성분 및 불순물의\n\n**[표 시작]**\n\n| 특성 검토 | 2, 2 | 1 | H3C | O | H | - 보관 조건(휘발성, 표준액 안정성 등) 검토 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 활성화 구조 특성 | 예시 | 개별 활성화 | ↓예 | H3C |\n**+2**\n| 기준설정 등 허가변경 후속 | 조치(인지일로부터 2년 이내, | 필요시 연장) |\n| 잠재력 점수가 = 3 인가?  | 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가. ",
        "original_sentence": "| monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "| AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 353,
        "word_count": 84,
        "page_number": 4,
        "window_text": "| 예 | 분류 3 | ~ 기준 이내 | ✓ |\n| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다. ",
        "original_sentence": "| AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 106,
        "word_count": 23,
        "page_number": 19,
        "window_text": "| 예 | 분류 1 |\n| ▼ | 예 | 발암 잠재력 분류 접근법(CPCA) | 검사 실시 | (식약처 검토) | 이내 | 초과 |\n| -L-glutamic acid | piperazine | 아리피프라졸 | 3 | 400 | - | 기준설정 완료시까지) |\n| 알림 > 니트로사민류 불순물 기준 설정 현황에서 확인 가능합니다.  | monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n",
        "original_sentence": "또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "- - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 96,
        "word_count": 22,
        "page_number": 20,
        "window_text": "| monoethylamine의 분해물 또는 합성 불순물로서 생성될 수 있음 | 매우 낮은 수준임 | 라사길린(rasagiline) | N-nitroso-rasagiline | ※ 초과 검출 시 식약처 보고(기준 미정 | AI = 400 ng/일 | 한시적 |\n**AI = 26.5 ng/일**\n| - 잔류용매 및 시약 등과의 특이성 확인 | 예) 메트포르민에서 NDMA와 DMF가 같이 용리되는지 특이성에서 확인 | 허용기준 | 13.3 × AI | 6.7 × AI |\n| ~ 30% 이하 | ✓ | 불순물은 검출 시 보고) |\n| ↓아니오 | * 국제의약품규제조화위원회(ICH) 가이드라인 M7(R1) 기준 (10만명 중 1명 이하) | 식 품 의 약 품 안 전 처  의 약 품 안 전 국  의 약 품 관 리 과 |\n| 0.00192 μg/kg/day × 50 kg(사람 체중을 보수적으로 가정) = 0.0959 μg/day | (자체주기적관리) |\n| 니트로사민류 | CAS no.  | AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나. ",
        "original_sentence": "- - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 326,
        "word_count": 73,
        "page_number": 20,
        "window_text": "| AI(ng/일) |\n| AI = 100 ng/일 | ICH |\n| 시험방법 밸리데이션 | 설정된 임시 기준으로, 해당 기준을 의약품 규격으로 설정하여 관리할 수 없음을 | - 주성분 및 첨가제가 불순물 분석법 밸리데이션에 영향을 |\n\n**[표 끝]**\n\n- - 물리·화학적 특성 고려\n예) 용해도, 분자량, Log P, boiling point 등\n\n미치는지 확인\n\n- - 「의약품등 시험방법 밸리데이션 가이드라인」 적용\n* 원료의약품과 구조가 유사한 니트로사민류 불순물(NDSRI)의 경우, 주성분과 불순물의 분자량 차이가\n\n작을 수 있기 때문에 분리도를 충분히 확보할 수 있도록 다양한 고정상(칼럼)을 고려하여 선정한다.\n\n 또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다. ",
        "original_sentence": "일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 390,
        "word_count": 87,
        "page_number": 23,
        "window_text": "또한, 일반적으로 NDSRI의 분자량이 주성분보다 크기 때문에 주성분 피크의 간섭을 최소화하는 분석\n\n조건(예: HILIC 칼럼을 통한 빠른 NDSRI 용리)을 검토하여 선정할 수 있다.\n\n - - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n",
        "original_sentence": "식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "<투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 144,
        "word_count": 39,
        "page_number": 21,
        "window_text": "- - 14 -\n<!-- PAGE_20 -->\n#### 4\n\n<!-- PAGE_20 -->\n#### 1일 섭취 허용량 설정\n\n<!-- PAGE_20 -->\n##### 가.  일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n",
        "original_sentence": "<투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 279,
        "word_count": 59,
        "page_number": 4,
        "window_text": "일반 원칙\n\n원료의약품 또는 완제의약품에 발암성 또는 변이원성이 있는 불순물이 존재\n\n하는 경우 1일 섭취 허용량*을 설정하고 그 이하로 관리될 수 있도록 하여야\n\nICH M7(R1) 가이드라인에 따라 검출된 불순물에 대한 충분한 발암성 양성\n\n데이터가 존재하는 경우에는 화합물 특이적인 위해 평가에 기반한 섭취 허용\n\n량 계산을 적용하며(예: TD50 적용), 그 외 일반적으로 변이원성 불순물에 대해서\n\n는 독성학적 역치(TTC : Threshold of Toxicological Concern) 개념을 적용하여 1\n\n일 섭취 허용량을 1,500 ng/day로 설정할 수 있다.  식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다. ",
        "original_sentence": "니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 175,
        "word_count": 36,
        "page_number": 4,
        "window_text": "식약처는 아지도 불순물(예:\n\n** TTC : 가장 감수성이 높은 동물종과 가장 감수성이 높은 종양유발부위에 대한 TD50\n\n데이터를 이용하여, 종양 발생률이 100만명 중 1명이 되는 확률이 되도록 계산된 수치\n\n그러나, TTC 이하의 섭취에도 이론상, 유의한 잠재적 발암 위해와 관련 있는\n\n활성이 높은 구조가 속하는 화학클래스인 “cohort of concern”이 발견되고 있\n\n한편, 변이원성 불순물의 TTC에 기초한 섭취 허용량 1.5 μg/day은 평생 동안\n\n매일 노출되어도 안전하다고 생각되는 기준으로, 투여기간이 평생보다 짧은 기간\n\n(LTL)일 것으로 예상되는 경우에는 ICH M7(R1) 가이드라인에 따른 투여기간별\n\n1일 섭취 허용량 기준을 아래와 같이 적용할 수 있다.\n\n <투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n",
        "original_sentence": "이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "- ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 40,
        "word_count": 13,
        "page_number": 4,
        "window_text": "<투여기간에 따른 불순물 1일 섭취 허용량>\n\n투여 기간\n\n≤ 1달\n\n> 1 – 12달\n\n> 1 - 10년\n\n> 10년 ~ 평생\n\n1일 섭취량 [μg/day]\n\n120\n\n20\n\n10\n\n- 1.5\n- - 15 -\n<!-- PAGE_21 -->\n##### 나.  니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n",
        "original_sentence": "- ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n"
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 344,
        "word_count": 71,
        "page_number": 4,
        "window_text": "니트로사민류 불순물의 1일 섭취 허용량 설정\n\n의약품의 개별 니트로사민류의 섭취 허용한도는 일반적으로는 평생 매일 노출\n\n되는 것을 고려하여 원칙적으로 10만분의 1의 발암 위해도를 초과하지 않도록\n\nTD50을 설정하기에 충분한 발암성 연구 결과가 존재하는 경우,\n\n견고성\n\n(Robustness)이 확보된 발암성 시험연구의 TD50을 독성 시작값(POD, Point of\n\ndeparture)으로 사용될 수 있으며, 아래의 예시와 같이 선형외삽에 의해 평생\n\n1일 섭취 허용량을 산출할 수 있다.  이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n",
        "original_sentence": "ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 4,
        "window_text": "이때 TD50은 발암성시험 데이터베이스\n\n(Carcinogenicity Potency Database) 등에서 미리 계산된 값을 사용할 수 있으며,\n\n또한, ICH M7(R1) 가이드라인에서 제시된 다음의 사항 중 1개 또는 그 이상에\n\n해당하는 경우에는 발암성 데이터의 견고성이 낮은 것으로 평가할 수 있다.\n\n - ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n",
        "original_sentence": "이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 174,
        "word_count": 37,
        "page_number": 22,
        "window_text": "- ③ 사람에 대한 1일 총 섭취 허용량은 다음과 같이 얻을 수 있다.\n ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다. ",
        "original_sentence": "구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 176,
        "word_count": 41,
        "page_number": 2,
        "window_text": "ð NDMA 1일 섭취 허용량 : 96 ng/day\n\n- - 16 -\n§\n\n성별·용량 당 50 개체 미만\n\n§\n\n3가지 용량 미만\n\n§\n\n동시 대조군 부재\n\n§\n\n간헐적인 투여(주5회 미만)\n\n§\n\n평생 보다 짧은 투여기간\n\n니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않거나 없는 경우에는\n\n➊ 구조-활성 상관관계(structure-activity-relationship)를 고려한 read-across 접근법\n\n견고한 발암성 데이터가 있는 구조적으로 유사한 니트로사민(참조물질)의\n\nTD50을 활용하여 ICH(M7)(R1) 가이드라인에 따른 선형외삽 방법으로 1일 섭취\n\n허용량을 설정할 수 있다.  이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다. ",
        "original_sentence": "또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "니트로사민류\n\nCAS no.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 13,
        "window_text": "이 방법으로 1일 섭취 허용량을 설정한 경우에는\n\n제약사가 그 설정에 대한 타당한 근거를 제시하여야 한다.\n\n 구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n",
        "original_sentence": "니트로사민류\n\nCAS no.\n\n"
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 423,
        "word_count": 74,
        "page_number": 23,
        "window_text": "구조-활성 상관관계 평가를 통한 read-across 접근을 통해 구조적으로 유사한\n\n니트로사민을 참조물질로 선정할 때는 N-니트로소기 주변 구조적 환경요소인\n\n치환 정도, 입체적 부피, 전자적 영향, 대사 활성화 가능성, 생성된 대사산물의\n\n안정성/반응성 및 전체 분자량 등 다양한 사항이 고려되어야 한다.\n\n 또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다. ",
        "original_sentence": "AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 97,
        "word_count": 21,
        "page_number": 88,
        "window_text": "또한, 선정한 참조물질의 견고한 발암성 연구 결과 여부가 중요하며, NDSRIs의\n\n- - 17 -\n구조 및 기전적 특성을 반영할 수 있으면서 견고한 발암성 연구결과를 가진\n\n참조물질이 드물기 때문에, 참조물질 선정시에는 변이원성 및 발암성 자료의\n\n견고성이 입증된 다음의 니트로사민류 화합물들을 고려해야 한다.\n\n 니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n",
        "original_sentence": "활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 68,
        "word_count": 16,
        "page_number": 13,
        "window_text": "니트로사민류\n\nCAS no.\n\n AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n",
        "original_sentence": "따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "* 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 111,
        "word_count": 14,
        "page_number": 13,
        "window_text": "AI(ng/day)\n\n발암잠재력 분류 접근법(CPCA)은 분자에 나타나는 활성 및 비활성 구조적\n\n특성에 대한 평가를 기반으로 N-니트로사민 불순물(NDSRIs 포함)을 예측되는\n\n* 분류 군에 따라 1일 섭취허용량 26.5 100 400 1500 1500 ng/일 설정\n\n이\n\n접근법은\n\nCPDB(Carcinogenic\n\nPotency\n\nDatabase)\n\n및\n\nLCDB(Lhasa\n\nCarcinogenicity Database)에서 확인할 수 있는 저분자 니트로사민에 대한 정보\n\n와 N-니트로사민 화합물을 다룬 최근 학술 간행물에서 설명한 구조-활성 상관\n\n발암잠재력 분류 접근법은 여러 니트로사민류에서 관찰되는 변이원성과 매우\n\n강력한 발암의 원인이 대사 활성의 α-하이드록실화(α-hydroxylation) 메커니즘이\n\n라고 가정*한다.  활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n",
        "original_sentence": "* 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 134,
        "word_count": 22,
        "page_number": 23,
        "window_text": "활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적 특징은 발암 잠재력에\n\n영향을 미칠 것으로 예상된다.  따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다. ",
        "original_sentence": "이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "- - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 90,
        "word_count": 24,
        "page_number": 4,
        "window_text": "따라서, 니트로사민류 불순물의 변이원성 및 발암\n\n성을 해당 화합물의 구조적 특징을 기반으로 예측치를 산출할 수 있다.\n\n * 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n",
        "original_sentence": "- - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 70,
        "word_count": 15,
        "page_number": 23,
        "window_text": "* 니트로사민류는 α-하이드록실화(α-hydroxylation)를 통해 활성화되어 다양한 디아조늄\n\n이온(예: methyldiazonium, ethyldiazonium ion) 등을 형성하게 된다.  이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n",
        "original_sentence": "발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "항을 제공한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 8,
        "window_text": "이후 활성화된\n\n친전자 카르베니움 이온(reactive electrophilic carbenium ions)이 되어 DNA와 직접\n\n반응함으로써 안정적인 DNA 부가 생성물(adduct)을 형성, 발암성을 나타내는\n\n것으로 알려져 있다.\n\n - - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다. ",
        "original_sentence": "항을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 589,
        "word_count": 120,
        "page_number": 13,
        "window_text": "- - 18 -\n다만, 발암잠재력 분류 접근법으로 도출된 섭취허용량 및 구조적 특성의 분석\n\n등은 과학이 발전하고 추가 자료가 생성됨에 따라 변경될 수 있다.\n\n 발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다. ",
        "original_sentence": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 259,
        "word_count": 66,
        "page_number": 13,
        "window_text": "발암잠재력 분류 접근법(CPCA)에 대한 적용범위, 일반원칙, 계산방법 및 흐름도\n\n등 상세한 방법은 부록 1을 참고한다.\n\n 항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다. ",
        "original_sentence": "만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 251,
        "word_count": 54,
        "page_number": 26,
        "window_text": "항을 제공한다.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4. ",
        "original_sentence": "다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 92,
        "word_count": 24,
        "page_number": 4,
        "window_text": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준\n\n조건에서 분석 민감도 감소가 보고되었으며, NDSRIs에 대한 Ames 시험의 민\n\n감도에 대해서는 알려진 바가 거의 없으므로, 부록 2에 제시된 강화된 Ames\n\n- - 니트로사민류 불순물 시험 시 전배양법(전배양시간 30분 권고)을 활용하고\n30% 농도의 랫드와 햄스터 S9을 모두 사용하며, 양성대조군 중 변이원성이\n\n또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한\n\nAmes 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라\n\n강화된 Ames 시험(EAT)에 대한 균주, 방법, S9의 종류 및 농도, 양성대조군 등\n\n상세 시험방법은 부록 2 및 그 외 모든 권장사항은 OECD 시험 가이드라인\n\n➍ 생체 내(in vivo) 변이원성 시험\n\n생체 내(in vivo) 변이원성 시험은 ICH 유전독성 가이드라인(GENOTOXICITY\n\nTESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED\n\nFOR HUMAN USE S2(R1))을 고려하여 수행하여야 한다.\n\n 만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬. ",
        "original_sentence": "상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 4,
        "window_text": "만약, 니트로사민류 불순물의 물질 특이적인 발암 결과가 충분하지 않고 구조-\n\n활성 상관관계 및 참조물질 기반 평가를 통해 기준 설정 불가 및 발암잠재력 분류\n\n- - 19 -\n접근법(CPCA)을 적용할 수 없는 경우, 공통으로 적용할 수 있는 기본 허용한도인\n\n- 26.5 ng/일로 1일 섭취 허용량을 적용할 수 있으며, 이는 국내‧\n외 규제기관에서\n\n1일 섭취 허용량을 정한 니트로사민류 중 가장 독성이 높은 NDEA의 1일 섭취\n\n허용량을 따른 것이다.\n\n 다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21. ",
        "original_sentence": "식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 278,
        "word_count": 54,
        "page_number": 4,
        "window_text": "다만, 식약처는 제약사가 과학적 근거 및 해외 규제기관 설정된 정보 등을 제시하는\n\n- - 20 -\n<!-- PAGE_26 -->\n###### < 국내 신규 니트로사민류 불순물 허용기준 설정 흐름도 >\n\n- - 21 -\n3) 평생보다 짧은 투여기간(LTL: Less-Than-LifeTime) 적용에 대한 고려\n\n니트로사민류는 “cohort of concern”에 해당하므로, 평생보다 짧은 투여기간\n\n(LTL)의 적용은 신중하게 접근하여야 한다.  상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13. ",
        "original_sentence": "이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 139,
        "word_count": 37,
        "page_number": 13,
        "window_text": "상기 절차에 따라 설정된 1일\n\n섭취허용량 한도 이하로 불순물을 줄이기 전까지 식약처와 협의하여 저감화\n\n등 추가 조치 시행될 때까지 임시 조치로 고려할 수 있다.  식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다. ",
        "original_sentence": "두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬. "
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 4,
        "window_text": "식약처는 ① 허용\n\n다음은 식약처에서 니트로사민류 불순물에 대한 1일 섭취 허용량을 설정한\n\n목록이다.  이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다. ",
        "original_sentence": "각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21. "
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 106,
        "word_count": 16,
        "page_number": 4,
        "window_text": "이는 개별 불순물의 독성값(TD50), 구조-활성 상관관계를 고려한\n\nread-across 방법, 발암잠재력 분류 접근법(CPCA), 박테리아를 이용한 복귀\n\n돌연변이 시험 및 생체 내 변이원성 시험 등을 반영하여 니트로사민류 불순물의\n\n식약처에서 설정한 니트로사민류 1일 섭취 허용량은 ‘의약품통합정보시스\n\n템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/알림 > 니트\n\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | A4.  두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다. ",
        "original_sentence": "위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 79,
        "word_count": 10,
        "page_number": 39,
        "window_text": "두 개의 N-니트로소기를 포함하는 니트로사민류의 경우 예측된 발암 가능성이 |\n| --- | --- | --- | --- | --- | --- |\n| 비고리형 N-니트로소기의 양쪽에 ≥5 인 | 연속된 비수소 원자(고리형 또는 비고리형) | 사슬.  각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다. ",
        "original_sentence": "의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "| ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 163,
        "word_count": 31,
        "page_number": 4,
        "window_text": "각 사슬에서 4개 이하의 원자가 | 동일한 고리에 있을 수 있음 |\n**A21.  위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다. ",
        "original_sentence": "| ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "| 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 4,
        "window_text": "위험도에 기반한 접근법으로 시험·검사할 의약품의 우선순위를 정하고, 계획을**\n**A23.‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7)**\n**A13.  의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16. ",
        "original_sentence": "| 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "| 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 146,
        "word_count": 35,
        "page_number": 4,
        "window_text": "의약품통합정보시스템(의약품안전나라, http://nedrug.mfds.go.kr) > 고시/공고/**\n| 영향도 있을 것으로 추정되고 있다.  | ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2. ",
        "original_sentence": "| 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "| ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 225,
        "word_count": 55,
        "page_number": 4,
        "window_text": "| ↓아니오 |\n| 63 | 1-(2,3-dichlorophenyl)-4-nitroso | 92 | N-nitroso-paroxetine | 파록세틴 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 불순물 검출 수준에 따른 단계별 조치사항은 다음과 같다.  | 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17. ",
        "original_sentence": "| ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "|\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 227,
        "word_count": 54,
        "page_number": 13,
        "window_text": "| 전문가 자문 및 중앙약사심의위원회 등을 거쳐 1일 섭취 허용량을 결정한다.  | 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "|\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "| 식약처에 신속히 보고하도록 하였으나, |\n| A2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 4,
        "window_text": "| 한시적 | 허용기준 | 178ng/일 | ② (2단계) 변이원성/발암성 불순물 특성 파악 | 두 가지 니트로사민류도 양성 대조군으로 포함되어야 함 | 등에서는 시험·검사를 통해 불순물 검출이 확인되는 경우 검출량에 무관하게 | 섭취허용량을 결정하게 됩니다.  | ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨. ",
        "original_sentence": "| 식약처에 신속히 보고하도록 하였으나, |\n| A2. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 13,
        "window_text": "| ↓아니오 |\n| 2 | N-nitrosoethylisopropylamine, | EIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| 잠재력점수= 3 + 1 + 0 = 4 | 잠재력 분류 4 | AI = 1500 ng/일 |\n| 특징은 발암잠재력에 상응하는 영향을 미칠 것으로 예상 | 견고성이 입증된 다음의 니트로사민류 화합물들을 고려하시기 바랍니다.  |\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 116,
        "word_count": 29,
        "page_number": 13,
        "window_text": "|\n| - 또한, 니트로사민류에 대해 강화된 Ames 시험 조건의 평가는 가장 견고한 Ames | - 우선순위를 정함에 있어, 1일 최대복용량, 치료 기간, 적응증, 투여 환자의 수, | 31 | N-nitroso-desethyllidocaine | 리도카인 | 2 | 100 | - | • 시험방법 및 밸리데이션 자료 | 수준3 | 기준의 10% 초과 | 물역학위해관리학회지, 2021:13:10-16.  | 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다. ",
        "original_sentence": "니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "| 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 185,
        "word_count": 46,
        "page_number": 4,
        "window_text": "| 식약처에 신속히 보고하도록 하였으나, |\n| A2.  니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다. ",
        "original_sentence": "| 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨. "
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "Methylene α-탄소가 | 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 4,
        "window_text": "니트로사민류의 섭취허용량 설정 시, 니트로사민류의 물질 특이적인 동물 발 | 만약, 세 개 이상의 N-니트로소기를 포함하는 NDSRIs의 경우 식약처에 문의 | A17.  니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다. ",
        "original_sentence": "Methylene α-탄소가 | 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "| 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 307,
        "word_count": 71,
        "page_number": 4,
        "window_text": "니트로사민류의 한시적 허용기준은 의약품 공급 부족 우려 등의 상황을 고려하여 | - ICH M7(R1) 가이드라인에서는 변이원성‧ | 구조 특성 점수(표 3)의 합계로 산출함 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다. ",
        "original_sentence": "| 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "| 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 189,
        "word_count": 48,
        "page_number": 23,
        "window_text": "| 예 | 분류 2 |\n| 64 | N-nitroso-desmethyl-azelastine | 아젤라스틴 | 2 | 100 | - | 93 | N-nitroso-phenylephrine | 페닐레프린 | 2 | 100 | - | 문 | 의 | 처 | * Methylene α-탄소가 ethyl기의 일부가 아닌 경우 3점이 적용됨.  Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다. ",
        "original_sentence": "| 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "| 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 79,
        "word_count": 21,
        "page_number": 23,
        "window_text": "Methylene α-탄소가 | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가? ",
        "original_sentence": "| 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "| 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 117,
        "word_count": 30,
        "page_number": 4,
        "window_text": "| 예 | 분류 2 |\n| 3 | N-nitrosodiisopropylamine, | DIPNA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| - ’23.12월부터는 시험·검사 결과 니트로사민류가 허용기준을 초과하여 검출된 | 32 | N-nitroso-rivaroxaban amide | 리바록사반 | 4 | 1,500 | - | ❍ (수준 1) | ② 원료의약품 제조공정에서 오염된 원료(예: 용매, 시약, 촉매 등) 사용 | 임산부·어린이·노약자 등 특정군 대상 여부 등의 요소가 고려될 수 있습니다.  | 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15. ",
        "original_sentence": "| 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "| • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 358,
        "word_count": 75,
        "page_number": 4,
        "window_text": "| 시험 조건 확립을 위해 계속 진행 중으로, 제시된 조건은 필요에 따라 업데이트 |\n| 94 | N-nitroso-perindopril | 페린도프릴 | 5 | 1,500 | - | - 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이 발전하고 | ethyl기의 일부인 경우 2점을 적용해야함 | 하시기 바랍니다.  | 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다. ",
        "original_sentence": "| • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "| 잠재력 점수가 = 2 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| 암결과가 불충분하고 구조-활성 상관관계 및 참조물질 기반 평가를 통해 기준 | 약물 사용 용량과 기간 정보를 후향적으로 파악할 수 있다.  | 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다. ",
        "original_sentence": "| 잠재력 점수가 = 2 인가? "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "| 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 170,
        "word_count": 43,
        "page_number": 4,
        "window_text": "| 단, 한시적 허용기준은 1,500ng/일 초과 불가 |\n| * 3차 α-탄소는 3개의 다른 탄소 원자에 결합된 sp3 혼성 상태의 α-탄소 원자로 정의됨 | 분석한 결과, 추정되는 생성원인은 다음과 같다.  | • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다. ",
        "original_sentence": "| 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15. "
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 406,
        "word_count": 92,
        "page_number": 20,
        "window_text": "| • 예방 및 시정조치 등 | AI = 100 ng/일 |\n| 33 | N-nitroso-rivaroxaban | 수준4 | 기준의 10% 이하 | ‘불검출’로 인정하여 업체 자율관리 | ❷ 1-Cyclopentyl-4-nitrosopiperazine (CAS # 61379-66-6), ❸ NDSRI | 업체 제출 근거자료 및 | N-nitrosodi-methylamine(NDMA) | 62-75-9 | 96 | NDMA 분석결과 * |\n| 65 | N-nitroso-azaerythromycin | 아지스로마이신 | - | 95 | N-nitroso-felodipine | 펠로디핀 | 5 | 1,500 | - | 될 수 있습니다.  | 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다. ",
        "original_sentence": "의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "| ↓아니오 | 알려드립니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 26,
        "window_text": "| 잠재력 점수가 = 2 인가?  | 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다. ",
        "original_sentence": "| ↓아니오 | 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "| 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 374,
        "word_count": 102,
        "page_number": 4,
        "window_text": "| 예 | 분류 2 | open-ring acid | 리바록사반 | 4 | 1,500 | - | 기준설정자문위원회 자문 | (일) | 최대복용량 (mg/일) | 초과발암위해도 | (허용기준(AI) > 1,500ng/일인 경우 예외) | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| A15.  의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다. ",
        "original_sentence": "| 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "| 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 112,
        "word_count": 25,
        "page_number": 4,
        "window_text": "의약품의 투여 기간과 무관하게“평생보다 짧은 기간 노출(Less than Lifetime, | 4 | N-nitroso-di-n-butylamine, | √ 허용기준을 초과한 제품에 대해서는 즉시 판매중지 및 회수조치, | 경우, 식약처 의약품관리과 신속하게 보고 및 관련 자료를 제출하고, 저감화 | 설정 불가 시, ‘발암잠재력 분류 접근법(CPCA)’을 적용하여 섭취허용량을 | - 질산염 함유 원료 등 아질산 불순물 유입 또는 아민류 함유 가능성 | ↓아니오 | (ppm) | NDBA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA |\n| N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 α-탄소에 결합된 전자 끄는 기** | 자료가 추가됨에 따라 변경될 수 있음을 알려드립니다.  | ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다. ",
        "original_sentence": "| 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "| 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 118,
        "word_count": 30,
        "page_number": 4,
        "window_text": "| ↓아니오 | 알려드립니다.  | 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "| 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "| 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 103,
        "word_count": 24,
        "page_number": 23,
        "window_text": "| 해외 규제기관 정보 | 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) | 64091-91-4 | 100 | 중앙약사심의위원회 |\n| 【관련문서】 | 구조적 특징을 기반으로 예측치를 산출 | •12개월 이내 한시적 허용기준 이내 | 제품만 출하 허용 | •12개월 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | 식 품 의 약 품 안 전 평 가 원  의 약 품 심 사 부  의 약 품 규 격 과 | (정기 및 수시) | •한시적 허용기준 이내 제품만 출하 | 허용 | •3년 이내 저감화 완료 | (조치 지시 후 1개월 이내 저감화 | +1 |\n| - 상세 내용은 [부록 2]를 참고하시기 바랍니다.  | 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "| 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "| 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 377,
        "word_count": 85,
        "page_number": 23,
        "window_text": "| 가) 원료의약품 제조공정(시약·용매·중간체 등) 유래 불순물 | AI = 100 ng/일 | ICH |\n| 34 | N-nitroso-N-desmethyl | 등 필요한 조치를 진행하여야 합니다.  | 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다. ",
        "original_sentence": "| 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "| 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| 0.010∼0.609 | 967 ∼ 8,774 | 1,000~2,550 | 0.21 | 검토 | 니트로사민류 공통 적용 | 잠재력 점수로 | ICH |\n| - 상세 내용은 [부록 1]을 참고하시기 바랍니다.  | 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다. ",
        "original_sentence": "| 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "| 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 84,
        "word_count": 20,
        "page_number": 4,
        "window_text": "| 96 | N-nitroso-calcium folinate | 폴리네이트칼슘 | - | √ 제조공정 개선 등을 통해 저감화하거나 규격에 기준을 설정하여 관리 | 설정할 수 있습니다.  | 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다. ",
        "original_sentence": "| 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "| 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 328,
        "word_count": 80,
        "page_number": 4,
        "window_text": "| 조 특성이 없는 경우 잠재력 점수는 α-수소 점수와 동일 | N-nitroso morpholine (NMOR) | 59-89-2 | 127 | LTL) 개념”을 적용한 한시적 허용기준 적용방안 2의 적용 가능하므로, 10년 이 | rivastigmine | 리바스티그민 | 2 | 100 | - | Q3A/Q3B에 | 따라 관리 | 비변이원성 불순물 |\n| ☞ ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인’(민원인안내서, ’22.7) 중 | 5 | N-nitrosodipropylamine, NDPA | - | - | 26.5 | SAR/read-across, | 참조물질NDEA | (예: 치명적인 질환, 미충족 의료수요, 희귀질환) 등을 고려할 수 있다.  | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다. ",
        "original_sentence": "| 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "|\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 4,
        "window_text": "| 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11. ",
        "original_sentence": "|\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "| ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 163,
        "word_count": 37,
        "page_number": 27,
        "window_text": "| 예 | 분류 1 |\n| 66 | N-nitroso-desmethylazithromycin | 아지스로마이신 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다. ",
        "original_sentence": "| ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 205,
        "word_count": 47,
        "page_number": 4,
        "window_text": "| 예 | 분류 1 | ↓아니오 | 기준(26.5 ng/일) 적용 | 섭취 허용량 계산 | Q3A/Q3B에 | 따라 관리 | (95% CI 0.12~0.30) | 비변이원성 불순물 |\n| - 다만, 식약처에서 설정한 허용기준이 없는 니트로사민류는 검출량과 무관하게 | N-nitroso piperidine (NPIP) | 100-75-4 | 1300 |\n| - 다만, N-니트로소기의 양쪽에 탄소 원자를 가지고 있고 해당 탄소가 헤테로 | 조치사항 | 이하로 관리될 수 있도록 자체적으로 관리하고, 10-5 초과시 허가변경 필요 | 상 투여하는 의약품 또한 적용 대상임을 알려드립니다.  |\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가? ",
        "original_sentence": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "| * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 62,
        "word_count": 18,
        "page_number": 4,
        "window_text": "|\n| 35 | N-nitroso-ribociclib impurity 1 | 리보시클립 | 3 | 400 | - | 용량 설정’ 부분을 참고한다.  | ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다. ",
        "original_sentence": "| * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 252,
        "word_count": 66,
        "page_number": 13,
        "window_text": "| ‘검출 수준에 따른 단계적 조치’ 참고 | 능성 있음 |\n| 97 | N-nitroso-furosemide | 푸로세미드 | 4 | 1,500 | - | 6 | N-nitrosodi-methylamine, | - 불순물 분석방법의 정량한계(LOQ)는 합리적 수준에서 가능한 낮아야 한다.  | N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다. ",
        "original_sentence": "라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "| 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 69,
        "word_count": 18,
        "page_number": 4,
        "window_text": "| N-nitroso pyrrolidine (NPYR) | 930-55-2 | 1700 | 잠재력 점수 = α-수소 점수 + 비활성화 구조특성 점수(니트로사민류에 나타나는 | AI = 26.5 ng/일 |\n| 67 | N-nitroso-atenolol | 아테놀롤 | 4 | 1,500 | - | 신속하게 식약처에 시험·검사 결과 등 관련 사항을 보고하여야 합니다.  | * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다. ",
        "original_sentence": "| 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가? "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "| 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 78,
        "word_count": 14,
        "page_number": 4,
        "window_text": "| * 제품별 1~9 배치 검출결과의 중앙값 | 발전하고 자료가 추가됨에 따라 변경될 수 있음 | 그림 11.  라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다. ",
        "original_sentence": "| 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "| - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 367,
        "word_count": 83,
        "page_number": 27,
        "window_text": "라니티딘과 니자티딘의 구조 및 NDMA 발생 원인 | NDMA | - | - | 96 | - | AI = 26.5 ng/일 |\n| N-니트로소기(고리형 또는 비고리형) | 양쪽에서 α-탄소에 결합된 전자 끄는 기** | 36 | N-nitroso-lisinopril | 리시노프릴 | 5 | 1,500 | - | 원자에 직접적으로 이중 결합되지 않는 니트로사민류 및 헤테로 방향족 고리 |\n| - 상세한 적용방법은 [부록 3]를 참고하시기 바랍니다.  | 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다. ",
        "original_sentence": "| - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "| acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 167,
        "word_count": 46,
        "page_number": 13,
        "window_text": "| 98 | N-nitroso-pramipexole | 프라미펙솔 | 3 | 400 | - | 잠재력 점수가 ≤ 1 인가?  | 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가? ",
        "original_sentence": "| acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "| 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 800,
        "word_count": 239,
        "page_number": 4,
        "window_text": "| 예 | 분류 1 | 트리메타지딘(trimetazidine) | N-nitroso-trimetazidine |\n| 음을 입증하여야 한다.  | - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가?  | 수소가 존재하는가? ",
        "original_sentence": "| 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "| Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 733,
        "word_count": 175,
        "page_number": 4,
        "window_text": "| - 용매 또는 시약의 회수과정에서 비의도적 불순물 오염 발생 가능 | 구조적 특성의 모든 점수 합계) + 활성화 구조특성 점수(니트로사민류에 나타나는 구조적 특성의 | 모든 제조번호별로 시험검사를 실시하여 적합한 제품만 출하 | +2 |\n| 37 | N-nitroso-meropenem | 메로페넴 | 4 | 1,500 | - | 68 | N-nitroso-Atomoxetine | 아토목세틴 | - | 100.0 | SAR/read-across, | 참조물질 NNK2) | 계획 제출 포함) | 계획 제출 포함) |\n| 7 | N-nitroso-N-methyl-4-aminobutyric | 내의 니트로사민류가 아닌 화합물에 한하여 적용 가능합니다.  | acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가?  | 수소가 존재하는가?  | 수소가 존재하는가? ",
        "original_sentence": "| Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "| 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 74,
        "window_text": "| acid, NMBA | - | - | 96 | SAR/read-across, | 참조물질 NDMA |\n| 10-5 이하로 관리될 수 있도록 자체적으로 기준 설정하여 주기적 관리 필요 | AI = 26.5 ng/일 |\n| 기간 동안 허용 기준 이내로 관리될 수 있도록 관리에 만전을 기해야 한다.  | 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가?  | 수소가 존재하는가?  | 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요? ",
        "original_sentence": "| 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "| 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 74,
        "window_text": "| 모든 점수 합계) |\n\n**[표 끝]**\n\n- - 22 -\n**[표 시작]**\n\n| 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 연번 | 불순물 명칭 | 발생성분 | CPCA | 분류 | 섭취허용량 | 섭취허용량 | 섭취허용량 | 섭취허용량 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <그림1> 니트로사민류의 잠재력 분류를 예측하기 위한 흐름도 | 라) 완제의약품 중 원료의약품(주성분) 유사구조 니트로사민 불순물(NDSRIs) |\n| 3 | 한시적 허용기준 적용 | 4 | 불순물 위험평가, 보고 및 조치방안 | 2 | 1일 섭취허용량 설정 | Q20 | Q22 | Q24 | 예시 | Q5 | Q8 | Q3 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 | (ng/일) | 비고 |\n| Ⅲ | 불순물 검출 시 조치방안 | N-니트로소기(고리형 또는 비고리형)의 | 한쪽에서만 β-탄소***에 결합된 하이드록실기 | Ⅳ | 질의응답 | Ⅴ | 참고문헌 | 3) 의약품 중 니트로사민류 제조공정 검증 | H | H | CH3 | CH3 |\n| 5 | 초과발암위해도를 이용한 인체영향평가 | 2 | 식약처 조치 | 차이를 줄일 필요가 있다.  | Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가?  | 수소가 존재하는가?  | 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요? ",
        "original_sentence": "| 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "| 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 74,
        "window_text": "| Q10 | Q6 | H | +1 |\n| 잠재력 | √ 기준을 초과한 제품은 없어 판매중지 및 회수조치는 불필요 | - 출발물질 혹은 중간체의 오염가능성이 있음 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | N-니트로사민의 α-탄소에 | Q18 | 섭취허용량 | 아니오 | 분류 5 | 아니오 | 분류 5 | 아니오 | 분류 5 |\n| Q12 | Q16 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 | α-수소의 개수 | 점수 | 빨간색으로 표시된 구조 특징 |\n| [예시 1] N-Nitroso-felodipine | 39 | N-nitroso-methylphenidate, NMPH | 메틸페니데이트 | - | 1,300 | SAR/read-across, | 참조물질 NPIP3) | 70 | N-nitroso-ambroxol | 암브록솔 | - | 1,500 | AMES 음성 | 8 | 1-Methyl-4-nitrosopiperazine, | ino)-1H-carbazole-6-carboxamide | (ng/일) | 설명 | MeNP(MNP) | - | - | 96 | SAR/read-across, | 참조물질 NDMA | HO |\n| ❍ (적용기준) 니트로사민류 불순물(NDSRIs 포함)의 섭취허용량 설정 시, | 분류 |\n| 각 α-탄소 상의 수소 원자 개수 | 생성되는 것으로 추정되고 있다.  | 수소가 존재하는가?  | 수소가 존재하는가?  | 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다. ",
        "original_sentence": "| 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "| H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 311,
        "word_count": 76,
        "page_number": 4,
        "window_text": "| 수소가 존재하는가?  | 수소가 존재하는가?  | 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요? ",
        "original_sentence": "| H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요? "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "| 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 13,
        "window_text": "| 수소가 존재하는가?  | 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요? ",
        "original_sentence": "| 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요? "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "| 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 4,
        "window_text": "| 수소가 존재하는가?  | H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요? ",
        "original_sentence": "| 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "| N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 108,
        "word_count": 31,
        "page_number": 13,
        "window_text": "| H | OH | AI = 1500 ng/일 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 100 | N-nitroso-propanolol | 프로프라놀롤 | 4 | 1,500 | - | 71 | N-nitroso-enalapril | 에날라프릴 | 5 | 1,500 | - | 발암잠재력 분류 접근법(CPCA)의 비활성화 구조 특성 중 N-니트로소기의 α- 탄소에 | 발암잠재력 분류 접근법(CPCA) 도입에 따라 기존 식약처에서 기준 설정한 불순물의 | 니트로사민류 발생가능성 평가, 시험검사 및 후속조치 기한은 어떻게 되나요?  | 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요? ",
        "original_sentence": "| N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요? "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "| 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 492,
        "word_count": 110,
        "page_number": 27,
        "window_text": "| 니트로사민류 발생가능성이 없거나, 시험·검사 결과 허용기준 이내인 경우에도 해당 | 사항을 식약처에 보고해야 하나요?  | 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요? ",
        "original_sentence": "| 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요? "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "| 허용기준이 재설정될 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 23,
        "window_text": "| 인체영향평가 사례 : NDMA 검출 메트포르민 | 1일 섭취 허용량을 비교하여 개인별 초과발암위해도를 산출한다.  | N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요? ",
        "original_sentence": "| 허용기준이 재설정될 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "| 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 113,
        "word_count": 28,
        "page_number": 4,
        "window_text": "| N-니트로사민의 α-탄소에 | (가장 작은 수부터 나열) | 예시 | α-수소 점수 | CH3 | 아니오 | 분류 5 |\n| 니트로사민류 검출로 식약처 보고 시 제출 자료는 무엇이 있나요?  | 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가? ",
        "original_sentence": "| 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요? "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "보고와 함께 제출해야 하는 자료는 무엇인가요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 60,
        "window_text": "| 발암잠재력 분류 접근법(CPCA) 적용대상으로 N-nitrosamides, N-nitrosoureas, | O | CH3 |\n| 발암잠재력 분류 접근법(CPCA)에 따라 N-nitroso-tamsulosin의 잠재력 점수 계산은 | 제시된 니트로사민류 1일 섭취허용량 기준 목록 중 비변이원성으로 분류된 불순물은 | Q14 | Q7 | H3COOC |\n| 40 | N-nitroso-moxifloxacin | 목시플록사신 | 4 | 1,500 | - | 72 | N-nitroso-esmolol | 에스몰롤 | 4 | 1,500 | - | 9 | N-nitrosomorpholine, NMOR | - | - | 127 | - | Q19 | ↓예 | ↓예 | ↓예 | H |\n| 101 | N-nitroso-flecainide | 플레카이니드 | 4 | 1,500 | - | 결합된 전자 끄는 기(Electron Withdrawing Group, EWG)는 어떤 것이 있나요?  | 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요? ",
        "original_sentence": "보고와 함께 제출해야 하는 자료는 무엇인가요? "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "| 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 23,
        "window_text": "| 허용기준이 재설정될 수 있나요?  | 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요? ",
        "original_sentence": "| 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요? "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "| - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 13,
        "window_text": "| 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우 허용기준은 어떻게 설정 | 불순물 초과검출로 식약처 보고할 때, 공급부족 발생 가능성이 있다면 한시적 허용 | 기준 적용을 제안할 수 있나요?  보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요? ",
        "original_sentence": "| - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가? "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "| CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 159,
        "word_count": 39,
        "page_number": 4,
        "window_text": "보고와 함께 제출해야 하는 자료는 무엇인가요?  | 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요? ",
        "original_sentence": "| CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요? "
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "| 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 147,
        "word_count": 41,
        "page_number": 23,
        "window_text": "| 신규 품목허가(신고) 시에도 한시적 허용기준 적용이 가능한가요?  | - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다.",
        "original_sentence": "| 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요? "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "| 총 니트로사민류 기준에 포함하여 관리하여야 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| - 니트로사민류 불순물의 물질 특이적인 동물 발암결과가 불충분하고 | 수소가 존재하는가?  | CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다. **\n| A19. ",
        "original_sentence": "| 총 니트로사민류 기준에 포함하여 관리하여야 하나요? "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "| 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요? ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 292,
        "word_count": 71,
        "page_number": 4,
        "window_text": "| CH3 | 잠재력 분류 5 | AI = 1500 ng/일 | 잠재력 분류 5 | AI = 1500 ng/일 | AI = 1500 ng/일 |\n| 1 | 발암잠재력 분류 접근법(CPCA) | N-nitrosoguanidines, nitrosated indole 등은 왜 제외되나요?  | 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다. **\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다. ",
        "original_sentence": "| 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요? "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "|\n**으로 추정되고 있다.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 40,
        "window_text": "| 저감화하거나 규격에 기준을 설정하여 관리 | 으로 혼입된 니트로소화합물이 완전하게 제거되지 않는 경우 | 2, 2 | 1 | H | OH | OH |\n| 41 | N-nitroso-mirabegron | 미라베그론 | 3 | 400 | - | 어떻게 하나요?  | 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다. **\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1. ",
        "original_sentence": "|\n**으로 추정되고 있다."
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "**\n| A19. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 4,
        "window_text": "| 총 니트로사민류 기준에 포함하여 관리하여야 하나요?  | 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다. **\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11. ",
        "original_sentence": "**\n| A19. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 89,
        "word_count": 21,
        "page_number": 13,
        "window_text": "| 1 | 26.5 | 1, 2 | 3 | NH |\n| 102 | N-nitroso-fluoxetine | 플루옥세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) | N-니트로소기(고리형 또는 비고리형)의 | 양쪽에서 β-탄소***에 결합된 하이드록실기 | 10 | N-nitroso-piperidine, NPIP | - | - | 1,300 | - | 73 | N-nitroso-folic acid, NFA | 엽산/폴산 | 4 | 1,500 | - |\n| 1 | 제약사 조치 | 하나요?  |\n**으로 추정되고 있다. **\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9. ",
        "original_sentence": "의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "|\n| A1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 4,
        "window_text": "|\n**으로 추정되고 있다. **\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다. ",
        "original_sentence": "|\n| A1. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 861,
        "word_count": 199,
        "page_number": 22,
        "window_text": "**\n| A19.  의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다. ",
        "original_sentence": "발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 316,
        "word_count": 64,
        "page_number": 27,
        "window_text": "의약품 등의 제조업자 및 수입자는 자율적으로 새로운 니트로사민류 불순물 정보수집, | 검증이 완료되기 전까지 완제의약품 제조공정이 완료된 것으로 볼 수 없다.  |\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n",
        "original_sentence": "구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 96,
        "word_count": 15,
        "page_number": 13,
        "window_text": "|\n| A1.  발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다. ",
        "original_sentence": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다. "
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 654,
        "word_count": 128,
        "page_number": 10,
        "window_text": "발암잠재력 분류 접근법(Carcinogenic Potency Categorization Approach, CPCA)은 | - 또한, 그 외의 방법을 사용하여 원료의약품 또는 완제의약품의 여러 니트로사민 |\n| - 상기 기한은 식약처 보고기한이 아니라, 평가 및 후속조치 기한으로 권고하는 | * 의약품 제조·수입자 점검 시 불순물 품질 안전관리 적정 이행 여부 점검 실시 | - 보고 시 다음과 같이 니트로사민류 시험·검사 결과, 발생원인 조사, 저감화 |\n*** (예 1) 대체의약품 유무, 의료적 필요성, 최근 3년간 공급량 및 해당 제품의 시장 점유율,**\n**▪ 일반적으로 배치 분석 결과의 80% 이상이 불검출 데이터인 경우에는 평균**\n**- 불순물 평가와 관련된 보고서 등 불순물 품질 안전관리 기록 일체는 품질부서**\n**- (정보수집) 식약처 제공 정보(예: 지침, 신규 불순물 허용기준 발표, 검출정보 등) 외에,**\n**• (식약처 기준설정 불순물) ①시험·검사 결과(시험한 제품 제조번호·제조원 정보,**\n| - 불순물의 특성에 따라 다음과 같이 방안1 또는 방안2로 구분하여 한시적 허용 | ** (예 2) 「의약품 불순물 유전독성 평가 가이드라인」 등 관련 지침 및 문헌, 실제 투약 |\n**▪ 최소 25개 배치를 분석한 결과에서 불검출 데이터 비율이 60% 이상 80% 이하일**\n**경우에는 해당 데이터에 0과 검출한계(혹은 정량한계)를 각각 적용하여 통계값의**\n| 22 | N-nitroso-duloxetine | 둘록세틴 | - | 100 | SAR/read-across, | 참조물질 NNK2) |\n**- (평가·조치) ➀원료의약품 합성공정 및 완제의약품 제조공정 등을 검토하여 불순물**\n| A11.  구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다. ",
        "original_sentence": "NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 150,
        "word_count": 32,
        "page_number": 4,
        "window_text": "구조-활성 상관관계 분석을 위한 적절한 참조물질 선택 시 중요하게 고려하여야 | - 한시적 허용기준 적용기준(방안1, 2)의 상세한 내용은 붙임O를 참고하기 바 |\n**• (식약처 기준 미설정 불순물) 상기 제출자료 외 추가로 1일 섭취허용량에**\n| 시타글립틴 | - | 37 | SAR/read-across, | 참조물질 NTHP4) |\n**※ 근거규정 : ｢약사법｣ 제37조의3(시판 후 안전관리), 제38조(생산관리 의무) 등**\n**▪ 불검출 데이터의 처리는 최대가능도추정법(MLE, Maximum Likelihood Estimation),**\n**A9.  N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시. ",
        "original_sentence": "그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "- - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 435,
        "word_count": 105,
        "page_number": 4,
        "window_text": "N-nitrosodi-methylamine(NDMA) 등 일부 니트로사민류는 표준 조건에서 분석**\n**또한, 선정한 참조물질의 견고한 발암성 연구결과 여부가 중요합니다.  NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다. ",
        "original_sentence": "- - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다. "
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 524,
        "word_count": 118,
        "page_number": 23,
        "window_text": "NDSRIs의**\n\n**[표 끝]**\n\n38\n\nN-nitroso-metoprolol\n\n메토프롤롤\n\n4\n\n1,500\n\n- -\n- - 23 -\n69\n\n3-amino-N-nitrosopiperidine\n\n알로글립틴\n\n3\n\n400\n\n- -\n- - 24 -\n99\n\nN-nitroso-frovatriptan/(3R)-2,3,4,9-\n\ntetrahydro-3-(N-methyl(nitroso)am\n\n프로바트립탄\n\n3\n\n400\n\n- -\n- - 25 -\n개별 니트로사민류의 기준은 일반적으로 ppm 또는 ppb 단위로 나타내 질 수\n\n있는데, 섭취 허용량(ng/일)을 허가사항 중 일일 최대 용량(mg/일)으로\n\n5) 2종 이상의 니트로사민류가 완제의약품에서 검출되는 경우\n\n원료의약품 또는 완제의약품에서 2종 이상의 니트로사민류가 검출되는 경우\n\n에는 모든 니트로사민 불순물의 합에 의한 발암 위해가 10-5 이하가 되도록\n\n예를 들면, 검출되는 니트로사민류의 개별 섭취 허용량 중 가장 보수적인 섭취\n\n예) 완제의약품에서 NDMA와 NDEA가 검출되는 경우, 2종의 니트로사민류의\n\n완제의약품 중 개별 불순물의 검출 수준이 허용기준의 10% 이하로 검출되는\n\n경우에는 독성학적 위험 수준이 무시할 만한 수준이므로, 개별 또는 총\n\n니트로사민류를 계산할 때 포함되지 않을 수 있다.  그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나. ",
        "original_sentence": "건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 272,
        "word_count": 71,
        "page_number": 4,
        "window_text": "그러나 니트로사민류의\n\n개별 검출 수준이 기준의 30% 이하여서 자체적으로 주기적으로 관리하더라도\n\n4종 이상의 니트로사민류가 검출되는 경우에는 모든 니트로사민류의 검출\n\n수준의 합이 발암 위해 10-5 이하가 되도록 자체적으로 기준을 설정하여 관리\n\n하여야 한다.\n\n - - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다. ",
        "original_sentence": "상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 211,
        "word_count": 48,
        "page_number": 4,
        "window_text": "- - 26 -\n변이원성‧발암성 불순물이 검출된 의약품의 복용이 인체에 미치는 영향을 알아\n\n보기 위한 잠재적으로 발암 가능성이 있는 불순물이 함유된 의약품에 노출된\n\n후의 암 발생 위험증가는 ICH M7(R1) 가이드라인에서 제시하고 있는 초과발암\n\n증가되는 암 발생률이 10-5 (10만명 중 1명) 수준까지 허용 가능한 것으로 설정\n\n- - 인체영향평가는 ① 노출평가, ② 평가대상 화학물질의 변이원성 특성 파악,\n- ① (1단계) 노출평가\n- - 노출평가는 해당 불순물에 노출되어 암이 발생될 가능성이 있는 인구집단\n- - 노출 양상은 환자들의 의약품 사용을 가정하여 적용한 ‘시나리오’로 정의\n- - 실제 환자들의 의약품 사용 양상을 전향적 자료수집 혹은 후향적 자료\n분석과 같은 ‘실제 사용데이터’(RWD, Real World Data) 기반으로 파악할\n\n수 있다.  건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다. ",
        "original_sentence": "초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 167,
        "word_count": 38,
        "page_number": 36,
        "window_text": "건강보험급여대상 의약품의 경우, 건강보험심사평가원이나 국민\n\n건강보험공단 청구자료를 이용하여 관심 의약품을 사용한 인구의 특성,\n\n- - 노출평가 시 ▴간헐적 투여, ▴단기 투여(예: 30일 이하), ▴특정 적응증\n* 분석기기 검출한계보다 낮은 수준의 농도로 존재하는 물질의 농도를 “0”으로 적용할 경우\n\n노출량을 과소평가할 우려가 있고, 검출한계 이하의 농도를 LOQ값으로 적용할 경우에는\n\n- - 27 -\n노출량을 과대평가할 우려가 있기 때문에 정량한계를 최대한 낮게 하여 두 가지 경우의\n\n- - 최대검출치, 최대허용치 등의 값은 보수적인 노출평가를 위해 활용할 수\n있지만, 항상 최대검출치, 최대허용치의 불순물이 포함된 의약품만 섭취하\n\n거나 사용하는 것이 아니므로 정확한 노출량 추정을 위해서는 의약품 중\n\n발암성 불순물을 5개 등급으로\n\n분류하고 있으며, 그 중 니트로사민류는 1등급(변이원성 및 발암성이 확인\n\n된 물질)으로 분류되어 화합물 특이적 섭취 허용량을 기준으로 초과발암\n\n위해도를 산출하여 평가하도록 권장한다.  상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다. ",
        "original_sentence": "발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 472,
        "word_count": 119,
        "page_number": 38,
        "window_text": "상세한 내용은 ‘ 1일 섭취 허\n\n- - 28 -\n- ③ (3단계) 개인별 초과발암위해도 산출\n- - 1단계에서 파악한 불순물 노출 양상과 2단계에서 산출한 평생 노출량 기반\n- - 산출된 위험도가 10-5보다 크면, 암 발생률이 10만명 중 1을 초과하므로\n· 오염도(ppm) : 의약품 중 불순물 분석방법 및 모니터링 자료에 근거(유통제품을 수거하여 시험\n\n· 복용기간 : 복용기간은 보수적으로 불순물 검출 품목의 최초 허가일자 ~ 당해 12.31 까지 기간을 적용할\n\n※ 예시.  초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다. ",
        "original_sentence": "검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 1749,
        "word_count": 349,
        "page_number": 39,
        "window_text": "초과발암위해도를 이용한 인체영향평가 사례\n\n- - 29 -\n❍ (복용기간 산정) NDMA 잠정관리기준을 초과한 제품을 복용했던 환자\n\n❍ (평가결과) NDMA 검출 제품 복용으로 인한 추가적 발암 발생 가능성은\n\n10만명 중 0.21명(95% 신뢰구간 0.12~0.30명)으로 무시할 만한 정도의\n\n- - 30 -\n출량과 무관하게 식약처에 관련 사실을 신속히 보고하여야 한다.  발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다. ",
        "original_sentence": "불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 398,
        "word_count": 94,
        "page_number": 10,
        "window_text": "발생가능성\n\n평가자료, 발생원인(추정원인 포함) 및 검출량, 1일 섭취 허용량에 관한 자료를\n\n첨부하여야 하며, 이 때 검출 수준은 ng 및 ppm 단위로 보고하고 1일 최대\n\n복용량에 기반하여 검출된 불순물에 대한 잠재적 노출량을 기술하는데 사용된\n\n<!-- PAGE_36 -->\n##### 나.  검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라. ",
        "original_sentence": "또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 506,
        "word_count": 115,
        "page_number": 13,
        "window_text": "검출 수준에 따른 단계적 조치\n\n제약사는 식약처가 마련‧\n\n배포한 ‘불순물 검출 수준에 따른 단계적 조치사항’에\n\n따라 불순물 검출량과 허용기준을 비교하여 시중 유통중인 제품 중 기준을\n\n초과한 제품(배치)에 대한 자진 회수 및 불순물 저감화 등 필요한 조치를 진행\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n- - 31 -\n❍ (수준 2)\n\n√ 다만, 허용기준을 초과할 가능성은 상존하므로 제조공정 개선 등을 통해\n\n√ 제조공정을 개선하여 허가변경 등을 하거나, 허가변경 등을 완료 전까지\n\n√ 다만, 제조방법 변경, 규격 설정 등 허가변경이 수반되지 않는 경우에는\n\n* 2종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 총 발암 위해가 10-5\n\n** 4종 이상의 니트로사민 불순물 검출 시, 모든 니트로사민류의 발암 위해의 합이\n\n- - 32 -\n<!-- PAGE_38 -->\n##### 다.  불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다. ",
        "original_sentence": "이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 296,
        "word_count": 64,
        "page_number": 44,
        "window_text": "불순물 함유 우려 의약품의 제조공정 검증\n\n의약품 중 니트로사민류 관련 제조공정 검증의 목적은 불순물의 발생 가능성\n\n이 있는 원료의약품이나 완제의약품의 제조공정 또는 보관조건에서 니트로사\n\n민류 발생이 효과적으로 제거 또는 저감화될 수 있도록 설계가 되었는지를 실\n\n인 및 공정변수를 파악하고, 실제 생산한 의약품에서 불순물의 검출 여부 및\n\n의약품 중 니트로사민류 제조공정 검증을 수행할 때 다음의 사항을 고려하\n\n- ① 2차, 3차 아민이나 4차 암모늄 존재 하에서 아질산나트륨(NaNO2) 혹은\n- - 2차 아민으로 분해 될 수 있는 용매는 N,N-dimethylformamide(DMF),\nN-methyl pyrrolidone(NMP), N,N-dimethylacetamide(DMA) 등이 있음\n\n- - 3차 아민은 triethylamine, diisopropylethylamine, N-methylmorpholine,\n- - 2차, 3차 아민은 4차 암모늄인 tetrabutylammonium 혹은 일차 아민인\n- ③ 원료의 회수과정 및 외부업체에 위탁하는 경우 여러 가지 오염원에 가\n- ④ 출발물질 또는 중간체를 NDMA 생성 가능성이 있는 공정이나 원료를\n- - 33 -\n사용하는 판매자로부터 제공받는 경우\n\n- ⑤ 원료의약품 제조공정의 마지막 단계에서 이전 단계 공정에서 비의도적\n으로(예: 습식 과립화과정) 존재하거나 고온(예: 건조단계)에서 유지되는\n\n- ② 원료의약품의 구조 자체의 반응성 또는 외인성 니트로화제 존재로 분해\n되거나, 보관 중 원료의약품이 온도 또는 습도에 의해 분해되어 불순물\n\n- - 포장재질상의 니트로셀룰로스와 프린터 잉크에 존재하는 아민류와의 결\n- ④ 원료의약품 중 2차, 3차 아민 구조가 탈수소화 또는 탈알킬화되어 첨가\n제, 용매, 제조용수, 포장 용기 등의 아질산염에 노출되어 원료의약품\n\n유사구조\n\n니트로사민\n\n불순물(Nitrosamine\n\ndrug\n\nsubstance-related\n\n<!-- PAGE_39 -->\n###### 2) 의약품 중 니트로사민류 발생 원인 분석\n\n니트로사민류 검출 사실이 보고되었던 의약품을 중심으로 불순물 생성원인을\n\n❍ 사르탄류 중 NDMA 및 NDEA 발생 원인\n\n제조공정에 테트라졸 환 생성 공정이 있는 6종(발사르탄, 로사르탄, 이르베\n\n사르탄, 올메사르탄, 칸데사르탄, 피마사르탄)의 사르탄 계열 원료의약품의\n\n합성과정에서 용매로 사용된 디메틸포름아미드(DMF) 또는 트리에틸아민\n\n- - 34 -\n(TEA)에 불순물로 혼입되거나, 고온에서 분해되면서 생성된 소량의 디메\n\n틸아민(DMA) 또는 디에틸아민(DEA)이 아질산염과 산성조건에서 반응하여\n\n❍ 리팜피신 중 1-methyl-4-nitrosopiperazine(MeNP) 발생원인\n\n원료의약품의 합성 단계에서 시약으로 사용되는 메틸아미노피페라진(AMP)의\n\n제조 과정에서 유전독성 물질인 1-methyl-4-nitrosopiperazine(MeNP)이 생성\n\n되거나 제거되지 않고 잔류하여 원료의약품에 혼입되는 것으로 추정되고\n\n- - 35 -\n원료의약품의 합성 단계에서 시약으로 사용되는 디프로필아민(di-N-propyl\n\namine)과 용매로 사용되는 메탄올 중 미량으로 존재하는 formic acid 등의\n\n- - 36 -\n❍ 메트포르민 중 NDMA 발생원인\n\n완제의약품 제조과정 또는 보관 중에 메트포르민 구조 내의(또는 불순물로\n\n존재하는) 디메틸아민기가 첨가제, 용매, 제조용수, 포장용기 등의 아질산\n\n염에 노출되어 NDMA 생성되는 것으로 추정되고 있다.  또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음. ",
        "original_sentence": "또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 109,
        "word_count": 28,
        "page_number": 13,
        "window_text": "또한, 열 또는 압\n\n건조 등 제조공정 조건에 따른\n\n- - 37 -\n❍ 라니티딘, 니자티딘 중 NDMA 발생원인\n\n라니티딘과 니자티딘은 구조적 특성상 아질산기와 디메틸아민기를 동시에\n\n가지고 있어, 원료의약품 또는 완제의약품의 보관 중 원료의약품이 자체\n\n- - 38 -\n완제의약품 제조 과정 또는 보관 중에 원료의약품의 아민 구조가 탈수소\n\n화 또는 탈알킬화되어 첨가제, 용매, 제조용수, 포장 용기 등의 아질산염에\n\n노출되어 원료의약품 유사구조 니트로사민 불순물(NDSRIs)이 생성되는 것\n\n- - 39 -\n시판중인 의약품의 니트로사민류 제조공정 검증은 NDMA 등 니트로사민\n\n불순물의 함유 우려가 있는 의약품에 관하여, 제조공정에서 불순물이 허용\n\n기준 이하로 관리됨을 입증하는 것을 목적으로 한다.  이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함. ",
        "original_sentence": "원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 2,
        "window_text": "이러한 제조공정 검증\n\n민류의 생성 원인을 파악하여야 하며, 불순물의 발생 또는 제거에 영향을\n\n에서 불순물의 함량을 분석하여 검출 여부, 검출량 및 변동성에 관하여 검\n\n증하여야 하며, 장기보존시험·가혹시험·시판 후 안정성 시험·보관 검체 분석\n\n결과 등을 통해 사용(유효)기간 이내에 불순물이 허용기준 이내임을 입증하\n\n이러한 공정검증 결과를 토대로 발생 가능한 불순물이 의약품의 규격으로\n\n설정한 허용 기준 이내로 관리할 수 있음을 입증하거나, 필요 시 제조공정\n\n에서 불순물이 잠정 관리기준의 30% 이내로 관리되도록 예방 및 시정조치\n\n니트로사민 불순물은 그 발생 원인에 따라 원료의약품 및 완제의약품의 제\n\n조공정 유래 불순물, 원료의약품 및 완제의약품의 분해산물로 구분할 수 있\n\n불순물이 완제의약품의 제조공정에서 불순물의 발생 가능성이 없고 원료의\n\n약품의 제조공정에서 유래(예: 발사르탄 중 NDMA 등)하는 경우에는 원료\n\n의약품의 제조공정을 중점으로 제조공정 검증을 수행하여야 한다.  또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨. ",
        "original_sentence": "허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다. "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 315,
        "word_count": 65,
        "page_number": 26,
        "window_text": "또한, 해\n\n당 원료의약품을 주성분으로 함유한 완제의약품은 원료의약품 제조원에서\n\n수행한 공정검증 자료를 포함하여, 완제의약품에서의 발생 가능성 평가 또\n\n는 실측치 등을 근거로 완제의약품 제조공정이 불순물의 발생에 영향이 없\n\n- - 40 -\n불순물이 완제의약품 제조공정 또는 보관 중에 원료의약품(또는 분해산물)의\n\n아민 구조가 첨가제, 용매, 제조용수, 포장용기 등의 아질산염에 노출되어\n\n생성되는 경우(예: 메트포르민 중 NDMA, NDSRIs 등), 완제의약품의 제조\n\n공정을 중점으로 제조공정 검증을 수행하여야 한다.  원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.",
        "original_sentence": "따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "| 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 80,
        "word_count": 20,
        "page_number": 4,
        "window_text": "원료의약품의 발생 원인\n\n평가 또는 분석 결과 등 원료의약품 제조원의 자료는 참고자료로 활용할\n\n까지 전 제조공정에 관한 검증을 수행하여야 하며, 원료의약품의 제조공정\n\n- - 41 -\n- 라.  허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n",
        "original_sentence": "| 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함. "
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 617,
        "word_count": 144,
        "page_number": 23,
        "window_text": "허가사항 변경 등\n제약사는 자사에서 허가(신고)받은 의약품에 대한 불순물 안전관리에 대한\n\n책임을 진다.  따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다. ",
        "original_sentence": "랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 39,
        "word_count": 8,
        "page_number": 4,
        "window_text": "따라서 허가·신고·등록(변경포함) 시 업체에서는 위해평가를 통해\n\n발생가능한 불순물을 예측하고 관리하여야 하며, 제품의 허가가 유지되고 제품\n\n**[표 시작]**\n\n| 726/2004, Nitrosamine impurities in human medicinal products, Procedure | 심사 자료로서 유전독성 |\n| --- | --- |\n**바 있으며, MNP와 NNV가 검출된 의약품 수급 상황 등을 고려하여 한시적**\n| 분류 2와 비교하여 이 분류의 니트로사민류는 예를 들어 약하게 | 비활성화되는 구조적 특성으로 인해 발암잠재력이 더 낮음.  | 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n",
        "original_sentence": "섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨."
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 547,
        "word_count": 123,
        "page_number": 23,
        "window_text": "| 섭취허용량은 분류 2의 발암잠재력의 4배 감소를 반영하기 | 위해 설정됨 |\n**(30% 랫드 및 30% 햄스터 간)하에서 수행되어야 함.  랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1. ",
        "original_sentence": "** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 192,
        "word_count": 47,
        "page_number": 4,
        "window_text": "랫드와 햄스터의**\n**하고 제출된 자료의 타당성이나 과학적 근거가 부족할 경우에는 추가 자료를**\n**등록된 품목도 불순물의 생성 및 오염 위험을 최소화**\n| S9은 개체에 cytochrome | P450 | 효소유도제로 처리된 후(예: | 제품만 출하토록 하고, 정해진 기한 내 저감화 등 개선토록 조치 |\n**하기 위해 의약품의 제조공정을 검토하여 필요시 새로이 설계하거나 변경하여야**\n**CHMP opinion for the Article 5(3) of regulation (EC) No 726/2004 referral**\n**제약사는 존재하는 불순물이 표 1에 있는 등급 1, 2, 또는 3에 해당하는 경우**\n**비활성 구조적 특성에 대한 평가를 기반으로 니트로사민류 불순물을**\n| 공정 변경 등으로 기준 및 시험방법 변경이 있는 경우에는 변경 | 분류 | 4로 | 분류된 | 니트로사민류는 | α-하이드록실화를 | 통해 |\n**원료의약품 및 완제의약품의 불순물 수준이 허용한계 이하임을 보증하는 관리**\n| 대사적으로 활성화 될 수 있지만, 예를 들어 해당 경로가 | 입체적 또는 전자적 영향으로 인해 선호되지 않거나 제거 경로가 | 선호되기 때문에 발암잠재력이 낮을 것으로 예측됨.  섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3. ",
        "original_sentence": "이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 659,
        "word_count": 161,
        "page_number": 50,
        "window_text": "섭취허용량 | 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. ** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4. ",
        "original_sentence": "상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 816,
        "word_count": 154,
        "page_number": 67,
        "window_text": "** |\n**전략을 수립하여야 하며, 식약처도 불순물 저감화 또는 규격 설정이 필요한**\n**- CPDB 및 LCDB를 통해 사용할 수 있는 소분자 니트로사민에 대한**\n| 경우에는 제조공정 검증 등을 통해 적절한 조치를 취하고 이를 입증하는 자료를 | 호환되어야 하며 물, 유기용매(아세톤, 메탄올 및 DMSO 등)를 사용 |\n**제조공정, 포장재, 제조원, 규격 변경**\n\n**[표 끝]**\n\n등을 고려할 수 있으며, 이러한 변경사항은 약사법 등 관련 규정에 따라 식약\n\n처에 변경허가(신고) 또는 변경보고를 하여야 하고, 관련 제약사에도 알려 연\n\n유전독성 불순물 평가 심사를 위한 근거자료 작성방법의 예시는 다음과 같으며,\n\n상세 자료 작성방법은 ‘의약품 중 유전독성 불순물 평가 질의응답집’을 참고할\n\n- - 42 -\n식약처는 제약사의 불순물 검출 사실 보고 정보와 해외 규제기관 등으로부터\n\n수집한 정보를 바탕으로 필요한 조치사항을 검토하고, 기준 신설(변경) 사항이\n\n있을 경우 신속하게 의약품안전나라(https://nedrug.mfds.go.kr)에 공고한다.\n\n 이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함. ",
        "original_sentence": "※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 677,
        "word_count": 142,
        "page_number": 67,
        "window_text": "이러한 정보가 국내 유통중인 의약품의 안전관리에 필요하다고 판단하는 경우\n\n식약처는 1일 섭취 허용량 설정을 위해 제약사가 제출한 자료의 타당성을 검\n\n토함과 동시에 해외 규제기관과의 정보교환을 통해 충분한 자료를 확보한 후,\n\n식약처는 1일 섭취 허용량 설정과 관련하여 때로는 의약품 수급 상황을 고려\n\n하여 한시적 기준을 설정할 수 있다.  상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함.",
        "original_sentence": "도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "적용범위\n\n<!-- PAGE_68 -->\n##### 4. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 32,
        "word_count": 6,
        "page_number": 68,
        "window_text": "상기 절차에 따라 설정한 1일 섭취 허용량\n\n- - 43 -\n이하로 불순물을 저감화하기 전까지 의약품 공급 부족이 우려되는 경우에는\n\n개별 의약품의 허가 시점을 고려한 인체영향평가, 의료적 필요성, 대체약 유무\n\n및 투여기간 등을 고려하여 제약사와 논의를 통해 투여기간을 평생보다 짧은\n\n기간(LTL)으로 적용하여 한시적 출하허용기준을 설정할 수 있고, 이 경우\n\nICH M7(R1) 가이드라인에 따른 투여기간별 1일 섭취 허용량 기준을 적용할\n\n참고로, 식약처에서는 TD50이 없는 니트로사민류(MNP, NNV)에 대하여 SAR\n\n평가결과 및 해외 규제 동향 등을 종합 검토하여 1일 섭취 허용량을 설정한\n\n제조공정 검증 시 제출하여야 하는 자료의 예시는 다음과 같으며, 그간의 검토\n\n식약처는 제약사가 제출한 불순물 저감화 등에 관한 자료를 검토하여 ‘불순물\n\n검출 수준에 따른 단계적 조치사항’에 따라 조치할 것을 지시하며, 제약사는\n\n식약처의 지시에 따라 필요한 안전조치를 취하고 불순물이 의약품의 사용(유효)\n\n- - 44 -\n<!-- PAGE_50 -->\n###### < 의약품 중 불순물 안전관리 절차(예) >\n\n- - 45 -\n- - 46 -\n- - 47 -\n- - 48 -\n- - 49 -\n니트로사민류 공통 허용기준(26.5 ng/일)을 적용할 수 있습니다.\n\n ※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n",
        "original_sentence": "적용범위\n\n<!-- PAGE_68 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 615,
        "word_count": 130,
        "page_number": 68,
        "window_text": "※ 강화된 Ames 시험 및 in vivo 시험결과를 제출하는 경우 식약처와 상의\n\n- - 50 -\n- - 51 -\n- - 52 -\n- - 53 -\n- - 54 -\n- - 55 -\n- - 56 -\n- - 57 -\n- - 58 -\n- - 59 -\n- - 60 -\n1) Control of nitrosamine impurities in human drugs, Guidance for industry,\n\n3) Assessment report, Procedure under Article 5(3) of regulation EC (No)\n\n4) Questions and answer for marketing authorisation holder/applicants on the\n\n5) Recommended Acceptable Intake Limits for Nitrosamine Drug Substance\n\n6) Assessment and control of DNA reactive (mutagenic) Impurities in\n\npharmaceuticals to limit potential carcinogenic risk M7(R1), ICH\n\n(International Council for Harmonisation of technical requirements for\n\n7) 인체적용제품의 위해성평가에 관한 법률 (식품의약품안전처)\n\n8) 인체적용제품의 위해성평가 공통지침서 (식품의약품안전평가원, 2019.8.2)\n\n9) 의약품 중 변이원성 불순물의 인체영향평가 방법론과 약물역학의 역할, 약\n\n- - 61 -\n<!-- PAGE_67 -->\n##### 1.  도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.",
        "original_sentence": "일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 4,
        "window_text": "도입배경\n\n<!-- PAGE_67 -->\n##### ❍ 신규 불순물은 지속적으로 발생하고 있으나, NDSRIs 자체 독성자료 부족\n\n<!-- PAGE_67 -->\n##### - 유럽 EMA, 미국 FDA등은 불순물 기준설정을 위한 발암잠재력 분류\n\n<!-- PAGE_67 -->\n##### ❍ (정의) ‘발암잠재력 분류 접근법’은 분자에 나타나는 활성 또는\n\n<!-- PAGE_67 -->\n##### 정보와 니트로사민류를 다룬 최근 학술 간행물에서 설명한 구조-활\n\n<!-- PAGE_67 -->\n##### ❍ (원리) 여러 니트로사민류에서 관찰되는 변이원성과 매우 강력한\n\n<!-- PAGE_67 -->\n##### 발암의 원인이 대사 활성의 α-하이드록실화 메커니즘이라고 가정\n\n<!-- PAGE_67 -->\n##### - 활성화 메커니즘의 선호도를 직접적으로 증가 또는 감소시키거나\n\n<!-- PAGE_67 -->\n##### 다른 생물학적 경로로 니트로사민 제거를 증가시키는 구조적\n\n<!-- PAGE_67 -->\n##### ➔ 니트로사민류 불순물의 변이원성 및 발암성을 해당 화합물의\n\n* 다만, CPCA로 도출된 섭취허용량 및 구조적 특징의 분석 등은 과학이\n\n<!-- PAGE_67 -->\n##### 부록 1  발암 잠재력 분류 접근법\n\n- - 62 -\n<!-- PAGE_68 -->\n##### 3.  적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1. ",
        "original_sentence": "니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함."
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "*\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 191,
        "word_count": 40,
        "page_number": 4,
        "window_text": "적용범위\n\n<!-- PAGE_68 -->\n##### 4.  일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2. ",
        "original_sentence": "*\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨.",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 4,
        "window_text": "일반원칙\n\n<!-- PAGE_68 -->\n##### ❍ (고려사항)\n\n<!-- PAGE_68 -->\n##### ①두 개의 N-니트로소기를 포함하는 니트로사민류의\n\n경우 예측된 발암 가능성이 가장 큰 그룹(즉, 가장 낮은 수치의\n\n<!-- PAGE_68 -->\n##### 잠재력 분류가 있는 그룹)이 전체 분자의 AI를 결정*,\n\n<!-- PAGE_68 -->\n##### ②α-탄소와\n\n[그림 1] 니트로사민류의 α-탄소와 β-탄소의 구조\n\n- - 63 -\n<!-- PAGE_69 -->\n##### ❍ (분류) 5가지 예측된 발암 잠재력 분류 및 섭취허용량\n\n* ‘의약품 중 변이원성·발암성 불순물 안전관리 가이드라인(민원인안내서)’(’22.7)\n\n** ICH M7 가이드라인 (ICH M7에서 설명한 독성학적 역치(TTC) 1,500ng/일은 미미한\n\n<!-- PAGE_69 -->\n##### ❍ (계산방법) 니트로사민류에 나타나는 지정된 구조적 특성을 기반\n\n<!-- PAGE_69 -->\n##### 으로 α-수소 점수(표 1), 비활성화 구조 특성 점수(표 2) 및 활성화\n\n* 니트로사민류에 표 2 및 3의 구조 중 하나 이상이 포함된 경우 잠재력\n\n점수는 아래의 계산식에 따라 계산해야 함.  니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. ",
        "original_sentence": "섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨."
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "**\n\n- - 64 -\n표 1. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 18,
        "word_count": 7,
        "page_number": 4,
        "window_text": "니트로사민류에 표 2 및 3의 구\n\n섭취허용량 26.5ng/일는 니트로사민류의 공통 적용 기준과 동일함. *\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n",
        "original_sentence": "**\n\n- - 64 -\n표 1. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 62,
        "word_count": 18,
        "page_number": 23,
        "window_text": "*\n\n분류 1로 분류된 니트로사민류는 발암잠재력이 높을 것으로\n\n예측되지만 니트로사민류의 공통 적용 기준은 환자를 충분히\n\n보호하는 것으로 간주됨\n\n분류 5로 분류된 니트로사민류는 입체장애 또는 α-수소의 부재로\n\nα-하이드록실화를 통해 대사적으로 활성화된다고 예측되지 않거나\n\nDNA와 반응하지 않는 불안정한 종을 형성할 것으로 예측됨.\n\n 섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3. ",
        "original_sentence": "각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2. "
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 83,
        "word_count": 21,
        "page_number": 13,
        "window_text": "섭취허용량 1,500ng/일은 ICH M7에 따라 TTC로 설정됨. **\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. ",
        "original_sentence": "비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 102,
        "word_count": 26,
        "page_number": 23,
        "window_text": "**\n\n- - 64 -\n표 1.  각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음. ",
        "original_sentence": "표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 81,
        "word_count": 25,
        "page_number": 23,
        "window_text": "각 α-탄소에 존재하는 수소 원자의 개수(가장 작은 수부터) 및 해당 α-수소 점수\n\n- - 65 -\n표 2.  비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5. ",
        "original_sentence": "다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 13,
        "window_text": "비활성화 구조 특성 및 관련 점수\n\n비활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel. ",
        "original_sentence": "활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 35,
        "word_count": 11,
        "page_number": 54,
        "window_text": "표의 각 비활성화 구조 특성 목록은 한 번씩만 계산할 수 있으며, N-니트로소기가\n\n둘 이상의 고리 내에 있는 N-니트로사민의 경우 일치하는 가장 작은 고리의 점수만 적용해야 함.\n\n 다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax. ",
        "original_sentence": "표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 76,
        "word_count": 22,
        "page_number": 75,
        "window_text": "다음 예는 예시일 뿐이며 모든 것을 포괄하지는 않음\n\n- - 66 -\n*** β-탄소가 sp3 혼성 상태에 있어야 함\n\n- - 67 -\n표 3.  활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel. ",
        "original_sentence": "다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5. "
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 1418,
        "word_count": 307,
        "page_number": 84,
        "window_text": "활성화 구조 특성 및 관련 점수\n\n활성화 구조 특성 점수의 산출은 N-니트로사민 구조에 존재하는 모든 나열된 특성의 개별 점수를\n\n합산해야 함.  표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax. ",
        "original_sentence": "검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": ": 043-719-2654  /  Fax. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": "표의 각 활성화 구조 특성 목록은 한 번씩만 계산할 수 있음.  다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel. ",
        "original_sentence": ": 043-719-2654  /  Fax. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": ": 043-719-2650**\n**Tel. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 24,
        "word_count": 3,
        "page_number": 4,
        "window_text": "다음 예는 예시일 뿐\n\n이며 모든 것을 포괄하지는 않음\n\n- - 68 -\n- - 69 -\n<!-- PAGE_75 -->\n##### 5.  검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel.  : 043-719-4618  /  Fax. ",
        "original_sentence": ": 043-719-2650**\n**Tel. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": ": 043-719-2997  /  Fax. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": "검토사례\n\n- - 70 -\n[예시 2] N-Nitroso-enalapril\n\n- - 71 -\n[예시 3] N-Nitroso-ketamine\n\n- - 72 -\n[예시 4] N-Nitroso-nebivolol\n\n*** β-탄소가 sp3 혼성 상태에 있어야함\n\n- - 73 -\n- - 74 -\n[예시 5] N-Nitroso-meropenem\n\n잠재력점수= 3 + 3 + 3 + 1 = 10\n\n잠재력 분류 4\n\nAI = 1500 ng/일\n\n- - 75 -\n- - 76 -\n[예시 6] N-Nitroso-desloratadine\n\n- - 77 -\n- - 78 -\n<!-- PAGE_84 -->\n##### ü Ames 시험에 대한 다른 모든 권고사항은 OECD 471 가이드라인 준수\n\n<!-- PAGE_84 -->\n##### ❍ 균주: S. typhimurium TA98, TA100, TA1535, TA1537, and E. coli\n\n<!-- PAGE_84 -->\n##### ❍ 용매 : 용매는 OECD 471 가이드라인에 따른 Ames 시험방법과\n\n* 유기용매를 사용하는 경우, 용매의 양이 니트로사민류의 대사 활성화를\n\n방해하지 않는다는 타당성 검증과 함께 배양 전 혼합물에 가능한 가장 적은\n\n<!-- PAGE_84 -->\n##### ❍ 양성대조군 : OECD 471 가이드라인에 따라 균주별 양성 대조군을\n\n<!-- PAGE_84 -->\n##### 포함해야 하며, S9 존재하에 변이원성이 있는 것으로 알려진\n\n<!-- PAGE_84 -->\n##### - 고려해야 할 니트로사민류 양성 대조군 : ❶ NDMA (CAS # 62-75-9),\n\n* 니트로사민류 양성 대조군의 선택은 니트로사민류과 관련 가능성이 가장\n\n높은 cytochrome P450 효소의 예상되는 대사를 기반으로 타당성이 검증\n\n되어야 하며, 또한, 시험 화합물을 용해시키기 위해 유기용매를 사용하는 경우,\n\n가능한 니트로사민류 양성 대조군을 용해시키기 위해 사용된 유기용매의 양이\n\n배양 전 혼합물의 시험 화합물과 유사한 농도가 되도록 하는 것이 권고됨\n\n<!-- PAGE_84 -->\n##### 부록 2  강화된 복귀돌연변이 시험(Ames 시험) 조건\n\n- - 79 -\n<!-- PAGE_85 -->\n##### ❍ (적용원칙)\n\n<!-- PAGE_85 -->\n##### ①허용기준(1일 섭취허용량) 설정 가능 여부,\n\n<!-- PAGE_85 -->\n##### ②불순물 검출\n\n<!-- PAGE_85 -->\n##### 수준, ③의료적 필요성 및 공급 부족 우려,\n\n<!-- PAGE_85 -->\n##### ④해외 규제기관 동향\n\n<!-- PAGE_85 -->\n##### ❍ (조치사항) 불순물별 적용방안 확정 후, 한시적 허용기준에 적합한\n\n**[표 시작]**\n\n**① 허용기준이 있으나, 검출량이**\n**② 저감화 등 시정·예방조치(CAPA)**\n**Tel.  : 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel.  : 043-719-4618  /  Fax.  : 043-719-4600\n",
        "original_sentence": ": 043-719-2997  /  Fax. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": ": 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 229,
        "word_count": 64,
        "page_number": 85,
        "window_text": ": 043-719-2654  /  Fax.  : 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel.  : 043-719-4618  /  Fax.  : 043-719-4600\n",
        "original_sentence": ": 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": ": 043-719-4618  /  Fax. ",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": ": 043-719-2650**\n**Tel.  : 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel.  : 043-719-4618  /  Fax.  : 043-719-4600\n",
        "original_sentence": ": 043-719-4618  /  Fax. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": ": 043-719-4600\n",
      "metadata": {
        "source": "★의약품+중+변이원성·발암성+불순물+안전관리+가이드라인(배포용).pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 15,
        "word_count": 2,
        "page_number": 4,
        "window_text": ": 043-719-2997  /  Fax.  : 043-719-2950**\n\n**[표 끝]**\n\n* LTL(Less than Lifetime, 평생보다 짧은 기간 노출)\n\n<!-- PAGE_85 -->\n##### 부록 3  한시적 허용기준 적용방안\n\n- - 80 -\n[참고] ‘한시적 허용기준’ 설정을 위한 의사결정 모식도\n\n- - 81 -\n- - 82 -\n식 품 의 약 품 안 전 평 가 원  의 료 제 품 연 구 부  의 약 품 연 구 과\n\nTel.  : 043-719-4618  /  Fax.  : 043-719-4600\n",
        "original_sentence": ": 043-719-4600\n"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 476,
    "avg_chunk_length": 139.81302521008402,
    "min_chunk_length": 3,
    "max_chunk_length": 1749,
    "total_characters": 66551,
    "total_words": 15662,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 2962,
    "heading_count": 90,
    "paragraph_count": 549,
    "list_item_count": 134,
    "table_cell_count": 2189,
    "tables_detected": 24,
    "chunks_generated": 476
  }
}